ticker,date,open,high,low,close,news
AXON,2001-06-19,0.51,0.51,0.46,0.46,
AXON,2001-06-20,0.46,0.46,0.45,0.45,
AXON,2001-06-21,0.45,0.45,0.45,0.45,
AXON,2001-06-22,0.45,0.48,0.45,0.48,
AXON,2001-06-25,0.48,0.48,0.47,0.48,
AXON,2001-06-26,0.47,0.52,0.47,0.52,
AXON,2001-06-27,0.5,0.51,0.5,0.51,
AXON,2001-06-28,0.51,0.51,0.51,0.51,
AXON,2001-06-29,0.52,0.54,0.52,0.53,
AXON,2001-07-02,0.53,0.54,0.53,0.53,
AXON,2001-07-03,0.53,0.53,0.53,0.53,
AXON,2001-07-05,0.53,0.53,0.53,0.53,
AXON,2001-07-06,0.52,0.52,0.52,0.52,
AXON,2001-07-09,0.52,0.52,0.5,0.5,
AXON,2001-07-10,0.5,0.5,0.5,0.5,
AXON,2001-07-11,0.5,0.5,0.5,0.5,
AXON,2001-07-12,0.5,0.5,0.5,0.5,
AXON,2001-07-13,0.5,0.5,0.5,0.5,
AXON,2001-07-16,0.49,0.49,0.49,0.49,
AXON,2001-07-17,0.48,0.48,0.48,0.48,
AXON,2001-07-18,0.48,0.48,0.48,0.48,
AXON,2001-07-19,0.47,0.47,0.47,0.47,
AXON,2001-07-20,0.48,0.48,0.47,0.47,
AXON,2001-07-23,0.48,0.49,0.47,0.47,
AXON,2001-07-24,0.49,0.5,0.48,0.48,
AXON,2001-07-25,0.47,0.47,0.47,0.47,
AXON,2001-07-26,0.47,0.48,0.47,0.48,
AXON,2001-07-27,0.48,0.49,0.48,0.49,
AXON,2001-07-30,0.49,0.51,0.49,0.51,
AXON,2001-07-31,0.5,0.52,0.5,0.52,
AXON,2001-08-01,0.52,0.52,0.52,0.52,
AXON,2001-08-02,0.52,0.52,0.51,0.52,
AXON,2001-08-03,0.52,0.52,0.52,0.52,
AXON,2001-08-06,0.51,0.52,0.5,0.52,
AXON,2001-08-07,0.52,0.54,0.52,0.54,
AXON,2001-08-08,0.54,0.56,0.53,0.55,
AXON,2001-08-09,0.55,0.57,0.55,0.57,
AXON,2001-08-10,0.57,0.59,0.57,0.59,
AXON,2001-08-13,0.59,0.65,0.59,0.64,
AXON,2001-08-14,0.64,0.65,0.62,0.64,
AXON,2001-08-15,0.65,0.66,0.64,0.66,
AXON,2001-08-16,0.66,0.68,0.65,0.67,
AXON,2001-08-17,0.67,0.68,0.66,0.66,
AXON,2001-08-20,0.67,0.68,0.61,0.63,
AXON,2001-08-21,0.63,0.65,0.62,0.64,
AXON,2001-08-22,0.65,0.65,0.61,0.64,
AXON,2001-08-23,0.64,0.66,0.64,0.65,
AXON,2001-08-24,0.66,0.71,0.66,0.71,
AXON,2001-08-27,0.72,0.74,0.68,0.74,
AXON,2001-08-28,0.74,0.75,0.7,0.71,
AXON,2001-08-29,0.7,0.71,0.69,0.71,
AXON,2001-08-30,0.7,0.7,0.68,0.69,
AXON,2001-08-31,0.68,0.72,0.68,0.71,
AXON,2001-09-04,0.71,0.77,0.71,0.76,
AXON,2001-09-05,0.76,0.76,0.74,0.75,
AXON,2001-09-06,0.73,0.75,0.73,0.73,
AXON,2001-09-07,0.72,0.73,0.7,0.72,
AXON,2001-09-10,0.7,0.73,0.7,0.73,
AXON,2001-09-17,0.75,0.75,0.63,0.7,
AXON,2001-09-18,0.69,0.73,0.69,0.71,
AXON,2001-09-19,0.72,0.72,0.62,0.66,
AXON,2001-09-20,0.64,0.64,0.59,0.59,
AXON,2001-09-21,0.58,0.62,0.55,0.57,
AXON,2001-09-24,0.59,0.64,0.59,0.63,
AXON,2001-09-25,0.62,0.67,0.62,0.65,
AXON,2001-09-26,0.66,0.69,0.66,0.69,
AXON,2001-09-27,0.69,0.73,0.69,0.73,
AXON,2001-09-28,0.73,0.78,0.71,0.71,
AXON,2001-10-01,0.71,0.71,0.69,0.69,
AXON,2001-10-02,0.69,0.72,0.69,0.72,
AXON,2001-10-03,0.73,0.76,0.72,0.75,
AXON,2001-10-04,0.74,0.74,0.74,0.74,
AXON,2001-10-05,0.74,0.74,0.7,0.74,
AXON,2001-10-08,0.74,0.74,0.73,0.73,
AXON,2001-10-09,0.74,0.95,0.74,0.93,
AXON,2001-10-10,0.94,0.95,0.88,0.9,
AXON,2001-10-11,0.94,0.94,0.87,0.91,
AXON,2001-10-12,0.91,0.91,0.83,0.85,
AXON,2001-10-15,0.86,0.87,0.81,0.85,
AXON,2001-10-16,0.87,0.89,0.86,0.88,
AXON,2001-10-17,0.88,0.89,0.83,0.83,
AXON,2001-10-18,0.84,0.9,0.84,0.87,
AXON,2001-10-19,0.89,1.04,0.89,1.02,
AXON,2001-10-22,1.03,1.05,0.86,0.89,
AXON,2001-10-23,0.88,0.92,0.81,0.81,
AXON,2001-10-24,0.82,0.87,0.8,0.85,
AXON,2001-10-25,0.85,0.87,0.83,0.83,
AXON,2001-10-26,0.84,0.85,0.81,0.83,
AXON,2001-10-29,0.82,0.82,0.77,0.78,
AXON,2001-10-30,0.77,0.8,0.75,0.79,
AXON,2001-10-31,0.8,0.83,0.79,0.8,
AXON,2001-11-01,0.8,0.8,0.79,0.8,
AXON,2001-11-02,0.81,0.83,0.8,0.82,
AXON,2001-11-05,0.81,0.82,0.81,0.82,
AXON,2001-11-06,0.81,0.82,0.79,0.8,
AXON,2001-11-07,0.8,0.88,0.8,0.87,
AXON,2001-11-08,0.88,0.88,0.87,0.88,
AXON,2001-11-09,0.88,0.94,0.87,0.93,
AXON,2001-11-12,0.93,0.99,0.93,0.95,
AXON,2001-11-13,0.95,0.96,0.93,0.94,
AXON,2001-11-14,0.93,0.93,0.88,0.9,
AXON,2001-11-15,0.91,1.12,0.9,1.11,
AXON,2001-11-16,1.15,1.26,1.13,1.18,
AXON,2001-11-19,1.23,1.24,1.09,1.16,
AXON,2001-11-20,1.16,1.17,1.13,1.16,
AXON,2001-11-21,1.18,1.22,1.12,1.16,
AXON,2001-11-23,1.16,1.19,1.15,1.17,
AXON,2001-11-26,1.17,1.18,1.13,1.14,
AXON,2001-11-27,1.15,1.15,1.04,1.05,
AXON,2001-11-28,1.02,1.02,0.98,1.0,
AXON,2001-11-29,1.0,1.04,0.98,1.01,
AXON,2001-11-30,0.98,1.1,0.98,1.09,
AXON,2001-12-03,1.1,1.1,1.03,1.08,
AXON,2001-12-04,1.09,1.12,1.08,1.09,
AXON,2001-12-05,1.1,1.1,1.02,1.03,
AXON,2001-12-06,1.03,1.04,0.99,1.01,
AXON,2001-12-07,0.98,1.02,0.96,1.01,
AXON,2001-12-10,0.99,1.01,0.98,1.0,
AXON,2001-12-11,0.98,1.01,0.95,0.97,
AXON,2001-12-12,0.98,0.98,0.96,0.98,
AXON,2001-12-13,0.97,1.06,0.96,1.0,
AXON,2001-12-14,1.02,1.06,1.01,1.03,
AXON,2001-12-17,1.03,1.04,1.01,1.02,
AXON,2001-12-18,1.02,1.06,1.01,1.05,
AXON,2001-12-19,1.05,1.05,1.02,1.02,
AXON,2001-12-20,1.02,1.02,1.01,1.01,
AXON,2001-12-21,1.01,1.01,1.0,1.0,
AXON,2001-12-24,1.0,1.03,1.0,1.03,
AXON,2001-12-26,1.03,1.03,1.01,1.01,
AXON,2001-12-27,1.02,1.03,1.01,1.03,
AXON,2001-12-28,1.02,1.05,1.01,1.05,
AXON,2001-12-31,1.05,1.15,1.04,1.15,
AXON,2002-01-02,1.14,1.14,1.08,1.12,
AXON,2002-01-03,1.13,1.14,1.11,1.12,
AXON,2002-01-04,1.12,1.14,1.1,1.1,
AXON,2002-01-07,1.11,1.11,1.09,1.09,
AXON,2002-01-08,1.19,1.27,1.17,1.22,
AXON,2002-01-09,1.46,1.52,1.4,1.48,
AXON,2002-01-10,1.48,1.62,1.41,1.53,
AXON,2002-01-11,1.57,1.58,1.51,1.52,
AXON,2002-01-14,1.43,1.48,1.33,1.36,
AXON,2002-01-15,1.38,1.47,1.38,1.41,
AXON,2002-01-16,1.4,1.4,1.31,1.35,
AXON,2002-01-17,1.35,1.45,1.35,1.43,
AXON,2002-01-18,1.43,1.43,1.4,1.41,
AXON,2002-01-22,1.42,1.47,1.41,1.41,
AXON,2002-01-23,1.43,1.45,1.38,1.4,
AXON,2002-01-24,1.46,1.46,1.39,1.4,
AXON,2002-01-25,1.42,1.42,1.36,1.37,
AXON,2002-01-28,1.37,1.38,1.33,1.33,
AXON,2002-01-29,1.33,1.33,1.27,1.33,
AXON,2002-01-30,1.32,1.47,1.32,1.44,
AXON,2002-01-31,1.49,1.49,1.4,1.42,
AXON,2002-02-01,1.38,1.48,1.38,1.47,
AXON,2002-02-04,1.47,1.47,1.39,1.41,
AXON,2002-02-05,1.4,1.42,1.38,1.41,
AXON,2002-02-06,1.41,1.46,1.39,1.42,
AXON,2002-02-07,1.44,1.46,1.39,1.41,
AXON,2002-02-08,1.41,1.42,1.39,1.42,
AXON,2002-02-11,1.42,1.58,1.4,1.57,
AXON,2002-02-12,1.58,1.58,1.46,1.49,
AXON,2002-02-13,1.49,1.54,1.48,1.53,
AXON,2002-02-14,1.52,1.52,1.47,1.47,
AXON,2002-02-15,1.48,1.5,1.46,1.46,
AXON,2002-02-19,1.47,1.5,1.4,1.4,
AXON,2002-02-20,1.4,1.44,1.38,1.4,
AXON,2002-02-21,1.36,1.41,1.29,1.32,
AXON,2002-02-22,1.29,1.34,1.27,1.34,
AXON,2002-02-25,1.35,1.43,1.35,1.42,
AXON,2002-02-26,1.43,1.45,1.4,1.41,
AXON,2002-02-27,1.42,1.43,1.39,1.39,
AXON,2002-02-28,1.42,1.51,1.42,1.47,
AXON,2002-03-01,1.47,1.49,1.42,1.47,
AXON,2002-03-04,1.5,1.5,1.47,1.48,
AXON,2002-03-05,1.47,1.5,1.45,1.48,
AXON,2002-03-06,1.48,1.5,1.46,1.47,
AXON,2002-03-07,1.47,1.48,1.46,1.47,
AXON,2002-03-08,1.47,1.67,1.33,1.37,
AXON,2002-03-11,1.41,1.46,1.35,1.41,
AXON,2002-03-12,1.42,1.42,1.27,1.38,
AXON,2002-03-13,1.38,1.38,1.34,1.35,
AXON,2002-03-14,1.36,1.36,1.35,1.35,
AXON,2002-03-15,1.49,1.6,1.47,1.53,
AXON,2002-03-18,1.58,1.58,1.51,1.54,
AXON,2002-03-19,1.55,1.56,1.5,1.51,
AXON,2002-03-20,1.5,1.52,1.46,1.5,
AXON,2002-03-21,1.49,1.56,1.49,1.55,
AXON,2002-03-22,1.56,1.56,1.54,1.54,
AXON,2002-03-25,1.55,1.56,1.52,1.54,
AXON,2002-03-26,1.53,1.65,1.53,1.58,
AXON,2002-03-27,1.63,1.69,1.56,1.64,
AXON,2002-03-28,1.65,1.65,1.57,1.6,
AXON,2002-04-01,1.62,1.64,1.59,1.62,
AXON,2002-04-02,1.63,1.64,1.59,1.6,
AXON,2002-04-03,1.59,1.6,1.55,1.58,
AXON,2002-04-04,1.57,1.58,1.5,1.51,
AXON,2002-04-05,1.54,1.54,1.48,1.49,
AXON,2002-04-08,1.48,1.55,1.48,1.55,
AXON,2002-04-09,1.56,1.56,1.49,1.51,
AXON,2002-04-10,1.5,1.51,1.5,1.51,
AXON,2002-04-11,1.52,1.58,1.52,1.58,
AXON,2002-04-12,1.56,1.66,1.55,1.59,
AXON,2002-04-15,1.6,1.64,1.6,1.61,
AXON,2002-04-16,1.61,1.62,1.57,1.61,
AXON,2002-04-17,1.6,1.64,1.6,1.62,
AXON,2002-04-18,1.62,1.68,1.6,1.6,
AXON,2002-04-19,1.61,1.66,1.6,1.64,
AXON,2002-04-22,1.67,1.74,1.63,1.72,
AXON,2002-04-23,1.75,1.75,1.64,1.7,
AXON,2002-04-24,1.73,1.75,1.69,1.69,
AXON,2002-04-25,1.73,1.73,1.62,1.64,
AXON,2002-04-26,1.68,1.68,1.52,1.54,
AXON,2002-04-29,1.59,1.62,1.57,1.62,
AXON,2002-04-30,1.64,1.65,1.56,1.61,
AXON,2002-05-01,1.62,1.62,1.54,1.55,
AXON,2002-05-02,1.57,1.57,1.48,1.55,
AXON,2002-05-03,1.55,1.61,1.55,1.61,
AXON,2002-05-06,1.61,1.61,1.55,1.59,
AXON,2002-05-07,1.58,1.61,1.58,1.6,
AXON,2002-05-08,1.61,1.61,1.55,1.57,
AXON,2002-05-09,1.59,1.59,1.42,1.45,
AXON,2002-05-10,1.41,1.43,1.23,1.3,
AXON,2002-05-13,1.32,1.33,1.17,1.18,
AXON,2002-05-14,1.17,1.32,1.14,1.31,
AXON,2002-05-15,1.31,1.32,1.25,1.3,
AXON,2002-05-16,1.29,1.29,1.21,1.22,
AXON,2002-05-17,1.25,1.28,1.22,1.26,
AXON,2002-05-20,1.31,1.36,1.28,1.36,
AXON,2002-05-21,1.35,1.52,1.31,1.52,
AXON,2002-05-22,1.57,1.58,1.48,1.54,
AXON,2002-05-23,1.54,1.54,1.46,1.5,
AXON,2002-05-24,1.48,1.48,1.44,1.48,
AXON,2002-05-28,1.42,1.42,1.27,1.33,
AXON,2002-05-29,1.31,1.44,1.29,1.4,
AXON,2002-05-30,1.41,1.43,1.41,1.42,
AXON,2002-05-31,1.42,1.46,1.42,1.43,
AXON,2002-06-03,1.45,1.45,1.42,1.43,
AXON,2002-06-04,1.42,1.45,1.41,1.42,
AXON,2002-06-05,1.42,1.42,1.38,1.4,
AXON,2002-06-06,1.41,1.41,1.4,1.4,
AXON,2002-06-07,1.39,1.39,1.36,1.37,
AXON,2002-06-10,1.38,1.38,1.34,1.34,
AXON,2002-06-11,1.34,1.34,1.21,1.22,
AXON,2002-06-12,1.24,1.27,1.23,1.23,
AXON,2002-06-13,1.23,1.26,1.17,1.18,
AXON,2002-06-14,1.2,1.21,1.1,1.18,
AXON,2002-06-17,1.19,1.2,1.18,1.2,
AXON,2002-06-18,1.19,1.27,1.19,1.26,
AXON,2002-06-19,1.25,1.3,1.23,1.25,
AXON,2002-06-20,1.25,1.25,1.15,1.18,
AXON,2002-06-21,1.18,1.18,1.09,1.11,
AXON,2002-06-24,1.1,1.1,1.02,1.08,
AXON,2002-06-25,1.08,1.11,1.06,1.1,
AXON,2002-06-26,1.07,1.07,0.97,0.99,
AXON,2002-06-27,0.99,1.02,0.97,1.0,
AXON,2002-06-28,1.0,1.06,0.99,1.0,
AXON,2002-07-01,1.01,1.04,0.93,1.02,
AXON,2002-07-02,1.01,1.04,0.97,0.97,
AXON,2002-07-03,0.97,0.99,0.92,0.97,
AXON,2002-07-05,0.97,0.99,0.94,0.99,
AXON,2002-07-08,1.0,1.0,1.0,1.0,
AXON,2002-07-09,1.0,1.0,0.98,0.99,
AXON,2002-07-10,1.0,1.0,0.94,0.94,
AXON,2002-07-11,0.93,0.93,0.86,0.86,
AXON,2002-07-12,0.87,0.89,0.87,0.89,
AXON,2002-07-15,0.88,0.91,0.82,0.83,
AXON,2002-07-16,0.85,0.85,0.74,0.75,
AXON,2002-07-17,0.77,0.8,0.74,0.75,
AXON,2002-07-18,0.76,0.76,0.66,0.69,
AXON,2002-07-19,0.68,0.71,0.66,0.69,
AXON,2002-07-22,0.68,0.7,0.64,0.69,
AXON,2002-07-23,0.58,0.61,0.5,0.51,
AXON,2002-07-24,0.46,0.51,0.44,0.49,
AXON,2002-07-25,0.5,0.5,0.45,0.47,
AXON,2002-07-26,0.46,0.46,0.42,0.44,
AXON,2002-07-29,0.44,0.45,0.4,0.41,
AXON,2002-07-30,0.36,0.4,0.33,0.39,
AXON,2002-07-31,0.38,0.42,0.38,0.4,
AXON,2002-08-01,0.41,0.42,0.4,0.41,
AXON,2002-08-02,0.42,0.46,0.42,0.45,
AXON,2002-08-05,0.46,0.48,0.46,0.46,
AXON,2002-08-06,0.46,0.48,0.45,0.48,
AXON,2002-08-07,0.48,0.48,0.47,0.47,
AXON,2002-08-08,0.47,0.54,0.47,0.53,
AXON,2002-08-09,0.54,0.58,0.52,0.58,
AXON,2002-08-12,0.58,0.61,0.56,0.61,
AXON,2002-08-13,0.61,0.64,0.59,0.6,
AXON,2002-08-14,0.62,0.62,0.6,0.62,
AXON,2002-08-15,0.61,0.62,0.6,0.6,
AXON,2002-08-16,0.61,0.61,0.56,0.58,
AXON,2002-08-19,0.57,0.59,0.56,0.59,
AXON,2002-08-20,0.59,0.59,0.56,0.58,
AXON,2002-08-21,0.59,0.59,0.55,0.57,
AXON,2002-08-22,0.57,0.58,0.56,0.56,
AXON,2002-08-23,0.58,0.58,0.56,0.57,
AXON,2002-08-26,0.57,0.58,0.56,0.58,
AXON,2002-08-27,0.58,0.58,0.56,0.56,
AXON,2002-08-28,0.56,0.57,0.56,0.57,
AXON,2002-08-29,0.57,0.57,0.53,0.54,
AXON,2002-08-30,0.53,0.54,0.52,0.52,
AXON,2002-09-03,0.53,0.53,0.48,0.48,
AXON,2002-09-04,0.49,0.56,0.49,0.54,
AXON,2002-09-05,0.55,0.55,0.54,0.54,
AXON,2002-09-06,0.55,0.57,0.55,0.56,
AXON,2002-09-09,0.56,0.56,0.54,0.56,
AXON,2002-09-10,0.55,0.56,0.53,0.53,
AXON,2002-09-11,0.53,0.53,0.52,0.52,
AXON,2002-09-12,0.52,0.52,0.5,0.5,
AXON,2002-09-13,0.5,0.5,0.48,0.5,
AXON,2002-09-16,0.49,0.5,0.48,0.48,
AXON,2002-09-17,0.48,0.48,0.48,0.48,
AXON,2002-09-18,0.48,0.48,0.47,0.47,
AXON,2002-09-19,0.47,0.47,0.42,0.45,
AXON,2002-09-20,0.46,0.47,0.46,0.47,
AXON,2002-09-23,0.47,0.5,0.47,0.49,
AXON,2002-09-24,0.48,0.5,0.48,0.48,
AXON,2002-09-25,0.48,0.5,0.47,0.5,
AXON,2002-09-26,0.49,0.49,0.47,0.49,
AXON,2002-09-27,0.48,0.48,0.47,0.47,
AXON,2002-09-30,0.45,0.45,0.4,0.43,
AXON,2002-10-01,0.4,0.4,0.33,0.34,
AXON,2002-10-02,0.33,0.35,0.32,0.33,
AXON,2002-10-03,0.34,0.35,0.33,0.35,
AXON,2002-10-04,0.34,0.35,0.34,0.34,
AXON,2002-10-07,0.34,0.35,0.32,0.35,
AXON,2002-10-08,0.34,0.34,0.33,0.33,
AXON,2002-10-09,0.32,0.32,0.31,0.31,
AXON,2002-10-10,0.3,0.31,0.28,0.28,
AXON,2002-10-11,0.3,0.31,0.28,0.29,
AXON,2002-10-14,0.3,0.3,0.28,0.28,
AXON,2002-10-15,0.29,0.31,0.28,0.28,
AXON,2002-10-16,0.28,0.31,0.28,0.31,
AXON,2002-10-17,0.31,0.31,0.3,0.3,
AXON,2002-10-18,0.29,0.29,0.28,0.28,
AXON,2002-10-21,0.29,0.29,0.28,0.28,
AXON,2002-10-22,0.28,0.31,0.28,0.29,
AXON,2002-10-23,0.3,0.31,0.28,0.29,
AXON,2002-10-24,0.29,0.3,0.28,0.28,
AXON,2002-10-25,0.28,0.29,0.28,0.29,
AXON,2002-10-28,0.3,0.3,0.28,0.28,
AXON,2002-10-29,0.29,0.3,0.28,0.28,
AXON,2002-10-30,0.28,0.29,0.28,0.29,
AXON,2002-10-31,0.3,0.3,0.28,0.3,
AXON,2002-11-01,0.3,0.3,0.29,0.3,
AXON,2002-11-04,0.29,0.3,0.29,0.3,
AXON,2002-11-05,0.3,0.3,0.29,0.29,
AXON,2002-11-06,0.3,0.3,0.29,0.3,
AXON,2002-11-07,0.3,0.31,0.3,0.31,
AXON,2002-11-08,0.31,0.4,0.31,0.4,
AXON,2002-11-11,0.41,0.41,0.35,0.35,
AXON,2002-11-12,0.35,0.38,0.35,0.37,
AXON,2002-11-13,0.37,0.38,0.35,0.35,
AXON,2002-11-14,0.36,0.36,0.35,0.35,
AXON,2002-11-15,0.35,0.35,0.35,0.35,
AXON,2002-11-18,0.36,0.36,0.35,0.35,
AXON,2002-11-19,0.35,0.37,0.35,0.36,
AXON,2002-11-20,0.36,0.36,0.34,0.34,
AXON,2002-11-21,0.34,0.34,0.29,0.3,
AXON,2002-11-22,0.3,0.32,0.29,0.31,
AXON,2002-11-25,0.32,0.33,0.32,0.32,
AXON,2002-11-26,0.33,0.33,0.32,0.32,
AXON,2002-11-27,0.33,0.33,0.32,0.33,
AXON,2002-11-29,0.33,0.34,0.32,0.34,
AXON,2002-12-02,0.34,0.34,0.33,0.34,
AXON,2002-12-03,0.34,0.34,0.33,0.34,
AXON,2002-12-04,0.33,0.35,0.33,0.34,
AXON,2002-12-05,0.34,0.35,0.34,0.35,
AXON,2002-12-06,0.35,0.36,0.34,0.36,
AXON,2002-12-09,0.35,0.36,0.34,0.35,
AXON,2002-12-10,0.35,0.36,0.34,0.35,
AXON,2002-12-11,0.34,0.34,0.33,0.34,
AXON,2002-12-12,0.33,0.34,0.33,0.33,
AXON,2002-12-13,0.33,0.33,0.32,0.33,
AXON,2002-12-16,0.32,0.32,0.31,0.31,
AXON,2002-12-17,0.31,0.33,0.31,0.33,
AXON,2002-12-18,0.33,0.33,0.32,0.32,
AXON,2002-12-19,0.32,0.33,0.32,0.33,
AXON,2002-12-20,0.33,0.35,0.33,0.34,
AXON,2002-12-23,0.35,0.37,0.34,0.35,
AXON,2002-12-24,0.35,0.35,0.34,0.34,
AXON,2002-12-26,0.35,0.35,0.34,0.34,
AXON,2002-12-27,0.34,0.34,0.33,0.34,
AXON,2002-12-30,0.33,0.34,0.33,0.33,
AXON,2002-12-31,0.33,0.34,0.33,0.34,
AXON,2003-01-02,0.34,0.35,0.34,0.35,
AXON,2003-01-03,0.36,0.37,0.35,0.36,
AXON,2003-01-06,0.37,0.37,0.35,0.35,
AXON,2003-01-07,0.35,0.36,0.35,0.36,
AXON,2003-01-08,0.36,0.36,0.35,0.35,
AXON,2003-01-09,0.35,0.36,0.35,0.35,
AXON,2003-01-10,0.36,0.36,0.35,0.35,
AXON,2003-01-13,0.34,0.36,0.34,0.35,
AXON,2003-01-14,0.35,0.35,0.35,0.35,
AXON,2003-01-15,0.35,0.35,0.35,0.35,
AXON,2003-01-16,0.35,0.36,0.34,0.35,
AXON,2003-01-17,0.35,0.35,0.32,0.35,
AXON,2003-01-21,0.34,0.38,0.34,0.37,
AXON,2003-01-22,0.38,0.38,0.36,0.37,
AXON,2003-01-23,0.38,0.38,0.35,0.36,
AXON,2003-01-24,0.36,0.36,0.35,0.35,
AXON,2003-01-27,0.34,0.36,0.33,0.35,
AXON,2003-01-28,0.35,0.35,0.33,0.34,
AXON,2003-01-29,0.34,0.36,0.34,0.36,
AXON,2003-01-30,0.34,0.35,0.33,0.35,
AXON,2003-01-31,0.34,0.35,0.34,0.34,
AXON,2003-02-03,0.35,0.35,0.34,0.35,
AXON,2003-02-04,0.34,0.35,0.33,0.34,
AXON,2003-02-05,0.34,0.34,0.33,0.34,
AXON,2003-02-06,0.33,0.34,0.33,0.33,
AXON,2003-02-07,0.34,0.34,0.33,0.34,
AXON,2003-02-10,0.34,0.34,0.32,0.33,
AXON,2003-02-11,0.33,0.34,0.33,0.34,
AXON,2003-02-12,0.34,0.34,0.33,0.33,
AXON,2003-02-13,0.33,0.33,0.31,0.31,
AXON,2003-02-14,0.31,0.32,0.31,0.31,
AXON,2003-02-18,0.31,0.31,0.31,0.31,
AXON,2003-02-19,0.31,0.31,0.3,0.31,
AXON,2003-02-20,0.31,0.33,0.31,0.33,
AXON,2003-02-21,0.32,0.32,0.32,0.32,
AXON,2003-02-24,0.32,0.34,0.32,0.33,
AXON,2003-02-25,0.33,0.34,0.32,0.33,
AXON,2003-02-26,0.34,0.34,0.33,0.33,
AXON,2003-02-27,0.33,0.34,0.33,0.33,
AXON,2003-02-28,0.33,0.33,0.33,0.33,
AXON,2003-03-03,0.33,0.34,0.33,0.33,
AXON,2003-03-04,0.33,0.33,0.32,0.32,
AXON,2003-03-05,0.33,0.33,0.32,0.32,
AXON,2003-03-06,0.32,0.33,0.32,0.33,
AXON,2003-03-07,0.32,0.33,0.32,0.33,
AXON,2003-03-10,0.32,0.33,0.32,0.33,
AXON,2003-03-11,0.32,0.32,0.32,0.32,
AXON,2003-03-12,0.32,0.33,0.32,0.32,
AXON,2003-03-13,0.32,0.33,0.32,0.33,
AXON,2003-03-14,0.33,0.33,0.32,0.33,
AXON,2003-03-17,0.33,0.33,0.31,0.32,
AXON,2003-03-18,0.32,0.34,0.32,0.34,
AXON,2003-03-19,0.34,0.38,0.33,0.37,
AXON,2003-03-20,0.38,0.38,0.35,0.36,
AXON,2003-03-21,0.35,0.35,0.34,0.35,
AXON,2003-03-24,0.36,0.36,0.34,0.34,
AXON,2003-03-25,0.34,0.35,0.34,0.35,
AXON,2003-03-26,0.35,0.35,0.35,0.35,
AXON,2003-03-27,0.36,0.36,0.35,0.35,
AXON,2003-03-28,0.35,0.35,0.35,0.35,
AXON,2003-03-31,0.35,0.36,0.35,0.36,
AXON,2003-04-01,0.36,0.38,0.35,0.38,
AXON,2003-04-02,0.38,0.39,0.36,0.39,
AXON,2003-04-03,0.39,0.42,0.39,0.4,
AXON,2003-04-04,0.39,0.39,0.37,0.38,
AXON,2003-04-07,0.37,0.4,0.37,0.38,
AXON,2003-04-08,0.38,0.39,0.38,0.38,
AXON,2003-04-09,0.38,0.39,0.38,0.39,
AXON,2003-04-10,0.39,0.4,0.39,0.39,
AXON,2003-04-11,0.4,0.4,0.4,0.4,
AXON,2003-04-14,0.41,0.41,0.4,0.41,
AXON,2003-04-15,0.4,0.42,0.4,0.42,
AXON,2003-04-16,0.42,0.46,0.42,0.45,
AXON,2003-04-17,0.45,0.48,0.45,0.45,
AXON,2003-04-21,0.47,0.49,0.45,0.45,
AXON,2003-04-22,0.49,0.52,0.47,0.5,
AXON,2003-04-23,0.51,0.52,0.49,0.49,
AXON,2003-04-24,0.49,0.51,0.49,0.5,
AXON,2003-04-25,0.51,0.54,0.5,0.54,
AXON,2003-04-28,0.54,0.6,0.54,0.59,
AXON,2003-04-29,0.6,0.65,0.6,0.63,
AXON,2003-04-30,0.65,0.68,0.64,0.68,
AXON,2003-05-01,0.69,0.7,0.66,0.67,
AXON,2003-05-02,0.67,0.67,0.59,0.61,
AXON,2003-05-05,0.6,0.61,0.55,0.56,
AXON,2003-05-06,0.56,0.61,0.56,0.6,
AXON,2003-05-07,0.6,0.62,0.6,0.62,
AXON,2003-05-08,0.61,0.62,0.6,0.62,
AXON,2003-05-09,0.62,0.63,0.61,0.63,
AXON,2003-05-12,0.62,0.66,0.61,0.65,
AXON,2003-05-13,0.66,0.71,0.65,0.71,
AXON,2003-05-14,0.74,0.78,0.72,0.75,
AXON,2003-05-15,0.76,0.77,0.74,0.75,
AXON,2003-05-16,0.75,0.75,0.74,0.75,
AXON,2003-05-19,0.74,0.75,0.67,0.7,
AXON,2003-05-20,0.68,0.7,0.67,0.69,
AXON,2003-05-21,0.69,0.76,0.69,0.73,
AXON,2003-05-22,0.72,0.75,0.72,0.75,
AXON,2003-05-23,0.74,0.77,0.74,0.75,
AXON,2003-05-27,0.76,0.77,0.74,0.75,
AXON,2003-05-28,0.75,0.76,0.74,0.74,
AXON,2003-05-29,0.75,0.78,0.71,0.75,
AXON,2003-05-30,0.77,0.83,0.76,0.82,
AXON,2003-06-02,0.82,0.85,0.77,0.81,
AXON,2003-06-03,0.8,0.81,0.79,0.79,
AXON,2003-06-04,0.8,0.83,0.79,0.81,
AXON,2003-06-05,0.81,0.82,0.78,0.79,
AXON,2003-06-06,0.78,0.82,0.78,0.81,
AXON,2003-06-09,0.81,0.87,0.78,0.87,
AXON,2003-06-10,0.91,0.99,0.88,0.95,
AXON,2003-06-11,0.99,1.02,0.98,1.0,
AXON,2003-06-12,1.02,1.02,0.92,0.97,
AXON,2003-06-13,0.98,0.98,0.92,0.93,
AXON,2003-06-16,0.92,0.98,0.92,0.96,
AXON,2003-06-17,0.95,0.96,0.94,0.95,
AXON,2003-06-18,0.97,0.97,0.91,0.92,
AXON,2003-06-19,0.93,0.94,0.92,0.92,
AXON,2003-06-20,0.92,0.92,0.88,0.92,
AXON,2003-06-23,0.89,0.93,0.89,0.9,
AXON,2003-06-24,0.9,0.93,0.89,0.93,
AXON,2003-06-25,0.93,0.96,0.93,0.94,
AXON,2003-06-26,0.93,1.02,0.92,1.02,
AXON,2003-06-27,1.02,1.08,1.02,1.07,
AXON,2003-06-30,1.08,1.12,1.04,1.08,
AXON,2003-07-01,1.09,1.09,0.98,1.02,
AXON,2003-07-02,1.02,1.06,1.02,1.05,
AXON,2003-07-03,1.02,1.06,1.02,1.05,
AXON,2003-07-07,1.06,1.08,1.04,1.07,
AXON,2003-07-08,1.06,1.08,1.05,1.05,
AXON,2003-07-09,1.05,1.07,1.05,1.06,
AXON,2003-07-10,1.06,1.08,1.02,1.04,
AXON,2003-07-11,1.04,1.05,0.99,1.03,
AXON,2003-07-14,1.03,1.06,1.03,1.05,
AXON,2003-07-15,1.07,1.08,1.04,1.08,
AXON,2003-07-16,1.08,1.08,1.03,1.08,
AXON,2003-07-17,1.06,1.08,1.0,1.05,
AXON,2003-07-18,1.02,1.06,1.02,1.06,
AXON,2003-07-21,1.04,1.07,1.01,1.03,
AXON,2003-07-22,1.07,1.2,1.06,1.19,
AXON,2003-07-23,1.2,1.22,1.08,1.21,
AXON,2003-07-24,1.21,1.38,1.21,1.34,
AXON,2003-07-25,1.36,1.41,1.32,1.38,
AXON,2003-07-28,1.42,1.53,1.4,1.53,
AXON,2003-07-29,1.56,1.56,1.43,1.48,
AXON,2003-07-30,1.51,1.61,1.49,1.6,
AXON,2003-07-31,1.65,1.73,1.61,1.69,
AXON,2003-08-01,1.69,1.69,1.61,1.65,
AXON,2003-08-04,1.67,1.67,1.44,1.52,
AXON,2003-08-05,1.54,1.57,1.44,1.5,
AXON,2003-08-06,1.46,1.52,1.46,1.49,
AXON,2003-08-07,1.48,1.56,1.48,1.55,
AXON,2003-08-08,1.55,1.75,1.55,1.71,
AXON,2003-08-11,1.76,2.01,1.71,2.0,
AXON,2003-08-12,2.05,2.25,2.01,2.04,
AXON,2003-08-13,2.06,2.09,1.88,1.89,
AXON,2003-08-14,1.77,1.96,1.74,1.95,
AXON,2003-08-15,1.95,2.02,1.9,1.96,
AXON,2003-08-18,1.98,2.1,1.98,2.06,
AXON,2003-08-19,2.05,2.08,1.89,1.95,
AXON,2003-08-20,1.93,2.06,1.9,2.0,
AXON,2003-08-21,2.02,2.02,1.92,2.0,
AXON,2003-08-22,2.0,2.01,1.92,1.97,
AXON,2003-08-25,1.96,1.96,1.78,1.9,
AXON,2003-08-26,1.87,1.92,1.7,1.75,
AXON,2003-08-27,1.75,1.9,1.72,1.89,
AXON,2003-08-28,1.89,2.0,1.83,1.94,
AXON,2003-08-29,1.9,2.07,1.9,2.06,
AXON,2003-09-02,2.07,2.1,2.02,2.06,
AXON,2003-09-03,2.05,2.1,1.91,1.92,
AXON,2003-09-04,1.9,2.0,1.9,1.97,
AXON,2003-09-05,1.96,2.02,1.92,2.01,
AXON,2003-09-08,2.02,2.02,1.91,1.94,
AXON,2003-09-09,1.93,1.97,1.85,1.87,
AXON,2003-09-10,1.84,1.96,1.78,1.96,
AXON,2003-09-11,1.96,1.99,1.88,1.92,
AXON,2003-09-12,1.91,1.95,1.89,1.95,
AXON,2003-09-15,1.97,1.97,1.84,1.88,
AXON,2003-09-16,2.01,2.04,1.88,2.01,
AXON,2003-09-17,2.04,2.5,2.02,2.5,
AXON,2003-09-18,2.51,2.7,2.4,2.49,
AXON,2003-09-19,2.51,2.55,2.42,2.44,
AXON,2003-09-22,2.32,2.45,2.31,2.38,
AXON,2003-09-23,2.35,2.45,2.35,2.43,
AXON,2003-09-24,2.45,2.63,2.42,2.48,
AXON,2003-09-25,2.49,2.6,2.42,2.5,
AXON,2003-09-26,2.5,2.51,2.17,2.23,
AXON,2003-09-29,2.18,2.37,1.98,2.18,
AXON,2003-09-30,2.14,2.21,2.06,2.19,
AXON,2003-10-01,2.21,2.45,2.17,2.4,
AXON,2003-10-02,2.45,2.64,2.35,2.64,
AXON,2003-10-03,2.7,2.81,2.66,2.78,
AXON,2003-10-06,2.86,3.04,2.81,3.02,
AXON,2003-10-07,2.97,3.0,2.72,2.91,
AXON,2003-10-08,2.9,3.02,2.9,2.94,
AXON,2003-10-09,2.95,3.0,2.78,2.83,
AXON,2003-10-10,2.77,2.92,2.77,2.86,
AXON,2003-10-13,2.89,3.14,2.86,3.11,
AXON,2003-10-14,3.15,3.4,3.13,3.39,
AXON,2003-10-15,3.42,3.53,3.4,3.45,
AXON,2003-10-16,3.48,3.57,3.3,3.52,
AXON,2003-10-17,3.53,3.61,3.43,3.5,
AXON,2003-10-20,3.43,3.64,3.43,3.63,
AXON,2003-10-21,4.15,4.33,4.01,4.12,
AXON,2003-10-22,4.11,4.39,4.05,4.39,
AXON,2003-10-23,4.23,4.77,4.19,4.68,
AXON,2003-10-24,4.69,4.87,4.51,4.54,
AXON,2003-10-27,4.62,4.62,4.28,4.5,
AXON,2003-10-28,4.62,4.82,4.52,4.82,
AXON,2003-10-29,4.87,5.39,4.84,5.39,
AXON,2003-10-30,5.43,5.78,5.41,5.56,
AXON,2003-10-31,5.55,5.7,5.2,5.23,
AXON,2003-11-03,5.12,5.22,4.49,4.54,
AXON,2003-11-04,4.38,4.98,4.36,4.98,
AXON,2003-11-05,5.04,5.23,4.8,4.99,
AXON,2003-11-06,4.96,5.08,4.84,5.01,
AXON,2003-11-07,5.04,5.39,5.04,5.19,
AXON,2003-11-10,5.08,5.32,4.93,5.19,
AXON,2003-11-11,5.29,5.29,4.87,4.9,
AXON,2003-11-12,4.7,4.96,4.64,4.91,
AXON,2003-11-13,4.79,5.14,4.79,5.03,
AXON,2003-11-14,5.29,5.31,4.96,5.09,
AXON,2003-11-17,5.1,5.21,4.87,5.19,
AXON,2003-11-18,5.29,5.32,5.04,5.16,
AXON,2003-11-19,5.19,5.58,5.09,5.57,
AXON,2003-11-20,5.67,5.91,5.63,5.72,
AXON,2003-11-21,5.82,5.94,5.68,5.89,
AXON,2003-11-24,6.0,6.21,5.96,6.18,
AXON,2003-11-25,6.21,6.21,5.88,5.94,
AXON,2003-11-26,5.92,6.37,5.92,6.37,
AXON,2003-11-28,6.38,6.57,6.24,6.54,
AXON,2003-12-01,6.68,6.85,6.58,6.84,
AXON,2003-12-02,6.83,6.99,6.7,6.81,
AXON,2003-12-03,6.79,7.06,6.27,6.36,
AXON,2003-12-04,6.38,6.65,6.12,6.58,
AXON,2003-12-05,6.67,6.9,6.5,6.9,
AXON,2003-12-08,6.91,7.19,6.91,7.13,
AXON,2003-12-09,7.43,7.65,7.23,7.64,
AXON,2003-12-10,7.77,7.79,6.91,7.1,
AXON,2003-12-11,7.08,7.53,6.98,7.52,
AXON,2003-12-12,7.69,7.75,7.16,7.29,
AXON,2003-12-15,7.74,7.75,7.05,7.17,
AXON,2003-12-16,7.13,7.32,6.61,6.92,
AXON,2003-12-17,6.77,6.87,6.53,6.84,
AXON,2003-12-18,6.89,7.25,6.89,7.23,
AXON,2003-12-19,7.19,7.29,6.94,7.06,
AXON,2003-12-22,7.1,7.2,6.83,6.9,
AXON,2003-12-23,6.87,7.0,6.72,6.88,
AXON,2003-12-24,7.0,7.03,6.78,7.02,
AXON,2003-12-26,6.88,7.28,6.83,7.27,
AXON,2003-12-29,7.31,7.41,7.27,7.34,
AXON,2003-12-30,7.33,7.37,7.18,7.21,
AXON,2003-12-31,7.22,7.26,6.86,6.86,
AXON,2004-01-02,6.91,7.16,6.87,7.08,
AXON,2004-01-05,7.21,7.24,6.98,7.07,
AXON,2004-01-06,7.0,7.36,6.92,7.26,
AXON,2004-01-07,7.36,7.38,7.04,7.22,
AXON,2004-01-08,7.33,7.33,7.09,7.13,
AXON,2004-01-09,7.08,7.88,7.02,7.83,
AXON,2004-01-12,8.04,8.62,7.93,8.62,
AXON,2004-01-13,8.62,8.67,8.17,8.44,
AXON,2004-01-14,9.08,9.77,8.55,9.65,
AXON,2004-01-15,9.37,9.62,8.67,9.26,
AXON,2004-01-16,9.41,10.41,9.14,9.94,
AXON,2004-01-20,10.2,10.41,9.72,9.88,
AXON,2004-01-21,9.76,10.13,9.53,9.91,
AXON,2004-01-22,9.84,10.31,9.75,9.88,
AXON,2004-01-23,10.04,10.04,9.73,9.96,
AXON,2004-01-26,9.98,11.24,9.88,11.22,
AXON,2004-01-27,11.26,12.23,11.11,11.14,
AXON,2004-01-28,11.11,11.65,10.53,10.86,
AXON,2004-01-29,11.17,11.2,10.13,10.82,
AXON,2004-01-30,10.59,11.21,10.42,11.13,
AXON,2004-02-02,10.71,11.64,10.66,11.25,
AXON,2004-02-03,12.78,12.84,10.44,10.6,
AXON,2004-02-04,10.01,10.78,9.85,10.16,
AXON,2004-02-05,10.33,10.38,9.77,10.12,
AXON,2004-02-06,10.07,11.01,9.92,10.18,
AXON,2004-02-09,10.42,10.67,10.27,10.38,
AXON,2004-02-10,10.54,10.85,10.42,10.82,
AXON,2004-02-11,11.52,12.65,11.31,12.43,
AXON,2004-02-12,13.44,16.94,13.0,14.9,
AXON,2004-02-13,15.5,16.18,14.25,14.84,
AXON,2004-02-17,15.78,15.86,14.84,15.27,
AXON,2004-02-18,14.94,15.31,14.66,14.85,
AXON,2004-02-19,15.1,15.17,12.94,12.98,
AXON,2004-02-20,12.5,14.42,11.9,14.24,
AXON,2004-02-23,14.39,14.46,13.41,13.64,
AXON,2004-02-24,12.9,13.85,12.9,13.38,
AXON,2004-02-25,13.46,13.93,13.27,13.37,
AXON,2004-02-26,13.46,13.62,13.28,13.4,
AXON,2004-02-27,13.74,13.86,13.44,13.61,
AXON,2004-03-01,13.81,13.86,13.45,13.52,
AXON,2004-03-02,13.38,13.66,12.81,13.09,
AXON,2004-03-03,12.88,13.4,12.88,13.02,
AXON,2004-03-04,12.88,13.24,12.88,12.98,
AXON,2004-03-05,12.79,12.94,12.06,12.15,
AXON,2004-03-08,13.15,14.78,12.81,14.27,
AXON,2004-03-09,14.28,15.03,13.65,13.74,
AXON,2004-03-10,13.88,14.1,13.29,13.35,
AXON,2004-03-11,12.79,14.35,12.78,13.7,
AXON,2004-03-12,14.3,14.52,13.65,13.95,
AXON,2004-03-15,14.07,14.37,13.64,13.8,
AXON,2004-03-16,14.16,14.21,13.63,13.97,
AXON,2004-03-17,14.17,14.29,13.92,14.19,
AXON,2004-03-18,14.25,15.62,14.07,15.6,
AXON,2004-03-19,16.01,16.45,14.89,14.9,
AXON,2004-03-22,14.65,15.69,14.5,15.62,
AXON,2004-03-23,16.17,16.19,15.1,15.3,
AXON,2004-03-24,15.31,15.68,15.16,15.45,
AXON,2004-03-25,15.64,16.09,15.46,16.07,
AXON,2004-03-26,16.02,17.48,15.93,17.25,
AXON,2004-03-29,17.83,19.06,17.52,18.57,
AXON,2004-03-30,19.59,20.21,18.75,20.2,
AXON,2004-03-31,20.48,21.89,19.17,19.59,
AXON,2004-04-01,19.99,20.75,19.57,20.69,
AXON,2004-04-02,21.63,21.95,20.94,21.25,
AXON,2004-04-05,19.77,20.74,19.45,19.62,
AXON,2004-04-06,20.43,23.87,19.64,23.06,
AXON,2004-04-07,23.41,25.08,23.16,24.51,
AXON,2004-04-08,25.6,25.68,24.52,24.95,
AXON,2004-04-12,24.98,25.12,24.01,24.38,
AXON,2004-04-13,24.58,25.08,23.14,23.83,
AXON,2004-04-14,23.5,24.38,23.42,24.15,
AXON,2004-04-15,24.76,25.0,23.9,25.0,
AXON,2004-04-16,25.22,28.78,25.19,28.52,
AXON,2004-04-19,29.38,32.08,27.77,29.67,
AXON,2004-04-20,26.54,27.86,21.02,21.1,
AXON,2004-04-21,17.66,22.98,17.66,20.94,
AXON,2004-04-22,21.76,22.45,18.73,19.29,
AXON,2004-04-23,19.2,20.77,18.88,20.29,
AXON,2004-04-26,20.09,21.17,19.87,20.41,
AXON,2004-04-27,20.63,20.71,19.12,19.51,
AXON,2004-04-28,17.14,19.44,16.85,17.12,
AXON,2004-04-29,17.61,19.18,16.51,18.92,
AXON,2004-04-30,18.72,18.75,16.12,16.17,
AXON,2004-05-03,14.81,16.8,14.16,15.64,
AXON,2004-05-04,16.25,16.5,15.48,15.9,
AXON,2004-05-05,16.92,17.01,15.73,15.89,
AXON,2004-05-06,15.65,16.0,15.18,15.27,
AXON,2004-05-07,15.06,15.68,14.38,14.4,
AXON,2004-05-10,13.77,14.05,12.6,12.89,
AXON,2004-05-11,13.55,13.85,12.81,13.15,
AXON,2004-05-12,12.83,14.18,12.82,14.1,
AXON,2004-05-13,14.23,15.62,14.1,14.56,
AXON,2004-05-14,15.0,15.4,14.26,14.41,
AXON,2004-05-17,14.58,14.87,14.3,14.64,
AXON,2004-05-18,15.35,15.62,14.74,14.9,
AXON,2004-05-19,15.44,15.52,14.75,14.91,
AXON,2004-05-20,14.8,14.81,14.05,14.26,
AXON,2004-05-21,14.45,14.55,13.8,14.05,
AXON,2004-05-24,14.4,14.41,13.16,13.75,
AXON,2004-05-25,13.59,14.1,13.32,13.91,
AXON,2004-05-26,14.23,14.5,14.01,14.14,
AXON,2004-05-27,14.34,14.44,13.76,13.93,
AXON,2004-05-28,13.83,14.22,13.74,14.22,
AXON,2004-06-01,14.13,14.31,13.94,14.09,
AXON,2004-06-02,14.1,14.16,13.53,13.59,
AXON,2004-06-03,13.45,13.49,13.0,13.14,
AXON,2004-06-04,13.65,13.73,12.9,12.94,
AXON,2004-06-07,12.82,12.94,12.02,12.4,
AXON,2004-06-08,12.1,13.98,11.88,13.66,
AXON,2004-06-09,13.6,14.32,13.16,13.23,
AXON,2004-06-10,13.44,13.59,12.95,13.21,
AXON,2004-06-14,12.9,13.56,12.78,12.89,
AXON,2004-06-15,13.12,13.15,12.75,12.85,
AXON,2004-06-16,12.89,12.9,12.62,12.8,
AXON,2004-06-17,12.83,12.86,12.52,12.55,
AXON,2004-06-18,12.45,13.24,12.38,12.89,
AXON,2004-06-21,14.84,15.52,12.65,15.23,
AXON,2004-06-22,15.14,15.39,14.51,14.75,
AXON,2004-06-23,14.76,16.5,14.76,16.35,
AXON,2004-06-24,17.15,18.04,17.05,17.71,
AXON,2004-06-25,19.03,21.33,18.62,21.05,
AXON,2004-06-28,22.99,24.25,21.02,21.47,
AXON,2004-06-29,20.82,22.02,19.67,19.88,
AXON,2004-06-30,22.57,22.94,21.16,21.61,
AXON,2004-07-01,21.6,22.15,20.85,21.85,
AXON,2004-07-02,22.43,22.67,21.85,22.15,
AXON,2004-07-06,22.36,22.83,21.86,22.25,
AXON,2004-07-07,22.17,22.43,20.3,20.5,
AXON,2004-07-08,20.23,20.5,19.2,19.7,
AXON,2004-07-09,20.39,20.92,20.0,20.31,
AXON,2004-07-12,20.66,21.01,20.33,20.78,
AXON,2004-07-13,21.03,21.17,20.3,20.35,
AXON,2004-07-14,19.68,20.39,19.35,19.88,
AXON,2004-07-15,20.5,20.7,19.85,20.12,
AXON,2004-07-16,20.3,20.52,20.07,20.12,
AXON,2004-07-19,18.82,19.31,18.14,18.16,
AXON,2004-07-20,17.12,18.35,15.12,15.52,
AXON,2004-07-21,15.89,16.58,15.44,15.69,
AXON,2004-07-22,15.78,16.0,14.09,14.64,
AXON,2004-07-23,15.07,15.22,14.48,14.76,
AXON,2004-07-26,14.85,15.05,12.53,12.61,
AXON,2004-07-27,13.39,15.01,13.01,14.99,
AXON,2004-07-28,16.07,16.6,15.32,16.04,
AXON,2004-07-29,16.68,17.0,15.12,15.72,
AXON,2004-07-30,15.38,16.12,15.38,15.65,
AXON,2004-08-02,14.35,15.38,14.28,15.14,
AXON,2004-08-03,15.06,15.44,14.45,14.53,
AXON,2004-08-04,14.35,14.52,13.86,14.37,
AXON,2004-08-05,14.55,14.69,14.0,14.2,
AXON,2004-08-06,13.57,13.8,12.92,13.43,
AXON,2004-08-09,13.34,13.68,12.82,13.31,
AXON,2004-08-10,14.67,14.69,13.94,14.06,
AXON,2004-08-11,13.87,14.05,13.65,13.82,
AXON,2004-08-12,13.68,13.77,13.26,13.27,
AXON,2004-08-13,13.49,13.61,12.8,13.1,
AXON,2004-08-16,13.13,13.36,12.88,12.95,
AXON,2004-08-17,13.21,13.4,13.05,13.17,
AXON,2004-08-18,13.78,13.88,13.38,13.73,
AXON,2004-08-19,13.74,14.1,13.52,13.88,
AXON,2004-08-20,13.65,13.88,13.57,13.72,
AXON,2004-08-23,13.78,13.87,13.5,13.63,
AXON,2004-08-24,13.72,13.73,13.1,13.31,
AXON,2004-08-25,13.42,13.73,13.16,13.55,
AXON,2004-08-26,13.98,14.75,13.98,14.13,
AXON,2004-08-27,14.4,14.4,13.82,13.92,
AXON,2004-08-30,14.15,14.18,13.74,13.89,
AXON,2004-08-31,13.9,13.94,13.55,13.8,
AXON,2004-09-01,13.6,14.09,13.6,13.88,
AXON,2004-09-02,13.88,16.1,13.79,15.82,
AXON,2004-09-03,16.28,16.99,15.78,15.88,
AXON,2004-09-07,16.59,16.66,16.06,16.28,
AXON,2004-09-08,16.22,17.94,16.12,17.77,
AXON,2004-09-09,18.25,18.66,15.66,16.08,
AXON,2004-09-10,16.4,16.8,16.08,16.43,
AXON,2004-09-13,16.48,16.9,16.41,16.69,
AXON,2004-09-14,17.55,17.79,17.25,17.67,
AXON,2004-09-15,17.99,23.0,17.8,21.55,
AXON,2004-09-16,21.5,21.5,19.88,19.94,
AXON,2004-09-17,20.35,20.9,19.96,20.32,
AXON,2004-09-20,20.45,20.73,18.73,18.94,
AXON,2004-09-21,19.6,20.0,19.11,19.52,
AXON,2004-09-22,19.67,19.83,19.13,19.34,
AXON,2004-09-23,19.15,19.7,18.9,19.39,
AXON,2004-09-24,19.62,20.17,19.42,19.6,
AXON,2004-09-27,19.53,19.58,18.86,19.18,
AXON,2004-09-28,19.07,19.19,18.0,18.25,
AXON,2004-09-29,17.92,18.98,17.38,18.24,
AXON,2004-09-30,18.12,19.09,18.01,18.77,
AXON,2004-10-01,19.05,19.44,18.91,19.11,
AXON,2004-10-04,19.4,19.61,19.23,19.5,
AXON,2004-10-05,19.33,19.69,19.02,19.47,
AXON,2004-10-06,19.32,19.46,18.75,19.15,
AXON,2004-10-07,19.0,19.35,18.78,19.05,
AXON,2004-10-08,18.96,19.12,18.52,18.72,
AXON,2004-10-11,18.5,18.88,18.33,18.51,
AXON,2004-10-12,18.24,19.48,17.95,19.34,
AXON,2004-10-13,19.61,19.88,19.0,19.08,
AXON,2004-10-14,18.85,19.12,18.67,18.73,
AXON,2004-10-15,19.0,19.03,18.43,18.74,
AXON,2004-10-18,19.49,19.91,18.9,19.03,
AXON,2004-10-19,20.25,20.92,19.69,20.12,
AXON,2004-10-20,20.02,20.62,19.93,20.17,
AXON,2004-10-21,20.3,20.35,19.98,20.11,
AXON,2004-10-22,20.07,21.17,20.01,20.18,
AXON,2004-10-25,20.57,21.65,20.34,21.64,
AXON,2004-10-26,22.09,22.09,20.76,20.99,
AXON,2004-10-27,21.72,21.75,21.07,21.12,
AXON,2004-10-28,21.26,21.33,20.0,20.17,
AXON,2004-10-29,20.47,20.86,20.06,20.45,
AXON,2004-11-01,20.93,21.19,20.56,20.76,
AXON,2004-11-02,20.77,21.43,20.68,20.91,
AXON,2004-11-03,21.43,21.43,20.38,20.67,
AXON,2004-11-04,21.19,23.48,20.75,23.41,
AXON,2004-11-05,23.45,24.05,22.77,23.25,
AXON,2004-11-08,24.94,28.35,24.5,27.06,
AXON,2004-11-09,27.97,28.0,24.71,25.5,
AXON,2004-11-10,25.88,27.78,25.38,27.42,
AXON,2004-11-11,29.07,29.64,28.16,28.98,
AXON,2004-11-12,28.35,29.9,27.81,28.75,
AXON,2004-11-15,30.19,30.98,29.75,30.42,
AXON,2004-11-16,29.97,30.43,29.28,29.83,
AXON,2004-11-17,30.17,30.36,27.91,28.5,
AXON,2004-11-18,28.77,29.55,28.63,29.05,
AXON,2004-11-19,27.66,28.38,25.6,26.08,
AXON,2004-11-22,23.5,25.33,23.45,24.9,
AXON,2004-11-23,25.32,26.38,25.25,25.7,
AXON,2004-11-24,26.0,26.27,25.01,25.25,
AXON,2004-11-26,23.43,24.12,23.23,23.5,
AXON,2004-11-29,24.25,25.83,23.64,25.46,
AXON,2004-11-30,26.45,27.9,26.16,27.44,
AXON,2004-12-01,29.03,29.13,27.75,28.22,
AXON,2004-12-02,28.22,28.5,26.7,27.76,
AXON,2004-12-03,28.09,28.58,27.24,28.23,
AXON,2004-12-06,27.7,28.23,27.52,27.66,
AXON,2004-12-07,26.9,27.2,25.11,25.62,
AXON,2004-12-08,25.96,26.24,25.42,25.99,
AXON,2004-12-09,25.58,26.46,25.15,26.21,
AXON,2004-12-10,26.38,27.88,26.32,27.03,
AXON,2004-12-13,28.19,28.23,27.1,27.22,
AXON,2004-12-14,27.32,27.55,26.74,27.23,
AXON,2004-12-15,27.55,27.7,27.01,27.28,
AXON,2004-12-16,27.62,27.89,27.3,27.31,
AXON,2004-12-17,27.45,27.5,26.8,27.22,
AXON,2004-12-20,27.67,28.98,27.67,28.34,
AXON,2004-12-21,28.57,28.7,27.28,28.03,
AXON,2004-12-22,27.9,28.95,27.8,28.64,
AXON,2004-12-23,28.77,28.85,28.28,28.34,
AXON,2004-12-27,28.36,28.58,27.55,27.77,
AXON,2004-12-28,27.77,28.6,27.73,28.43,
AXON,2004-12-29,28.62,31.13,28.53,31.09,
AXON,2004-12-30,32.54,33.45,32.08,32.59,
AXON,2004-12-31,32.7,32.87,31.56,31.65,
AXON,2005-01-03,32.35,32.49,28.88,29.98,
AXON,2005-01-04,30.27,30.27,28.5,28.69,
AXON,2005-01-05,28.1,29.35,27.5,28.86,
AXON,2005-01-06,28.42,28.7,27.52,27.62,
AXON,2005-01-07,23.78,25.0,21.29,22.72,
AXON,2005-01-10,21.32,22.23,19.81,20.05,
AXON,2005-01-11,14.33,17.5,13.96,14.1,
AXON,2005-01-12,14.35,17.32,14.25,17.01,
AXON,2005-01-13,20.81,21.94,19.46,20.8,
AXON,2005-01-14,21.71,21.72,19.17,19.64,
AXON,2005-01-18,19.75,20.37,19.15,19.76,
AXON,2005-01-19,19.33,19.4,17.26,17.47,
AXON,2005-01-20,16.54,18.35,15.9,17.57,
AXON,2005-01-21,18.28,18.56,17.0,17.28,
AXON,2005-01-24,17.27,17.74,15.57,15.95,
AXON,2005-01-25,16.67,16.72,15.91,16.07,
AXON,2005-01-26,16.44,16.44,16.0,16.28,
AXON,2005-01-27,16.49,18.03,16.18,17.56,
AXON,2005-01-28,18.11,18.34,16.94,17.18,
AXON,2005-01-31,18.19,18.19,17.49,17.98,
AXON,2005-02-01,18.17,18.31,17.25,17.57,
AXON,2005-02-02,17.46,17.72,17.06,17.15,
AXON,2005-02-03,17.2,17.2,16.3,16.41,
AXON,2005-02-04,16.7,17.19,16.53,16.69,
AXON,2005-02-07,16.7,17.39,16.65,17.16,
AXON,2005-02-08,14.27,15.93,14.1,15.22,
AXON,2005-02-09,15.1,15.37,14.9,14.97,
AXON,2005-02-10,15.15,15.2,14.24,14.42,
AXON,2005-02-11,13.82,14.01,13.05,13.48,
AXON,2005-02-14,14.25,15.15,14.02,14.51,
AXON,2005-02-15,15.04,15.13,14.62,14.68,
AXON,2005-02-16,14.6,14.68,14.22,14.48,
AXON,2005-02-17,14.82,14.87,14.1,14.38,
AXON,2005-02-18,14.38,14.38,14.02,14.11,
AXON,2005-02-22,13.97,14.87,13.75,13.95,
AXON,2005-02-23,14.19,14.45,13.72,13.79,
AXON,2005-02-24,13.74,14.18,13.56,13.89,
AXON,2005-02-25,13.95,13.96,13.31,13.38,
AXON,2005-02-28,13.31,13.7,12.53,13.01,
AXON,2005-03-01,13.02,13.35,12.97,13.18,
AXON,2005-03-02,13.07,13.99,13.05,13.5,
AXON,2005-03-03,15.08,15.44,14.12,14.22,
AXON,2005-03-04,14.7,14.7,14.33,14.52,
AXON,2005-03-07,14.83,14.89,14.06,14.3,
AXON,2005-03-08,14.28,14.31,13.7,13.82,
AXON,2005-03-09,14.04,14.45,13.75,14.15,
AXON,2005-03-10,14.32,14.32,13.47,13.8,
AXON,2005-03-11,13.64,13.7,13.48,13.65,
AXON,2005-03-14,13.54,13.65,13.2,13.41,
AXON,2005-03-15,13.31,13.87,13.3,13.51,
AXON,2005-03-16,13.4,13.72,13.3,13.48,
AXON,2005-03-17,13.4,13.51,12.85,12.92,
AXON,2005-03-18,12.91,13.1,12.41,12.52,
AXON,2005-03-21,12.4,12.83,12.2,12.37,
AXON,2005-03-22,12.92,12.98,12.36,12.43,
AXON,2005-03-23,12.43,12.6,12.02,12.08,
AXON,2005-03-24,12.09,14.2,11.21,13.91,
AXON,2005-03-28,13.4,13.47,12.54,12.54,
AXON,2005-03-29,12.49,12.79,11.92,11.99,
AXON,2005-03-30,12.1,12.95,11.7,12.44,
AXON,2005-03-31,12.4,12.55,11.89,12.0,
AXON,2005-04-01,10.71,10.84,10.21,10.42,
AXON,2005-04-04,10.26,10.4,9.75,10.09,
AXON,2005-04-05,10.1,10.19,9.63,9.68,
AXON,2005-04-06,9.62,9.95,9.48,9.57,
AXON,2005-04-07,9.61,9.67,9.36,9.4,
AXON,2005-04-08,9.4,9.68,9.13,9.16,
AXON,2005-04-11,9.16,9.64,9.16,9.27,
AXON,2005-04-12,9.31,9.39,8.79,8.85,
AXON,2005-04-13,8.97,9.08,8.41,8.57,
AXON,2005-04-14,8.44,8.6,8.19,8.23,
AXON,2005-04-15,8.07,8.59,8.0,8.09,
AXON,2005-04-18,8.13,8.34,7.91,7.97,
AXON,2005-04-19,7.47,8.3,7.33,7.9,
AXON,2005-04-20,7.95,8.0,7.6,7.64,
AXON,2005-04-21,8.27,9.67,7.89,9.53,
AXON,2005-04-22,9.08,9.24,8.53,8.81,
AXON,2005-04-25,8.93,9.54,8.6,9.21,
AXON,2005-04-26,9.28,9.84,9.01,9.08,
AXON,2005-04-27,9.18,9.49,9.07,9.16,
AXON,2005-04-28,9.11,9.32,8.74,8.81,
AXON,2005-04-29,8.97,9.03,8.48,8.64,
AXON,2005-05-02,8.57,8.65,8.25,8.38,
AXON,2005-05-03,8.35,8.68,8.3,8.56,
AXON,2005-05-04,8.63,8.95,8.6,8.83,
AXON,2005-05-05,8.85,9.77,8.75,9.22,
AXON,2005-05-06,9.34,9.68,9.3,9.44,
AXON,2005-05-09,9.35,11.03,9.35,10.94,
AXON,2005-05-10,10.61,11.15,10.25,10.49,
AXON,2005-05-11,10.82,11.11,10.3,10.66,
AXON,2005-05-12,10.81,11.5,10.75,11.2,
AXON,2005-05-13,12.27,12.55,11.27,11.38,
AXON,2005-05-16,11.9,11.96,11.44,11.68,
AXON,2005-05-17,11.51,11.6,10.21,10.33,
AXON,2005-05-18,10.18,10.69,10.02,10.54,
AXON,2005-05-19,10.54,11.75,10.54,11.2,
AXON,2005-05-20,11.4,11.67,11.04,11.12,
AXON,2005-05-23,11.12,11.39,10.8,10.84,
AXON,2005-05-24,11.17,11.8,10.85,11.5,
AXON,2005-05-25,11.54,11.54,11.15,11.21,
AXON,2005-05-26,11.45,11.45,11.17,11.22,
AXON,2005-05-27,11.17,11.26,10.91,10.97,
AXON,2005-05-31,11.1,11.72,11.0,11.34,
AXON,2005-06-01,11.43,11.58,11.17,11.27,
AXON,2005-06-02,11.25,11.65,11.2,11.4,
AXON,2005-06-03,11.34,11.44,11.05,11.1,
AXON,2005-06-06,11.1,11.66,11.02,11.18,
AXON,2005-06-07,11.3,11.37,10.9,11.06,
AXON,2005-06-08,11.03,11.22,10.0,10.67,
AXON,2005-06-09,10.75,10.98,10.66,10.97,
AXON,2005-06-10,10.93,11.0,10.7,10.84,
AXON,2005-06-13,11.52,11.8,11.15,11.22,
AXON,2005-06-14,11.15,11.35,11.04,11.11,
AXON,2005-06-15,11.14,11.18,10.77,10.95,
AXON,2005-06-16,10.87,10.97,10.67,10.83,
AXON,2005-06-17,10.92,10.92,10.6,10.65,
AXON,2005-06-20,10.56,10.83,10.5,10.52,
AXON,2005-06-21,10.49,11.24,10.38,10.77,
AXON,2005-06-22,10.88,10.9,10.63,10.63,
AXON,2005-06-23,10.65,10.85,10.33,10.41,
AXON,2005-06-24,10.45,10.51,10.1,10.35,
AXON,2005-06-27,10.24,10.34,9.98,10.17,
AXON,2005-06-28,10.15,10.52,10.15,10.25,
AXON,2005-06-29,10.41,10.42,10.17,10.25,
AXON,2005-06-30,10.22,10.28,10.01,10.04,
AXON,2005-07-01,10.23,10.25,10.04,10.1,
AXON,2005-07-05,9.9,10.0,9.5,9.75,
AXON,2005-07-06,9.7,10.03,9.65,9.94,
AXON,2005-07-07,10.09,10.12,9.89,9.9,
AXON,2005-07-08,9.92,10.3,9.85,10.2,
AXON,2005-07-11,10.15,10.22,10.0,10.06,
AXON,2005-07-12,10.03,10.59,10.01,10.17,
AXON,2005-07-13,10.25,10.34,10.05,10.17,
AXON,2005-07-14,10.55,10.62,10.19,10.24,
AXON,2005-07-15,10.25,10.28,10.0,10.0,
AXON,2005-07-18,10.2,10.2,10.01,10.1,
AXON,2005-07-19,10.12,10.18,9.93,10.03,
AXON,2005-07-20,9.52,9.89,9.51,9.67,
AXON,2005-07-21,9.64,9.91,9.55,9.7,
AXON,2005-07-22,9.7,9.8,9.56,9.59,
AXON,2005-07-25,9.7,9.72,9.55,9.66,
AXON,2005-07-26,9.66,9.72,9.56,9.58,
AXON,2005-07-27,10.06,10.2,9.58,9.96,
AXON,2005-07-28,10.1,10.1,9.79,9.98,
AXON,2005-07-29,10.04,10.04,9.71,9.72,
AXON,2005-08-01,9.86,9.95,9.64,9.65,
AXON,2005-08-02,9.65,9.72,9.5,9.53,
AXON,2005-08-03,9.52,9.6,9.47,9.5,
AXON,2005-08-04,9.54,9.54,9.08,9.24,
AXON,2005-08-05,9.15,9.27,9.01,9.05,
AXON,2005-08-08,9.05,9.11,8.69,8.8,
AXON,2005-08-09,8.88,9.0,8.79,8.82,
AXON,2005-08-10,8.85,8.9,8.52,8.6,
AXON,2005-08-11,8.52,8.6,8.31,8.44,
AXON,2005-08-12,9.01,9.55,9.0,9.35,
AXON,2005-08-15,9.68,10.08,9.58,9.71,
AXON,2005-08-16,9.8,9.8,9.35,9.37,
AXON,2005-08-17,9.43,9.48,9.15,9.21,
AXON,2005-08-18,9.32,9.48,9.15,9.23,
AXON,2005-08-19,9.3,9.44,9.01,9.04,
AXON,2005-08-22,9.13,9.19,9.0,9.01,
AXON,2005-08-23,9.22,9.6,9.06,9.09,
AXON,2005-08-24,9.14,9.14,8.98,8.98,
AXON,2005-08-25,9.06,9.06,8.76,8.85,
AXON,2005-08-26,8.82,8.88,8.75,8.76,
AXON,2005-08-29,8.67,8.82,8.65,8.7,
AXON,2005-08-30,8.75,8.85,8.63,8.66,
AXON,2005-08-31,8.66,8.77,8.52,8.65,
AXON,2005-09-01,8.69,8.7,8.52,8.54,
AXON,2005-09-02,8.5,8.54,8.34,8.38,
AXON,2005-09-06,8.36,8.47,8.34,8.37,
AXON,2005-09-07,8.35,8.37,8.3,8.35,
AXON,2005-09-08,8.37,8.41,8.26,8.29,
AXON,2005-09-09,8.37,8.39,8.1,8.12,
AXON,2005-09-12,8.19,8.19,7.84,7.87,
AXON,2005-09-13,8.3,8.42,8.09,8.1,
AXON,2005-09-14,8.05,8.18,7.9,7.9,
AXON,2005-09-15,7.9,7.99,7.76,7.77,
AXON,2005-09-16,7.77,7.86,7.6,7.67,
AXON,2005-09-19,7.73,7.74,7.51,7.52,
AXON,2005-09-20,7.55,7.65,7.39,7.42,
AXON,2005-09-21,7.5,7.52,7.11,7.14,
AXON,2005-09-22,7.56,7.56,7.14,7.22,
AXON,2005-09-23,7.21,7.27,7.11,7.24,
AXON,2005-09-26,7.43,7.53,7.21,7.31,
AXON,2005-09-27,6.67,6.82,6.32,6.35,
AXON,2005-09-28,6.31,6.37,5.83,5.88,
AXON,2005-09-29,5.95,6.38,5.9,6.13,
AXON,2005-09-30,6.25,6.26,6.0,6.17,
AXON,2005-10-03,6.17,6.22,5.98,5.99,
AXON,2005-10-04,6.03,6.1,5.86,5.89,
AXON,2005-10-05,5.99,6.0,5.69,5.72,
AXON,2005-10-06,5.7,5.8,5.53,5.61,
AXON,2005-10-07,5.55,5.69,5.38,5.42,
AXON,2005-10-10,5.39,5.98,5.37,5.9,
AXON,2005-10-11,5.9,5.97,5.51,5.64,
AXON,2005-10-12,5.66,5.89,5.62,5.66,
AXON,2005-10-13,5.68,5.68,5.31,5.51,
AXON,2005-10-14,5.55,5.61,5.52,5.61,
AXON,2005-10-17,5.69,6.05,5.62,5.94,
AXON,2005-10-18,6.0,6.0,5.66,5.7,
AXON,2005-10-19,5.78,5.78,5.5,5.58,
AXON,2005-10-20,5.85,5.9,5.58,5.61,
AXON,2005-10-21,5.62,5.65,5.44,5.46,
AXON,2005-10-24,6.23,6.8,6.13,6.52,
AXON,2005-10-25,6.68,7.08,6.48,6.97,
AXON,2005-10-26,7.02,7.16,6.34,6.53,
AXON,2005-10-27,6.42,6.44,6.08,6.11,
AXON,2005-10-28,6.31,6.37,6.04,6.14,
AXON,2005-10-31,6.18,6.24,6.06,6.15,
AXON,2005-11-01,6.13,6.35,6.13,6.3,
AXON,2005-11-02,6.31,6.55,6.21,6.53,
AXON,2005-11-03,6.76,7.31,6.73,7.3,
AXON,2005-11-04,7.4,7.99,7.15,7.98,
AXON,2005-11-07,8.35,8.61,7.68,7.92,
AXON,2005-11-08,8.1,8.19,7.62,7.73,
AXON,2005-11-09,7.64,7.8,7.21,7.65,
AXON,2005-11-10,7.79,7.91,7.52,7.67,
AXON,2005-11-11,7.7,7.74,7.41,7.53,
AXON,2005-11-14,7.5,7.57,7.21,7.26,
AXON,2005-11-15,7.01,7.14,6.88,7.11,
AXON,2005-11-16,7.05,7.38,7.03,7.35,
AXON,2005-11-17,7.38,7.54,7.28,7.35,
AXON,2005-11-18,7.45,7.45,7.13,7.16,
AXON,2005-11-21,7.13,7.21,7.01,7.14,
AXON,2005-11-22,7.1,7.36,7.07,7.12,
AXON,2005-11-23,7.12,7.5,7.07,7.4,
AXON,2005-11-25,6.75,6.9,6.35,6.5,
AXON,2005-11-28,6.25,6.38,6.02,6.28,
AXON,2005-11-29,6.24,6.38,6.07,6.19,
AXON,2005-11-30,6.13,6.23,6.08,6.1,
AXON,2005-12-01,6.15,6.29,5.97,6.14,
AXON,2005-12-02,6.06,6.18,6.01,6.02,
AXON,2005-12-05,6.12,6.22,5.97,6.03,
AXON,2005-12-06,6.03,6.14,5.94,6.03,
AXON,2005-12-07,5.95,6.08,5.95,6.02,
AXON,2005-12-08,6.0,6.31,6.0,6.13,
AXON,2005-12-09,6.14,6.28,6.11,6.14,
AXON,2005-12-12,6.14,6.2,6.09,6.12,
AXON,2005-12-13,7.15,7.43,6.93,7.04,
AXON,2005-12-14,7.12,7.12,6.64,6.81,
AXON,2005-12-15,6.76,6.85,6.61,6.73,
AXON,2005-12-16,6.7,6.84,6.42,6.54,
AXON,2005-12-19,6.52,6.63,6.25,6.28,
AXON,2005-12-20,6.27,6.43,6.12,6.15,
AXON,2005-12-21,6.53,7.0,6.52,6.83,
AXON,2005-12-22,7.29,7.31,7.04,7.2,
AXON,2005-12-23,7.7,7.75,7.52,7.65,
AXON,2005-12-27,7.81,7.98,7.26,7.31,
AXON,2005-12-28,7.43,7.48,7.01,7.15,
AXON,2005-12-29,7.09,7.25,6.93,7.0,
AXON,2005-12-30,6.94,7.0,6.75,6.96,
AXON,2006-01-03,7.12,7.18,6.95,7.06,
AXON,2006-01-04,7.1,7.32,7.01,7.3,
AXON,2006-01-05,7.26,7.42,7.2,7.24,
AXON,2006-01-06,7.59,7.64,7.5,7.57,
AXON,2006-01-09,7.75,8.38,7.6,8.2,
AXON,2006-01-10,8.25,8.95,8.0,8.79,
AXON,2006-01-11,8.95,9.38,8.8,9.05,
AXON,2006-01-12,9.27,9.3,8.58,8.65,
AXON,2006-01-13,8.58,8.65,8.26,8.56,
AXON,2006-01-17,8.73,8.79,8.28,8.3,
AXON,2006-01-18,8.05,8.36,7.75,8.32,
AXON,2006-01-19,8.33,8.5,8.24,8.45,
AXON,2006-01-20,8.46,8.51,8.12,8.18,
AXON,2006-01-23,8.29,8.3,7.87,8.05,
AXON,2006-01-24,8.11,9.0,8.11,8.78,
AXON,2006-01-25,9.08,9.18,8.83,8.97,
AXON,2006-01-26,9.02,9.79,8.72,9.77,
AXON,2006-01-27,9.97,9.97,9.53,9.66,
AXON,2006-01-30,9.55,9.74,9.25,9.37,
AXON,2006-01-31,9.44,9.58,9.06,9.44,
AXON,2006-02-01,9.6,9.8,9.45,9.51,
AXON,2006-02-02,9.68,9.74,9.12,9.22,
AXON,2006-02-03,9.11,9.4,9.09,9.35,
AXON,2006-02-06,9.47,9.48,9.06,9.15,
AXON,2006-02-07,9.03,9.44,8.96,9.01,
AXON,2006-02-08,9.04,9.28,9.0,9.17,
AXON,2006-02-09,9.15,9.65,9.15,9.49,
AXON,2006-02-10,9.85,10.0,9.57,9.75,
AXON,2006-02-13,9.97,10.65,9.81,10.56,
AXON,2006-02-14,11.05,11.31,10.83,10.91,
AXON,2006-02-15,10.69,10.82,10.4,10.43,
AXON,2006-02-16,10.62,10.7,10.1,10.24,
AXON,2006-02-17,10.32,10.35,10.09,10.18,
AXON,2006-02-21,10.35,10.69,10.3,10.4,
AXON,2006-02-22,9.95,10.31,9.46,10.2,
AXON,2006-02-23,10.15,10.42,9.9,10.11,
AXON,2006-02-24,10.06,10.25,9.91,10.0,
AXON,2006-02-27,10.0,10.09,9.87,9.93,
AXON,2006-02-28,9.81,9.93,9.51,9.56,
AXON,2006-03-01,9.5,10.08,9.3,10.03,
AXON,2006-03-02,10.0,10.25,9.82,9.94,
AXON,2006-03-03,9.96,9.99,9.8,9.81,
AXON,2006-03-06,9.8,10.05,9.8,9.91,
AXON,2006-03-07,9.95,9.95,9.55,9.71,
AXON,2006-03-08,9.55,9.7,9.24,9.38,
AXON,2006-03-09,9.38,9.75,9.36,9.45,
AXON,2006-03-10,9.5,9.5,9.34,9.36,
AXON,2006-03-13,9.34,9.7,9.32,9.56,
AXON,2006-03-14,9.62,9.9,9.5,9.74,
AXON,2006-03-15,9.72,10.42,9.67,10.36,
AXON,2006-03-16,10.44,10.49,10.1,10.11,
AXON,2006-03-17,10.06,10.22,10.0,10.0,
AXON,2006-03-20,10.05,10.34,10.0,10.23,
AXON,2006-03-21,10.57,10.61,10.3,10.39,
AXON,2006-03-22,10.32,10.84,10.26,10.7,
AXON,2006-03-23,11.0,11.24,10.71,10.88,
AXON,2006-03-24,10.79,11.13,10.7,10.85,
AXON,2006-03-27,10.86,10.92,10.35,10.76,
AXON,2006-03-28,10.51,10.75,10.41,10.55,
AXON,2006-03-29,10.52,10.8,10.52,10.72,
AXON,2006-03-30,10.66,10.81,10.49,10.61,
AXON,2006-03-31,10.59,10.64,10.46,10.59,
AXON,2006-04-03,10.6,10.65,10.35,10.42,
AXON,2006-04-04,10.38,10.8,10.29,10.72,
AXON,2006-04-05,10.7,11.09,10.7,11.04,
AXON,2006-04-06,11.1,11.38,10.68,11.02,
AXON,2006-04-07,11.07,11.14,10.57,10.68,
AXON,2006-04-10,10.8,10.87,10.08,10.25,
AXON,2006-04-11,10.24,10.32,9.75,9.78,
AXON,2006-04-12,10.02,10.18,9.91,10.1,
AXON,2006-04-13,10.1,10.4,10.07,10.33,
AXON,2006-04-17,10.27,10.36,9.93,10.15,
AXON,2006-04-18,10.11,10.38,9.99,10.29,
AXON,2006-04-19,10.18,10.73,10.18,10.67,
AXON,2006-04-20,10.64,10.88,10.45,10.76,
AXON,2006-04-21,10.79,10.95,10.3,10.34,
AXON,2006-04-24,10.3,10.34,10.15,10.2,
AXON,2006-04-25,10.25,10.62,10.21,10.4,
AXON,2006-04-26,10.81,11.1,10.51,10.98,
AXON,2006-04-27,10.89,11.0,10.51,10.52,
AXON,2006-04-28,10.58,11.08,10.3,10.7,
AXON,2006-05-01,10.79,10.79,10.32,10.39,
AXON,2006-05-02,10.7,10.7,10.39,10.53,
AXON,2006-05-03,10.47,10.55,10.35,10.52,
AXON,2006-05-04,10.76,10.76,10.36,10.37,
AXON,2006-05-05,10.5,10.64,10.41,10.61,
AXON,2006-05-08,10.54,10.83,10.53,10.62,
AXON,2006-05-09,10.56,10.64,10.47,10.51,
AXON,2006-05-10,10.61,10.7,10.47,10.5,
AXON,2006-05-11,10.5,10.6,10.0,10.14,
AXON,2006-05-12,9.77,9.79,9.13,9.44,
AXON,2006-05-15,9.44,10.75,9.27,9.57,
AXON,2006-05-16,9.65,9.83,9.37,9.44,
AXON,2006-05-17,9.75,9.79,9.38,9.54,
AXON,2006-05-18,9.68,9.68,9.1,9.15,
AXON,2006-05-19,9.2,9.51,8.71,9.25,
AXON,2006-05-22,9.43,9.58,9.1,9.17,
AXON,2006-05-23,9.3,9.49,9.25,9.4,
AXON,2006-05-24,9.51,9.64,9.31,9.58,
AXON,2006-05-25,9.53,9.69,9.32,9.58,
AXON,2006-05-26,9.6,9.8,9.51,9.61,
AXON,2006-05-30,9.51,9.66,9.28,9.3,
AXON,2006-05-31,9.33,9.42,9.2,9.32,
AXON,2006-06-01,9.35,9.75,9.26,9.75,
AXON,2006-06-02,9.82,9.88,9.6,9.66,
AXON,2006-06-05,9.6,9.91,9.37,9.4,
AXON,2006-06-06,9.48,9.6,9.3,9.35,
AXON,2006-06-07,9.35,9.54,9.25,9.27,
AXON,2006-06-08,9.21,9.3,8.7,9.18,
AXON,2006-06-09,9.31,9.38,9.01,9.06,
AXON,2006-06-12,9.0,9.14,8.5,8.57,
AXON,2006-06-13,8.5,8.56,7.28,7.47,
AXON,2006-06-14,7.55,8.3,7.51,8.02,
AXON,2006-06-15,8.08,8.35,7.94,8.26,
AXON,2006-06-16,8.26,8.31,7.92,8.22,
AXON,2006-06-19,8.23,8.25,8.0,8.02,
AXON,2006-06-20,8.0,8.2,8.0,8.14,
AXON,2006-06-21,8.15,8.32,8.06,8.23,
AXON,2006-06-22,8.19,8.19,8.0,8.05,
AXON,2006-06-23,8.01,8.12,8.0,8.08,
AXON,2006-06-26,8.16,8.16,8.0,8.08,
AXON,2006-06-27,8.1,8.2,7.83,7.85,
AXON,2006-06-28,7.85,8.02,7.65,7.77,
AXON,2006-06-29,7.87,7.98,7.72,7.92,
AXON,2006-06-30,7.91,8.0,7.75,7.91,
AXON,2006-07-03,7.91,8.33,7.91,8.33,
AXON,2006-07-05,8.3,8.34,8.03,8.11,
AXON,2006-07-06,8.28,8.48,8.23,8.28,
AXON,2006-07-07,8.28,8.46,8.2,8.23,
AXON,2006-07-10,8.33,8.33,8.14,8.25,
AXON,2006-07-11,8.2,8.83,7.91,8.57,
AXON,2006-07-12,8.57,8.73,8.15,8.22,
AXON,2006-07-13,8.25,8.29,7.85,7.9,
AXON,2006-07-14,7.94,7.98,7.43,7.61,
AXON,2006-07-17,7.63,7.94,7.59,7.6,
AXON,2006-07-18,7.67,7.74,7.45,7.55,
AXON,2006-07-19,7.52,7.71,7.47,7.63,
AXON,2006-07-20,7.63,7.77,7.32,7.39,
AXON,2006-07-21,7.38,7.52,7.35,7.4,
AXON,2006-07-24,7.7,8.04,7.62,8.01,
AXON,2006-07-25,8.15,8.6,8.08,8.5,
AXON,2006-07-26,8.12,8.12,7.22,7.3,
AXON,2006-07-27,7.65,7.66,7.22,7.24,
AXON,2006-07-28,7.22,7.3,6.98,7.14,
AXON,2006-07-31,7.1,7.23,7.1,7.22,
AXON,2006-08-01,7.2,7.21,6.95,7.0,
AXON,2006-08-02,7.01,7.37,6.93,7.35,
AXON,2006-08-03,7.23,7.31,7.03,7.23,
AXON,2006-08-04,7.3,7.33,7.05,7.14,
AXON,2006-08-07,7.03,7.19,7.0,7.06,
AXON,2006-08-08,7.04,7.18,7.01,7.07,
AXON,2006-08-09,7.1,7.15,6.86,6.89,
AXON,2006-08-10,7.07,7.1,6.93,6.93,
AXON,2006-08-11,6.94,7.03,6.87,6.9,
AXON,2006-08-14,7.0,7.07,6.91,6.97,
AXON,2006-08-15,7.09,7.14,7.01,7.14,
AXON,2006-08-16,7.21,7.7,7.21,7.68,
AXON,2006-08-17,7.68,7.73,7.45,7.68,
AXON,2006-08-18,7.72,7.93,7.68,7.91,
AXON,2006-08-21,8.0,8.08,7.76,7.88,
AXON,2006-08-22,7.88,7.9,7.74,7.84,
AXON,2006-08-23,7.86,7.87,7.5,7.53,
AXON,2006-08-24,7.58,7.7,7.47,7.53,
AXON,2006-08-25,7.51,7.85,7.47,7.71,
AXON,2006-08-28,7.65,7.81,7.65,7.74,
AXON,2006-08-29,7.73,7.88,7.73,7.86,
AXON,2006-08-30,7.75,7.88,7.75,7.8,
AXON,2006-08-31,7.78,7.89,7.74,7.77,
AXON,2006-09-01,7.85,7.91,7.8,7.86,
AXON,2006-09-05,8.0,8.01,7.9,7.97,
AXON,2006-09-06,7.96,7.96,7.69,7.7,
AXON,2006-09-07,7.75,7.75,7.5,7.55,
AXON,2006-09-08,7.56,7.64,7.49,7.5,
AXON,2006-09-11,7.41,7.76,7.4,7.59,
AXON,2006-09-12,7.63,7.67,7.51,7.63,
AXON,2006-09-13,7.58,7.66,7.55,7.61,
AXON,2006-09-14,7.61,7.67,7.51,7.61,
AXON,2006-09-15,7.71,7.74,7.5,7.59,
AXON,2006-09-18,7.5,7.55,7.42,7.47,
AXON,2006-09-19,7.39,7.52,7.33,7.41,
AXON,2006-09-20,7.45,7.5,7.35,7.4,
AXON,2006-09-21,7.39,7.5,7.28,7.29,
AXON,2006-09-22,7.26,7.37,7.18,7.27,
AXON,2006-09-25,7.27,7.52,7.18,7.44,
AXON,2006-09-26,7.4,7.5,7.32,7.35,
AXON,2006-09-27,7.3,7.47,7.24,7.31,
AXON,2006-09-28,7.29,7.37,7.19,7.24,
AXON,2006-09-29,7.25,7.85,7.25,7.66,
AXON,2006-10-02,7.6,7.8,7.46,7.54,
AXON,2006-10-03,7.7,7.79,7.61,7.62,
AXON,2006-10-04,7.57,7.69,7.52,7.65,
AXON,2006-10-05,8.17,8.74,8.1,8.54,
AXON,2006-10-06,8.73,8.85,8.55,8.76,
AXON,2006-10-09,8.85,9.5,8.79,9.3,
AXON,2006-10-10,9.4,9.4,9.01,9.25,
AXON,2006-10-11,9.15,9.29,9.0,9.05,
AXON,2006-10-12,9.07,9.69,9.07,9.65,
AXON,2006-10-13,9.54,9.72,9.31,9.63,
AXON,2006-10-16,9.6,9.98,9.43,9.69,
AXON,2006-10-17,9.67,9.75,9.39,9.63,
AXON,2006-10-18,9.68,9.71,9.37,9.39,
AXON,2006-10-19,9.42,9.59,9.41,9.41,
AXON,2006-10-20,9.48,9.48,9.15,9.16,
AXON,2006-10-23,9.25,9.55,9.21,9.4,
AXON,2006-10-24,9.32,9.44,9.08,9.2,
AXON,2006-10-25,9.9,10.2,9.45,9.45,
AXON,2006-10-26,9.5,9.71,9.43,9.61,
AXON,2006-10-27,9.61,9.81,9.57,9.62,
AXON,2006-10-30,9.6,9.83,9.55,9.67,
AXON,2006-10-31,9.63,9.7,9.25,9.31,
AXON,2006-11-01,9.25,9.29,8.75,8.99,
AXON,2006-11-02,8.89,8.97,8.7,8.77,
AXON,2006-11-03,8.82,8.97,8.78,8.86,
AXON,2006-11-06,8.92,9.44,8.8,9.16,
AXON,2006-11-07,9.18,9.31,9.07,9.12,
AXON,2006-11-08,9.06,9.22,9.0,9.18,
AXON,2006-11-09,9.25,9.29,8.98,9.05,
AXON,2006-11-10,9.07,9.35,9.0,9.22,
AXON,2006-11-13,9.25,9.37,9.07,9.25,
AXON,2006-11-14,9.24,9.28,9.05,9.28,
AXON,2006-11-15,9.08,9.36,9.08,9.21,
AXON,2006-11-16,9.25,9.28,9.05,9.07,
AXON,2006-11-17,9.06,9.11,9.0,9.02,
AXON,2006-11-20,9.05,9.08,8.94,8.98,
AXON,2006-11-21,8.97,8.99,8.78,8.81,
AXON,2006-11-22,8.82,8.86,8.69,8.85,
AXON,2006-11-24,8.76,9.05,8.69,8.97,
AXON,2006-11-27,8.87,8.87,8.5,8.55,
AXON,2006-11-28,8.52,8.66,8.32,8.46,
AXON,2006-11-29,8.48,8.57,8.37,8.54,
AXON,2006-11-30,8.6,8.6,8.38,8.48,
AXON,2006-12-01,8.59,8.59,8.16,8.28,
AXON,2006-12-04,8.23,8.53,8.21,8.43,
AXON,2006-12-05,8.4,8.6,8.36,8.46,
AXON,2006-12-06,8.48,8.68,8.46,8.56,
AXON,2006-12-07,8.56,8.65,8.35,8.36,
AXON,2006-12-08,8.47,8.54,8.42,8.46,
AXON,2006-12-11,8.3,8.35,7.88,8.32,
AXON,2006-12-12,8.27,8.28,8.05,8.13,
AXON,2006-12-13,8.14,8.32,7.98,8.04,
AXON,2006-12-14,8.02,8.18,7.98,8.0,
AXON,2006-12-15,8.0,8.13,7.85,7.85,
AXON,2006-12-18,7.94,7.95,7.74,7.78,
AXON,2006-12-19,7.71,7.77,7.58,7.6,
AXON,2006-12-20,7.68,7.81,7.66,7.69,
AXON,2006-12-21,7.66,7.77,7.55,7.6,
AXON,2006-12-22,7.54,7.62,7.5,7.53,
AXON,2006-12-26,7.5,7.64,7.42,7.43,
AXON,2006-12-27,7.4,7.8,7.39,7.5,
AXON,2006-12-28,7.6,8.24,7.45,7.81,
AXON,2006-12-29,7.91,8.11,7.59,7.61,
AXON,2007-01-03,7.95,8.05,7.75,7.9,
AXON,2007-01-04,7.95,8.09,7.91,7.99,
AXON,2007-01-05,8.16,8.2,7.9,8.07,
AXON,2007-01-08,8.25,8.32,8.06,8.19,
AXON,2007-01-09,8.51,8.63,8.35,8.48,
AXON,2007-01-10,8.43,8.45,8.26,8.33,
AXON,2007-01-11,8.34,8.4,8.15,8.22,
AXON,2007-01-12,8.16,8.3,8.09,8.2,
AXON,2007-01-16,8.2,8.29,8.13,8.18,
AXON,2007-01-17,8.15,8.19,8.02,8.04,
AXON,2007-01-18,8.02,8.05,7.77,7.81,
AXON,2007-01-19,7.77,7.97,7.75,7.82,
AXON,2007-01-22,7.88,7.9,7.75,7.85,
AXON,2007-01-23,7.82,8.08,7.8,7.82,
AXON,2007-01-24,7.82,7.88,7.65,7.75,
AXON,2007-01-25,7.75,7.76,7.54,7.61,
AXON,2007-01-26,7.63,7.69,7.5,7.64,
AXON,2007-01-29,7.82,7.84,7.68,7.73,
AXON,2007-01-30,7.67,7.85,7.67,7.83,
AXON,2007-01-31,7.78,7.83,7.65,7.75,
AXON,2007-02-01,7.76,7.83,7.67,7.8,
AXON,2007-02-02,7.8,7.88,7.74,7.82,
AXON,2007-02-05,7.82,8.0,7.57,7.83,
AXON,2007-02-06,7.84,7.94,7.8,7.9,
AXON,2007-02-07,8.0,8.08,7.94,7.98,
AXON,2007-02-08,7.98,7.99,7.86,7.89,
AXON,2007-02-09,7.85,7.94,7.75,7.76,
AXON,2007-02-12,7.71,7.83,7.71,7.79,
AXON,2007-02-13,7.79,7.85,7.68,7.74,
AXON,2007-02-14,7.86,8.15,7.8,8.03,
AXON,2007-02-15,8.04,8.15,8.03,8.12,
AXON,2007-02-16,8.14,8.14,7.92,8.12,
AXON,2007-02-20,8.19,8.4,8.05,8.32,
AXON,2007-02-21,8.75,9.27,8.52,8.54,
AXON,2007-02-22,8.73,8.73,8.42,8.43,
AXON,2007-02-23,8.42,8.68,8.26,8.56,
AXON,2007-02-26,8.58,8.68,8.39,8.42,
AXON,2007-02-27,8.3,8.32,8.06,8.11,
AXON,2007-02-28,8.09,8.14,7.9,7.94,
AXON,2007-03-01,7.8,7.99,7.66,7.91,
AXON,2007-03-02,7.86,7.9,7.69,7.74,
AXON,2007-03-05,7.59,7.7,7.44,7.44,
AXON,2007-03-06,7.66,7.9,7.64,7.89,
AXON,2007-03-07,7.9,7.93,7.72,7.73,
AXON,2007-03-08,7.83,7.94,7.74,7.79,
AXON,2007-03-09,7.81,7.91,7.75,7.78,
AXON,2007-03-12,7.76,7.85,7.75,7.85,
AXON,2007-03-13,7.96,8.03,7.78,7.8,
AXON,2007-03-14,7.84,7.93,7.72,7.89,
AXON,2007-03-15,7.9,7.93,7.83,7.89,
AXON,2007-03-16,7.84,7.9,7.76,7.81,
AXON,2007-03-19,8.0,8.12,7.91,8.03,
AXON,2007-03-20,8.1,8.27,8.07,8.2,
AXON,2007-03-21,8.26,8.32,8.11,8.32,
AXON,2007-03-22,8.35,8.37,8.21,8.34,
AXON,2007-03-23,8.38,8.4,8.15,8.26,
AXON,2007-03-26,8.31,8.33,8.17,8.28,
AXON,2007-03-27,8.22,8.31,8.17,8.28,
AXON,2007-03-28,8.27,8.27,8.15,8.18,
AXON,2007-03-29,8.22,8.24,7.98,8.03,
AXON,2007-03-30,8.0,8.17,7.93,8.03,
AXON,2007-04-02,8.0,8.13,8.0,8.12,
AXON,2007-04-03,7.9,8.26,7.8,8.2,
AXON,2007-04-04,8.24,8.25,8.06,8.08,
AXON,2007-04-05,8.06,8.08,7.97,7.98,
AXON,2007-04-09,7.96,7.98,7.85,7.85,
AXON,2007-04-10,7.82,7.92,7.76,7.91,
AXON,2007-04-11,7.83,7.98,7.83,7.88,
AXON,2007-04-12,7.84,8.1,7.8,8.04,
AXON,2007-04-13,8.05,8.18,8.0,8.15,
AXON,2007-04-16,8.15,8.22,8.11,8.16,
AXON,2007-04-17,8.2,8.27,8.08,8.25,
AXON,2007-04-18,8.2,8.65,8.2,8.59,
AXON,2007-04-19,8.5,8.59,8.34,8.37,
AXON,2007-04-20,8.5,8.52,8.29,8.34,
AXON,2007-04-23,8.39,8.5,8.21,8.24,
AXON,2007-04-24,8.5,8.6,8.25,8.56,
AXON,2007-04-25,8.22,8.38,7.92,8.19,
AXON,2007-04-26,8.19,8.29,8.0,8.01,
AXON,2007-04-27,8.06,8.27,7.99,8.27,
AXON,2007-04-30,8.21,8.75,8.13,8.63,
AXON,2007-05-01,8.76,9.14,8.65,9.1,
AXON,2007-05-02,9.17,9.24,8.86,9.16,
AXON,2007-05-03,9.38,9.65,9.32,9.45,
AXON,2007-05-04,9.55,9.63,9.41,9.53,
AXON,2007-05-07,9.97,10.25,9.68,9.92,
AXON,2007-05-08,9.8,9.8,9.36,9.57,
AXON,2007-05-09,9.46,9.72,9.4,9.62,
AXON,2007-05-10,9.58,9.69,9.15,9.41,
AXON,2007-05-11,9.48,9.6,9.3,9.42,
AXON,2007-05-14,9.4,9.48,9.16,9.2,
AXON,2007-05-15,9.2,9.24,8.97,8.99,
AXON,2007-05-16,9.14,9.34,9.0,9.33,
AXON,2007-05-17,9.29,9.4,9.07,9.24,
AXON,2007-05-18,9.28,9.32,9.14,9.3,
AXON,2007-05-21,9.26,9.45,9.23,9.33,
AXON,2007-05-22,9.29,9.42,9.22,9.22,
AXON,2007-05-23,9.33,9.63,9.33,9.54,
AXON,2007-05-24,10.0,10.34,9.79,10.07,
AXON,2007-05-25,10.26,10.58,10.1,10.29,
AXON,2007-05-29,10.5,10.62,10.35,10.45,
AXON,2007-05-30,10.58,11.22,10.33,10.99,
AXON,2007-05-31,11.09,11.09,10.42,10.54,
AXON,2007-06-01,10.57,10.72,10.5,10.63,
AXON,2007-06-04,10.55,10.59,10.31,10.48,
AXON,2007-06-05,10.49,10.59,10.33,10.38,
AXON,2007-06-06,10.32,10.75,10.09,10.56,
AXON,2007-06-07,10.56,10.69,10.37,10.65,
AXON,2007-06-08,10.8,10.95,10.65,10.9,
AXON,2007-06-11,11.1,11.93,11.03,11.9,
AXON,2007-06-12,11.67,12.5,11.67,12.05,
AXON,2007-06-13,12.2,12.36,11.4,11.7,
AXON,2007-06-14,12.0,12.39,11.92,12.18,
AXON,2007-06-15,12.54,12.66,12.2,12.29,
AXON,2007-06-18,12.48,12.57,12.07,12.12,
AXON,2007-06-19,12.53,13.04,12.39,12.65,
AXON,2007-06-20,12.78,12.78,12.22,12.42,
AXON,2007-06-21,12.38,12.7,12.22,12.63,
AXON,2007-06-22,13.42,13.63,13.15,13.43,
AXON,2007-06-25,13.91,14.03,13.5,13.77,
AXON,2007-06-26,13.94,13.99,13.08,13.21,
AXON,2007-06-27,13.09,13.44,12.77,13.27,
AXON,2007-06-28,13.78,13.8,13.31,13.4,
AXON,2007-06-29,14.15,14.25,13.7,13.96,
AXON,2007-07-02,14.1,14.39,14.0,14.39,
AXON,2007-07-03,14.42,14.49,14.18,14.26,
AXON,2007-07-05,14.35,14.38,14.04,14.13,
AXON,2007-07-06,14.04,14.15,13.7,14.06,
AXON,2007-07-09,14.0,16.65,13.93,16.62,
AXON,2007-07-10,16.89,17.37,16.01,16.26,
AXON,2007-07-11,16.36,16.65,16.05,16.16,
AXON,2007-07-12,16.17,16.3,15.25,15.51,
AXON,2007-07-13,15.35,16.65,15.3,16.27,
AXON,2007-07-16,16.3,16.95,16.15,16.23,
AXON,2007-07-17,16.37,16.54,16.0,16.18,
AXON,2007-07-18,16.0,16.16,15.76,15.85,
AXON,2007-07-19,16.41,17.65,16.25,17.41,
AXON,2007-07-20,17.25,17.58,16.92,17.14,
AXON,2007-07-23,19.16,19.36,16.52,16.56,
AXON,2007-07-24,16.07,16.07,14.75,15.21,
AXON,2007-07-25,15.44,15.67,14.2,14.76,
AXON,2007-07-26,14.27,14.99,13.52,14.06,
AXON,2007-07-27,14.33,14.94,14.12,14.23,
AXON,2007-07-30,14.52,15.28,14.44,15.17,
AXON,2007-07-31,15.92,16.05,15.02,15.27,
AXON,2007-08-01,14.95,15.17,14.37,14.59,
AXON,2007-08-02,13.9,15.25,13.07,14.93,
AXON,2007-08-03,14.8,14.97,14.25,14.26,
AXON,2007-08-06,14.46,14.57,13.5,14.13,
AXON,2007-08-07,13.9,14.57,13.48,14.57,
AXON,2007-08-08,14.75,15.75,14.71,15.68,
AXON,2007-08-09,15.06,16.35,14.97,16.25,
AXON,2007-08-10,15.57,16.18,15.3,15.37,
AXON,2007-08-13,15.63,15.87,15.0,15.04,
AXON,2007-08-14,15.0,15.1,14.2,14.26,
AXON,2007-08-15,14.1,14.43,13.71,13.8,
AXON,2007-08-16,13.5,13.72,11.75,13.56,
AXON,2007-08-17,14.74,14.75,13.8,14.1,
AXON,2007-08-20,14.34,14.36,13.49,13.58,
AXON,2007-08-21,13.5,13.77,13.1,13.46,
AXON,2007-08-22,13.72,13.73,13.42,13.57,
AXON,2007-08-23,13.66,13.72,13.29,13.36,
AXON,2007-08-24,13.25,14.1,13.0,14.08,
AXON,2007-08-27,13.87,14.34,13.76,14.1,
AXON,2007-08-28,13.91,13.99,13.27,13.34,
AXON,2007-08-29,13.41,13.68,13.37,13.6,
AXON,2007-08-30,14.01,14.61,13.9,14.31,
AXON,2007-08-31,14.62,14.63,14.18,14.31,
AXON,2007-09-04,14.25,14.95,14.0,14.86,
AXON,2007-09-05,14.64,14.85,14.5,14.67,
AXON,2007-09-06,15.3,15.6,14.87,15.15,
AXON,2007-09-07,14.77,14.79,14.31,14.52,
AXON,2007-09-10,14.59,14.97,14.18,14.47,
AXON,2007-09-11,14.52,14.65,14.31,14.59,
AXON,2007-09-12,14.5,14.71,14.41,14.45,
AXON,2007-09-13,14.82,14.83,14.4,14.43,
AXON,2007-09-14,14.29,14.48,14.23,14.37,
AXON,2007-09-17,14.75,14.96,14.35,14.91,
AXON,2007-09-18,14.85,15.25,14.71,15.02,
AXON,2007-09-19,15.25,15.77,15.2,15.77,
AXON,2007-09-20,15.8,15.87,15.52,15.65,
AXON,2007-09-21,15.93,15.97,15.25,15.3,
AXON,2007-09-24,15.37,15.44,15.1,15.23,
AXON,2007-09-25,15.1,15.5,15.0,15.33,
AXON,2007-09-26,15.34,15.83,15.34,15.63,
AXON,2007-09-27,15.93,15.97,15.74,15.86,
AXON,2007-09-28,15.86,15.95,15.58,15.69,
AXON,2007-10-01,15.63,16.5,15.63,16.2,
AXON,2007-10-02,16.39,17.08,16.21,16.97,
AXON,2007-10-03,16.97,17.3,16.55,16.58,
AXON,2007-10-04,16.63,18.12,16.4,18.05,
AXON,2007-10-05,18.15,18.42,17.75,17.87,
AXON,2007-10-08,18.3,18.89,18.08,18.56,
AXON,2007-10-09,18.75,19.1,18.53,18.81,
AXON,2007-10-10,18.53,18.69,17.95,17.99,
AXON,2007-10-11,18.04,18.37,16.75,17.34,
AXON,2007-10-12,17.42,17.86,17.29,17.85,
AXON,2007-10-15,17.92,18.03,17.24,17.56,
AXON,2007-10-16,17.06,17.2,16.77,17.11,
AXON,2007-10-17,17.25,17.45,16.21,16.69,
AXON,2007-10-18,16.2,16.75,16.12,16.51,
AXON,2007-10-19,16.7,16.7,15.54,15.6,
AXON,2007-10-22,15.5,17.16,15.05,16.7,
AXON,2007-10-23,17.0,17.27,16.35,17.24,
AXON,2007-10-24,17.97,18.44,15.0,17.18,
AXON,2007-10-25,17.56,17.58,16.75,16.78,
AXON,2007-10-26,16.93,17.0,16.21,16.65,
AXON,2007-10-29,16.52,16.86,16.28,16.38,
AXON,2007-10-30,16.25,16.43,15.9,16.0,
AXON,2007-10-31,16.12,16.73,15.91,16.65,
AXON,2007-11-01,16.3,16.41,15.77,15.95,
AXON,2007-11-02,16.17,16.2,15.75,15.98,
AXON,2007-11-05,15.85,16.29,15.51,15.63,
AXON,2007-11-06,15.65,15.97,15.4,15.76,
AXON,2007-11-07,15.4,15.65,15.06,15.26,
AXON,2007-11-08,15.37,15.37,13.77,14.84,
AXON,2007-11-09,14.36,14.57,13.89,14.11,
AXON,2007-11-12,14.0,14.06,13.0,13.17,
AXON,2007-11-13,13.46,14.3,13.46,14.28,
AXON,2007-11-14,15.1,15.1,14.3,14.42,
AXON,2007-11-15,14.23,14.5,13.71,13.88,
AXON,2007-11-16,14.01,14.19,13.42,13.66,
AXON,2007-11-19,13.33,13.57,13.09,13.16,
AXON,2007-11-20,13.33,13.46,12.93,13.44,
AXON,2007-11-21,13.02,13.25,12.77,13.05,
AXON,2007-11-23,13.1,13.19,12.94,13.04,
AXON,2007-11-26,12.78,13.25,12.61,12.68,
AXON,2007-11-27,12.73,13.04,12.66,12.9,
AXON,2007-11-28,13.28,14.51,13.15,14.17,
AXON,2007-11-29,14.11,14.16,13.8,13.91,
AXON,2007-11-30,14.38,14.94,13.85,14.01,
AXON,2007-12-03,14.0,14.75,14.0,14.62,
AXON,2007-12-04,14.63,15.14,14.35,14.84,
AXON,2007-12-05,15.02,15.25,14.93,15.22,
AXON,2007-12-06,15.13,15.94,15.01,15.94,
AXON,2007-12-07,16.0,16.0,15.5,15.66,
AXON,2007-12-10,15.67,15.91,15.27,15.46,
AXON,2007-12-11,15.5,15.6,14.75,14.83,
AXON,2007-12-12,15.06,15.5,14.86,15.04,
AXON,2007-12-13,14.8,14.93,14.28,14.61,
AXON,2007-12-14,14.3,14.74,14.3,14.42,
AXON,2007-12-17,14.3,14.49,13.76,13.85,
AXON,2007-12-18,14.0,14.6,13.93,14.6,
AXON,2007-12-19,14.72,14.85,14.3,14.72,
AXON,2007-12-20,14.84,14.88,14.45,14.86,
AXON,2007-12-21,15.07,15.21,14.96,15.17,
AXON,2007-12-24,15.25,15.31,15.06,15.18,
AXON,2007-12-26,15.2,15.27,14.82,15.27,
AXON,2007-12-27,15.17,15.3,14.86,14.86,
AXON,2007-12-28,15.0,15.09,14.67,14.69,
AXON,2007-12-31,14.56,14.68,14.32,14.39,
AXON,2008-01-02,14.41,14.74,13.84,14.04,
AXON,2008-01-03,14.01,14.29,13.95,14.06,
AXON,2008-01-04,13.88,13.98,13.2,13.23,
AXON,2008-01-07,13.6,13.75,13.0,13.11,
AXON,2008-01-08,13.28,13.73,13.26,13.28,
AXON,2008-01-09,13.2,13.46,10.11,12.54,
AXON,2008-01-10,11.56,12.9,11.08,11.97,
AXON,2008-01-11,11.95,12.2,11.41,11.57,
AXON,2008-01-14,11.96,11.98,11.55,11.75,
AXON,2008-01-15,11.54,11.64,11.3,11.32,
AXON,2008-01-16,11.03,11.36,10.6,10.85,
AXON,2008-01-17,10.85,11.0,9.77,9.95,
AXON,2008-01-18,9.99,10.32,9.58,9.65,
AXON,2008-01-22,8.52,9.28,8.31,8.9,
AXON,2008-01-23,8.74,9.14,8.16,9.14,
AXON,2008-01-24,9.3,9.96,9.21,9.7,
AXON,2008-01-25,10.5,10.8,10.35,10.48,
AXON,2008-01-28,10.57,10.82,10.35,10.67,
AXON,2008-01-29,11.0,11.4,10.91,11.2,
AXON,2008-01-30,11.22,11.27,10.72,10.88,
AXON,2008-01-31,10.6,11.55,10.58,11.49,
AXON,2008-02-01,11.78,11.96,11.33,11.7,
AXON,2008-02-04,11.7,11.75,11.36,11.61,
AXON,2008-02-05,11.38,11.8,10.93,11.01,
AXON,2008-02-06,11.08,11.38,10.82,10.86,
AXON,2008-02-07,10.65,11.16,10.52,10.97,
AXON,2008-02-08,10.92,11.19,10.76,10.96,
AXON,2008-02-11,11.5,12.19,11.25,11.65,
AXON,2008-02-12,11.69,11.74,11.36,11.53,
AXON,2008-02-13,12.3,12.8,11.94,12.76,
AXON,2008-02-14,12.85,12.92,11.76,11.86,
AXON,2008-02-15,11.77,12.02,11.66,11.94,
AXON,2008-02-19,12.15,12.47,11.97,11.99,
AXON,2008-02-20,11.97,12.12,11.84,12.1,
AXON,2008-02-21,12.16,12.39,11.91,11.96,
AXON,2008-02-22,11.95,12.02,11.16,11.55,
AXON,2008-02-25,11.65,11.8,11.28,11.8,
AXON,2008-02-26,11.58,11.81,11.53,11.68,
AXON,2008-02-27,11.41,11.96,11.41,11.69,
AXON,2008-02-28,11.63,12.0,11.52,11.75,
AXON,2008-02-29,11.65,11.84,11.14,11.27,
AXON,2008-03-03,11.41,11.49,11.06,11.37,
AXON,2008-03-04,11.27,11.36,10.52,11.08,
AXON,2008-03-05,11.11,11.38,11.09,11.28,
AXON,2008-03-06,11.28,11.3,11.01,11.01,
AXON,2008-03-07,10.75,11.1,10.67,10.78,
AXON,2008-03-10,10.83,10.83,10.36,10.43,
AXON,2008-03-11,10.9,11.42,10.75,11.41,
AXON,2008-03-12,11.66,11.68,10.51,10.54,
AXON,2008-03-13,10.27,10.59,10.05,10.58,
AXON,2008-03-14,10.65,10.68,9.83,9.94,
AXON,2008-03-17,9.59,9.74,9.32,9.36,
AXON,2008-03-18,9.61,10.08,9.51,10.03,
AXON,2008-03-19,10.01,10.08,9.55,9.6,
AXON,2008-03-20,9.74,9.76,9.37,9.65,
AXON,2008-03-24,9.71,10.25,9.6,9.82,
AXON,2008-03-25,9.84,10.19,9.72,10.15,
AXON,2008-03-26,10.07,10.26,9.96,10.21,
AXON,2008-03-27,10.17,10.39,9.83,9.89,
AXON,2008-03-28,10.0,10.1,9.49,9.56,
AXON,2008-03-31,9.79,9.79,9.25,9.4,
AXON,2008-04-01,9.85,10.03,9.54,9.86,
AXON,2008-04-02,9.92,9.98,9.7,9.77,
AXON,2008-04-03,10.08,10.57,9.92,10.27,
AXON,2008-04-04,10.31,10.34,10.02,10.14,
AXON,2008-04-07,10.26,10.39,10.05,10.14,
AXON,2008-04-08,10.05,10.16,9.59,9.75,
AXON,2008-04-09,9.73,9.87,9.3,9.43,
AXON,2008-04-10,9.45,9.62,9.35,9.5,
AXON,2008-04-11,9.37,9.52,9.28,9.35,
AXON,2008-04-14,9.41,9.49,9.28,9.32,
AXON,2008-04-15,9.36,9.42,8.8,9.06,
AXON,2008-04-16,9.17,9.48,9.16,9.44,
AXON,2008-04-17,9.66,9.7,9.35,9.42,
AXON,2008-04-18,9.64,9.73,9.45,9.58,
AXON,2008-04-21,9.58,9.87,9.55,9.85,
AXON,2008-04-22,9.85,9.89,9.36,9.52,
AXON,2008-04-23,9.52,9.67,9.23,9.42,
AXON,2008-04-24,8.25,8.25,7.3,7.53,
AXON,2008-04-25,7.65,7.67,7.3,7.32,
AXON,2008-04-28,7.48,7.53,7.32,7.51,
AXON,2008-04-29,7.57,7.57,7.41,7.52,
AXON,2008-04-30,7.56,7.57,7.42,7.46,
AXON,2008-05-01,7.48,7.49,7.35,7.41,
AXON,2008-05-02,7.46,7.46,7.26,7.28,
AXON,2008-05-05,7.3,7.5,7.21,7.33,
AXON,2008-05-06,7.45,7.52,7.34,7.47,
AXON,2008-05-07,7.5,7.61,7.37,7.38,
AXON,2008-05-08,7.55,7.55,7.35,7.44,
AXON,2008-05-09,7.4,7.44,7.3,7.37,
AXON,2008-05-12,7.4,7.69,7.4,7.68,
AXON,2008-05-13,7.74,7.91,7.72,7.91,
AXON,2008-05-14,7.92,8.09,7.86,7.9,
AXON,2008-05-15,7.92,7.97,7.79,7.87,
AXON,2008-05-16,7.89,7.89,7.45,7.52,
AXON,2008-05-19,7.55,7.73,7.46,7.48,
AXON,2008-05-20,7.43,7.49,7.38,7.44,
AXON,2008-05-21,7.45,7.49,7.22,7.24,
AXON,2008-05-22,7.47,7.49,7.27,7.33,
AXON,2008-05-23,7.29,7.33,7.09,7.11,
AXON,2008-05-27,7.16,7.22,7.09,7.21,
AXON,2008-05-28,7.23,7.25,7.1,7.13,
AXON,2008-05-29,7.16,7.2,6.97,7.0,
AXON,2008-05-30,7.01,7.1,6.99,7.03,
AXON,2008-06-02,7.0,7.08,6.97,7.06,
AXON,2008-06-03,7.06,7.09,6.93,6.99,
AXON,2008-06-04,6.99,7.05,6.83,6.97,
AXON,2008-06-05,6.97,7.05,6.97,7.03,
AXON,2008-06-06,6.95,7.02,6.88,6.9,
AXON,2008-06-09,6.4,6.4,6.0,6.13,
AXON,2008-06-10,6.12,6.18,6.01,6.16,
AXON,2008-06-11,6.12,6.15,5.75,5.92,
AXON,2008-06-12,6.1,6.1,5.75,5.78,
AXON,2008-06-13,5.78,5.88,5.75,5.83,
AXON,2008-06-16,5.9,5.95,5.87,5.92,
AXON,2008-06-17,6.0,6.0,5.71,5.73,
AXON,2008-06-18,5.67,5.73,5.5,5.51,
AXON,2008-06-19,5.52,5.75,5.36,5.75,
AXON,2008-06-20,5.7,5.77,5.52,5.77,
AXON,2008-06-23,5.8,5.81,5.54,5.56,
AXON,2008-06-24,5.5,5.7,5.45,5.56,
AXON,2008-06-25,5.55,5.59,5.37,5.4,
AXON,2008-06-26,5.3,5.32,5.09,5.11,
AXON,2008-06-27,5.09,5.1,4.95,5.05,
AXON,2008-06-30,4.98,5.09,4.96,4.99,
AXON,2008-07-01,4.91,5.14,4.89,5.14,
AXON,2008-07-02,5.15,5.18,5.0,5.01,
AXON,2008-07-03,5.0,5.09,4.96,5.02,
AXON,2008-07-07,5.06,5.15,5.03,5.1,
AXON,2008-07-08,5.15,5.5,5.06,5.47,
AXON,2008-07-09,5.46,5.5,5.22,5.23,
AXON,2008-07-10,5.18,5.2,5.06,5.14,
AXON,2008-07-11,5.07,5.28,5.05,5.21,
AXON,2008-07-14,5.2,5.21,5.09,5.1,
AXON,2008-07-15,5.08,5.53,4.99,5.39,
AXON,2008-07-16,5.45,5.96,5.43,5.96,
AXON,2008-07-17,5.97,5.99,5.62,5.74,
AXON,2008-07-18,5.73,5.74,5.47,5.65,
AXON,2008-07-21,5.64,5.8,5.43,5.58,
AXON,2008-07-22,5.48,5.66,5.46,5.66,
AXON,2008-07-23,5.7,5.77,5.63,5.7,
AXON,2008-07-24,5.08,5.5,4.85,5.06,
AXON,2008-07-25,4.87,5.09,4.86,5.04,
AXON,2008-07-28,5.15,5.16,4.98,5.02,
AXON,2008-07-29,5.05,5.16,5.05,5.14,
AXON,2008-07-30,5.14,5.19,5.05,5.13,
AXON,2008-07-31,5.02,5.13,5.01,5.04,
AXON,2008-08-01,5.04,5.2,5.04,5.12,
AXON,2008-08-04,5.16,5.16,5.06,5.09,
AXON,2008-08-05,5.05,5.18,5.05,5.11,
AXON,2008-08-06,5.12,5.34,5.09,5.34,
AXON,2008-08-07,5.34,5.38,5.11,5.17,
AXON,2008-08-08,5.16,5.34,5.16,5.34,
AXON,2008-08-11,5.36,5.57,5.36,5.57,
AXON,2008-08-12,5.51,5.7,5.49,5.64,
AXON,2008-08-13,5.64,5.66,5.51,5.65,
AXON,2008-08-14,5.63,5.88,5.63,5.79,
AXON,2008-08-15,5.87,5.97,5.7,5.86,
AXON,2008-08-18,5.9,5.96,5.75,5.95,
AXON,2008-08-19,5.95,6.66,5.9,6.27,
AXON,2008-08-20,6.26,6.4,6.13,6.2,
AXON,2008-08-21,6.17,6.2,6.06,6.11,
AXON,2008-08-22,6.11,6.23,6.09,6.2,
AXON,2008-08-25,6.31,6.31,6.08,6.13,
AXON,2008-08-26,6.15,6.24,6.09,6.14,
AXON,2008-08-27,6.15,6.26,6.11,6.23,
AXON,2008-08-28,6.24,6.49,6.2,6.47,
AXON,2008-08-29,6.47,6.58,6.44,6.5,
AXON,2008-09-02,6.59,6.83,6.42,6.5,
AXON,2008-09-03,6.53,6.63,6.41,6.5,
AXON,2008-09-04,6.46,6.76,6.42,6.65,
AXON,2008-09-05,6.66,6.66,6.52,6.57,
AXON,2008-09-08,6.63,6.68,6.34,6.54,
AXON,2008-09-09,6.48,6.54,6.16,6.19,
AXON,2008-09-10,6.2,6.22,6.06,6.2,
AXON,2008-09-11,6.06,6.26,6.05,6.25,
AXON,2008-09-12,6.22,6.5,6.14,6.45,
AXON,2008-09-15,6.2,6.29,6.11,6.15,
AXON,2008-09-16,5.75,6.4,5.61,6.33,
AXON,2008-09-17,6.04,6.34,6.0,6.13,
AXON,2008-09-18,6.13,7.06,6.13,7.04,
AXON,2008-09-19,7.4,7.63,6.71,7.25,
AXON,2008-09-22,7.11,7.23,7.01,7.01,
AXON,2008-09-23,7.02,7.14,6.8,7.09,
AXON,2008-09-24,7.12,7.21,6.99,7.01,
AXON,2008-09-25,7.02,7.5,7.0,7.48,
AXON,2008-09-26,7.24,7.43,7.08,7.28,
AXON,2008-09-29,7.12,7.32,6.71,6.85,
AXON,2008-09-30,7.08,7.25,6.95,7.15,
AXON,2008-10-01,7.01,7.2,6.8,6.85,
AXON,2008-10-02,6.87,7.0,6.65,6.94,
AXON,2008-10-03,7.0,7.15,6.58,6.61,
AXON,2008-10-06,6.5,6.71,6.15,6.58,
AXON,2008-10-07,6.56,6.75,5.99,5.99,
AXON,2008-10-08,5.76,6.09,5.5,5.92,
AXON,2008-10-09,5.97,6.05,5.04,5.05,
AXON,2008-10-10,4.85,4.95,3.75,4.65,
AXON,2008-10-13,4.91,5.37,4.85,5.37,
AXON,2008-10-14,5.46,5.63,5.1,5.26,
AXON,2008-10-15,5.13,5.22,4.6,4.6,
AXON,2008-10-16,4.65,4.94,4.24,4.8,
AXON,2008-10-17,4.55,4.99,4.54,4.76,
AXON,2008-10-20,4.9,5.06,4.81,5.06,
AXON,2008-10-21,4.99,5.07,4.78,4.85,
AXON,2008-10-22,4.74,4.82,4.6,4.67,
AXON,2008-10-23,4.71,4.89,4.55,4.87,
AXON,2008-10-24,4.44,4.76,4.25,4.48,
AXON,2008-10-27,4.51,4.61,4.25,4.27,
AXON,2008-10-28,4.46,4.5,3.97,4.22,
AXON,2008-10-29,4.28,4.69,4.08,4.58,
AXON,2008-10-30,4.74,4.8,4.55,4.76,
AXON,2008-10-31,4.75,5.08,4.56,5.01,
AXON,2008-11-03,5.0,5.33,5.0,5.16,
AXON,2008-11-04,5.35,5.38,5.21,5.36,
AXON,2008-11-05,5.25,5.39,4.98,4.99,
AXON,2008-11-06,4.91,5.17,4.75,4.75,
AXON,2008-11-07,4.75,5.0,4.51,4.67,
AXON,2008-11-10,4.82,4.86,4.59,4.69,
AXON,2008-11-11,4.64,4.73,4.32,4.39,
AXON,2008-11-12,4.33,4.49,3.87,3.9,
AXON,2008-11-13,3.91,4.0,3.55,3.94,
AXON,2008-11-14,3.89,4.04,3.77,3.78,
AXON,2008-11-17,3.75,3.85,3.52,3.53,
AXON,2008-11-18,3.53,3.7,3.42,3.56,
AXON,2008-11-19,3.55,3.62,2.92,2.92,
AXON,2008-11-20,2.79,3.03,2.64,2.68,
AXON,2008-11-21,2.79,2.98,2.54,2.69,
AXON,2008-11-24,3.18,3.72,3.0,3.68,
AXON,2008-11-25,3.73,4.05,3.57,3.84,
AXON,2008-11-26,3.89,4.1,3.63,4.1,
AXON,2008-11-28,4.05,4.37,4.02,4.35,
AXON,2008-12-01,4.27,4.27,3.8,3.81,
AXON,2008-12-02,3.91,4.34,3.85,4.27,
AXON,2008-12-03,4.05,4.51,4.01,4.33,
AXON,2008-12-04,4.21,4.4,3.9,3.97,
AXON,2008-12-05,3.88,3.98,3.7,3.98,
AXON,2008-12-08,4.07,4.3,4.01,4.23,
AXON,2008-12-09,4.16,4.38,4.0,4.08,
AXON,2008-12-10,4.07,4.26,4.05,4.23,
AXON,2008-12-11,4.12,4.22,3.95,4.01,
AXON,2008-12-12,3.8,4.24,3.8,4.24,
AXON,2008-12-15,4.29,4.29,4.1,4.18,
AXON,2008-12-16,4.25,4.44,4.19,4.43,
AXON,2008-12-17,4.32,4.99,4.32,4.81,
AXON,2008-12-18,4.77,5.04,4.45,4.57,
AXON,2008-12-19,4.75,4.99,4.69,4.99,
AXON,2008-12-22,5.0,5.0,4.6,4.75,
AXON,2008-12-23,4.88,5.15,4.73,4.81,
AXON,2008-12-24,4.83,5.1,4.72,5.04,
AXON,2008-12-26,5.11,5.34,4.94,5.28,
AXON,2008-12-29,5.29,5.49,5.2,5.35,
AXON,2008-12-30,5.38,5.49,5.05,5.25,
AXON,2008-12-31,5.15,5.39,5.0,5.28,
AXON,2009-01-02,5.3,5.5,5.22,5.41,
AXON,2009-01-05,5.6,5.75,5.45,5.57,
AXON,2009-01-06,5.65,5.69,5.48,5.51,
AXON,2009-01-07,5.45,5.47,5.25,5.37,
AXON,2009-01-08,5.39,5.65,5.32,5.65,
AXON,2009-01-09,5.63,5.73,5.46,5.46,
AXON,2009-01-12,5.45,5.55,5.16,5.19,
AXON,2009-01-13,5.2,5.31,5.03,5.22,
AXON,2009-01-14,4.98,5.32,4.87,4.92,
AXON,2009-01-15,5.12,5.15,4.68,4.99,
AXON,2009-01-16,5.03,5.35,5.03,5.35,
AXON,2009-01-20,5.24,5.24,4.94,5.06,
AXON,2009-01-21,5.02,5.15,4.76,5.14,
AXON,2009-01-22,5.06,5.14,4.82,4.94,
AXON,2009-01-23,4.78,5.05,4.77,4.91,
AXON,2009-01-26,5.25,5.25,4.93,5.06,
AXON,2009-01-27,5.07,5.19,4.96,5.13,
AXON,2009-01-28,5.18,5.35,5.17,5.35,
AXON,2009-01-29,5.26,5.41,5.14,5.25,
AXON,2009-01-30,5.24,5.32,5.06,5.07,
AXON,2009-02-02,5.05,5.29,4.99,5.25,
AXON,2009-02-03,5.25,5.45,5.21,5.41,
AXON,2009-02-04,5.36,5.6,5.36,5.53,
AXON,2009-02-05,5.26,5.88,5.26,5.58,
AXON,2009-02-06,5.52,5.78,5.52,5.73,
AXON,2009-02-09,5.64,5.83,5.6,5.74,
AXON,2009-02-10,5.61,5.79,5.28,5.32,
AXON,2009-02-11,5.37,5.49,5.15,5.26,
AXON,2009-02-12,5.14,5.28,5.02,5.19,
AXON,2009-02-13,5.12,5.21,5.02,5.13,
AXON,2009-02-17,5.05,5.12,4.9,4.91,
AXON,2009-02-18,4.9,4.99,4.65,4.69,
AXON,2009-02-19,4.69,4.76,4.51,4.58,
AXON,2009-02-20,4.5,4.56,4.2,4.3,
AXON,2009-02-23,4.33,4.47,4.03,4.06,
AXON,2009-02-24,4.36,4.84,4.24,4.65,
AXON,2009-02-25,4.65,4.74,4.3,4.35,
AXON,2009-02-26,4.38,4.54,4.31,4.31,
AXON,2009-02-27,4.2,4.44,4.15,4.3,
AXON,2009-03-02,4.13,4.13,3.6,3.61,
AXON,2009-03-03,3.65,3.68,3.11,3.12,
AXON,2009-03-04,3.34,3.52,3.25,3.5,
AXON,2009-03-05,3.39,3.6,3.15,3.26,
AXON,2009-03-06,3.51,3.83,3.5,3.65,
AXON,2009-03-09,3.51,3.83,3.51,3.69,
AXON,2009-03-10,3.79,4.19,3.79,4.07,
AXON,2009-03-11,4.12,4.39,4.02,4.17,
AXON,2009-03-12,4.13,4.37,3.93,4.33,
AXON,2009-03-13,4.17,4.35,4.13,4.21,
AXON,2009-03-16,4.24,4.31,4.03,4.09,
AXON,2009-03-17,4.04,4.26,3.75,4.16,
AXON,2009-03-18,4.12,4.46,3.98,4.37,
AXON,2009-03-19,4.43,4.45,4.19,4.22,
AXON,2009-03-20,4.27,4.3,4.01,4.08,
AXON,2009-03-23,4.27,4.73,4.15,4.73,
AXON,2009-03-24,4.58,4.81,4.52,4.73,
AXON,2009-03-25,4.73,4.99,4.37,4.69,
AXON,2009-03-26,4.75,4.83,4.57,4.82,
AXON,2009-03-27,4.69,4.95,4.55,4.62,
AXON,2009-03-30,4.45,4.5,4.32,4.35,
AXON,2009-03-31,4.43,4.96,4.39,4.68,
AXON,2009-04-01,4.56,4.88,4.4,4.76,
AXON,2009-04-02,4.88,4.99,4.77,4.91,
AXON,2009-04-03,4.87,4.94,4.68,4.8,
AXON,2009-04-06,4.74,4.94,4.63,4.93,
AXON,2009-04-07,4.76,4.94,4.73,4.79,
AXON,2009-04-08,4.78,5.0,4.76,4.81,
AXON,2009-04-09,4.92,5.3,4.85,5.24,
AXON,2009-04-13,5.05,5.43,5.05,5.4,
AXON,2009-04-14,5.27,5.36,4.86,4.88,
AXON,2009-04-15,4.79,4.95,4.77,4.88,
AXON,2009-04-16,4.93,5.15,4.89,5.09,
AXON,2009-04-17,5.11,5.17,4.98,5.13,
AXON,2009-04-20,4.97,5.02,4.68,4.72,
AXON,2009-04-21,4.65,5.0,4.63,5.0,
AXON,2009-04-22,4.87,5.25,4.87,5.11,
AXON,2009-04-23,5.3,5.36,4.86,4.9,
AXON,2009-04-24,4.95,5.09,4.84,5.01,
AXON,2009-04-27,4.88,5.01,4.74,4.75,
AXON,2009-04-28,4.72,4.85,4.63,4.72,
AXON,2009-04-29,4.74,5.0,4.74,4.98,
AXON,2009-04-30,5.02,5.12,4.79,4.8,
AXON,2009-05-01,4.73,4.9,4.72,4.79,
AXON,2009-05-04,4.86,5.06,4.85,5.0,
AXON,2009-05-05,4.85,4.88,4.68,4.76,
AXON,2009-05-06,4.81,4.84,4.6,4.7,
AXON,2009-05-07,4.61,4.74,4.36,4.42,
AXON,2009-05-08,4.45,4.64,4.38,4.6,
AXON,2009-05-11,4.63,4.63,4.42,4.49,
AXON,2009-05-12,4.54,4.56,4.33,4.45,
AXON,2009-05-13,4.33,4.4,4.18,4.18,
AXON,2009-05-14,4.2,4.29,4.2,4.25,
AXON,2009-05-15,4.28,4.28,4.11,4.17,
AXON,2009-05-18,4.21,4.39,4.19,4.38,
AXON,2009-05-19,4.38,4.45,4.24,4.27,
AXON,2009-05-20,4.33,4.42,4.2,4.21,
AXON,2009-05-21,4.12,4.22,4.08,4.12,
AXON,2009-05-22,4.14,4.2,4.04,4.05,
AXON,2009-05-26,4.04,4.32,4.04,4.3,
AXON,2009-05-27,4.24,4.32,4.17,4.2,
AXON,2009-05-28,4.29,4.34,4.06,4.19,
AXON,2009-05-29,4.17,4.36,4.15,4.36,
AXON,2009-06-01,4.41,4.63,4.4,4.56,
AXON,2009-06-02,4.55,4.67,4.51,4.57,
AXON,2009-06-03,4.54,4.72,4.46,4.72,
AXON,2009-06-04,4.71,4.73,4.65,4.7,
AXON,2009-06-05,4.72,4.77,4.65,4.68,
AXON,2009-06-08,4.63,4.66,4.49,4.49,
AXON,2009-06-09,4.53,4.56,4.46,4.49,
AXON,2009-06-10,4.55,4.55,4.31,4.42,
AXON,2009-06-11,4.42,4.54,4.4,4.51,
AXON,2009-06-12,4.45,4.5,4.41,4.46,
AXON,2009-06-15,4.36,4.36,4.1,4.21,
AXON,2009-06-16,4.2,4.31,4.1,4.11,
AXON,2009-06-17,4.11,4.4,4.06,4.39,
AXON,2009-06-18,4.37,4.53,4.31,4.44,
AXON,2009-06-19,4.53,4.54,4.46,4.54,
AXON,2009-06-22,4.5,4.52,4.38,4.45,
AXON,2009-06-23,4.48,4.49,4.38,4.41,
AXON,2009-06-24,4.44,4.49,4.35,4.43,
AXON,2009-06-25,4.4,4.56,4.4,4.55,
AXON,2009-06-26,4.5,4.73,4.44,4.73,
AXON,2009-06-29,4.61,4.84,4.47,4.55,
AXON,2009-06-30,4.62,4.74,4.55,4.56,
AXON,2009-07-01,4.62,4.79,4.62,4.67,
AXON,2009-07-02,4.56,4.69,4.47,4.5,
AXON,2009-07-06,4.54,4.67,4.45,4.5,
AXON,2009-07-07,4.5,4.61,4.43,4.43,
AXON,2009-07-08,4.47,4.49,4.22,4.28,
AXON,2009-07-09,4.33,4.35,4.19,4.21,
AXON,2009-07-10,4.16,4.31,4.16,4.26,
AXON,2009-07-13,4.29,4.57,4.25,4.48,
AXON,2009-07-14,4.45,4.75,4.45,4.73,
AXON,2009-07-15,4.79,5.11,4.72,5.11,
AXON,2009-07-16,5.0,5.21,4.97,5.18,
AXON,2009-07-17,5.19,5.25,5.01,5.07,
AXON,2009-07-20,5.1,5.17,5.0,5.13,
AXON,2009-07-21,5.14,5.16,5.01,5.15,
AXON,2009-07-22,5.07,5.3,5.04,5.29,
AXON,2009-07-23,5.26,5.43,5.24,5.42,
AXON,2009-07-24,5.26,5.54,5.26,5.54,
AXON,2009-07-27,5.5,5.7,5.5,5.58,
AXON,2009-07-28,5.62,5.67,5.35,5.55,
AXON,2009-07-29,5.47,5.48,5.22,5.24,
AXON,2009-07-30,5.3,5.47,5.26,5.37,
AXON,2009-07-31,5.39,5.46,5.22,5.25,
AXON,2009-08-03,5.36,5.37,5.19,5.31,
AXON,2009-08-04,5.24,5.36,5.15,5.27,
AXON,2009-08-05,5.23,5.29,5.1,5.12,
AXON,2009-08-06,5.13,5.2,5.03,5.03,
AXON,2009-08-07,5.09,5.22,5.0,5.18,
AXON,2009-08-10,5.15,5.24,5.11,5.15,
AXON,2009-08-11,5.25,5.25,5.02,5.12,
AXON,2009-08-12,5.14,5.16,5.05,5.07,
AXON,2009-08-13,5.09,5.11,5.01,5.01,
AXON,2009-08-14,5.01,5.06,4.89,4.96,
AXON,2009-08-17,4.89,4.94,4.65,4.75,
AXON,2009-08-18,4.8,4.88,4.76,4.83,
AXON,2009-08-19,4.78,4.94,4.77,4.94,
AXON,2009-08-20,4.91,4.98,4.84,4.97,
AXON,2009-08-21,5.04,5.1,4.93,5.01,
AXON,2009-08-24,5.01,5.05,4.75,4.84,
AXON,2009-08-25,4.85,4.97,4.84,4.87,
AXON,2009-08-26,4.85,4.9,4.8,4.85,
AXON,2009-08-27,4.8,4.83,4.75,4.78,
AXON,2009-08-28,4.78,4.83,4.66,4.69,
AXON,2009-08-31,4.65,4.69,4.51,4.55,
AXON,2009-09-01,4.56,4.69,4.45,4.48,
AXON,2009-09-02,4.45,4.49,4.38,4.44,
AXON,2009-09-03,4.45,4.56,4.45,4.53,
AXON,2009-09-04,4.5,4.61,4.45,4.61,
AXON,2009-09-08,4.63,4.66,4.55,4.61,
AXON,2009-09-09,4.66,4.7,4.53,4.55,
AXON,2009-09-10,4.55,4.59,4.47,4.53,
AXON,2009-09-11,4.53,4.68,4.5,4.65,
AXON,2009-09-14,4.62,4.97,4.61,4.86,
AXON,2009-09-15,4.86,4.93,4.69,4.81,
AXON,2009-09-16,4.84,4.9,4.77,4.8,
AXON,2009-09-17,4.75,4.87,4.62,4.69,
AXON,2009-09-18,4.7,4.76,4.63,4.74,
AXON,2009-09-21,4.7,4.71,4.55,4.66,
AXON,2009-09-22,4.69,4.72,4.59,4.65,
AXON,2009-09-23,4.64,4.7,4.56,4.57,
AXON,2009-09-24,4.61,4.67,4.5,4.53,
AXON,2009-09-25,4.5,4.56,4.46,4.48,
AXON,2009-09-28,4.48,4.64,4.48,4.59,
AXON,2009-09-29,4.74,4.9,4.63,4.82,
AXON,2009-09-30,4.85,4.88,4.63,4.72,
AXON,2009-10-01,4.76,4.77,4.51,4.51,
AXON,2009-10-02,4.5,4.57,4.45,4.5,
AXON,2009-10-05,4.51,4.61,4.45,4.53,
AXON,2009-10-06,4.58,4.6,4.51,4.53,
AXON,2009-10-07,4.47,4.57,4.47,4.53,
AXON,2009-10-08,4.56,4.62,4.5,4.5,
AXON,2009-10-09,4.51,4.58,4.5,4.57,
AXON,2009-10-12,4.55,4.62,4.55,4.57,
AXON,2009-10-13,4.54,4.62,4.54,4.62,
AXON,2009-10-14,4.66,4.68,4.6,4.67,
AXON,2009-10-15,4.62,4.68,4.6,4.66,
AXON,2009-10-16,4.63,4.66,4.53,4.61,
AXON,2009-10-19,4.64,4.64,4.54,4.6,
AXON,2009-10-20,4.59,4.59,4.51,4.52,
AXON,2009-10-21,4.51,4.67,4.5,4.56,
AXON,2009-10-22,4.46,4.5,4.36,4.5,
AXON,2009-10-23,4.4,4.52,4.28,4.37,
AXON,2009-10-26,4.44,4.55,4.34,4.4,
AXON,2009-10-27,4.4,4.47,4.36,4.39,
AXON,2009-10-28,4.39,4.41,4.08,4.08,
AXON,2009-10-29,4.08,4.23,4.06,4.22,
AXON,2009-10-30,4.21,4.26,4.07,4.09,
AXON,2009-11-02,4.1,4.17,3.94,4.01,
AXON,2009-11-03,4.05,4.1,4.01,4.08,
AXON,2009-11-04,4.09,4.09,3.95,3.97,
AXON,2009-11-05,4.05,4.09,4.03,4.06,
AXON,2009-11-06,4.24,4.53,4.22,4.41,
AXON,2009-11-09,4.42,4.47,4.37,4.41,
AXON,2009-11-10,4.5,4.58,4.26,4.28,
AXON,2009-11-11,4.31,4.4,4.25,4.28,
AXON,2009-11-12,4.26,4.29,4.11,4.11,
AXON,2009-11-13,4.15,4.2,4.03,4.16,
AXON,2009-11-16,4.19,4.35,4.1,4.34,
AXON,2009-11-17,4.21,4.28,4.19,4.23,
AXON,2009-11-18,4.23,4.25,4.15,4.18,
AXON,2009-11-19,4.15,4.19,4.07,4.07,
AXON,2009-11-20,4.04,4.09,4.03,4.08,
AXON,2009-11-23,4.12,4.37,4.12,4.2,
AXON,2009-11-24,4.24,4.45,4.16,4.3,
AXON,2009-11-25,4.3,4.43,4.3,4.38,
AXON,2009-11-27,4.2,4.37,4.15,4.27,
AXON,2009-11-30,4.26,4.26,4.15,4.23,
AXON,2009-12-01,4.28,4.32,4.23,4.27,
AXON,2009-12-02,4.27,4.3,4.0,4.25,
AXON,2009-12-03,4.25,4.28,4.18,4.19,
AXON,2009-12-04,4.28,4.34,4.24,4.32,
AXON,2009-12-07,4.45,4.49,4.27,4.34,
AXON,2009-12-08,4.32,4.38,4.25,4.37,
AXON,2009-12-09,4.36,4.37,4.25,4.33,
AXON,2009-12-10,4.34,4.39,4.24,4.34,
AXON,2009-12-11,4.35,4.37,4.25,4.31,
AXON,2009-12-14,4.34,4.4,4.22,4.39,
AXON,2009-12-15,4.39,4.47,4.34,4.44,
AXON,2009-12-16,4.47,4.58,4.44,4.49,
AXON,2009-12-17,4.45,4.5,4.43,4.46,
AXON,2009-12-18,4.49,4.49,4.35,4.47,
AXON,2009-12-21,4.48,4.5,4.39,4.44,
AXON,2009-12-22,4.44,4.56,4.41,4.5,
AXON,2009-12-23,4.5,4.5,4.36,4.47,
AXON,2009-12-24,4.5,4.5,4.4,4.41,
AXON,2009-12-28,4.4,4.4,4.27,4.35,
AXON,2009-12-29,4.34,4.49,4.33,4.35,
AXON,2009-12-30,4.35,4.45,4.32,4.35,
AXON,2009-12-31,4.4,4.43,4.32,4.38,
AXON,2010-01-04,4.46,4.66,4.41,4.65,
AXON,2010-01-05,4.62,4.72,4.62,4.7,
AXON,2010-01-06,5.05,5.95,5.03,5.84,
AXON,2010-01-07,5.74,6.05,5.46,5.66,
AXON,2010-01-08,5.64,5.8,5.43,5.56,
AXON,2010-01-11,5.62,6.36,5.52,6.19,
AXON,2010-01-12,6.13,6.43,5.91,5.93,
AXON,2010-01-13,6.08,6.4,6.0,6.27,
AXON,2010-01-14,6.28,6.69,6.26,6.39,
AXON,2010-01-15,6.42,6.43,5.99,6.29,
AXON,2010-01-19,6.32,6.69,6.29,6.32,
AXON,2010-01-20,6.29,6.36,6.11,6.25,
AXON,2010-01-21,6.25,6.28,5.86,5.88,
AXON,2010-01-22,5.88,6.09,5.58,5.74,
AXON,2010-01-25,5.77,5.93,5.64,5.8,
AXON,2010-01-26,5.76,5.87,5.65,5.82,
AXON,2010-01-27,5.8,5.95,5.78,5.92,
AXON,2010-01-28,5.96,5.96,5.8,5.9,
AXON,2010-01-29,5.91,6.0,5.56,5.64,
AXON,2010-02-01,5.71,5.91,5.66,5.89,
AXON,2010-02-02,5.91,5.98,5.83,5.97,
AXON,2010-02-03,5.93,6.0,5.81,5.85,
AXON,2010-02-04,5.78,5.8,5.63,5.63,
AXON,2010-02-05,5.62,5.65,5.33,5.47,
AXON,2010-02-08,5.49,5.67,5.47,5.51,
AXON,2010-02-09,5.57,5.71,5.55,5.66,
AXON,2010-02-10,5.73,5.77,5.58,5.67,
AXON,2010-02-11,5.65,5.84,5.56,5.77,
AXON,2010-02-12,5.62,5.72,5.57,5.72,
AXON,2010-02-16,5.76,5.99,5.73,5.95,
AXON,2010-02-17,6.0,6.5,5.99,6.41,
AXON,2010-02-18,6.47,6.61,6.32,6.58,
AXON,2010-02-19,6.86,7.34,6.82,7.15,
AXON,2010-02-22,7.16,7.88,7.15,7.63,
AXON,2010-02-23,7.5,7.7,6.94,6.97,
AXON,2010-02-24,7.01,7.26,7.0,7.23,
AXON,2010-02-25,7.03,7.29,6.95,7.25,
AXON,2010-02-26,7.28,7.75,7.27,7.56,
AXON,2010-03-01,7.25,7.27,6.88,6.98,
AXON,2010-03-02,7.05,7.1,6.79,7.02,
AXON,2010-03-03,7.04,7.09,6.8,6.93,
AXON,2010-03-04,6.92,7.02,6.68,6.78,
AXON,2010-03-05,6.84,6.99,6.79,6.97,
AXON,2010-03-08,7.06,7.1,6.87,6.99,
AXON,2010-03-09,6.95,7.35,6.95,7.15,
AXON,2010-03-10,7.2,7.29,7.02,7.07,
AXON,2010-03-11,7.06,7.16,7.0,7.03,
AXON,2010-03-12,7.1,7.1,6.91,6.94,
AXON,2010-03-15,6.96,7.09,6.86,6.89,
AXON,2010-03-16,6.88,6.96,6.77,6.78,
AXON,2010-03-17,6.85,6.88,6.68,6.7,
AXON,2010-03-18,6.75,6.78,6.39,6.39,
AXON,2010-03-19,6.43,6.49,6.32,6.32,
AXON,2010-03-22,6.27,6.48,6.15,6.44,
AXON,2010-03-23,6.42,6.6,6.4,6.6,
AXON,2010-03-24,6.58,6.72,6.52,6.63,
AXON,2010-03-25,6.7,6.74,6.29,6.31,
AXON,2010-03-26,6.32,6.37,5.87,6.0,
AXON,2010-03-29,6.01,6.07,5.9,6.06,
AXON,2010-03-30,6.07,6.11,5.97,6.03,
AXON,2010-03-31,6.01,6.03,5.86,5.87,
AXON,2010-04-01,5.93,5.97,5.76,5.78,
AXON,2010-04-05,5.61,5.64,5.35,5.59,
AXON,2010-04-06,5.6,5.8,5.54,5.62,
AXON,2010-04-07,5.6,5.72,5.5,5.54,
AXON,2010-04-08,5.54,5.57,5.43,5.48,
AXON,2010-04-09,5.5,5.6,5.37,5.52,
AXON,2010-04-12,5.49,5.57,5.4,5.47,
AXON,2010-04-13,5.47,5.47,5.27,5.33,
AXON,2010-04-14,5.39,5.43,5.33,5.43,
AXON,2010-04-15,5.44,5.46,5.27,5.37,
AXON,2010-04-16,5.37,5.4,5.21,5.21,
AXON,2010-04-19,5.27,5.4,5.2,5.3,
AXON,2010-04-20,5.35,5.43,5.31,5.39,
AXON,2010-04-21,5.39,5.43,5.31,5.38,
AXON,2010-04-22,5.34,5.63,5.32,5.61,
AXON,2010-04-23,5.33,5.39,4.87,4.9,
AXON,2010-04-26,4.93,4.96,4.74,4.77,
AXON,2010-04-27,4.92,5.07,4.8,4.95,
AXON,2010-04-28,4.99,4.99,4.8,4.83,
AXON,2010-04-29,4.86,4.9,4.81,4.87,
AXON,2010-04-30,4.86,4.91,4.73,4.75,
AXON,2010-05-03,4.76,4.85,4.61,4.84,
AXON,2010-05-04,4.79,4.81,4.69,4.76,
AXON,2010-05-05,4.74,4.78,4.65,4.75,
AXON,2010-05-06,4.72,4.78,4.48,4.61,
AXON,2010-05-07,4.55,4.65,4.4,4.41,
AXON,2010-05-10,4.63,4.67,4.52,4.65,
AXON,2010-05-11,4.6,4.76,4.56,4.68,
AXON,2010-05-12,4.68,4.9,4.65,4.89,
AXON,2010-05-13,4.9,5.17,4.85,5.1,
AXON,2010-05-14,5.05,5.12,4.89,5.04,
AXON,2010-05-17,5.07,5.1,4.95,5.06,
AXON,2010-05-18,5.11,5.17,4.93,4.96,
AXON,2010-05-19,4.95,4.98,4.83,4.86,
AXON,2010-05-20,4.75,4.82,4.52,4.52,
AXON,2010-05-21,4.45,4.64,4.45,4.52,
AXON,2010-05-24,4.53,4.62,4.34,4.34,
AXON,2010-05-25,4.21,4.37,4.11,4.33,
AXON,2010-05-26,4.35,4.53,4.3,4.34,
AXON,2010-05-27,4.44,4.53,4.35,4.53,
AXON,2010-05-28,4.52,4.55,4.25,4.47,
AXON,2010-06-01,4.41,4.47,4.13,4.13,
AXON,2010-06-02,4.18,4.33,4.14,4.32,
AXON,2010-06-03,4.32,4.4,4.15,4.32,
AXON,2010-06-04,4.21,4.32,4.18,4.28,
AXON,2010-06-07,4.29,4.35,4.12,4.13,
AXON,2010-06-08,4.15,4.19,4.07,4.1,
AXON,2010-06-09,4.15,4.2,4.1,4.12,
AXON,2010-06-10,4.17,4.22,4.08,4.18,
AXON,2010-06-11,4.16,4.23,4.1,4.13,
AXON,2010-06-14,4.18,4.27,4.18,4.2,
AXON,2010-06-15,4.23,4.25,3.98,4.2,
AXON,2010-06-16,4.15,4.18,4.05,4.16,
AXON,2010-06-17,4.15,4.18,4.11,4.18,
AXON,2010-06-18,4.21,4.22,4.13,4.15,
AXON,2010-06-21,4.21,4.24,4.0,4.01,
AXON,2010-06-22,4.02,4.08,3.81,3.85,
AXON,2010-06-23,3.86,3.96,3.83,3.94,
AXON,2010-06-24,3.93,4.05,3.92,3.96,
AXON,2010-06-25,3.96,4.07,3.88,4.07,
AXON,2010-06-28,4.02,4.07,3.96,3.98,
AXON,2010-06-29,3.9,3.95,3.79,3.8,
AXON,2010-06-30,3.81,4.13,3.81,3.9,
AXON,2010-07-01,3.58,3.79,3.55,3.7,
AXON,2010-07-02,3.71,3.75,3.59,3.71,
AXON,2010-07-06,3.77,3.96,3.68,3.74,
AXON,2010-07-07,3.76,3.84,3.7,3.79,
AXON,2010-07-08,3.82,3.85,3.68,3.77,
AXON,2010-07-09,3.75,3.87,3.66,3.87,
AXON,2010-07-12,3.85,3.94,3.75,3.86,
AXON,2010-07-13,3.9,4.0,3.86,4.0,
AXON,2010-07-14,4.0,4.02,3.82,3.84,
AXON,2010-07-15,3.83,3.89,3.73,3.76,
AXON,2010-07-16,3.75,3.78,3.62,3.73,
AXON,2010-07-19,3.72,3.81,3.72,3.78,
AXON,2010-07-20,3.73,3.86,3.72,3.85,
AXON,2010-07-21,3.87,4.39,3.84,4.33,
AXON,2010-07-22,4.4,4.42,4.26,4.4,
AXON,2010-07-23,4.39,4.39,4.16,4.2,
AXON,2010-07-26,4.24,4.38,4.17,4.37,
AXON,2010-07-27,4.29,4.62,4.22,4.25,
AXON,2010-07-28,4.26,4.28,4.05,4.11,
AXON,2010-07-29,4.13,4.14,3.9,3.91,
AXON,2010-07-30,3.87,4.14,3.87,4.1,
AXON,2010-08-02,4.18,4.18,4.01,4.1,
AXON,2010-08-03,4.07,4.11,4.01,4.04,
AXON,2010-08-04,4.07,4.13,4.0,4.04,
AXON,2010-08-05,4.0,4.07,4.0,4.01,
AXON,2010-08-06,3.96,4.09,3.92,4.06,
AXON,2010-08-09,4.1,4.1,4.02,4.08,
AXON,2010-08-10,4.02,4.15,4.0,4.06,
AXON,2010-08-11,4.0,4.03,3.92,3.94,
AXON,2010-08-12,3.89,4.03,3.85,3.99,
AXON,2010-08-13,3.96,4.04,3.87,3.87,
AXON,2010-08-16,3.85,3.97,3.85,3.95,
AXON,2010-08-17,4.0,4.06,3.96,4.06,
AXON,2010-08-18,4.04,4.04,3.95,4.0,
AXON,2010-08-19,4.0,4.02,3.82,3.82,
AXON,2010-08-20,3.82,3.9,3.8,3.86,
AXON,2010-08-23,3.87,3.93,3.82,3.86,
AXON,2010-08-24,3.8,3.9,3.63,3.63,
AXON,2010-08-25,3.6,3.65,3.52,3.62,
AXON,2010-08-26,3.62,3.69,3.54,3.58,
AXON,2010-08-27,3.63,3.72,3.58,3.72,
AXON,2010-08-30,3.69,3.72,3.64,3.64,
AXON,2010-08-31,3.63,3.74,3.62,3.63,
AXON,2010-09-01,3.75,3.91,3.73,3.9,
AXON,2010-09-02,3.9,3.98,3.87,3.97,
AXON,2010-09-03,4.0,4.01,3.93,3.99,
AXON,2010-09-07,3.99,4.0,3.92,3.92,
AXON,2010-09-08,3.94,3.98,3.91,3.93,
AXON,2010-09-09,3.98,3.98,3.9,3.95,
AXON,2010-09-10,3.95,4.0,3.87,3.9,
AXON,2010-09-13,3.96,4.06,3.93,4.05,
AXON,2010-09-14,4.03,4.04,3.95,3.98,
AXON,2010-09-15,3.97,4.01,3.89,3.93,
AXON,2010-09-16,3.91,3.97,3.89,3.9,
AXON,2010-09-17,3.95,3.96,3.8,3.88,
AXON,2010-09-20,3.9,4.01,3.86,4.0,
AXON,2010-09-21,3.98,4.01,3.95,3.95,
AXON,2010-09-22,3.92,3.98,3.87,3.94,
AXON,2010-09-23,3.9,3.99,3.86,3.86,
AXON,2010-09-24,3.9,4.0,3.89,3.98,
AXON,2010-09-27,3.85,3.93,3.84,3.91,
AXON,2010-09-28,3.91,3.92,3.8,3.82,
AXON,2010-09-29,3.81,3.9,3.81,3.84,
AXON,2010-09-30,3.87,3.89,3.82,3.88,
AXON,2010-10-01,3.88,3.89,3.82,3.88,
AXON,2010-10-04,3.9,3.93,3.61,3.61,
AXON,2010-10-05,3.71,3.95,3.7,3.95,
AXON,2010-10-06,3.93,4.1,3.82,4.0,
AXON,2010-10-07,4.03,4.12,3.98,4.12,
AXON,2010-10-08,4.11,4.13,4.05,4.06,
AXON,2010-10-11,4.04,4.1,3.99,4.01,
AXON,2010-10-12,4.01,4.07,3.99,4.06,
AXON,2010-10-13,4.07,4.2,4.05,4.16,
AXON,2010-10-14,4.17,4.26,4.14,4.15,
AXON,2010-10-15,4.21,4.24,4.13,4.18,
AXON,2010-10-18,4.18,4.49,4.16,4.49,
AXON,2010-10-19,4.42,4.57,4.24,4.26,
AXON,2010-10-20,4.29,4.53,4.29,4.46,
AXON,2010-10-21,4.49,4.61,4.4,4.54,
AXON,2010-10-22,4.54,4.59,4.5,4.53,
AXON,2010-10-25,4.58,4.59,4.43,4.45,
AXON,2010-10-26,4.42,4.53,4.41,4.43,
AXON,2010-10-27,4.27,4.28,3.99,4.13,
AXON,2010-10-28,4.15,4.16,3.93,3.95,
AXON,2010-10-29,3.93,4.01,3.88,3.97,
AXON,2010-11-01,3.99,4.04,3.86,3.89,
AXON,2010-11-02,3.94,3.99,3.9,3.92,
AXON,2010-11-03,3.94,4.0,3.9,3.97,
AXON,2010-11-04,3.99,4.18,3.97,4.12,
AXON,2010-11-05,4.12,4.2,4.07,4.11,
AXON,2010-11-08,4.1,4.14,4.03,4.11,
AXON,2010-11-09,4.08,4.27,4.08,4.21,
AXON,2010-11-10,4.2,4.21,4.13,4.17,
AXON,2010-11-11,4.12,4.15,4.0,4.04,
AXON,2010-11-12,4.0,4.07,3.91,3.92,
AXON,2010-11-15,3.95,4.15,3.94,4.06,
AXON,2010-11-16,4.02,4.07,3.99,4.03,
AXON,2010-11-17,4.03,4.13,4.02,4.12,
AXON,2010-11-18,4.16,4.21,4.12,4.21,
AXON,2010-11-19,4.22,4.3,4.21,4.27,
AXON,2010-11-22,4.25,4.29,4.07,4.1,
AXON,2010-11-23,4.05,4.09,4.0,4.04,
AXON,2010-11-24,4.07,4.2,4.05,4.11,
AXON,2010-11-26,4.08,4.25,4.08,4.16,
AXON,2010-11-29,4.16,4.19,4.05,4.08,
AXON,2010-11-30,4.03,4.1,4.0,4.03,
AXON,2010-12-01,4.1,4.17,4.04,4.11,
AXON,2010-12-02,4.11,4.15,4.07,4.1,
AXON,2010-12-03,4.07,4.14,4.04,4.1,
AXON,2010-12-06,4.07,4.2,4.06,4.13,
AXON,2010-12-07,4.19,4.2,4.08,4.09,
AXON,2010-12-08,4.15,4.92,4.14,4.88,
AXON,2010-12-09,4.84,4.85,4.53,4.55,
AXON,2010-12-10,4.55,4.69,4.41,4.57,
AXON,2010-12-13,4.57,4.82,4.56,4.67,
AXON,2010-12-14,4.67,4.85,4.57,4.59,
AXON,2010-12-15,4.6,4.66,4.48,4.52,
AXON,2010-12-16,4.52,4.69,4.52,4.67,
AXON,2010-12-17,4.66,4.95,4.57,4.88,
AXON,2010-12-20,4.93,5.1,4.87,4.87,
AXON,2010-12-21,4.88,5.07,4.86,4.88,
AXON,2010-12-22,4.88,4.92,4.69,4.8,
AXON,2010-12-23,4.81,4.85,4.7,4.74,
AXON,2010-12-27,4.71,4.87,4.65,4.84,
AXON,2010-12-28,4.83,4.95,4.78,4.85,
AXON,2010-12-29,4.87,4.88,4.74,4.77,
AXON,2010-12-30,4.76,4.79,4.71,4.72,
AXON,2010-12-31,4.71,4.75,4.65,4.7,
AXON,2011-01-03,4.76,5.02,4.75,5.0,
AXON,2011-01-04,4.98,5.09,4.77,4.77,
AXON,2011-01-05,4.77,4.88,4.69,4.88,
AXON,2011-01-06,4.92,4.98,4.74,4.77,
AXON,2011-01-07,4.8,4.88,4.72,4.79,
AXON,2011-01-10,4.75,4.83,4.68,4.78,
AXON,2011-01-11,4.8,4.91,4.76,4.87,
AXON,2011-01-12,4.91,4.91,4.77,4.79,
AXON,2011-01-13,4.77,4.82,4.74,4.77,
AXON,2011-01-14,4.73,4.81,4.7,4.81,
AXON,2011-01-18,4.77,4.84,4.71,4.75,
AXON,2011-01-19,4.92,4.94,4.76,4.76,
AXON,2011-01-20,4.77,4.83,4.69,4.69,
AXON,2011-01-21,4.75,4.76,4.6,4.61,
AXON,2011-01-24,4.6,4.7,4.56,4.6,
AXON,2011-01-25,4.6,4.61,4.15,4.2,
AXON,2011-01-26,4.2,4.34,4.14,4.15,
AXON,2011-01-27,4.16,4.24,4.16,4.22,
AXON,2011-01-28,4.21,4.27,4.19,4.2,
AXON,2011-01-31,4.25,4.26,4.17,4.19,
AXON,2011-02-01,4.22,4.3,4.18,4.3,
AXON,2011-02-02,4.28,4.35,4.22,4.22,
AXON,2011-02-03,4.22,4.26,4.12,4.13,
AXON,2011-02-04,4.11,4.17,4.07,4.12,
AXON,2011-02-07,4.11,4.17,4.06,4.13,
AXON,2011-02-08,4.11,4.16,4.11,4.15,
AXON,2011-02-09,4.15,4.15,4.11,4.12,
AXON,2011-02-10,4.12,4.15,4.05,4.05,
AXON,2011-02-11,4.05,4.06,3.99,4.01,
AXON,2011-02-14,4.03,4.22,4.0,4.1,
AXON,2011-02-15,4.1,4.17,4.06,4.09,
AXON,2011-02-16,4.19,4.34,4.13,4.25,
AXON,2011-02-17,4.26,4.34,4.09,4.27,
AXON,2011-02-18,4.28,4.3,4.17,4.29,
AXON,2011-02-22,4.22,4.35,4.16,4.17,
AXON,2011-02-23,4.1,4.12,3.9,3.96,
AXON,2011-02-24,3.94,4.01,3.74,3.76,
AXON,2011-02-25,3.78,3.86,3.75,3.84,
AXON,2011-02-28,3.84,3.86,3.72,3.78,
AXON,2011-03-01,3.78,3.8,3.68,3.69,
AXON,2011-03-02,3.69,3.9,3.69,3.89,
AXON,2011-03-03,4.0,4.1,3.91,4.09,
AXON,2011-03-04,4.07,4.1,4.0,4.06,
AXON,2011-03-07,4.05,4.07,4.01,4.02,
AXON,2011-03-08,3.98,4.12,3.98,4.09,
AXON,2011-03-09,4.08,4.2,4.06,4.18,
AXON,2011-03-10,4.1,4.18,4.04,4.09,
AXON,2011-03-11,4.06,4.2,4.03,4.16,
AXON,2011-03-14,4.1,4.14,4.0,4.0,
AXON,2011-03-15,3.99,4.0,3.85,3.96,
AXON,2011-03-16,3.94,3.96,3.84,3.85,
AXON,2011-03-17,3.89,3.91,3.76,3.76,
AXON,2011-03-18,3.8,3.84,3.72,3.78,
AXON,2011-03-21,3.84,3.92,3.79,3.83,
AXON,2011-03-22,3.81,3.84,3.73,3.73,
AXON,2011-03-23,3.73,3.78,3.72,3.76,
AXON,2011-03-24,3.8,4.05,3.8,4.04,
AXON,2011-03-25,4.07,4.17,4.0,4.1,
AXON,2011-03-28,4.13,4.2,3.69,3.96,
AXON,2011-03-29,4.02,4.2,3.9,4.12,
AXON,2011-03-30,4.15,4.15,4.03,4.04,
AXON,2011-03-31,4.03,4.1,4.02,4.06,
AXON,2011-04-01,4.09,4.19,3.99,4.03,
AXON,2011-04-04,4.07,4.07,3.97,4.06,
AXON,2011-04-05,4.02,4.2,4.02,4.09,
AXON,2011-04-06,4.1,4.18,4.09,4.09,
AXON,2011-04-07,4.05,4.11,4.01,4.02,
AXON,2011-04-08,4.03,4.04,3.86,3.89,
AXON,2011-04-11,3.92,3.97,3.88,3.9,
AXON,2011-04-12,3.87,3.92,3.8,3.83,
AXON,2011-04-13,3.9,3.9,3.79,3.81,
AXON,2011-04-14,3.8,3.91,3.79,3.89,
AXON,2011-04-15,3.88,3.92,3.84,3.9,
AXON,2011-04-18,3.85,3.87,3.84,3.85,
AXON,2011-04-19,3.9,4.06,3.88,3.89,
AXON,2011-04-20,3.96,4.1,3.96,4.09,
AXON,2011-04-21,4.14,4.24,3.94,3.96,
AXON,2011-04-25,4.18,4.44,4.14,4.44,
AXON,2011-04-26,4.46,4.5,4.27,4.4,
AXON,2011-04-27,4.4,4.47,4.32,4.46,
AXON,2011-04-28,4.4,4.47,4.39,4.45,
AXON,2011-04-29,4.46,4.5,4.4,4.46,
AXON,2011-05-02,4.44,4.47,4.39,4.42,
AXON,2011-05-03,4.41,4.41,4.29,4.39,
AXON,2011-05-04,4.35,4.41,4.27,4.34,
AXON,2011-05-05,4.31,4.42,4.29,4.39,
AXON,2011-05-06,4.39,4.46,4.35,4.39,
AXON,2011-05-09,4.37,4.54,4.35,4.44,
AXON,2011-05-10,4.47,4.68,4.39,4.6,
AXON,2011-05-11,4.59,4.66,4.48,4.5,
AXON,2011-05-12,4.45,4.68,4.43,4.65,
AXON,2011-05-13,4.64,4.68,4.52,4.53,
AXON,2011-05-16,4.5,4.59,4.45,4.5,
AXON,2011-05-17,4.5,4.56,4.36,4.4,
AXON,2011-05-18,4.4,4.55,4.38,4.54,
AXON,2011-05-19,4.52,4.56,4.45,4.51,
AXON,2011-05-20,4.55,4.55,4.46,4.48,
AXON,2011-05-23,4.4,4.57,4.35,4.48,
AXON,2011-05-24,4.49,4.5,4.38,4.38,
AXON,2011-05-25,4.4,4.54,4.37,4.54,
AXON,2011-05-26,4.49,4.6,4.41,4.6,
AXON,2011-05-27,4.61,4.72,4.6,4.65,
AXON,2011-05-31,4.59,4.64,4.4,4.53,
AXON,2011-06-01,4.53,4.54,4.4,4.46,
AXON,2011-06-02,4.46,4.57,4.46,4.48,
AXON,2011-06-03,4.45,4.49,4.4,4.43,
AXON,2011-06-06,4.43,4.52,4.43,4.46,
AXON,2011-06-07,4.49,4.49,4.41,4.41,
AXON,2011-06-08,4.4,4.41,4.28,4.29,
AXON,2011-06-09,4.29,4.34,4.28,4.3,
AXON,2011-06-10,4.27,4.35,4.26,4.3,
AXON,2011-06-13,4.3,4.36,4.27,4.3,
AXON,2011-06-14,4.39,4.49,4.29,4.35,
AXON,2011-06-15,4.3,4.37,4.23,4.23,
AXON,2011-06-16,4.23,4.32,4.15,4.27,
AXON,2011-06-17,4.3,4.33,4.17,4.24,
AXON,2011-06-20,4.2,4.29,4.2,4.23,
AXON,2011-06-21,4.26,4.32,4.21,4.24,
AXON,2011-06-22,4.22,4.31,4.15,4.28,
AXON,2011-06-23,4.23,4.38,4.17,4.38,
AXON,2011-06-24,4.38,4.38,4.25,4.26,
AXON,2011-06-27,4.31,4.4,4.24,4.4,
AXON,2011-06-28,4.4,4.53,4.3,4.49,
AXON,2011-06-29,4.49,4.5,4.44,4.48,
AXON,2011-06-30,4.48,4.55,4.45,4.55,
AXON,2011-07-01,4.55,4.58,4.52,4.57,
AXON,2011-07-05,4.55,4.58,4.46,4.49,
AXON,2011-07-06,4.48,4.53,4.43,4.49,
AXON,2011-07-07,4.51,4.54,4.46,4.52,
AXON,2011-07-08,4.44,4.52,4.41,4.5,
AXON,2011-07-11,4.46,4.49,4.41,4.43,
AXON,2011-07-12,4.42,4.49,4.35,4.38,
AXON,2011-07-13,4.4,4.43,4.31,4.35,
AXON,2011-07-14,4.34,4.39,4.25,4.26,
AXON,2011-07-15,4.27,4.32,4.25,4.29,
AXON,2011-07-18,4.26,4.26,4.17,4.17,
AXON,2011-07-19,4.22,4.29,4.17,4.27,
AXON,2011-07-20,4.15,4.28,4.14,4.28,
AXON,2011-07-21,4.28,4.32,4.19,4.3,
AXON,2011-07-22,4.27,4.28,4.21,4.21,
AXON,2011-07-25,4.15,4.25,4.15,4.23,
AXON,2011-07-26,4.2,4.23,4.18,4.21,
AXON,2011-07-27,4.18,4.18,4.08,4.11,
AXON,2011-07-28,4.1,4.17,4.06,4.14,
AXON,2011-07-29,4.1,4.28,4.08,4.11,
AXON,2011-08-01,4.16,4.28,4.13,4.26,
AXON,2011-08-02,4.23,4.34,4.14,4.15,
AXON,2011-08-03,4.17,4.29,4.04,4.27,
AXON,2011-08-04,4.24,4.26,4.1,4.1,
AXON,2011-08-05,4.13,4.16,3.98,4.0,
AXON,2011-08-08,3.83,4.02,3.61,3.62,
AXON,2011-08-09,3.68,3.89,3.55,3.89,
AXON,2011-08-10,3.85,3.9,3.57,3.59,
AXON,2011-08-11,3.62,3.93,3.6,3.85,
AXON,2011-08-12,3.88,3.91,3.77,3.89,
AXON,2011-08-15,3.93,4.0,3.86,3.98,
AXON,2011-08-16,3.92,4.1,3.91,4.01,
AXON,2011-08-17,4.02,4.14,4.0,4.07,
AXON,2011-08-18,4.04,4.05,3.81,3.82,
AXON,2011-08-19,3.77,3.92,3.73,3.78,
AXON,2011-08-22,3.86,3.94,3.76,3.8,
AXON,2011-08-23,3.81,4.14,3.78,4.11,
AXON,2011-08-24,4.09,4.27,4.02,4.26,
AXON,2011-08-25,4.27,4.29,4.12,4.12,
AXON,2011-08-26,4.11,4.34,4.08,4.26,
AXON,2011-08-29,4.34,4.5,4.27,4.5,
AXON,2011-08-30,4.46,4.52,4.42,4.48,
AXON,2011-08-31,4.52,4.6,4.39,4.45,
AXON,2011-09-01,4.44,4.53,4.31,4.33,
AXON,2011-09-02,4.25,4.29,4.2,4.21,
AXON,2011-09-06,4.17,4.34,4.13,4.33,
AXON,2011-09-07,4.39,4.47,4.36,4.45,
AXON,2011-09-08,4.4,4.46,4.35,4.39,
AXON,2011-09-09,4.33,4.38,4.18,4.24,
AXON,2011-09-12,4.16,4.33,4.16,4.32,
AXON,2011-09-13,4.33,4.47,4.33,4.45,
AXON,2011-09-14,4.47,4.54,4.4,4.49,
AXON,2011-09-15,4.49,4.56,4.45,4.54,
AXON,2011-09-16,4.57,4.59,4.35,4.53,
AXON,2011-09-19,4.45,4.58,4.38,4.51,
AXON,2011-09-20,4.54,4.54,4.4,4.4,
AXON,2011-09-21,4.4,4.49,4.22,4.24,
AXON,2011-09-22,4.17,4.32,4.15,4.22,
AXON,2011-09-23,4.21,4.5,4.2,4.28,
AXON,2011-09-26,4.35,4.47,4.29,4.46,
AXON,2011-09-27,4.53,4.56,4.45,4.51,
AXON,2011-09-28,4.49,4.54,4.33,4.33,
AXON,2011-09-29,4.44,4.5,4.27,4.42,
AXON,2011-09-30,4.34,4.48,4.31,4.31,
AXON,2011-10-03,4.27,4.45,4.21,4.21,
AXON,2011-10-04,4.18,4.28,4.04,4.26,
AXON,2011-10-05,4.26,4.33,4.19,4.2,
AXON,2011-10-06,4.2,4.45,4.2,4.45,
AXON,2011-10-07,4.47,4.53,4.36,4.43,
AXON,2011-10-10,4.49,4.57,4.44,4.57,
AXON,2011-10-11,4.51,4.65,4.51,4.61,
AXON,2011-10-12,4.64,4.67,4.54,4.6,
AXON,2011-10-13,4.55,4.59,4.52,4.56,
AXON,2011-10-14,4.62,4.75,4.56,4.62,
AXON,2011-10-17,4.66,4.68,4.49,4.5,
AXON,2011-10-18,4.52,4.73,4.47,4.7,
AXON,2011-10-19,4.67,4.7,4.58,4.61,
AXON,2011-10-20,4.61,4.7,4.52,4.66,
AXON,2011-10-21,4.74,4.81,4.68,4.79,
AXON,2011-10-24,4.79,4.93,4.77,4.89,
AXON,2011-10-25,4.76,4.9,4.76,4.84,
AXON,2011-10-26,4.89,4.92,4.77,4.92,
AXON,2011-10-27,4.96,5.02,4.92,5.02,
AXON,2011-10-28,5.0,5.0,4.83,4.84,
AXON,2011-10-31,4.85,5.04,4.84,4.97,
AXON,2011-11-01,4.91,5.04,4.86,4.95,
AXON,2011-11-02,5.02,5.18,5.01,5.18,
AXON,2011-11-03,5.2,5.49,5.13,5.47,
AXON,2011-11-04,5.4,5.5,5.3,5.44,
AXON,2011-11-07,5.38,5.55,5.3,5.51,
AXON,2011-11-08,5.51,5.65,5.43,5.6,
AXON,2011-11-09,5.45,5.5,5.38,5.42,
AXON,2011-11-10,5.46,5.53,5.4,5.45,
AXON,2011-11-11,5.51,5.56,5.41,5.55,
AXON,2011-11-14,5.57,5.87,5.56,5.73,
AXON,2011-11-15,5.67,5.83,5.62,5.8,
AXON,2011-11-16,5.76,5.85,5.7,5.71,
AXON,2011-11-17,5.71,5.86,5.7,5.76,
AXON,2011-11-18,5.79,5.89,5.72,5.85,
AXON,2011-11-21,5.73,5.91,5.68,5.87,
AXON,2011-11-22,5.87,6.11,5.87,5.97,
AXON,2011-11-23,5.94,5.96,5.65,5.66,
AXON,2011-11-25,5.64,5.8,5.54,5.57,
AXON,2011-11-28,5.76,5.95,5.6,5.89,
AXON,2011-11-29,5.87,5.95,5.82,5.83,
AXON,2011-11-30,6.0,6.08,5.97,6.02,
AXON,2011-12-01,5.99,6.22,5.86,6.14,
AXON,2011-12-02,6.16,6.27,6.08,6.11,
AXON,2011-12-05,6.23,6.23,6.09,6.15,
AXON,2011-12-06,6.11,6.49,6.08,6.38,
AXON,2011-12-07,6.36,6.44,6.3,6.36,
AXON,2011-12-08,6.31,6.33,6.21,6.22,
AXON,2011-12-09,6.23,6.39,6.23,6.33,
AXON,2011-12-12,6.24,6.28,6.1,6.14,
AXON,2011-12-13,6.17,6.21,5.76,5.79,
AXON,2011-12-14,5.74,5.85,5.62,5.74,
AXON,2011-12-15,5.82,5.83,5.66,5.68,
AXON,2011-12-16,5.75,5.8,5.61,5.66,
AXON,2011-12-19,5.7,5.95,5.5,5.52,
AXON,2011-12-20,5.61,5.8,5.61,5.7,
AXON,2011-12-21,5.68,5.75,5.52,5.7,
AXON,2011-12-22,5.73,5.75,5.57,5.59,
AXON,2011-12-23,5.59,5.63,5.38,5.39,
AXON,2011-12-27,5.37,5.44,5.27,5.4,
AXON,2011-12-28,5.4,5.48,5.34,5.39,
AXON,2011-12-29,5.41,5.47,5.31,5.38,
AXON,2011-12-30,5.36,5.38,5.11,5.12,
AXON,2012-01-03,5.24,5.34,5.23,5.3,
AXON,2012-01-04,5.27,5.33,5.15,5.15,
AXON,2012-01-05,5.13,5.19,4.95,5.15,
AXON,2012-01-06,5.15,5.2,5.07,5.12,
AXON,2012-01-09,5.14,5.17,5.1,5.15,
AXON,2012-01-10,5.16,5.27,5.12,5.21,
AXON,2012-01-11,5.17,5.2,5.08,5.16,
AXON,2012-01-12,5.19,5.23,5.11,5.22,
AXON,2012-01-13,5.17,5.18,5.08,5.16,
AXON,2012-01-17,5.16,5.32,5.07,5.08,
AXON,2012-01-18,5.13,5.29,5.13,5.26,
AXON,2012-01-19,5.27,5.31,5.07,5.11,
AXON,2012-01-20,5.1,5.11,4.89,4.92,
AXON,2012-01-23,4.92,4.98,4.86,4.91,
AXON,2012-01-24,4.89,4.89,4.8,4.86,
AXON,2012-01-25,4.84,4.84,4.8,4.83,
AXON,2012-01-26,4.83,4.84,4.64,4.7,
AXON,2012-01-27,4.66,4.73,4.6,4.7,
AXON,2012-01-30,4.67,4.79,4.65,4.67,
AXON,2012-01-31,4.7,4.77,4.64,4.76,
AXON,2012-02-01,4.78,4.96,4.76,4.95,
AXON,2012-02-02,4.97,5.05,4.86,4.91,
AXON,2012-02-03,4.97,5.01,4.87,4.98,
AXON,2012-02-06,4.94,4.97,4.8,4.91,
AXON,2012-02-07,4.95,4.95,4.8,4.81,
AXON,2012-02-08,4.85,4.9,4.76,4.89,
AXON,2012-02-09,4.91,4.94,4.86,4.92,
AXON,2012-02-10,4.85,4.92,4.8,4.8,
AXON,2012-02-13,4.82,4.87,4.71,4.76,
AXON,2012-02-14,4.75,4.77,4.54,4.57,
AXON,2012-02-15,4.57,4.58,4.44,4.45,
AXON,2012-02-16,4.45,4.45,4.23,4.26,
AXON,2012-02-17,4.27,4.5,4.22,4.49,
AXON,2012-02-21,4.54,4.6,4.42,4.44,
AXON,2012-02-22,4.5,4.56,4.42,4.5,
AXON,2012-02-23,4.4,4.49,4.05,4.21,
AXON,2012-02-24,4.23,4.32,4.14,4.17,
AXON,2012-02-27,4.15,4.16,3.99,4.05,
AXON,2012-02-28,4.08,4.21,4.05,4.17,
AXON,2012-02-29,4.19,4.22,4.03,4.03,
AXON,2012-03-01,4.13,4.35,4.12,4.22,
AXON,2012-03-02,4.22,4.27,4.05,4.05,
AXON,2012-03-05,4.08,4.09,4.01,4.04,
AXON,2012-03-06,4.04,4.07,3.98,3.99,
AXON,2012-03-07,4.0,4.04,3.98,3.99,
AXON,2012-03-08,4.05,4.05,3.99,4.01,
AXON,2012-03-09,4.07,4.12,4.03,4.05,
AXON,2012-03-12,4.04,4.1,4.02,4.06,
AXON,2012-03-13,4.09,4.14,4.05,4.12,
AXON,2012-03-14,4.14,4.14,4.01,4.04,
AXON,2012-03-15,4.05,4.08,4.0,4.07,
AXON,2012-03-16,4.1,4.1,4.0,4.05,
AXON,2012-03-19,4.05,4.09,4.02,4.05,
AXON,2012-03-20,4.03,4.08,3.98,3.98,
AXON,2012-03-21,4.07,4.25,4.03,4.19,
AXON,2012-03-22,4.22,4.59,4.19,4.56,
AXON,2012-03-23,4.56,4.56,4.28,4.34,
AXON,2012-03-26,4.35,4.5,4.35,4.41,
AXON,2012-03-27,4.43,4.65,4.42,4.6,
AXON,2012-03-28,4.6,4.65,4.34,4.4,
AXON,2012-03-29,4.36,4.44,4.28,4.34,
AXON,2012-03-30,4.38,4.47,4.34,4.34,
AXON,2012-04-02,4.41,4.41,4.29,4.34,
AXON,2012-04-03,4.35,4.43,4.3,4.31,
AXON,2012-04-04,4.26,4.28,4.16,4.18,
AXON,2012-04-05,4.15,4.19,4.04,4.09,
AXON,2012-04-09,4.03,4.1,3.96,3.96,
AXON,2012-04-10,3.97,4.08,3.96,4.07,
AXON,2012-04-11,4.11,4.14,4.08,4.12,
AXON,2012-04-12,4.13,4.22,4.1,4.2,
AXON,2012-04-13,4.2,4.2,4.06,4.09,
AXON,2012-04-16,4.09,4.15,4.05,4.09,
AXON,2012-04-17,4.12,4.27,4.12,4.22,
AXON,2012-04-18,4.19,4.21,4.12,4.15,
AXON,2012-04-19,4.17,4.19,4.07,4.13,
AXON,2012-04-20,4.17,4.2,4.04,4.08,
AXON,2012-04-23,4.02,4.05,4.0,4.01,
AXON,2012-04-24,4.02,4.11,4.0,4.11,
AXON,2012-04-25,4.12,4.2,4.11,4.16,
AXON,2012-04-26,4.45,4.58,4.29,4.33,
AXON,2012-04-27,4.54,4.55,4.43,4.45,
AXON,2012-04-30,4.6,4.65,4.52,4.6,
AXON,2012-05-01,4.61,4.7,4.52,4.64,
AXON,2012-05-02,4.68,4.94,4.6,4.9,
AXON,2012-05-03,4.93,4.96,4.77,4.92,
AXON,2012-05-04,4.89,4.92,4.75,4.76,
AXON,2012-05-07,4.74,4.86,4.67,4.83,
AXON,2012-05-08,4.78,5.06,4.73,5.05,
AXON,2012-05-09,4.96,5.06,4.76,5.04,
AXON,2012-05-10,5.06,5.25,4.98,5.24,
AXON,2012-05-11,5.17,5.34,5.11,5.2,
AXON,2012-05-14,5.13,5.29,4.95,5.2,
AXON,2012-05-15,5.19,5.27,5.15,5.16,
AXON,2012-05-16,5.16,5.27,5.13,5.16,
AXON,2012-05-17,5.19,5.32,5.04,5.05,
AXON,2012-05-18,5.08,5.2,5.07,5.13,
AXON,2012-05-21,5.15,5.39,5.09,5.32,
AXON,2012-05-22,5.34,5.4,5.26,5.27,
AXON,2012-05-23,5.26,5.41,5.26,5.4,
AXON,2012-05-24,5.42,5.51,5.31,5.4,
AXON,2012-05-25,5.39,5.54,5.36,5.46,
AXON,2012-05-29,5.48,5.55,5.36,5.46,
AXON,2012-05-30,5.4,5.43,5.32,5.32,
AXON,2012-05-31,5.31,5.46,5.23,5.38,
AXON,2012-06-01,5.27,5.35,5.22,5.25,
AXON,2012-06-04,5.27,5.31,5.16,5.19,
AXON,2012-06-05,5.19,5.23,5.06,5.16,
AXON,2012-06-06,5.18,5.34,5.18,5.32,
AXON,2012-06-07,5.43,5.43,5.21,5.22,
AXON,2012-06-08,5.2,5.31,5.19,5.25,
AXON,2012-06-11,5.3,5.37,5.25,5.27,
AXON,2012-06-12,5.29,5.34,5.19,5.32,
AXON,2012-06-13,5.31,5.32,5.18,5.2,
AXON,2012-06-14,5.19,5.28,5.09,5.17,
AXON,2012-06-15,5.17,5.2,5.06,5.07,
AXON,2012-06-18,5.16,5.39,5.15,5.37,
AXON,2012-06-19,5.4,5.58,5.37,5.44,
AXON,2012-06-20,5.47,5.51,5.41,5.43,
AXON,2012-06-21,5.41,5.45,5.27,5.29,
AXON,2012-06-22,5.31,5.34,5.22,5.29,
AXON,2012-06-25,5.2,5.25,5.15,5.21,
AXON,2012-06-26,5.27,5.51,5.23,5.4,
AXON,2012-06-27,5.38,5.39,5.16,5.2,
AXON,2012-06-28,5.17,5.21,4.95,4.99,
AXON,2012-06-29,5.1,5.32,5.01,5.24,
AXON,2012-07-02,5.21,5.29,5.11,5.29,
AXON,2012-07-03,5.2,5.3201,5.2,5.32,
AXON,2012-07-05,5.29,5.34,5.22,5.33,
AXON,2012-07-06,5.25,5.29,5.17,5.23,
AXON,2012-07-09,5.22,5.4,5.14,5.34,
AXON,2012-07-10,5.35,5.39,5.15,5.16,
AXON,2012-07-11,5.18,5.24,5.0,5.03,
AXON,2012-07-12,4.99,5.09,4.85,5.06,
AXON,2012-07-13,5.06,5.19,5.0009,5.13,
AXON,2012-07-16,5.08,5.22,5.07,5.2,
AXON,2012-07-17,5.21,5.2323,5.0601,5.23,
AXON,2012-07-18,5.2,5.31,4.95,5.01,
AXON,2012-07-19,5.02,5.06,4.85,4.86,
AXON,2012-07-20,4.82,4.87,4.75,4.84,
AXON,2012-07-23,4.75,4.77,4.62,4.68,
AXON,2012-07-24,4.7,4.75,4.6,4.745,
AXON,2012-07-25,4.79,4.93,4.76,4.87,
AXON,2012-07-26,5.21,5.4,5.16,5.3,
AXON,2012-07-27,5.35,5.49,5.23,5.38,
AXON,2012-07-30,5.4,5.5,5.39,5.45,
AXON,2012-07-31,5.42,5.49,5.39,5.41,
AXON,2012-08-01,5.44,5.48,5.3,5.34,
AXON,2012-08-02,5.31,5.59,5.26,5.5,
AXON,2012-08-03,5.6,5.63,5.48,5.491,
AXON,2012-08-06,5.51,5.595,5.48,5.55,
AXON,2012-08-07,5.58,5.69,5.53,5.61,
AXON,2012-08-08,5.6,5.665,5.53,5.65,
AXON,2012-08-09,5.64,5.7,5.6,5.69,
AXON,2012-08-10,5.67,5.7,5.58,5.59,
AXON,2012-08-13,5.56,5.5898,5.39,5.545,
AXON,2012-08-14,5.56,5.62,5.4,5.45,
AXON,2012-08-15,5.53,5.57,5.46,5.5,
AXON,2012-08-16,5.51,5.59,5.49,5.54,
AXON,2012-08-17,5.53,5.57,5.42,5.46,
AXON,2012-08-20,5.43,5.56,5.39,5.55,
AXON,2012-08-21,5.55,5.59,5.5,5.51,
AXON,2012-08-22,5.5,5.51,5.37,5.42,
AXON,2012-08-23,5.43,5.44,5.25,5.39,
AXON,2012-08-24,5.36,5.41,5.27,5.29,
AXON,2012-08-27,5.29,5.515,5.29,5.45,
AXON,2012-08-28,5.44,5.565,5.4,5.55,
AXON,2012-08-29,5.53,5.59,5.49,5.555,
AXON,2012-08-30,5.47,5.545,5.45,5.5,
AXON,2012-08-31,5.54,5.54,5.34,5.35,
AXON,2012-09-04,5.35,5.43,5.3199,5.42,
AXON,2012-09-05,5.4,5.47,5.35,5.35,
AXON,2012-09-06,5.4,5.531,5.39,5.42,
AXON,2012-09-07,5.47,5.51,5.41,5.5,
AXON,2012-09-10,5.45,5.51,5.16,5.17,
AXON,2012-09-11,5.23,5.48,5.23,5.47,
AXON,2012-09-12,5.47,5.55,5.39,5.45,
AXON,2012-09-13,5.43,5.48,5.319,5.42,
AXON,2012-09-14,5.42,5.77,5.41,5.745,
AXON,2012-09-17,5.7,6.12,5.66,5.99,
AXON,2012-09-18,6.29,6.3999,5.9,5.965,
AXON,2012-09-19,5.99,5.99,5.75,5.77,
AXON,2012-09-20,5.75,5.81,5.67,5.78,
AXON,2012-09-21,5.84,5.85,5.66,5.68,
AXON,2012-09-24,5.61,5.71,5.57,5.61,
AXON,2012-09-25,5.63,5.9,5.61,5.84,
AXON,2012-09-26,5.82,5.93,5.72,5.88,
AXON,2012-09-27,5.92,6.07,5.89,6.04,
AXON,2012-09-28,6.01,6.11,5.94,6.035,
AXON,2012-10-01,6.01,6.15,6.01,6.15,
AXON,2012-10-02,6.22,6.22,5.94,6.05,
AXON,2012-10-03,6.06,6.06,5.81,5.91,
AXON,2012-10-04,5.9,6.0,5.88,5.985,
AXON,2012-10-05,5.97,6.0,5.85,5.96,
AXON,2012-10-08,5.9,6.02,5.88,5.97,
AXON,2012-10-09,6.0,6.08,5.83,5.85,
AXON,2012-10-10,5.84,6.01,5.75,5.95,
AXON,2012-10-11,6.0,6.0,5.88,5.92,
AXON,2012-10-12,5.91,6.0,5.87,5.99,
AXON,2012-10-15,5.98,6.1,5.9,6.09,
AXON,2012-10-16,6.1,6.24,6.0817,6.21,
AXON,2012-10-17,6.2,6.48,6.2,6.4,
AXON,2012-10-18,6.38,6.47,6.27,6.43,
AXON,2012-10-19,6.37,6.45,6.27,6.38,
AXON,2012-10-22,6.38,6.54,6.3,6.42,
AXON,2012-10-23,6.38,6.52,6.31,6.52,
AXON,2012-10-24,6.52,6.65,6.46,6.51,
AXON,2012-10-25,6.54,6.54,6.38,6.39,
AXON,2012-10-26,6.83,8.45,6.83,8.07,
AXON,2012-10-31,8.0,8.15,7.76,7.81,
AXON,2012-11-01,7.8,8.15,7.8,8.06,
AXON,2012-11-02,8.05,8.1,7.87,7.92,
AXON,2012-11-05,7.9,8.21,7.64,8.14,
AXON,2012-11-06,8.09,8.41,7.97,8.24,
AXON,2012-11-07,8.14,8.24,7.81,8.16,
AXON,2012-11-08,8.16,8.25,7.97,8.0914,
AXON,2012-11-09,8.02,8.22,8.01,8.04,
AXON,2012-11-12,8.03,8.06,7.865,7.95,
AXON,2012-11-13,7.84,8.05,7.83,7.96,
AXON,2012-11-14,8.0,8.07,7.8,7.88,
AXON,2012-11-15,7.86,7.94,7.55,7.68,
AXON,2012-11-16,7.51,7.75,7.5,7.7,
AXON,2012-11-19,7.76,8.16,7.69,8.11,
AXON,2012-11-20,8.06,8.18,7.9584,8.07,
AXON,2012-11-21,8.05,8.25,8.0111,8.13,
AXON,2012-11-23,8.14,8.2,8.01,8.07,
AXON,2012-11-26,8.04,8.58,7.89,8.54,
AXON,2012-11-27,8.49,8.99,8.4401,8.72,
AXON,2012-11-28,8.5901,9.26,8.45,9.02,
AXON,2012-11-29,8.63,8.67,8.15,8.28,
AXON,2012-11-30,8.27,8.48,8.2,8.26,
AXON,2012-12-03,8.29,8.3,7.71,8.1202,
AXON,2012-12-04,8.0,8.33,8.0,8.3,
AXON,2012-12-05,8.32,8.35,8.013,8.15,
AXON,2012-12-06,8.26,8.36,8.08,8.24,
AXON,2012-12-07,8.24,8.29,8.12,8.27,
AXON,2012-12-10,8.14,8.35,8.14,8.2,
AXON,2012-12-11,8.16,8.28,8.14,8.22,
AXON,2012-12-12,8.26,8.2899,7.94,7.94,
AXON,2012-12-13,7.96,8.015,7.51,7.69,
AXON,2012-12-14,7.65,7.74,7.55,7.65,
AXON,2012-12-17,7.68,7.98,7.61,7.65,
AXON,2012-12-18,7.84,8.46,7.7,8.46,
AXON,2012-12-19,8.43,8.52,8.14,8.15,
AXON,2012-12-20,8.38,8.87,8.2,8.75,
AXON,2012-12-21,8.56,9.12,8.34,8.69,
AXON,2012-12-24,8.77,8.91,8.67,8.76,
AXON,2012-12-26,8.8,8.88,8.58,8.63,
AXON,2012-12-27,8.63,8.71,8.39,8.65,
AXON,2012-12-28,8.6,8.9,8.5814,8.63,
AXON,2012-12-31,8.62,9.02,8.51,8.94,
AXON,2013-01-02,9.1,9.14,8.68,8.94,
AXON,2013-01-03,9.54,9.8,9.13,9.22,
AXON,2013-01-04,9.34,9.43,9.1,9.24,
AXON,2013-01-07,9.24,9.2999,8.86,9.0,
AXON,2013-01-08,8.98,9.22,8.98,9.14,
AXON,2013-01-09,9.14,9.56,9.14,9.44,
AXON,2013-01-10,9.47,9.57,9.22,9.34,
AXON,2013-01-11,9.35,9.45,9.22,9.36,
AXON,2013-01-14,9.41,9.49,9.2,9.22,
AXON,2013-01-15,9.21,9.41,9.1,9.39,
AXON,2013-01-16,9.35,9.382,9.17,9.25,
AXON,2013-01-17,9.3,9.56,9.15,9.42,
AXON,2013-01-18,9.46,9.5,9.16,9.31,
AXON,2013-01-22,9.31,9.52,9.2,9.46,
AXON,2013-01-23,9.46,9.5,9.1701,9.33,
AXON,2013-01-24,9.3,9.53,9.21,9.35,
AXON,2013-01-25,9.36,9.41,9.1,9.18,
AXON,2013-01-28,9.24,9.24,8.7,8.82,
AXON,2013-01-29,8.84,8.99,8.77,8.87,
AXON,2013-01-30,8.84,8.94,8.26,8.35,
AXON,2013-01-31,8.32,8.62,8.25,8.37,
AXON,2013-02-01,8.44,8.59,8.4,8.41,
AXON,2013-02-04,8.35,8.41,8.03,8.04,
AXON,2013-02-05,8.06,8.26,8.06,8.24,
AXON,2013-02-06,8.21,8.29,8.1,8.17,
AXON,2013-02-07,8.23,8.25,7.94,8.09,
AXON,2013-02-08,8.09,8.49,8.06,8.37,
AXON,2013-02-11,8.37,8.6299,8.29,8.56,
AXON,2013-02-12,8.57,8.8,8.51,8.77,
AXON,2013-02-13,8.83,8.85,8.39,8.48,
AXON,2013-02-14,8.45,8.86,8.45,8.82,
AXON,2013-02-15,8.87,8.89,8.55,8.68,
AXON,2013-02-19,8.71,8.8,8.35,8.5,
AXON,2013-02-20,8.51,8.78,8.37,8.59,
AXON,2013-02-21,8.59,8.79,6.7,6.9,
AXON,2013-02-22,7.38,7.55,6.98,7.12,
AXON,2013-02-25,7.22,7.25,6.82,6.85,
AXON,2013-02-26,7.14,7.16,6.85,6.93,
AXON,2013-02-27,6.93,7.13,6.93,7.02,
AXON,2013-02-28,7.27,7.52,7.25,7.47,
AXON,2013-03-01,7.32,7.64,7.18,7.51,
AXON,2013-03-04,7.47,7.87,7.43,7.85,
AXON,2013-03-05,7.91,7.96,7.76,7.93,
AXON,2013-03-06,7.92,8.06,7.88,7.91,
AXON,2013-03-07,7.89,8.0,7.86,7.99,
AXON,2013-03-08,8.05,8.06,7.8,7.87,
AXON,2013-03-11,7.84,7.9,7.75,7.88,
AXON,2013-03-12,7.84,7.86,7.74,7.82,
AXON,2013-03-13,7.82,7.84,7.7,7.83,
AXON,2013-03-14,7.87,7.9,7.75,7.87,
AXON,2013-03-15,7.84,7.89,7.67,7.79,
AXON,2013-03-18,7.7,7.89,7.67,7.79,
AXON,2013-03-19,7.78,7.89,7.67,7.87,
AXON,2013-03-20,7.94,8.1,7.93,8.06,
AXON,2013-03-21,7.92,8.17,7.92,8.04,
AXON,2013-03-22,8.08,8.24,7.99,8.15,
AXON,2013-03-25,8.16,8.2,7.95,8.02,
AXON,2013-03-26,8.04,8.1,7.975,8.02,
AXON,2013-03-27,7.95,7.9899,7.8,7.95,
AXON,2013-03-28,7.97,8.05,7.86,7.95,
AXON,2013-04-01,7.93,7.93,7.51,7.61,
AXON,2013-04-02,7.66,7.89,7.51,7.52,
AXON,2013-04-03,7.52,7.65,7.24,7.37,
AXON,2013-04-04,7.35,7.62,7.31,7.52,
AXON,2013-04-05,7.39,7.72,7.39,7.67,
AXON,2013-04-08,7.67,7.78,7.5,7.74,
AXON,2013-04-09,7.73,7.74,7.52,7.7,
AXON,2013-04-10,7.74,8.12,7.72,8.06,
AXON,2013-04-11,8.03,8.3,7.91,8.26,
AXON,2013-04-12,8.19,8.3,8.02,8.09,
AXON,2013-04-15,8.06,8.17,7.61,7.65,
AXON,2013-04-16,7.75,7.95,7.7,7.93,
AXON,2013-04-17,7.91,7.97,7.69,7.93,
AXON,2013-04-18,7.93,8.025,7.78,7.93,
AXON,2013-04-19,7.95,8.11,7.895,8.03,
AXON,2013-04-22,8.06,8.06,7.78,7.98,
AXON,2013-04-23,8.02,8.15,8.01,8.14,
AXON,2013-04-24,8.14,8.37,8.09,8.3,
AXON,2013-04-25,8.55,9.1,8.45,8.88,
AXON,2013-04-26,8.86,9.22,8.81,8.95,
AXON,2013-04-29,8.99,8.99,8.7,8.72,
AXON,2013-04-30,8.7,8.9,8.55,8.81,
AXON,2013-05-01,8.81,8.85,8.57,8.64,
AXON,2013-05-02,8.66,8.84,8.5699,8.74,
AXON,2013-05-03,8.83,8.98,8.69,8.78,
AXON,2013-05-06,8.8,9.0,8.69,9.0,
AXON,2013-05-07,8.94,9.1,8.84,9.0,
AXON,2013-05-08,9.0,9.04,8.885,8.98,
AXON,2013-05-09,8.98,9.17,8.915,9.0,
AXON,2013-05-10,8.98,9.13,8.96,9.05,
AXON,2013-05-13,9.03,9.16,8.86,8.94,
AXON,2013-05-14,8.93,9.17,8.93,9.1,
AXON,2013-05-15,9.09,9.14,8.95,9.0,
AXON,2013-05-16,8.95,9.05,8.91,8.97,
AXON,2013-05-17,8.99,9.07,8.97,9.06,
AXON,2013-05-20,9.02,9.53,8.99,9.21,
AXON,2013-05-21,9.2,9.21,8.87,8.91,
AXON,2013-05-22,8.94,9.09,8.51,8.53,
AXON,2013-05-23,8.5,9.13,8.45,9.12,
AXON,2013-05-24,9.12,9.65,9.1,9.55,
AXON,2013-05-28,9.64,9.79,9.47,9.59,
AXON,2013-05-29,9.5,9.68,9.4,9.58,
AXON,2013-05-30,9.59,9.74,9.49,9.53,
AXON,2013-05-31,9.46,9.67,9.35,9.49,
AXON,2013-06-03,9.51,9.62,9.28,9.5,
AXON,2013-06-04,9.51,9.59,9.39,9.48,
AXON,2013-06-05,9.45,9.5,9.13,9.23,
AXON,2013-06-06,9.22,9.41,9.15,9.4,
AXON,2013-06-07,9.45,9.48,9.31,9.43,
AXON,2013-06-10,9.41,9.5,9.31,9.4,
AXON,2013-06-11,9.29,9.45,9.21,9.37,
AXON,2013-06-12,9.45,9.48,9.311,9.41,
AXON,2013-06-13,9.38,9.47,9.3299,9.41,
AXON,2013-06-14,9.44,9.47,9.2,9.26,
AXON,2013-06-17,9.33,9.42,9.32,9.4,
AXON,2013-06-18,9.39,9.43,9.27,9.4,
AXON,2013-06-19,9.4,9.4,9.11,9.21,
AXON,2013-06-20,9.1,9.1155,8.82,8.86,
AXON,2013-06-21,8.88,9.09,8.8,8.91,
AXON,2013-06-24,8.8,9.03,8.69,8.785,
AXON,2013-06-25,8.88,8.94,8.6,8.72,
AXON,2013-06-26,8.74,8.74,8.57,8.59,
AXON,2013-06-27,8.62,8.73,8.59,8.64,
AXON,2013-06-28,8.59,8.7,8.43,8.52,
AXON,2013-07-01,8.58,8.9,8.546,8.84,
AXON,2013-07-02,8.85,9.021,8.52,8.57,
AXON,2013-07-03,8.55,8.8,8.51,8.73,
AXON,2013-07-05,8.88,8.98,8.75,8.98,
AXON,2013-07-08,9.03,9.0699,8.84,8.89,
AXON,2013-07-09,8.95,8.99,8.77,8.885,
AXON,2013-07-10,8.95,9.03,8.86,9.01,
AXON,2013-07-11,9.15,9.22,9.0101,9.22,
AXON,2013-07-12,9.2,9.3,9.13,9.2,
AXON,2013-07-15,9.19,9.28,9.04,9.1,
AXON,2013-07-16,9.12,9.23,9.0701,9.11,
AXON,2013-07-17,9.15,9.17,8.96,9.09,
AXON,2013-07-18,9.13,9.18,9.05,9.09,
AXON,2013-07-19,9.06,9.06,8.9,9.0,
AXON,2013-07-22,8.98,9.08,8.97,8.98,
AXON,2013-07-23,9.02,9.06,8.75,8.91,
AXON,2013-07-24,8.93,9.01,8.9,8.95,
AXON,2013-07-25,8.91,8.9599,8.77,8.83,
AXON,2013-07-26,8.76,8.99,8.75,8.94,
AXON,2013-07-29,8.94,9.01,8.88,8.96,
AXON,2013-07-30,9.0,9.03,8.93,8.93,
AXON,2013-07-31,9.0,9.02,8.43,8.88,
AXON,2013-08-01,8.98,9.052,8.89,8.91,
AXON,2013-08-02,8.89,8.9,8.73,8.84,
AXON,2013-08-05,8.84,8.9,8.73,8.77,
AXON,2013-08-06,8.69,8.73,8.62,8.7,
AXON,2013-08-07,8.7,8.79,8.635,8.72,
AXON,2013-08-08,8.75,8.84,8.63,8.74,
AXON,2013-08-09,8.74,8.83,8.66,8.66,
AXON,2013-08-12,8.64,8.6945,8.58,8.6,
AXON,2013-08-13,8.6,8.74,8.57,8.7,
AXON,2013-08-14,8.74,9.4,8.74,9.34,
AXON,2013-08-15,9.33,10.12,9.28,9.8,
AXON,2013-08-16,9.89,10.46,9.89,10.21,
AXON,2013-08-19,10.18,10.77,10.0,10.43,
AXON,2013-08-20,10.5,10.99,10.38,10.87,
AXON,2013-08-21,11.05,11.5,10.9,11.19,
AXON,2013-08-22,11.24,11.46,11.03,11.37,
AXON,2013-08-23,11.4,11.47,11.27,11.39,
AXON,2013-08-26,11.37,11.79,11.22,11.49,
AXON,2013-08-27,11.47,12.17,11.36,11.85,
AXON,2013-08-28,11.49,11.68,11.05,11.15,
AXON,2013-08-29,11.09,12.1,11.06,11.92,
AXON,2013-08-30,12.0,12.12,11.6,11.64,
AXON,2013-09-03,11.9,11.99,11.7,11.97,
AXON,2013-09-04,12.0,12.68,12.0,12.37,
AXON,2013-09-05,12.33,12.53,12.24,12.26,
AXON,2013-09-06,12.3,12.42,11.88,12.13,
AXON,2013-09-09,12.16,12.3,11.98,12.15,
AXON,2013-09-10,12.21,12.49,12.16,12.28,
AXON,2013-09-11,12.27,12.62,12.16,12.48,
AXON,2013-09-12,12.45,12.48,12.21,12.26,
AXON,2013-09-13,12.32,12.37,12.04,12.33,
AXON,2013-09-16,12.69,13.42,12.53,13.16,
AXON,2013-09-17,13.21,13.37,13.02,13.26,
AXON,2013-09-18,13.5,14.2,13.36,14.09,
AXON,2013-09-19,14.15,14.42,14.01,14.255,
AXON,2013-09-20,14.6,15.22,14.35,14.79,
AXON,2013-09-23,14.83,14.85,14.21,14.49,
AXON,2013-09-24,14.44,15.09,14.42,14.65,
AXON,2013-09-25,14.66,15.3,14.66,14.96,
AXON,2013-09-26,15.03,15.2,14.9,15.15,
AXON,2013-09-27,15.04,15.14,14.71,14.86,
AXON,2013-09-30,14.61,15.16,14.37,14.88,
AXON,2013-10-01,14.89,15.96,14.89,15.94,
AXON,2013-10-02,15.97,17.16,15.62,16.65,
AXON,2013-10-03,16.36,16.57,14.51,14.9,
AXON,2013-10-04,14.85,15.28,13.45,14.03,
AXON,2013-10-07,14.15,15.18,13.85,14.65,
AXON,2013-10-08,14.87,15.82,14.63,14.73,
AXON,2013-10-09,14.91,15.22,14.25,14.54,
AXON,2013-10-10,14.8,15.36,14.75,15.09,
AXON,2013-10-11,15.12,15.37,14.86,15.11,
AXON,2013-10-14,14.97,15.18,14.63,15.12,
AXON,2013-10-15,15.04,15.25,14.8,14.93,
AXON,2013-10-16,15.0,15.26,14.91,15.11,
AXON,2013-10-17,15.09,15.8,15.08,15.7,
AXON,2013-10-18,15.85,16.14,15.58,15.81,
AXON,2013-10-21,15.88,15.95,15.16,15.43,
AXON,2013-10-22,15.48,15.66,15.28,15.52,
AXON,2013-10-23,15.47,15.61,15.24,15.35,
AXON,2013-10-24,15.38,15.6,15.24,15.35,
AXON,2013-10-25,15.4,15.58,14.93,15.09,
AXON,2013-10-28,15.04,15.25,14.99,15.25,
AXON,2013-10-29,15.25,15.73,15.25,15.66,
AXON,2013-10-30,16.34,18.32,16.31,17.97,
AXON,2013-10-31,18.01,18.52,17.6,17.779,
AXON,2013-11-01,17.71,17.89,16.81,16.86,
AXON,2013-11-04,16.87,17.82,16.87,17.32,
AXON,2013-11-05,17.36,17.81,17.26,17.6,
AXON,2013-11-06,17.73,17.89,16.92,17.17,
AXON,2013-11-07,17.2,17.42,15.9,16.01,
AXON,2013-11-08,15.98,17.08,15.8,16.87,
AXON,2013-11-11,16.86,17.13,16.56,16.76,
AXON,2013-11-12,16.77,17.0,16.35,16.46,
AXON,2013-11-13,16.36,17.84,16.3,17.71,
AXON,2013-11-14,17.75,17.89,17.22,17.31,
AXON,2013-11-15,17.26,17.82,17.2,17.49,
AXON,2013-11-18,17.72,17.8,17.01,17.08,
AXON,2013-11-19,17.15,17.47,16.59,16.7,
AXON,2013-11-20,16.82,17.24,16.67,16.81,
AXON,2013-11-21,16.83,17.17,16.75,16.99,
AXON,2013-11-22,17.04,17.65,16.79,17.5,
AXON,2013-11-25,17.75,18.4,17.56,17.76,
AXON,2013-11-26,17.83,18.02,17.65,17.76,
AXON,2013-11-27,17.71,17.87,17.43,17.6,
AXON,2013-11-29,17.59,17.689,17.17,17.19,
AXON,2013-12-02,17.25,17.45,16.53,16.6,
AXON,2013-12-03,16.49,16.58,15.96,16.18,
AXON,2013-12-04,16.21,16.38,15.78,16.01,
AXON,2013-12-05,16.02,16.56,15.89,16.51,
AXON,2013-12-06,16.64,16.98,16.4,16.8,
AXON,2013-12-09,16.84,17.04,16.63,16.73,
AXON,2013-12-10,16.84,17.3,16.84,16.91,
AXON,2013-12-11,17.01,17.1,16.25,16.4,
AXON,2013-12-12,16.37,16.81,16.23,16.44,
AXON,2013-12-13,16.39,16.505,15.23,15.52,
AXON,2013-12-16,16.05,17.17,15.94,16.89,
AXON,2013-12-17,16.94,16.98,16.25,16.28,
AXON,2013-12-18,16.29,16.81,16.05,16.77,
AXON,2013-12-19,16.68,16.68,16.1,16.14,
AXON,2013-12-20,16.22,16.43,16.09,16.2,
AXON,2013-12-23,16.27,16.33,15.851,15.94,
AXON,2013-12-24,15.92,16.24,15.81,16.16,
AXON,2013-12-26,16.27,16.54,16.21,16.4,
AXON,2013-12-27,16.45,16.69,15.87,15.95,
AXON,2013-12-30,16.0,16.08,15.85,15.9,
AXON,2013-12-31,15.91,16.15,15.8,15.88,
AXON,2014-01-02,15.84,15.84,14.89,15.38,
AXON,2014-01-03,15.32,15.74,15.32,15.67,
AXON,2014-01-06,15.79,15.92,15.29,15.64,
AXON,2014-01-07,15.62,15.91,15.45,15.91,
AXON,2014-01-08,16.51,18.57,16.5,17.93,
AXON,2014-01-09,17.97,18.12,17.42,17.79,
AXON,2014-01-10,17.79,18.88,17.5,18.68,
AXON,2014-01-13,18.66,18.68,17.34,17.49,
AXON,2014-01-14,17.64,18.14,17.45,18.07,
AXON,2014-01-15,18.12,18.19,17.65,17.94,
AXON,2014-01-16,17.94,18.07,17.5,17.57,
AXON,2014-01-17,17.6,17.79,17.32,17.67,
AXON,2014-01-21,17.75,18.6,17.6,17.79,
AXON,2014-01-22,17.86,18.12,17.35,18.0,
AXON,2014-01-23,17.9,17.98,17.53,17.71,
AXON,2014-01-24,17.51,17.52,16.6,16.74,
AXON,2014-01-27,16.78,16.88,16.08,16.52,
AXON,2014-01-28,16.53,16.97,16.3,16.65,
AXON,2014-01-29,16.41,16.6,15.8,15.89,
AXON,2014-01-30,16.12,16.52,16.0,16.3,
AXON,2014-01-31,16.08,16.32,15.93,16.06,
AXON,2014-02-03,16.63,17.52,16.63,16.9,
AXON,2014-02-04,16.98,17.13,16.46,16.83,
AXON,2014-02-05,16.62,16.7,15.76,16.52,
AXON,2014-02-06,16.47,17.09,16.41,16.72,
AXON,2014-02-07,16.76,17.2,16.66,16.78,
AXON,2014-02-10,16.84,16.92,16.33,16.91,
AXON,2014-02-11,16.94,17.16,16.66,16.91,
AXON,2014-02-12,16.87,17.08,16.6,16.79,
AXON,2014-02-13,16.62,17.23,16.4,17.13,
AXON,2014-02-14,17.08,17.189,16.854,17.09,
AXON,2014-02-18,17.11,18.48,17.01,18.08,
AXON,2014-02-19,18.12,19.0,18.12,18.56,
AXON,2014-02-20,18.64,19.06,17.82,19.02,
AXON,2014-02-21,19.14,19.38,18.61,18.8,
AXON,2014-02-24,18.9,19.47,18.9,19.07,
AXON,2014-02-25,19.29,19.54,19.01,19.1,
AXON,2014-02-26,20.0,20.01,18.07,18.93,
AXON,2014-02-27,18.81,20.83,18.75,20.5,
AXON,2014-02-28,20.0,20.11,19.01,19.23,
AXON,2014-03-03,19.05,19.79,18.801,19.56,
AXON,2014-03-04,19.83,20.39,19.83,20.28,
AXON,2014-03-05,20.29,20.44,19.54,19.87,
AXON,2014-03-06,19.83,19.95,19.51,19.65,
AXON,2014-03-07,19.65,19.85,18.72,18.89,
AXON,2014-03-10,18.91,19.52,18.65,19.5,
AXON,2014-03-11,19.57,19.58,18.8,18.91,
AXON,2014-03-12,18.95,19.189,18.58,18.65,
AXON,2014-03-13,18.72,18.83,18.0,18.3,
AXON,2014-03-14,18.3,18.486,18.09,18.33,
AXON,2014-03-17,18.35,18.6,18.11,18.31,
AXON,2014-03-18,18.38,18.86,18.27,18.5,
AXON,2014-03-19,18.55,18.79,18.06,18.23,
AXON,2014-03-20,18.14,18.42,18.0,18.09,
AXON,2014-03-21,18.2,18.48,18.09,18.11,
AXON,2014-03-24,18.15,18.25,17.37,17.85,
AXON,2014-03-25,17.99,18.95,17.87,18.91,
AXON,2014-03-26,19.27,19.73,18.82,18.85,
AXON,2014-03-27,18.76,18.9,18.13,18.27,
AXON,2014-03-28,18.26,18.63,18.15,18.32,
AXON,2014-03-31,18.4,18.61,18.18,18.29,
AXON,2014-04-01,18.4,19.17,18.4,18.99,
AXON,2014-04-02,19.01,19.09,18.45,18.65,
AXON,2014-04-03,18.65,18.79,18.176,18.34,
AXON,2014-04-04,18.45,18.5,17.51,17.62,
AXON,2014-04-07,17.55,17.73,16.82,17.06,
AXON,2014-04-08,17.0,17.28,16.627,17.03,
AXON,2014-04-09,17.03,17.41,16.86,17.34,
AXON,2014-04-10,17.34,17.4,16.2,16.43,
AXON,2014-04-11,16.16,17.17,16.16,16.74,
AXON,2014-04-14,16.95,17.24,16.49,16.78,
AXON,2014-04-15,16.86,17.57,16.78,17.3,
AXON,2014-04-16,17.48,17.83,17.27,17.79,
AXON,2014-04-17,17.79,17.94,17.39,17.88,
AXON,2014-04-21,17.86,17.93,17.36,17.7,
AXON,2014-04-22,17.74,18.42,17.68,18.23,
AXON,2014-04-23,18.24,18.59,18.17,18.26,
AXON,2014-04-24,18.3,18.436,17.71,18.19,
AXON,2014-04-25,18.07,18.07,17.52,17.71,
AXON,2014-04-28,17.85,17.933,16.51,16.78,
AXON,2014-04-29,16.84,17.2,16.62,17.08,
AXON,2014-04-30,17.02,17.19,15.33,16.15,
AXON,2014-05-01,15.99,16.122,15.09,15.25,
AXON,2014-05-02,15.25,15.34,14.1,14.13,
AXON,2014-05-05,14.12,14.59,13.82,14.41,
AXON,2014-05-06,14.28,14.28,13.18,13.2,
AXON,2014-05-07,13.2,13.39,12.55,13.13,
AXON,2014-05-08,13.05,13.5,13.01,13.14,
AXON,2014-05-09,13.12,13.39,13.03,13.26,
AXON,2014-05-12,13.6,14.31,13.5,14.06,
AXON,2014-05-13,14.17,14.24,13.55,13.64,
AXON,2014-05-14,13.58,13.61,12.97,13.01,
AXON,2014-05-15,12.93,13.13,12.62,13.05,
AXON,2014-05-16,13.03,13.33,12.82,13.32,
AXON,2014-05-19,13.31,13.66,13.111,13.52,
AXON,2014-05-20,13.48,13.48,12.76,12.87,
AXON,2014-05-21,12.91,13.09,12.82,13.06,
AXON,2014-05-22,13.06,13.16,12.97,13.08,
AXON,2014-05-23,13.06,13.38,12.99,13.35,
AXON,2014-05-27,13.43,13.605,13.33,13.48,
AXON,2014-05-28,13.46,13.61,13.19,13.27,
AXON,2014-05-29,13.41,13.555,13.23,13.52,
AXON,2014-05-30,13.52,13.57,13.23,13.27,
AXON,2014-06-02,13.28,13.355,13.04,13.32,
AXON,2014-06-03,13.19,13.32,12.98,13.0,
AXON,2014-06-04,12.96,13.19,12.87,13.05,
AXON,2014-06-05,13.22,13.37,12.95,13.36,
AXON,2014-06-06,13.42,13.64,13.29,13.35,
AXON,2014-06-09,13.31,13.66,13.26,13.53,
AXON,2014-06-10,13.42,14.65,13.18,14.28,
AXON,2014-06-11,14.06,14.23,13.7,13.91,
AXON,2014-06-12,13.9,14.08,13.51,14.03,
AXON,2014-06-13,14.08,14.09,13.62,13.87,
AXON,2014-06-16,13.84,13.955,13.65,13.78,
AXON,2014-06-17,13.85,14.19,13.65,14.07,
AXON,2014-06-18,14.08,14.12,13.81,13.86,
AXON,2014-06-19,14.0,14.0,13.62,13.695,
AXON,2014-06-20,13.74,14.25,13.57,13.85,
AXON,2014-06-23,13.82,13.82,13.572,13.7,
AXON,2014-06-24,13.73,13.73,13.36,13.43,
AXON,2014-06-25,13.36,13.488,13.18,13.46,
AXON,2014-06-26,13.45,13.53,13.14,13.29,
AXON,2014-06-27,13.22,13.42,13.13,13.39,
AXON,2014-06-30,13.31,13.32,12.99,13.3,
AXON,2014-07-01,13.35,13.74,13.2,13.5,
AXON,2014-07-02,13.48,13.69,13.22,13.28,
AXON,2014-07-03,13.33,13.36,13.11,13.18,
AXON,2014-07-07,13.12,13.17,12.86,12.89,
AXON,2014-07-08,12.88,13.02,11.97,12.0,
AXON,2014-07-09,12.09,12.36,11.27,11.37,
AXON,2014-07-10,11.2,11.29,10.81,11.24,
AXON,2014-07-11,11.26,11.48,11.0,11.2,
AXON,2014-07-14,11.32,11.4,11.14,11.21,
AXON,2014-07-15,11.22,11.29,10.81,10.88,
AXON,2014-07-16,10.96,10.97,10.7,10.78,
AXON,2014-07-17,10.68,10.79,10.46,10.5,
AXON,2014-07-18,10.63,11.4,10.5,11.36,
AXON,2014-07-21,11.29,11.55,11.06,11.46,
AXON,2014-07-22,11.51,11.72,11.43,11.53,
AXON,2014-07-23,11.57,11.57,11.22,11.23,
AXON,2014-07-24,11.24,11.6,11.24,11.44,
AXON,2014-07-25,11.35,11.75,11.3,11.49,
AXON,2014-07-28,11.48,11.62,11.19,11.31,
AXON,2014-07-29,11.32,11.61,11.284,11.5,
AXON,2014-07-30,12.33,13.57,12.25,13.36,
AXON,2014-07-31,13.13,13.2,12.0,12.06,
AXON,2014-08-01,12.01,12.08,11.37,11.515,
AXON,2014-08-04,11.51,11.64,11.28,11.44,
AXON,2014-08-05,11.49,11.9,11.44,11.64,
AXON,2014-08-06,11.86,12.38,11.8,12.35,
AXON,2014-08-07,12.68,12.69,12.17,12.18,
AXON,2014-08-08,12.22,12.43,12.02,12.38,
AXON,2014-08-11,12.43,12.49,12.141,12.38,
AXON,2014-08-12,12.34,12.46,11.97,12.02,
AXON,2014-08-13,12.05,12.45,12.02,12.36,
AXON,2014-08-14,12.39,12.74,12.2,12.71,
AXON,2014-08-15,13.15,14.14,13.14,13.91,
AXON,2014-08-18,14.71,15.58,14.57,14.68,
AXON,2014-08-19,15.43,16.12,15.1,16.11,
AXON,2014-08-20,15.82,15.98,15.22,15.46,
AXON,2014-08-21,15.63,15.91,15.31,15.89,
AXON,2014-08-22,15.91,16.48,15.43,15.71,
AXON,2014-08-25,16.17,16.54,15.86,15.95,
AXON,2014-08-26,15.99,16.0,15.47,15.67,
AXON,2014-08-27,15.79,16.16,15.51,15.95,
AXON,2014-08-28,15.74,15.9,15.45,15.67,
AXON,2014-08-29,15.68,15.83,15.35,15.67,
AXON,2014-09-02,16.1,17.7,15.85,17.54,
AXON,2014-09-03,18.06,18.24,16.62,16.74,
AXON,2014-09-04,17.28,18.39,17.27,17.55,
AXON,2014-09-05,18.62,18.76,17.93,18.27,
AXON,2014-09-08,18.31,18.35,17.36,17.82,
AXON,2014-09-09,17.83,17.87,17.11,17.22,
AXON,2014-09-10,17.25,17.83,17.05,17.73,
AXON,2014-09-11,17.9,18.16,17.54,17.79,
AXON,2014-09-12,18.29,18.7,17.87,18.43,
AXON,2014-09-15,18.62,18.65,17.77,17.79,
AXON,2014-09-16,17.65,18.22,17.31,18.01,
AXON,2014-09-17,17.76,17.95,17.08,17.2,
AXON,2014-09-18,17.24,17.3,16.35,16.91,
AXON,2014-09-19,16.96,17.04,16.08,16.13,
AXON,2014-09-22,16.0,16.07,15.3,15.97,
AXON,2014-09-23,15.68,16.07,15.68,15.81,
AXON,2014-09-24,16.16,16.37,15.95,16.08,
AXON,2014-09-25,16.1,16.59,15.98,15.99,
AXON,2014-09-26,16.01,16.08,15.4,15.67,
AXON,2014-09-29,15.31,15.52,15.17,15.4,
AXON,2014-09-30,15.88,15.95,15.21,15.44,
AXON,2014-10-01,15.34,15.34,14.3,14.59,
AXON,2014-10-02,14.6,15.37,14.59,15.26,
AXON,2014-10-03,15.37,15.39,14.65,15.07,
AXON,2014-10-06,15.82,15.85,14.781,14.985,
AXON,2014-10-07,14.78,14.809,14.42,14.44,
AXON,2014-10-08,14.64,14.76,14.06,14.54,
AXON,2014-10-09,14.46,14.97,14.36,14.71,
AXON,2014-10-10,14.63,14.76,13.91,14.06,
AXON,2014-10-13,14.04,14.2,13.4,13.61,
AXON,2014-10-14,13.8,14.51,13.77,14.2,
AXON,2014-10-15,13.79,14.85,13.61,14.69,
AXON,2014-10-16,14.31,15.13,14.11,14.97,
AXON,2014-10-17,15.19,15.46,14.99,15.05,
AXON,2014-10-20,14.95,15.07,14.6,14.73,
AXON,2014-10-21,14.83,15.23,14.61,15.07,
AXON,2014-10-22,15.18,15.25,14.82,14.98,
AXON,2014-10-23,15.07,15.42,14.9,15.26,
AXON,2014-10-24,15.22,15.57,15.11,15.465,
AXON,2014-10-27,15.29,15.69,15.22,15.63,
AXON,2014-10-28,15.72,16.35,15.33,16.28,
AXON,2014-10-29,16.27,16.5,15.83,16.47,
AXON,2014-10-30,17.55,18.42,16.86,17.7,
AXON,2014-10-31,18.03,18.98,17.9,18.84,
AXON,2014-11-03,18.51,19.45,18.37,19.17,
AXON,2014-11-04,19.05,19.17,18.25,18.49,
AXON,2014-11-05,18.97,19.05,18.53,18.58,
AXON,2014-11-06,18.67,18.72,18.19,18.43,
AXON,2014-11-07,18.34,18.53,17.73,18.52,
AXON,2014-11-10,18.6,19.13,18.24,18.93,
AXON,2014-11-11,19.05,19.95,19.02,19.51,
AXON,2014-11-12,19.43,20.03,19.07,19.75,
AXON,2014-11-13,19.8,20.36,19.2,19.64,
AXON,2014-11-14,19.51,20.69,19.42,20.19,
AXON,2014-11-17,20.11,20.2,19.48,19.51,
AXON,2014-11-18,19.6,20.53,19.6,20.13,
AXON,2014-11-19,20.08,20.36,19.8,20.05,
AXON,2014-11-20,19.93,20.94,19.76,20.57,
AXON,2014-11-21,20.9,21.01,18.86,19.34,
AXON,2014-11-24,19.17,19.78,19.17,19.72,
AXON,2014-11-25,20.1,20.83,19.7,20.59,
AXON,2014-11-26,21.55,22.35,21.14,21.87,
AXON,2014-11-28,22.02,22.12,20.93,21.48,
AXON,2014-12-01,21.35,22.4,20.79,22.09,
AXON,2014-12-02,22.93,24.44,22.75,23.34,
AXON,2014-12-03,22.33,22.98,21.63,22.86,
AXON,2014-12-04,23.69,24.45,23.27,24.15,
AXON,2014-12-05,24.5,25.02,24.1,24.82,
AXON,2014-12-08,24.0,24.1,21.66,23.32,
AXON,2014-12-09,21.57,23.32,21.06,23.26,
AXON,2014-12-10,23.15,23.73,22.3,22.52,
AXON,2014-12-11,23.5,23.73,22.86,23.19,
AXON,2014-12-12,22.98,23.88,22.8,23.19,
AXON,2014-12-15,23.4,23.44,22.76,22.87,
AXON,2014-12-16,22.76,23.31,22.55,22.85,
AXON,2014-12-17,24.15,24.86,23.76,24.61,
AXON,2014-12-18,25.05,25.14,23.64,24.18,
AXON,2014-12-19,24.25,24.26,23.61,23.98,
AXON,2014-12-22,24.81,26.39,24.74,26.06,
AXON,2014-12-23,26.69,27.1,25.65,26.02,
AXON,2014-12-24,26.5,26.97,26.12,26.865,
AXON,2014-12-26,27.01,27.65,26.54,26.91,
AXON,2014-12-29,26.71,27.18,26.27,26.71,
AXON,2014-12-30,26.55,27.0,26.46,26.82,
AXON,2014-12-31,26.84,27.15,26.45,26.48,
AXON,2015-01-02,26.7,26.75,25.56,26.51,
AXON,2015-01-05,26.15,26.4,25.46,25.69,
AXON,2015-01-06,26.11,26.22,24.74,25.57,
AXON,2015-01-07,25.89,26.2,25.22,25.98,
AXON,2015-01-08,26.19,26.66,25.75,26.63,
AXON,2015-01-09,26.62,26.63,26.01,26.27,
AXON,2015-01-12,26.24,26.41,25.53,25.84,
AXON,2015-01-13,26.11,26.84,25.4,25.72,
AXON,2015-01-14,25.43,26.24,25.12,25.91,
AXON,2015-01-15,26.18,26.33,25.21,25.23,
AXON,2015-01-16,25.32,25.62,24.972,25.36,
AXON,2015-01-20,25.57,27.45,25.25,26.91,
AXON,2015-01-21,26.78,27.189,26.28,26.8,
AXON,2015-01-22,26.97,27.79,26.35,27.44,
AXON,2015-01-23,27.38,28.3,27.18,27.61,
AXON,2015-01-26,27.68,28.23,27.6,27.89,
AXON,2015-01-27,27.47,28.03,27.38,27.69,
AXON,2015-01-28,27.9,28.19,27.28,27.29,
AXON,2015-01-29,27.23,27.82,26.56,27.81,
AXON,2015-01-30,27.52,27.97,27.0,27.01,
AXON,2015-02-02,26.98,27.02,25.92,26.9,
AXON,2015-02-03,26.9,27.24,25.66,25.8,
AXON,2015-02-04,25.8,26.65,25.77,26.42,
AXON,2015-02-05,26.55,27.0,26.28,26.98,
AXON,2015-02-06,26.98,27.16,26.3,26.64,
AXON,2015-02-09,26.31,26.77,26.12,26.28,
AXON,2015-02-10,26.39,26.69,26.01,26.58,
AXON,2015-02-11,26.5,26.7,26.25,26.27,
AXON,2015-02-12,26.36,27.39,26.36,27.38,
AXON,2015-02-13,27.45,27.88,26.89,26.96,
AXON,2015-02-17,27.05,27.32,26.6,26.87,
AXON,2015-02-18,26.76,27.18,26.4,26.99,
AXON,2015-02-19,26.84,27.64,26.77,27.16,
AXON,2015-02-20,27.23,27.77,27.04,27.58,
AXON,2015-02-23,27.76,27.93,27.22,27.76,
AXON,2015-02-24,27.62,27.92,27.25,27.51,
AXON,2015-02-25,27.42,27.57,26.73,27.05,
AXON,2015-02-26,25.77,25.85,22.19,22.68,
AXON,2015-02-27,23.41,23.93,23.1,23.48,
AXON,2015-03-02,23.4,23.5,22.38,22.64,
AXON,2015-03-03,22.78,22.9,21.54,21.93,
AXON,2015-03-04,21.75,22.98,21.45,22.65,
AXON,2015-03-05,22.83,22.92,22.3,22.53,
AXON,2015-03-06,22.32,22.71,22.06,22.65,
AXON,2015-03-09,22.6,22.8,21.94,22.03,
AXON,2015-03-10,21.67,21.96,21.39,21.84,
AXON,2015-03-11,21.83,22.25,21.7,22.06,
AXON,2015-03-12,22.47,24.4,22.3,23.52,
AXON,2015-03-13,24.1,24.19,23.69,23.93,
AXON,2015-03-16,23.95,24.15,23.38,23.53,
AXON,2015-03-17,23.38,23.7,23.24,23.44,
AXON,2015-03-18,23.36,23.98,23.35,23.96,
AXON,2015-03-19,23.83,24.49,23.8,24.37,
AXON,2015-03-20,24.59,24.6,24.0,24.09,
AXON,2015-03-23,24.04,24.62,24.01,24.29,
AXON,2015-03-24,24.39,25.65,24.39,25.3,
AXON,2015-03-25,25.22,25.45,24.21,24.35,
AXON,2015-03-26,24.17,24.38,23.79,24.21,
AXON,2015-03-27,24.15,24.62,23.92,24.07,
AXON,2015-03-30,24.15,24.88,24.13,24.63,
AXON,2015-03-31,25.0,25.0,24.06,24.11,
AXON,2015-04-01,24.01,24.38,23.41,24.24,
AXON,2015-04-02,24.21,24.47,24.04,24.44,
AXON,2015-04-06,24.19,24.71,24.16,24.51,
AXON,2015-04-07,24.46,25.0,24.4,24.53,
AXON,2015-04-08,24.81,25.32,24.14,25.16,
AXON,2015-04-09,26.27,27.48,26.2,27.4,
AXON,2015-04-10,27.48,27.5,26.8,27.07,
AXON,2015-04-13,27.28,27.46,26.82,27.02,
AXON,2015-04-14,27.15,27.58,26.6,26.83,
AXON,2015-04-15,27.09,27.36,26.53,27.15,
AXON,2015-04-16,27.01,28.61,26.85,27.83,
AXON,2015-04-17,29.41,29.65,28.06,28.4,
AXON,2015-04-20,29.01,30.47,28.6,30.37,
AXON,2015-04-21,29.96,30.0,28.74,29.5,
AXON,2015-04-22,28.79,29.67,28.7,29.5,
AXON,2015-04-23,29.27,30.18,28.78,29.68,
AXON,2015-04-24,29.63,30.0,29.51,29.67,
AXON,2015-04-27,29.76,29.9,28.1,28.37,
AXON,2015-04-28,28.85,29.35,28.05,28.89,
AXON,2015-04-29,28.76,28.79,27.88,28.07,
AXON,2015-04-30,30.73,31.15,29.24,30.19,
AXON,2015-05-01,30.6,33.23,30.5,32.37,
AXON,2015-05-04,32.83,34.24,32.18,33.7,
AXON,2015-05-05,33.97,35.0,33.87,34.6,
AXON,2015-05-06,34.98,34.98,33.51,34.41,
AXON,2015-05-07,33.25,33.35,31.94,32.58,
AXON,2015-05-08,32.79,32.89,31.12,31.94,
AXON,2015-05-11,32.0,33.9,31.86,33.19,
AXON,2015-05-12,32.83,34.0,32.53,33.66,
AXON,2015-05-13,34.0,34.49,33.47,33.54,
AXON,2015-05-14,33.55,33.95,33.0,33.7,
AXON,2015-05-15,33.61,33.69,32.62,32.97,
AXON,2015-05-18,31.83,32.49,30.38,32.43,
AXON,2015-05-19,32.51,33.0,32.25,32.35,
AXON,2015-05-20,32.3,32.48,31.42,31.86,
AXON,2015-05-21,31.99,32.9,31.9,32.26,
AXON,2015-05-22,32.38,32.43,31.73,31.87,
AXON,2015-05-26,31.76,31.83,30.48,31.3,
AXON,2015-05-27,31.35,31.65,31.24,31.41,
AXON,2015-05-28,31.43,32.4,31.27,31.91,
AXON,2015-05-29,31.71,31.91,31.42,31.58,
AXON,2015-06-01,31.7,31.87,30.73,30.89,
AXON,2015-06-02,30.77,31.61,30.62,31.51,
AXON,2015-06-03,32.15,32.35,31.37,31.72,
AXON,2015-06-04,31.53,32.25,31.03,31.36,
AXON,2015-06-05,31.4,32.5,31.17,32.21,
AXON,2015-06-08,32.35,33.17,32.0,32.88,
AXON,2015-06-09,33.02,33.9,32.93,33.59,
AXON,2015-06-10,33.75,35.16,33.75,34.96,
AXON,2015-06-11,35.26,35.95,34.55,35.03,
AXON,2015-06-12,34.74,34.77,33.75,33.99,
AXON,2015-06-15,33.73,35.12,33.11,34.91,
AXON,2015-06-16,34.75,35.22,34.42,34.6,
AXON,2015-06-17,35.09,35.33,34.44,34.65,
AXON,2015-06-18,35.35,35.79,34.81,34.96,
AXON,2015-06-19,35.0,35.15,34.12,34.56,
AXON,2015-06-22,34.72,34.88,33.79,34.0,
AXON,2015-06-23,33.77,34.8,33.42,34.65,
AXON,2015-06-24,34.5,34.6,33.71,33.78,
AXON,2015-06-25,34.02,34.37,33.63,33.82,
AXON,2015-06-26,33.86,34.11,33.46,33.56,
AXON,2015-06-29,32.23,33.22,31.11,31.6,
AXON,2015-06-30,32.04,33.47,31.61,33.31,
AXON,2015-07-01,33.5,33.53,32.67,33.18,
AXON,2015-07-02,33.19,33.4,32.3,32.51,
AXON,2015-07-06,31.82,32.9,31.79,32.23,
AXON,2015-07-07,32.36,32.7,31.31,32.61,
AXON,2015-07-08,32.18,32.49,31.11,31.39,
AXON,2015-07-09,32.19,32.73,31.9,32.4,
AXON,2015-07-10,32.95,33.18,32.6,33.04,
AXON,2015-07-13,33.14,33.44,32.52,33.07,
AXON,2015-07-14,33.01,33.33,32.44,32.59,
AXON,2015-07-15,32.64,33.06,32.06,32.96,
AXON,2015-07-16,32.93,34.8,32.93,34.37,
AXON,2015-07-17,34.6,34.6,33.81,34.0,
AXON,2015-07-20,34.24,34.91,32.5,32.55,
AXON,2015-07-21,32.46,32.96,32.01,32.63,
AXON,2015-07-22,32.59,33.36,32.15,32.2,
AXON,2015-07-23,32.22,32.53,31.62,31.71,
AXON,2015-07-24,31.84,32.2,30.64,30.9,
AXON,2015-07-27,30.76,30.9,29.17,30.33,
AXON,2015-07-28,30.38,31.1,29.35,30.78,
AXON,2015-07-29,31.1,31.78,30.4,31.7,
AXON,2015-07-30,32.03,32.82,27.63,28.11,
AXON,2015-07-31,28.61,28.8,26.25,27.22,
AXON,2015-08-03,27.03,27.08,25.1,25.13,
AXON,2015-08-04,25.53,26.54,25.29,26.23,
AXON,2015-08-05,26.05,26.42,25.26,25.32,
AXON,2015-08-06,25.45,25.59,23.95,24.45,
AXON,2015-08-07,24.2,24.28,23.03,24.04,
AXON,2015-08-10,24.03,25.23,23.79,24.65,
AXON,2015-08-11,24.25,24.84,23.82,24.23,
AXON,2015-08-12,23.6,23.85,22.73,23.25,
AXON,2015-08-13,23.76,24.48,23.24,24.08,
AXON,2015-08-14,23.91,24.2,23.53,23.99,
AXON,2015-08-17,23.6,24.41,23.57,24.29,
AXON,2015-08-18,23.98,24.23,23.5,23.91,
AXON,2015-08-19,23.5,23.65,22.6,23.02,
AXON,2015-08-20,22.56,22.87,21.45,21.7,
AXON,2015-08-21,21.0,22.08,20.26,21.29,
AXON,2015-08-24,19.01,21.495,18.05,20.4,
AXON,2015-08-25,21.2,22.21,20.73,21.36,
AXON,2015-08-26,21.88,22.83,21.36,22.36,
AXON,2015-08-27,22.85,23.79,22.35,23.63,
AXON,2015-08-28,23.59,23.89,23.32,23.71,
AXON,2015-08-31,23.45,23.83,23.3,23.4,
AXON,2015-09-01,22.75,23.07,22.4,22.5,
AXON,2015-09-02,23.19,24.18,22.97,23.87,
AXON,2015-09-03,23.83,24.25,23.37,23.45,
AXON,2015-09-04,23.24,23.95,23.02,23.63,
AXON,2015-09-08,24.03,24.49,23.91,24.28,
AXON,2015-09-09,24.45,24.5,23.71,23.76,
AXON,2015-09-10,23.65,24.02,23.54,23.76,
AXON,2015-09-11,23.45,23.85,23.25,23.73,
AXON,2015-09-14,23.68,24.03,23.63,23.87,
AXON,2015-09-15,23.97,24.32,23.35,24.14,
AXON,2015-09-16,24.17,24.32,23.95,24.02,
AXON,2015-09-17,23.94,24.5,23.94,24.18,
AXON,2015-09-18,23.75,24.17,23.75,23.96,
AXON,2015-09-21,24.0,24.16,23.56,23.81,
AXON,2015-09-22,23.41,23.78,23.18,23.37,
AXON,2015-09-23,23.41,23.89,23.14,23.21,
AXON,2015-09-24,23.56,24.43,23.34,24.04,
AXON,2015-09-25,24.36,24.38,23.44,23.58,
AXON,2015-09-28,23.48,23.54,21.77,21.95,
AXON,2015-09-29,21.99,22.05,21.3,21.58,
AXON,2015-09-30,21.89,22.23,21.6,22.02,
AXON,2015-10-01,22.07,22.45,21.75,22.23,
AXON,2015-10-02,21.84,22.64,21.71,22.59,
AXON,2015-10-05,22.76,23.4,22.661,23.31,
AXON,2015-10-06,23.35,24.22,23.23,23.97,
AXON,2015-10-07,24.24,25.73,24.129,25.66,
AXON,2015-10-08,25.73,26.11,24.62,25.34,
AXON,2015-10-09,26.48,26.48,24.55,24.7,
AXON,2015-10-12,24.65,24.7,24.02,24.22,
AXON,2015-10-13,24.1,24.34,23.64,23.72,
AXON,2015-10-14,23.65,23.99,23.32,23.39,
AXON,2015-10-15,23.57,24.25,23.5,24.22,
AXON,2015-10-16,24.32,24.68,24.05,24.63,
AXON,2015-10-19,24.55,24.9,24.47,24.77,
AXON,2015-10-20,24.67,25.83,20.99,22.095,
AXON,2015-10-21,22.21,22.25,21.4,21.83,
AXON,2015-10-22,21.86,22.26,21.63,22.03,
AXON,2015-10-23,22.17,22.62,22.0,22.36,
AXON,2015-10-26,23.22,24.23,22.83,23.56,
AXON,2015-10-27,23.98,23.99,22.56,22.92,
AXON,2015-10-28,23.03,23.49,22.55,23.48,
AXON,2015-10-29,23.5,24.1,23.02,23.39,
AXON,2015-10-30,23.44,23.59,22.73,23.41,
AXON,2015-11-02,23.4,24.19,23.19,23.88,
AXON,2015-11-03,23.0,23.0,20.25,20.91,
AXON,2015-11-04,21.42,21.97,20.27,20.58,
AXON,2015-11-05,20.44,20.91,18.8,20.16,
AXON,2015-11-06,20.07,20.36,19.88,20.19,
AXON,2015-11-09,20.18,20.2,18.96,19.24,
AXON,2015-11-10,19.05,19.25,18.55,18.81,
AXON,2015-11-11,18.75,18.86,18.39,18.55,
AXON,2015-11-12,18.38,18.47,18.07,18.11,
AXON,2015-11-13,18.0,18.07,17.08,17.4,
AXON,2015-11-16,17.25,17.62,17.19,17.38,
AXON,2015-11-17,17.4,17.5,16.74,16.76,
AXON,2015-11-18,18.12,19.1,18.0,18.33,
AXON,2015-11-19,18.55,18.64,17.66,17.82,
AXON,2015-11-20,17.89,18.16,17.75,18.16,
AXON,2015-11-23,18.28,18.42,18.01,18.24,
AXON,2015-11-24,19.48,19.84,18.78,19.31,
AXON,2015-11-25,19.35,19.5,19.1,19.27,
AXON,2015-11-27,19.22,19.27,18.51,18.84,
AXON,2015-11-30,18.96,19.17,18.62,18.7,
AXON,2015-12-01,18.77,18.85,18.2,18.39,
AXON,2015-12-02,18.31,18.44,17.78,18.03,
AXON,2015-12-03,18.13,18.34,17.66,17.84,
AXON,2015-12-04,17.68,17.97,17.46,17.77,
AXON,2015-12-07,17.88,17.92,16.98,17.27,
AXON,2015-12-08,16.99,17.15,16.7,16.93,
AXON,2015-12-09,16.78,17.04,16.33,16.63,
AXON,2015-12-10,16.95,17.94,16.8,17.73,
AXON,2015-12-11,17.37,17.62,16.95,17.03,
AXON,2015-12-14,17.06,17.11,16.14,16.29,
AXON,2015-12-15,16.39,17.22,16.38,17.0,
AXON,2015-12-16,17.15,17.16,16.55,16.78,
AXON,2015-12-17,16.81,17.31,16.76,16.98,
AXON,2015-12-18,16.89,17.36,16.78,16.89,
AXON,2015-12-21,17.08,18.1,17.01,17.93,
AXON,2015-12-22,18.0,18.05,17.14,17.5,
AXON,2015-12-23,17.58,18.34,17.43,18.03,
AXON,2015-12-24,17.93,18.226,17.62,17.85,
AXON,2015-12-28,17.7,17.82,17.14,17.245,
AXON,2015-12-29,17.29,17.65,17.025,17.41,
AXON,2015-12-30,17.52,18.75,17.5,17.81,
AXON,2015-12-31,17.76,17.81,17.25,17.29,
AXON,2016-01-04,17.0,17.09,16.5,16.83,
AXON,2016-01-05,16.98,17.21,16.62,17.02,
AXON,2016-01-06,17.92,18.37,17.4,17.64,
AXON,2016-01-07,17.2,17.49,16.5,16.59,
AXON,2016-01-08,16.8,17.12,16.24,16.28,
AXON,2016-01-11,16.5,16.72,15.57,15.86,
AXON,2016-01-12,16.02,16.4617,15.58,16.02,
AXON,2016-01-13,16.09,16.36,15.33,15.41,
AXON,2016-01-14,15.44,15.8,14.93,15.48,
AXON,2016-01-15,14.7,15.205,14.245,14.63,
AXON,2016-01-19,14.63,14.89,14.19,14.5,
AXON,2016-01-20,14.15,15.4162,13.5601,15.1,
AXON,2016-01-21,15.86,16.68,15.58,15.66,
AXON,2016-01-22,16.06,16.206,15.28,15.43,
AXON,2016-01-25,15.27,15.35,14.72,15.02,
AXON,2016-01-26,15.08,15.87,14.72,15.85,
AXON,2016-01-27,15.63,15.73,15.12,15.15,
AXON,2016-01-28,15.33,15.55,14.735,14.8,
AXON,2016-01-29,14.86,15.4,14.86,15.39,
AXON,2016-02-01,15.17,15.55,14.8003,15.43,
AXON,2016-02-02,15.22,15.33,14.46,14.75,
AXON,2016-02-03,14.8,15.15,14.22,15.06,
AXON,2016-02-04,15.06,15.94,15.01,15.8,
AXON,2016-02-05,15.64,15.95,15.18,15.53,
AXON,2016-02-08,15.24,15.38,14.72,15.38,
AXON,2016-02-09,15.1,15.45,14.84,15.37,
AXON,2016-02-10,15.45,16.19,15.394,15.48,
AXON,2016-02-11,15.09,15.72,15.03,15.41,
AXON,2016-02-12,15.55,15.68,15.0,15.43,
AXON,2016-02-16,15.63,16.35,15.41,16.32,
AXON,2016-02-17,16.4,17.23,16.2,17.13,
AXON,2016-02-18,17.2,17.39,16.64,17.11,
AXON,2016-02-19,17.03,17.13,16.71,17.12,
AXON,2016-02-22,17.24,17.32,17.05,17.26,
AXON,2016-02-23,17.13,17.27,16.96,17.0,
AXON,2016-02-24,16.8,17.235,16.3005,17.22,
AXON,2016-02-25,17.2,17.37,16.84,17.21,
AXON,2016-02-26,17.28,17.8,17.27,17.48,
AXON,2016-02-29,20.52,20.69,19.3,19.38,
AXON,2016-03-01,19.11,19.57,18.52,19.44,
AXON,2016-03-02,19.39,19.78,19.25,19.52,
AXON,2016-03-03,19.48,19.74,19.115,19.47,
AXON,2016-03-04,19.44,19.85,19.17,19.45,
AXON,2016-03-07,19.4,20.58,19.3365,19.85,
AXON,2016-03-08,19.81,20.22,19.52,19.54,
AXON,2016-03-09,19.63,19.82,19.4,19.54,
AXON,2016-03-10,19.68,19.91,19.16,19.33,
AXON,2016-03-11,19.46,19.72,19.22,19.53,
AXON,2016-03-14,19.45,19.5289,19.16,19.33,
AXON,2016-03-15,19.17,19.29,18.32,18.37,
AXON,2016-03-16,18.22,18.83,18.2,18.5,
AXON,2016-03-17,18.5,19.1,18.44,18.88,
AXON,2016-03-18,18.98,19.21,18.94,19.08,
AXON,2016-03-21,19.0,19.47,18.78,18.96,
AXON,2016-03-22,18.89,19.21,18.71,18.73,
AXON,2016-03-23,18.63,18.76,18.37,18.38,
AXON,2016-03-24,18.28,18.41,18.1,18.27,
AXON,2016-03-28,18.32,18.6006,18.2,18.31,
AXON,2016-03-29,18.35,19.53,18.28,19.52,
AXON,2016-03-30,19.72,19.832,19.42,19.62,
AXON,2016-03-31,19.58,19.89,19.38,19.63,
AXON,2016-04-01,19.42,19.6,19.0,19.05,
AXON,2016-04-04,19.0,19.21,18.6,18.62,
AXON,2016-04-05,18.52,18.66,18.41,18.54,
AXON,2016-04-06,18.49,18.77,18.45,18.68,
AXON,2016-04-07,18.47,18.95,18.44,18.61,
AXON,2016-04-08,18.86,18.93,18.24,18.3,
AXON,2016-04-11,18.46,18.77,18.3913,18.46,
AXON,2016-04-12,18.52,19.0,18.39,18.83,
AXON,2016-04-13,18.99,19.63,18.92,19.52,
AXON,2016-04-14,19.57,19.73,19.28,19.32,
AXON,2016-04-15,19.21,19.39,18.89,19.14,
AXON,2016-04-18,18.0,18.97,17.8,18.49,
AXON,2016-04-19,18.51,18.93,18.29,18.63,
AXON,2016-04-20,18.68,18.9,18.43,18.54,
AXON,2016-04-21,19.01,19.1,18.57,18.67,
AXON,2016-04-22,18.54,18.8,18.45,18.67,
AXON,2016-04-25,18.52,18.72,18.0329,18.15,
AXON,2016-04-26,18.14,18.4799,18.07,18.43,
AXON,2016-04-27,18.36,18.71,18.22,18.61,
AXON,2016-04-28,18.41,18.69,18.085,18.11,
AXON,2016-04-29,18.13,18.515,18.11,18.27,
AXON,2016-05-02,18.25,18.6,18.13,18.53,
AXON,2016-05-03,18.28,18.37,17.57,17.8,
AXON,2016-05-04,17.61,17.75,17.18,17.66,
AXON,2016-05-05,18.24,19.13,17.76,18.31,
AXON,2016-05-06,18.0,18.39,17.755,18.14,
AXON,2016-05-09,18.09,18.6699,18.05,18.56,
AXON,2016-05-10,18.66,19.41,18.48,19.41,
AXON,2016-05-11,19.33,20.0,19.2,19.79,
AXON,2016-05-12,19.87,19.99,19.32,19.7,
AXON,2016-05-13,19.64,19.72,19.31,19.37,
AXON,2016-05-16,19.39,19.96,19.34,19.37,
AXON,2016-05-17,19.42,20.93,19.37,20.7,
AXON,2016-05-18,20.64,21.27,20.48,20.78,
AXON,2016-05-19,20.6,21.2,20.3101,21.12,
AXON,2016-05-20,21.15,21.75,21.03,21.7,
AXON,2016-05-23,21.74,21.77,21.38,21.45,
AXON,2016-05-24,21.51,21.92,21.47,21.85,
AXON,2016-05-25,21.95,22.16,21.8763,21.95,
AXON,2016-05-26,21.94,22.07,21.77,22.02,
AXON,2016-05-27,22.01,22.16,21.83,21.95,
AXON,2016-05-31,22.01,22.42,21.82,22.37,
AXON,2016-06-01,22.31,22.4,21.98,22.32,
AXON,2016-06-02,22.26,22.88,22.05,22.85,
AXON,2016-06-03,22.87,22.94,22.57,22.775,
AXON,2016-06-06,22.76,23.04,22.75,22.97,
AXON,2016-06-07,23.0,23.31,22.88,23.08,
AXON,2016-06-08,23.18,23.55,23.0783,23.52,
AXON,2016-06-09,23.47,23.765,23.23,23.3,
AXON,2016-06-10,23.14,23.22,22.65,22.76,
AXON,2016-06-13,22.73,22.955,22.4,22.75,
AXON,2016-06-14,22.65,22.97,22.43,22.67,
AXON,2016-06-15,22.82,22.9586,22.56,22.77,
AXON,2016-06-16,22.63,22.69,22.1999,22.62,
AXON,2016-06-17,22.7,23.09,22.32,22.93,
AXON,2016-06-20,23.16,23.59,22.93,23.35,
AXON,2016-06-21,23.3,23.4,22.965,23.12,
AXON,2016-06-22,23.24,23.88,23.22,23.67,
AXON,2016-06-23,23.95,24.0834,23.7,23.96,
AXON,2016-06-24,22.43,23.41,22.25,22.98,
AXON,2016-06-27,22.74,23.29,22.53,22.76,
AXON,2016-06-28,23.1,23.9199,23.1,23.55,
AXON,2016-06-29,23.89,24.3,23.66,24.22,
AXON,2016-06-30,24.38,24.94,24.09,24.88,
AXON,2016-07-01,25.0,25.0,24.65,24.89,
AXON,2016-07-05,24.67,25.13,24.46,25.1,
AXON,2016-07-06,25.57,25.59,24.952,25.04,
AXON,2016-07-07,25.09,25.8483,25.09,25.77,
AXON,2016-07-08,26.99,27.8,26.7,27.3,
AXON,2016-07-11,27.6,28.58,27.5,27.66,
AXON,2016-07-12,28.02,28.18,26.39,27.0,
AXON,2016-07-13,27.04,27.3331,26.71,27.01,
AXON,2016-07-14,27.17,27.74,27.1,27.65,
AXON,2016-07-15,27.7,27.855,27.12,27.22,
AXON,2016-07-18,27.77,28.42,27.4292,27.99,
AXON,2016-07-19,28.0,28.469,27.63,28.12,
AXON,2016-07-20,28.17,28.71,27.82,28.26,
AXON,2016-07-21,28.2,28.442,28.005,28.2,
AXON,2016-07-22,28.14,28.65,27.8678,28.48,
AXON,2016-07-25,28.53,28.74,28.4073,28.5,
AXON,2016-07-26,28.68,28.9165,28.389,28.66,
AXON,2016-07-27,28.82,28.99,28.57,28.78,
AXON,2016-07-28,28.8,28.85,28.42,28.49,
AXON,2016-07-29,28.6,29.0799,28.0531,28.97,
AXON,2016-08-01,29.21,29.58,28.935,29.16,
AXON,2016-08-02,29.18,29.42,28.53,28.84,
AXON,2016-08-03,28.8,29.0,28.4,28.72,
AXON,2016-08-04,28.72,29.15,28.51,28.95,
AXON,2016-08-05,29.6,30.15,28.48,29.26,
AXON,2016-08-08,29.25,29.4648,28.63,28.74,
AXON,2016-08-09,28.73,29.07,28.53,28.69,
AXON,2016-08-10,28.54,28.76,28.18,28.68,
AXON,2016-08-11,28.63,29.44,28.63,29.12,
AXON,2016-08-12,29.0,29.35,28.85,29.12,
AXON,2016-08-15,29.12,29.53,28.91,29.43,
AXON,2016-08-16,29.52,29.8,29.29,29.45,
AXON,2016-08-17,29.34,29.6,29.25,29.35,
AXON,2016-08-18,29.26,29.56,29.14,29.43,
AXON,2016-08-19,29.38,29.4,29.03,29.11,
AXON,2016-08-22,29.05,29.205,28.63,29.04,
AXON,2016-08-23,29.1,29.285,28.85,28.93,
AXON,2016-08-24,28.93,29.15,28.35,28.5,
AXON,2016-08-25,28.45,28.88,28.41,28.69,
AXON,2016-08-26,28.67,28.84,28.42,28.51,
AXON,2016-08-29,28.56,28.95,28.56,28.76,
AXON,2016-08-30,28.66,29.68,28.66,29.41,
AXON,2016-08-31,29.37,29.38,26.6101,27.08,
AXON,2016-09-01,27.21,27.58,26.45,26.85,
AXON,2016-09-02,26.97,27.18,26.45,26.57,
AXON,2016-09-06,26.75,26.98,26.241,26.405,
AXON,2016-09-07,26.38,26.51,25.92,26.13,
AXON,2016-09-08,25.98,26.24,25.76,25.86,
AXON,2016-09-09,25.64,25.84,25.05,25.18,
AXON,2016-09-12,25.02,25.52,25.01,25.39,
AXON,2016-09-13,25.26,25.6,24.92,25.01,
AXON,2016-09-14,25.49,26.02,25.01,25.175,
AXON,2016-09-15,25.18,25.63,25.18,25.545,
AXON,2016-09-16,26.44,26.44,25.35,25.45,
AXON,2016-09-19,25.53,26.21,25.5,26.02,
AXON,2016-09-20,26.27,26.47,26.06,26.42,
AXON,2016-09-21,26.66,27.6,26.54,27.57,
AXON,2016-09-22,28.22,28.5738,28.03,28.24,
AXON,2016-09-23,28.11,28.22,27.92,28.095,
AXON,2016-09-26,27.93,28.41,27.93,28.3,
AXON,2016-09-27,28.3,28.5277,28.19,28.41,
AXON,2016-09-28,28.57,28.919,28.41,28.85,
AXON,2016-09-29,28.71,29.0,28.54,28.925,
AXON,2016-09-30,28.93,28.99,28.57,28.61,
AXON,2016-10-03,25.92,26.0,24.22,24.29,
AXON,2016-10-04,24.65,24.7,23.62,23.71,
AXON,2016-10-05,23.87,23.99,22.9221,23.2,
AXON,2016-10-06,23.09,23.42,22.81,23.3,
AXON,2016-10-07,23.16,23.21,22.42,22.43,
AXON,2016-10-10,22.51,22.91,22.51,22.72,
AXON,2016-10-11,23.82,23.82,22.18,22.4,
AXON,2016-10-12,22.47,22.69,22.26,22.49,
AXON,2016-10-13,21.79,22.2,21.5,22.09,
AXON,2016-10-14,22.65,23.2799,22.33,22.74,
AXON,2016-10-17,22.68,23.05,22.62,22.92,
AXON,2016-10-18,23.05,23.17,22.58,22.63,
AXON,2016-10-19,22.69,23.34,22.69,23.22,
AXON,2016-10-20,23.25,23.29,23.08,23.11,
AXON,2016-10-21,23.0,23.2,22.86,23.2,
AXON,2016-10-24,23.28,23.62,23.27,23.54,
AXON,2016-10-25,23.64,23.73,23.05,23.19,
AXON,2016-10-26,23.11,23.3,22.95,22.99,
AXON,2016-10-27,22.96,23.13,22.32,22.52,
AXON,2016-10-28,22.5,22.81,22.4,22.47,
AXON,2016-10-31,22.47,22.4765,22.18,22.38,
AXON,2016-11-01,22.36,22.77,22.36,22.61,
AXON,2016-11-02,22.55,22.9499,22.285,22.32,
AXON,2016-11-03,23.25,23.25,21.93,21.98,
AXON,2016-11-04,22.06,22.45,21.93,21.98,
AXON,2016-11-07,22.29,22.48,22.17,22.28,
AXON,2016-11-08,22.21,22.49,21.93,22.49,
AXON,2016-11-09,22.0,24.09,21.9,23.67,
AXON,2016-11-10,26.34,28.0,25.81,26.82,
AXON,2016-11-11,26.09,27.24,26.04,27.18,
AXON,2016-11-14,27.24,27.91,27.18,27.51,
AXON,2016-11-15,27.59,28.3,27.32,27.78,
AXON,2016-11-16,27.59,27.95,27.33,27.76,
AXON,2016-11-17,27.84,28.2,27.67,27.96,"10 biotech companies ripe for a buyout, courtesy of Donald Trump ‘Stay long,’ says one analyst, as the industry gets newfound support from government ‘Stay long,’ says one analyst, as the industry gets newfound support from government."
AXON,2016-11-18,27.97,28.1353,27.76,27.79,
AXON,2016-11-21,27.78,28.0,27.021,27.31,
AXON,2016-11-22,27.37,28.0294,27.33,27.99,
AXON,2016-11-23,27.85,28.38,27.8,28.11,
AXON,2016-11-25,28.1,28.22,27.87,28.07,
AXON,2016-11-28,28.0,28.1,27.73,27.82,"Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails “Significant but not fatal blow” for beta amyloid hypothesis in drug development, analyst says Biogen is using the same scientific approach to treating the disease as Eli Lilly."
AXON,2016-11-29,27.7,28.0,27.54,27.55,
AXON,2016-11-30,27.59,27.9604,27.13,27.23,
AXON,2016-12-01,27.37,27.74,27.358,27.72,
AXON,2016-12-02,27.6,28.01,27.4565,27.92,
AXON,2016-12-05,28.0,28.49,28.0,28.07,
AXON,2016-12-06,28.3,28.37,27.886,28.19,
AXON,2016-12-07,28.44,28.44,27.4501,27.52,
AXON,2016-12-08,27.69,27.7,24.92,25.26,
AXON,2016-12-09,25.27,25.46,23.75,23.85,
AXON,2016-12-12,23.65,23.92,23.32,23.52,
AXON,2016-12-13,23.56,23.98,23.34,23.58,
AXON,2016-12-14,23.6,24.67,23.6,24.2,
AXON,2016-12-15,24.47,24.61,23.99,24.16,
AXON,2016-12-16,24.19,24.43,23.91,23.98,
AXON,2016-12-19,23.98,24.25,23.75,23.99,
AXON,2016-12-20,24.65,24.76,24.02,24.37,
AXON,2016-12-21,24.44,25.59,24.15,25.01,
AXON,2016-12-22,25.18,25.34,24.24,24.3,
AXON,2016-12-23,24.74,24.74,24.18,24.53,
AXON,2016-12-27,24.54,25.03,24.27,24.82,
AXON,2016-12-28,24.88,24.98,24.5,24.56,
AXON,2016-12-29,24.56,25.01,24.56,24.8,
AXON,2016-12-30,24.8,24.8,24.21,24.24,
AXON,2017-01-03,24.4,24.83,24.19,24.58,
AXON,2017-01-04,24.59,24.863,24.48,24.85,
AXON,2017-01-05,24.84,25.0,24.5,24.68,
AXON,2017-01-06,24.79,24.81,24.4687,24.55,
AXON,2017-01-09,24.52,24.637,24.26,24.27,
AXON,2017-01-10,24.38,25.0,24.27,24.63,
AXON,2017-01-11,24.7,24.75,24.2878,24.63,
AXON,2017-01-12,24.5,24.685,23.48,24.275,
AXON,2017-01-13,24.29,25.4697,24.29,25.23,
AXON,2017-01-17,25.17,25.17,24.445,24.82,
AXON,2017-01-18,24.86,25.37,24.69,25.1,
AXON,2017-01-19,25.02,25.36,24.83,25.09,
AXON,2017-01-20,25.24,25.24,24.7532,24.85,
AXON,2017-01-23,24.8,24.98,24.67,24.81,
AXON,2017-01-24,24.84,25.45,24.82,25.18,
AXON,2017-01-25,25.39,25.5,24.89,25.11,
AXON,2017-01-26,25.11,25.26,24.73,24.88,
AXON,2017-01-27,24.88,24.96,24.65,24.83,
AXON,2017-01-30,24.62,24.99,24.33,24.89,
AXON,2017-01-31,24.83,25.03,24.5,24.98,
AXON,2017-02-01,25.13,25.3,24.91,25.13,
AXON,2017-02-02,25.18,25.99,25.13,25.72,
AXON,2017-02-03,25.74,26.35,25.52,26.27,
AXON,2017-02-06,26.33,26.99,26.18,26.92,
AXON,2017-02-07,27.02,27.41,26.68,26.81,
AXON,2017-02-08,26.79,26.85,26.22,26.54,
AXON,2017-02-09,26.5,27.17,26.4,26.89,
AXON,2017-02-10,27.0,27.4,26.87,27.34,
AXON,2017-02-13,27.4,27.56,27.15,27.18,
AXON,2017-02-14,27.16,27.19,26.89,27.01,
AXON,2017-02-15,26.7,26.85,26.35,26.53,
AXON,2017-02-16,26.49,26.68,26.27,26.68,
AXON,2017-02-17,26.5,26.6889,26.29,26.5,
AXON,2017-02-21,26.42,26.7,26.36,26.57,
AXON,2017-02-22,26.42,26.59,26.02,26.24,
AXON,2017-02-23,26.31,26.4299,25.41,25.47,
AXON,2017-02-24,25.47,25.78,25.26,25.625,
AXON,2017-02-27,25.67,26.23,25.63,26.08,
AXON,2017-02-28,26.13,26.24,25.44,25.67,
AXON,2017-03-01,24.77,25.13,22.905,24.34,
AXON,2017-03-02,24.23,24.23,22.52,22.96,
AXON,2017-03-03,23.01,23.27,22.1,22.81,
AXON,2017-03-06,22.8,23.111,22.4,22.53,
AXON,2017-03-07,22.42,22.7,22.4,22.49,
AXON,2017-03-08,22.61,22.64,22.3,22.37,
AXON,2017-03-09,22.36,22.62,22.22,22.49,
AXON,2017-03-10,22.62,22.86,22.5,22.63,
AXON,2017-03-13,22.58,22.84,22.5,22.81,
AXON,2017-03-14,22.7,22.96,22.58,22.89,
AXON,2017-03-15,22.99,23.1,22.63,23.01,
AXON,2017-03-16,23.03,23.19,22.718,22.76,
AXON,2017-03-17,22.77,23.48,22.715,23.39,
AXON,2017-03-20,23.46,23.63,22.88,22.94,
AXON,2017-03-21,23.01,23.33,22.43,22.46,
AXON,2017-03-22,22.47,22.93,22.22,22.45,
AXON,2017-03-23,22.5,22.7701,22.32,22.63,
AXON,2017-03-24,22.67,22.89,22.36,22.5,
AXON,2017-03-27,22.22,22.575,22.05,22.47,
AXON,2017-03-28,22.43,22.82,22.25,22.79,
AXON,2017-03-29,22.76,22.82,22.56,22.64,
AXON,2017-03-30,22.63,23.3442,22.63,23.22,
AXON,2017-03-31,23.18,23.215,22.77,22.79,
AXON,2017-04-03,22.78,22.83,22.48,22.5,
AXON,2017-04-04,22.47,22.64,21.97,22.0,
AXON,2017-04-05,23.35,23.393,21.18,21.9,
AXON,2017-04-06,23.08,23.1,23.08,23.08,
AXON,2017-04-07,23.25,23.61,22.67,23.27,
AXON,2017-04-10,23.3,24.58,23.27,23.27,
AXON,2017-04-11,23.27,23.42,22.95,23.18,
AXON,2017-04-12,23.27,23.35,22.34,22.42,
AXON,2017-04-13,22.22,22.5,22.02,22.04,
AXON,2017-04-17,22.04,22.17,21.95,22.08,
AXON,2017-04-18,22.06,22.51,22.02,22.5,
AXON,2017-04-19,22.55,22.91,22.545,22.73,
AXON,2017-04-20,22.94,23.36,22.79,23.3,
AXON,2017-04-21,23.34,23.78,23.29,23.69,
AXON,2017-04-24,24.0,24.05,23.72,24.02,
AXON,2017-04-25,24.21,24.3,24.0801,24.17,
AXON,2017-04-26,24.12,24.48,24.0,24.27,
AXON,2017-04-27,24.36,24.73,24.36,24.7,
AXON,2017-04-28,24.75,24.75,24.4374,24.58,
AXON,2017-05-01,24.72,24.82,24.54,24.75,
AXON,2017-05-02,24.66,24.82,24.61,24.78,
AXON,2017-05-03,24.58,24.77,24.5,24.74,
AXON,2017-05-04,24.77,24.9,24.68,24.84,
AXON,2017-05-05,24.88,24.95,24.675,24.95,
AXON,2017-05-08,24.84,25.07,24.59,25.04,
AXON,2017-05-09,24.9,25.51,24.9,25.18,
AXON,2017-05-10,26.97,28.17,25.66,26.25,
AXON,2017-05-11,26.06,26.29,25.75,26.0,
AXON,2017-05-12,26.0,26.3,25.96,25.99,
AXON,2017-05-15,25.99,26.04,25.15,25.16,
AXON,2017-05-16,25.1,25.61,24.83,25.56,
AXON,2017-05-17,25.36,25.36,24.56,24.59,
AXON,2017-05-18,24.5,24.65,24.08,24.13,
AXON,2017-05-19,24.13,24.84,24.13,24.6,
AXON,2017-05-22,24.72,24.82,24.53,24.73,
AXON,2017-05-23,24.75,24.94,24.46,24.88,
AXON,2017-05-24,24.88,25.01,24.69,24.78,
AXON,2017-05-25,24.96,25.15,24.765,24.99,
AXON,2017-05-26,25.0,25.0336,24.62,24.89,
AXON,2017-05-30,24.75,24.8657,24.45,24.59,
AXON,2017-05-31,24.67,24.74,23.98,24.01,
AXON,2017-06-01,24.1,24.5,23.9953,24.46,
AXON,2017-06-02,24.42,24.83,24.4,24.52,
AXON,2017-06-05,24.44,24.59,24.14,24.4,
AXON,2017-06-06,24.24,24.74,24.2,24.66,
AXON,2017-06-07,24.6,24.71,24.17,24.26,
AXON,2017-06-08,24.25,24.58,24.18,24.44,
AXON,2017-06-09,24.34,24.67,24.1754,24.37,
AXON,2017-06-12,24.33,24.46,24.11,24.2,
AXON,2017-06-13,24.26,24.5,24.12,24.47,
AXON,2017-06-14,24.38,24.5,24.17,24.27,
AXON,2017-06-15,24.1,25.0,24.04,24.76,"S&P 500 maintains support amid second FAANG-fueled downturn Focus: 10-year yield violates 200-day average after the Fed, Crude oil confirms downtrend, tags 14-month lows, TNX, USO, XBI, BABA, RF, AXON U.S. stocks are lower early Thursday, pressured amid ongoing reaction to the Federal Reserve’s policy directive, combined with a second round of FAANG-fueled selling pressure. Against this backdrop, the S&P 500 has thus far maintained near-term support, circa 2,416, while the Nasdaq Composite remains more firmly pressured, partly as a source of funds deployed to other sectors."
AXON,2017-06-16,24.5,25.5,24.33,25.36,
AXON,2017-06-19,25.53,25.69,25.29,25.41,
AXON,2017-06-20,25.6,27.0,25.55,25.77,
AXON,2017-06-21,25.76,26.375,25.735,26.02,
AXON,2017-06-22,26.0,26.4,25.815,26.29,
AXON,2017-06-23,26.32,26.42,26.14,26.32,
AXON,2017-06-26,26.27,26.39,25.88,25.96,
AXON,2017-06-27,25.93,25.99,25.35,25.45,
AXON,2017-06-28,25.61,26.02,25.52,25.86,
AXON,2017-06-29,25.87,25.97,24.76,25.17,
AXON,2017-06-30,25.2,25.46,24.97,25.14,
AXON,2017-07-03,25.22,25.45,25.02,25.16,
AXON,2017-07-05,25.09,25.5,25.03,25.27,
AXON,2017-07-06,25.28,25.39,24.94,25.05,
AXON,2017-07-07,23.95,25.25,23.7739,25.09,
AXON,2017-07-10,25.04,25.31,24.71,25.02,
AXON,2017-07-11,24.93,25.55,24.87,25.32,
AXON,2017-07-12,25.42,25.71,25.28,25.47,
AXON,2017-07-13,25.43,25.5,25.07,25.23,
AXON,2017-07-14,25.13,25.4,24.85,25.29,
AXON,2017-07-17,25.24,25.85,25.19,25.82,
AXON,2017-07-18,25.72,25.72,25.1971,25.24,
AXON,2017-07-19,25.2,25.56,25.15,25.39,
AXON,2017-07-20,25.45,25.45,25.061,25.38,
AXON,2017-07-21,25.58,25.58,25.19,25.24,
AXON,2017-07-24,25.23,25.53,25.106,25.3601,
AXON,2017-07-25,25.42,25.521,25.18,25.41,
AXON,2017-07-26,25.47,25.48,24.96,25.22,
AXON,2017-07-27,25.23,25.37,24.8,24.99,
AXON,2017-07-28,24.85,25.0,24.67,24.72,
AXON,2017-07-31,24.66,24.74,24.18,24.59,
AXON,2017-08-01,24.6,24.88,24.27,24.87,
AXON,2017-08-02,24.8,25.04,24.645,24.86,
AXON,2017-08-03,24.75,25.06,24.75,25.0,
AXON,2017-08-04,25.0,25.46,24.7,25.39,
AXON,2017-08-07,25.26,25.8796,25.15,25.72,
AXON,2017-08-08,25.77,26.31,25.29,25.31,
AXON,2017-08-09,24.3,25.26,21.8001,23.02,
AXON,2017-08-10,23.0,23.05,22.24,22.46,
AXON,2017-08-11,22.65,22.73,21.91,22.36,
AXON,2017-08-14,22.56,22.65,22.04,22.18,
AXON,2017-08-15,22.1,22.37,21.52,21.63,
AXON,2017-08-16,21.65,21.8,21.34,21.66,
AXON,2017-08-17,21.55,21.86,21.445,21.48,
AXON,2017-08-18,21.36,22.15,21.25,22.08,
AXON,2017-08-21,22.03,22.14,21.85,22.08,
AXON,2017-08-22,21.5,22.13,21.4001,21.77,
AXON,2017-08-23,21.58,21.99,21.45,21.64,
AXON,2017-08-24,21.81,22.09,21.7525,21.85,
AXON,2017-08-25,21.62,21.83,21.57,21.58,
AXON,2017-08-28,21.63,21.95,21.61,21.88,
AXON,2017-08-29,21.77,21.91,21.61,21.62,
AXON,2017-08-30,21.6,21.69,21.44,21.59,
AXON,2017-08-31,21.69,21.87,21.6318,21.71,
AXON,2017-09-01,21.73,21.98,21.64,21.73,
AXON,2017-09-05,21.66,21.98,21.53,21.98,
AXON,2017-09-06,22.0,22.0,21.7,21.73,
AXON,2017-09-07,21.74,21.99,21.48,21.49,
AXON,2017-09-08,21.51,21.96,21.46,21.64,
AXON,2017-09-11,21.79,22.25,21.72,21.86,
AXON,2017-09-12,21.87,22.35,21.86,22.35,
AXON,2017-09-13,22.34,22.56,22.21,22.4,
AXON,2017-09-14,22.52,22.76,22.4,22.54,
AXON,2017-09-15,22.59,22.73,21.945,22.3,
AXON,2017-09-18,22.34,22.68,22.3,22.4,
AXON,2017-09-19,22.45,22.5065,22.02,22.07,
AXON,2017-09-20,22.21,23.22,22.085,22.91,
AXON,2017-09-21,22.91,23.1199,22.7,22.8,
AXON,2017-09-22,22.77,23.06,22.64,22.65,
AXON,2017-09-25,22.66,22.7312,22.18,22.59,
AXON,2017-09-26,22.59,22.95,22.54,22.66,"[""UPDATE: Axovant shares tumble 71% after late-stage trial of Alzheimer's treatment fails to meet primary goals Axovant Sciences Ltd. shares cratered 71% in premarket trade Tuesday, after the company said a late-stage trial of a treatment for Alzheimer's disease failed to meet its primary goals. The company said the phase 3 trial of intepirdine in patients with mild to moderate Alzheimer's disease who were receiving donepezil therapy did not meet its primary endpoints. \""At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), respectively, compared to patients treated with placebo,\"" the company said in a statement. Alzheimer's is the most common form of dementia and is fifth leading cause of death for people age 65 and older in the U.S. Axovant shares had gained 95% in 2017 through Monday, while the S&P 500 has gained 12%."", ""Why tech bulls need to step up big time today Critical information for the U.S. trading day An early-week pullback for tech stocks may have left investors a bit stymied. Sure, it\u2019s just one day and North Korea had something to do with the jitters, but our call of the day says bulls need to step up.""]"
AXON,2017-09-27,22.72,23.07,22.67,23.05,
AXON,2017-09-28,23.1,23.49,22.89,23.09,
AXON,2017-09-29,23.08,23.2,22.65,22.67,
AXON,2017-10-02,22.77,23.04,22.66,22.91,
AXON,2017-10-03,23.04,23.31,23.04,23.2,
AXON,2017-10-04,23.26,23.77,23.2,23.77,
AXON,2017-10-05,23.72,23.86,23.5492,23.64,
AXON,2017-10-06,23.64,23.78,23.5005,23.72,
AXON,2017-10-09,23.72,23.82,23.53,23.56,
AXON,2017-10-10,23.57,23.835,23.39,23.82,
AXON,2017-10-11,23.77,24.0,23.77,23.92,
AXON,2017-10-12,24.03,24.55,23.96,24.45,
AXON,2017-10-13,24.62,24.73,24.42,24.6,
AXON,2017-10-16,24.65,24.7,24.225,24.31,
AXON,2017-10-17,24.19,24.47,24.11,24.44,
AXON,2017-10-18,23.9,25.02,23.6,24.99,
AXON,2017-10-19,24.78,24.919,24.42,24.62,
AXON,2017-10-20,23.5,24.03,22.86,23.01,
AXON,2017-10-23,22.8,22.9699,22.3275,22.59,
AXON,2017-10-24,22.48,22.54,22.115,22.32,
AXON,2017-10-25,22.14,22.46,22.09,22.17,
AXON,2017-10-26,22.1,22.47,22.0824,22.43,
AXON,2017-10-27,22.43,22.93,22.2952,22.92,
AXON,2017-10-30,22.76,22.91,22.66,22.87,
AXON,2017-10-31,22.96,23.15,22.89,22.97,
AXON,2017-11-01,23.0,23.045,22.81,23.03,
AXON,2017-11-02,23.0,23.5,22.9,23.48,
AXON,2017-11-03,23.45,23.45,23.175,23.41,
AXON,2017-11-06,23.4,23.49,23.16,23.22,
AXON,2017-11-07,23.2,23.35,22.84,22.86,
AXON,2017-11-08,22.62,22.73,20.57,21.43,
AXON,2017-11-09,21.31,22.38,20.92,21.54,
AXON,2017-11-10,21.43,21.46,21.15,21.16,
AXON,2017-11-13,21.02,21.47,21.02,21.12,
AXON,2017-11-14,21.01,21.44,20.8099,21.4,
AXON,2017-11-15,21.17,21.95,21.13,21.89,
AXON,2017-11-16,21.88,22.46,21.8,22.39,
AXON,2017-11-17,22.5,23.45,22.49,23.13,
AXON,2017-11-20,23.19,23.85,23.19,23.61,
AXON,2017-11-21,23.74,23.88,23.265,23.85,
AXON,2017-11-22,23.86,24.0,23.55,23.77,
AXON,2017-11-24,23.87,24.07,23.72,24.06,
AXON,2017-11-27,24.1,24.45,23.92,24.43,
AXON,2017-11-28,24.46,25.01,24.27,24.87,
AXON,2017-11-29,24.79,25.09,24.54,24.97,
AXON,2017-11-30,24.99,25.22,24.725,24.88,
AXON,2017-12-01,24.9,24.91,23.82,24.48,
AXON,2017-12-04,24.64,24.879,24.06,24.1,
AXON,2017-12-05,24.1,24.385,23.95,24.09,
AXON,2017-12-06,24.09,24.28,23.85,24.0,
AXON,2017-12-07,24.04,24.69,23.9578,24.33,
AXON,2017-12-08,24.36,24.78,24.32,24.505,
AXON,2017-12-11,24.53,24.79,24.16,24.59,
AXON,2017-12-12,24.69,25.2,24.528,25.16,
AXON,2017-12-13,25.21,26.01,25.16,25.59,
AXON,2017-12-14,25.59,25.92,25.34,25.43,
AXON,2017-12-15,25.85,26.4,25.53,26.35,
AXON,2017-12-18,26.4,27.06,26.37,27.0,
AXON,2017-12-19,27.09,27.09,26.3304,26.5,
AXON,2017-12-20,26.67,26.67,25.75,25.8,
AXON,2017-12-21,25.96,26.6,25.54,26.38,
AXON,2017-12-22,26.41,26.52,26.05,26.44,
AXON,2017-12-26,26.16,26.7,26.16,26.47,
AXON,2017-12-27,26.55,26.74,26.42,26.68,
AXON,2017-12-28,26.7,26.96,26.5968,26.93,
AXON,2017-12-29,26.9,26.92,26.47,26.5,
AXON,2018-01-02,26.52,26.58,26.22,26.55,
AXON,2018-01-03,26.45,26.79,26.08,26.75,
AXON,2018-01-04,26.8,26.89,26.5,26.83,
AXON,2018-01-05,26.85,27.1,26.6204,26.85,
AXON,2018-01-08,26.82,26.825,26.27,26.77,"Axovant's stock tumbles toward record low after disappointing drug trial results Shares of Axovant Sciences Ltd. plunged 46% toward a record low in premarket trade Monday, after the biopharmaceutical company said it would discontinue its intepirdine program for the treatment of dementia after it failed to meet its primary efficacy endpoints in a phase 2 trials. ""Based on the totality of intepirdine data to date, there is no evidence to support its further development,"" said Chief Executive David Hung. ""We are incredibly disappointed and saddened for the millions of people living with these difficult conditions, and are deeply grateful to the patients, caregivers and investigators who participated in our trials."" Separately, the company said its investigational drug nelotanserin met its primary safety endpoing in a phase 2 visual hallucination study. The stock has tumbled 24% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has lost 3.2% and the S&P 500 has gained 7.6%."
AXON,2018-01-09,26.77,27.08,26.65,26.82,
AXON,2018-01-10,26.78,26.88,26.4,26.56,
AXON,2018-01-11,26.58,27.0,26.52,26.9,
AXON,2018-01-12,26.99,27.75,26.87,27.56,
AXON,2018-01-16,27.59,27.96,27.276,27.29,
AXON,2018-01-17,27.39,27.79,27.3552,27.71,
AXON,2018-01-18,27.63,27.73,27.27,27.44,
AXON,2018-01-19,27.41,27.5661,27.16,27.48,
AXON,2018-01-22,27.48,27.48,27.07,27.47,
AXON,2018-01-23,27.44,27.49,27.17,27.46,
AXON,2018-01-24,27.43,27.65,26.9,27.21,
AXON,2018-01-25,27.31,27.52,27.01,27.52,
AXON,2018-01-26,27.59,27.74,27.16,27.48,
AXON,2018-01-29,27.4,27.63,27.205,27.41,
AXON,2018-01-30,27.13,27.86,26.7308,27.36,
AXON,2018-01-31,27.48,27.585,26.34,26.46,
AXON,2018-02-01,26.33,26.37,25.75,25.83,
AXON,2018-02-02,25.66,26.14,25.4606,25.82,
AXON,2018-02-05,25.74,25.99,24.84,25.03,
AXON,2018-02-06,24.85,25.34,24.501,25.15,
AXON,2018-02-07,25.2,26.07,25.2,25.95,
AXON,2018-02-08,25.89,25.97,25.32,25.32,
AXON,2018-02-09,25.54,25.88,24.85,25.28,
AXON,2018-02-12,25.4,25.8899,25.22,25.59,"Axovant shares slide 21% premarket on news of CEO, COO departures Axovant Sciences Ltd. shares slid 21% in premarket trade Monday, after the company said Chief Executive David Hung and Chief Operating Officer Marion McCourt are leaving the company to pursue other opportunities. The biotech, which specializes in developing treatments for patients with life-threatening neurological conditions, said directors Kate Falberg, Tony Vernon and Patrick Machado have resigned as members of the board. Pavan Cheruvu has joined the company as CEO, while Roger Jeffs, a former president and co-CEO of United Therapeutics, and George Bickerstaff, former chief financial officer of Novartis Pharma, have joined the board of directors. Hung will remain at the company as a scientific adviser. Shares have tumbled 85% in the last 12 months, while the S&P 500 has gained 13%."
AXON,2018-02-13,25.58,27.04,25.52,26.84,
AXON,2018-02-14,26.64,27.97,26.64,27.92,
AXON,2018-02-15,28.0,28.489,27.88,28.4,
AXON,2018-02-16,28.4,29.0,28.4,28.74,
AXON,2018-02-20,28.66,28.94,28.06,28.07,
AXON,2018-02-21,28.16,28.71,28.06,28.1,
AXON,2018-02-22,28.15,28.47,28.1,28.19,
AXON,2018-02-23,28.38,28.6,28.07,28.58,
AXON,2018-02-26,28.66,28.78,28.11,28.16,
AXON,2018-02-27,28.1,28.11,27.19,27.25,
AXON,2018-02-28,32.01,36.3,31.06,34.83,
AXON,2018-03-01,34.9,39.74,34.85,37.69,
AXON,2018-03-02,36.37,38.87,35.95,38.75,
AXON,2018-03-05,38.74,39.75,36.91,38.28,
AXON,2018-03-06,37.5,39.7,37.42,39.09,
AXON,2018-03-07,38.97,40.24,38.7,39.77,
AXON,2018-03-08,39.72,40.1,39.39,39.79,
AXON,2018-03-09,40.01,40.16,39.11,39.86,
AXON,2018-03-12,40.34,40.491,39.15,39.42,
AXON,2018-03-13,39.56,39.88,38.95,39.35,
AXON,2018-03-14,39.49,39.585,38.95,39.01,
AXON,2018-03-15,38.92,39.02,38.33,38.62,
AXON,2018-03-16,37.95,38.39,37.54,37.97,
AXON,2018-03-19,37.81,37.95,37.11,37.4,
AXON,2018-03-20,37.5,38.66,37.46,38.36,
AXON,2018-03-21,38.45,38.98,38.13,38.8,
AXON,2018-03-22,38.56,39.3,38.31,38.55,
AXON,2018-03-23,38.57,39.16,37.89,37.9,
AXON,2018-03-26,38.26,38.77,37.521,38.72,
AXON,2018-03-27,38.67,39.31,38.32,38.63,
AXON,2018-03-28,38.78,38.8,37.62,37.92,
AXON,2018-03-29,38.19,39.89,38.15,39.31,
AXON,2018-04-02,39.35,39.61,38.83,39.48,
AXON,2018-04-03,39.78,42.45,39.501,42.4,
AXON,2018-04-04,41.91,42.65,40.56,41.98,
AXON,2018-04-05,42.38,43.16,42.1,42.86,
AXON,2018-04-06,42.47,42.95,41.55,41.84,
AXON,2018-04-09,42.24,42.34,40.84,41.31,
AXON,2018-04-10,41.62,42.3,41.38,42.09,
AXON,2018-04-11,42.78,43.19,42.0,42.78,
AXON,2018-04-12,43.1,44.06,43.0,43.1,
AXON,2018-04-13,43.77,43.77,42.65,42.79,
AXON,2018-04-16,43.33,43.71,42.8,42.97,
AXON,2018-04-17,43.06,43.84,42.97,43.01,
AXON,2018-04-18,43.26,43.671,42.72,42.74,
AXON,2018-04-19,42.7,43.43,42.15,42.99,
AXON,2018-04-20,42.92,43.27,42.63,42.7,
AXON,2018-04-23,43.06,43.43,42.45,42.74,
AXON,2018-04-24,43.03,43.7319,41.7,42.8,
AXON,2018-04-25,42.64,43.07,42.1124,43.0,
AXON,2018-04-26,44.3,44.749,42.6,42.74,
AXON,2018-04-27,42.9,43.24,41.3708,41.61,
AXON,2018-04-30,41.79,42.44,41.6,41.98,
AXON,2018-05-01,41.95,42.14,41.16,41.51,
AXON,2018-05-02,41.77,42.8,41.77,41.99,
AXON,2018-05-03,41.99,41.99,41.1,41.44,
AXON,2018-05-04,42.24,45.5,42.24,44.55,
AXON,2018-05-07,45.19,45.48,43.68,44.93,
AXON,2018-05-08,44.73,45.25,44.25,44.65,
AXON,2018-05-09,50.4,56.22,49.96,54.62,
AXON,2018-05-10,54.44,56.73,53.55,55.44,
AXON,2018-05-11,55.44,57.44,55.16,57.26,
AXON,2018-05-14,57.43,58.1778,56.505,56.99,
AXON,2018-05-15,53.87,54.67,52.22,54.54,
AXON,2018-05-16,54.54,56.81,53.67,54.33,
AXON,2018-05-17,55.27,57.89,54.28,57.12,
AXON,2018-05-18,57.52,58.47,57.01,57.95,
AXON,2018-05-21,58.28,59.73,57.72,59.65,
AXON,2018-05-22,60.08,62.2,59.1,61.72,
AXON,2018-05-23,61.26,61.96,59.16,59.8,
AXON,2018-05-24,60.0,62.5,59.4,62.08,
AXON,2018-05-25,61.99,63.5,61.5,63.01,
AXON,2018-05-29,63.71,64.94,63.15,63.97,
AXON,2018-05-30,64.35,64.779,62.66,63.74,
AXON,2018-05-31,63.7,64.74,63.165,63.68,
AXON,2018-06-01,63.97,65.4,63.441,65.3,
AXON,2018-06-04,65.27,66.13,64.6748,66.07,
AXON,2018-06-05,66.07,67.45,65.33,67.06,
AXON,2018-06-06,67.64,69.09,66.93,67.9,"UPDATE: Axovant shares soar 51% premarket on $842.5 mln licensing pact for Parkinson's treatment Shares of Axovant Sciences Ltd. soared more than 50% in premarket trade Wednesday, after Oxford BioMedica plc said it has entered an $842.5 million licensing agreement for OXB-102, a gene therapy treatment for Parkinson's disease. Under the terms of the deal, Oxford BioMedica will receive a $30 million upfront payment, and is eligible for $55 million upon reaching certain milestones. It will receive $757.5 million on reaching regulatory and sales milestones and 7% to 10% tiered royalties on net sales of AXO-Lenti-PD. Axovant will fund all clinical development costs and expects to start a Phase 1/11 dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson's by year-end. The companies will host a conference call with investors at 9.30 a.m. Eastern. Axovant shares have fallen 68.8% in 2018 so far, while the S&P 500 has gained 2.8%. Oxford BioMedica shares were up 18% in London."
AXON,2018-06-07,65.45,65.5,62.25,63.53,
AXON,2018-06-08,63.16,65.74,63.1,65.28,
AXON,2018-06-11,65.43,66.18,64.34,65.2,
AXON,2018-06-12,65.14,66.42,64.75,65.28,
AXON,2018-06-13,65.53,65.59,64.35,64.88,
AXON,2018-06-14,65.21,65.506,62.89,63.67,
AXON,2018-06-15,63.26,64.53,61.57,64.4,
AXON,2018-06-18,64.4,66.2199,63.77,66.13,
AXON,2018-06-19,65.5,65.66,63.09,65.54,
AXON,2018-06-20,66.33,68.855,66.2,68.45,
AXON,2018-06-21,68.79,71.0,65.729,67.05,
AXON,2018-06-22,67.13,68.15,66.29,67.65,
AXON,2018-06-25,67.21,67.6,61.8,61.97,
AXON,2018-06-26,62.28,63.989,62.0238,63.17,
AXON,2018-06-27,63.17,63.97,62.0,62.01,
AXON,2018-06-28,61.84,64.42,61.75,64.04,
AXON,2018-06-29,64.47,64.9559,62.22,63.18,
AXON,2018-07-02,64.0,64.81,63.01,64.43,
AXON,2018-07-03,64.46,65.306,63.85,64.09,
AXON,2018-07-05,64.69,65.0,63.7,64.98,
AXON,2018-07-06,64.82,66.03,64.04,65.96,
AXON,2018-07-09,66.5,67.0,65.53,66.95,
AXON,2018-07-10,67.28,68.06,66.05,67.35,
AXON,2018-07-11,66.88,67.9891,66.52,66.96,
AXON,2018-07-12,67.47,69.22,66.0,68.94,
AXON,2018-07-13,69.08,70.425,67.43,67.79,
AXON,2018-07-16,67.79,69.18,67.79,69.02,
AXON,2018-07-17,69.12,70.89,68.68,70.64,
AXON,2018-07-18,70.9,72.06,69.31,71.55,
AXON,2018-07-19,71.46,73.3399,71.45,73.07,
AXON,2018-07-20,73.49,74.75,72.51,73.83,
AXON,2018-07-23,73.6,75.18,73.1488,74.89,
AXON,2018-07-24,75.25,76.4544,70.78,72.24,
AXON,2018-07-25,71.06,72.96,68.3678,72.89,
AXON,2018-07-26,72.22,72.99,70.94,72.5,
AXON,2018-07-27,72.87,73.11,67.51,68.76,
AXON,2018-07-30,69.0,69.34,65.49,66.42,
AXON,2018-07-31,66.5,68.32,66.3502,67.93,
AXON,2018-08-01,68.35,69.43,67.64,68.42,
AXON,2018-08-02,68.38,70.0,67.93,69.78,
AXON,2018-08-03,70.64,71.0,67.93,69.09,
AXON,2018-08-06,68.1,69.115,65.19,66.86,
AXON,2018-08-07,67.01,68.16,66.14,67.62,
AXON,2018-08-08,63.19,63.19,56.09,59.78,
AXON,2018-08-09,60.5,61.86,59.22,59.33,
AXON,2018-08-10,59.27,61.94,58.04,61.47,
AXON,2018-08-13,61.21,62.585,60.57,60.98,
AXON,2018-08-14,61.1,62.59,60.83,62.31,
AXON,2018-08-15,61.26,62.55,59.72,61.02,
AXON,2018-08-16,61.49,62.77,61.14,62.66,
AXON,2018-08-17,62.69,64.18,62.1001,64.15,
AXON,2018-08-20,64.45,64.68,63.0753,64.16,
AXON,2018-08-21,64.15,64.77,63.72,63.81,
AXON,2018-08-22,63.5,64.97,63.1,64.35,
AXON,2018-08-23,64.4,65.39,63.71,64.01,
AXON,2018-08-24,64.0,65.8,64.0,65.55,
AXON,2018-08-27,65.89,67.3,65.8,66.66,
AXON,2018-08-28,66.97,67.92,66.45,67.3,
AXON,2018-08-29,67.5,67.6,66.66,67.08,
AXON,2018-08-30,67.0,67.41,66.17,66.46,
AXON,2018-08-31,66.24,68.485,66.24,68.26,
AXON,2018-09-04,68.0,70.2363,67.15,69.88,
AXON,2018-09-05,69.7,69.88,66.84,68.77,
AXON,2018-09-06,68.89,70.5,68.77,70.29,
AXON,2018-09-07,69.92,71.962,69.28,70.46,
AXON,2018-09-10,70.96,72.05,70.54,71.88,
AXON,2018-09-11,71.94,73.64,71.6,72.94,
AXON,2018-09-12,72.8,73.3,70.35,70.36,
AXON,2018-09-13,70.58,72.13,70.48,71.43,
AXON,2018-09-14,72.24,73.61,71.64,73.41,
AXON,2018-09-17,73.43,74.14,68.3701,68.67,
AXON,2018-09-18,69.05,70.75,68.95,69.08,
AXON,2018-09-19,68.89,69.3,66.225,67.37,
AXON,2018-09-20,67.78,68.0382,64.96,65.46,
AXON,2018-09-21,65.65,66.58,64.371,64.79,
AXON,2018-09-24,64.35,64.87,63.2,63.62,
AXON,2018-09-25,63.91,67.34,63.83,66.97,
AXON,2018-09-26,67.15,67.7099,66.09,66.39,
AXON,2018-09-27,66.75,67.9399,66.4,67.61,
AXON,2018-09-28,67.47,69.3477,67.47,68.43,
AXON,2018-10-01,68.61,69.82,66.5813,66.84,
AXON,2018-10-02,66.28,66.48,63.635,64.23,
AXON,2018-10-03,64.59,65.83,63.6501,64.76,
AXON,2018-10-04,64.09,64.3457,62.3,62.81,
AXON,2018-10-05,62.91,64.2399,61.2381,62.67,
AXON,2018-10-08,62.46,64.335,61.55,63.41,
AXON,2018-10-09,63.41,64.77,62.17,62.84,
AXON,2018-10-10,62.28,62.28,57.54,57.66,
AXON,2018-10-11,57.02,58.8,56.08,56.19,
AXON,2018-10-12,57.85,59.12,57.29,58.86,
AXON,2018-10-15,57.15,57.5,54.39,57.06,
AXON,2018-10-16,57.6,61.37,57.35,61.24,
AXON,2018-10-17,62.73,62.73,59.52,61.65,
AXON,2018-10-18,61.11,61.9,58.17,58.26,
AXON,2018-10-19,58.49,59.86,57.71,58.52,
AXON,2018-10-22,55.9,59.03,55.11,57.98,
AXON,2018-10-23,56.34,58.45,55.7301,58.04,
AXON,2018-10-24,58.45,59.0,57.37,57.65,
AXON,2018-10-25,58.22,59.439,57.83,58.95,
AXON,2018-10-26,57.45,59.32,55.09,56.95,
AXON,2018-10-29,58.08,59.35,54.81,55.9,
AXON,2018-10-30,55.75,58.08,55.1134,57.95,
AXON,2018-10-31,58.85,62.14,58.85,61.72,
AXON,2018-11-01,62.09,62.09,59.521,61.4,
AXON,2018-11-02,61.93,62.855,60.6944,61.2,
AXON,2018-11-05,61.2,61.94,59.2,60.44,
AXON,2018-11-06,60.24,61.71,59.25,60.08,
AXON,2018-11-07,54.8,56.0,49.64,50.7,
AXON,2018-11-08,52.82,52.9,50.29,50.66,
AXON,2018-11-09,51.75,53.18,51.1,52.25,
AXON,2018-11-12,52.16,52.665,49.22,50.0,
AXON,2018-11-13,50.26,51.78,49.33,50.29,
AXON,2018-11-14,50.29,50.6832,48.92,49.57,
AXON,2018-11-15,49.36,50.07,47.8,49.58,
AXON,2018-11-16,49.09,50.02,48.04,49.95,
AXON,2018-11-19,50.0,50.03,46.77,46.99,
AXON,2018-11-20,45.09,46.28,43.7,45.22,
AXON,2018-11-21,45.76,47.17,45.56,46.66,
AXON,2018-11-23,46.2,47.5,46.2,46.68,
AXON,2018-11-26,47.26,47.6907,46.0401,46.86,
AXON,2018-11-27,46.68,47.4,46.4,46.52,
AXON,2018-11-28,46.66,47.1573,45.26,45.38,
AXON,2018-11-29,45.3,45.93,43.33,44.07,
AXON,2018-11-30,43.71,44.28,42.83,43.47,
AXON,2018-12-03,43.91,45.5,43.8,45.18,
AXON,2018-12-04,45.15,46.045,43.57,43.64,
AXON,2018-12-06,42.6,44.65,42.0,44.51,
AXON,2018-12-07,44.37,45.08,42.895,43.52,
AXON,2018-12-10,43.31,44.82,43.31,44.3,"[""UPDATE: Axovant shares slide 30% premarket after trial of treatment for sleep disorder fails to meet main goal Axovant Sciences Ltd. shares slid 30% in premarket trade Monday, after the company said a trial of a treatment for REM sleep behavior disorder in patients with Lewy body dementia failed to meet its main goal. the Basel, Switzerland-based biotech said the phase 2 trial involving 34 patients using nelotanserin failed to meet its primary endpoint and that it would discontinue clinical development of the therapy. Lewy body dementia is the second most common type of dementia after that associated with Alzheimer's disease. Axovant shares have fallen 67.6% in 2018, while the S&P 500 has fallen 1.5%."", ""Dow roars back from 500-point decline as stocks close higher China\u2019s exports slow sharply Stocks close higher Monday as major indexes bounced back from earlier losses as renewed confidence in the strength of the U.S. economy offset lingering worries over the U.S.-China trade dispute.""]"
AXON,2018-12-11,45.59,46.29,43.67,44.21,
AXON,2018-12-12,45.88,46.88,45.0,45.59,
AXON,2018-12-13,46.0,46.0,44.85,45.12,
AXON,2018-12-14,44.6,45.86,44.5,44.65,
AXON,2018-12-17,44.5,45.07,43.475,43.8,
AXON,2018-12-18,44.44,45.43,44.13,44.46,
AXON,2018-12-19,44.45,45.53,44.35,44.82,
AXON,2018-12-20,44.44,45.43,40.01,41.37,
AXON,2018-12-21,41.5,43.4,41.3333,41.79,
AXON,2018-12-24,40.45,40.86,39.43,39.74,
AXON,2018-12-26,39.81,41.81,39.54,41.76,
AXON,2018-12-27,41.17,43.01,41.0,43.0,
AXON,2018-12-28,43.04,43.74,42.02,43.03,
AXON,2018-12-31,43.58,44.26,43.13,43.75,
AXON,2019-01-02,42.99,45.12,42.62,45.11,
AXON,2019-01-03,44.34,44.697,42.42,43.29,
AXON,2019-01-04,43.95,46.21,43.19,46.01,
AXON,2019-01-07,46.45,48.71,46.39,48.15,
AXON,2019-01-08,48.98,49.91,48.6466,49.41,
AXON,2019-01-09,49.84,50.61,49.13,50.26,
AXON,2019-01-10,49.85,50.22,48.81,49.69,
AXON,2019-01-11,49.56,49.89,48.499,49.45,
AXON,2019-01-14,49.0,50.11,48.24,49.78,
AXON,2019-01-15,50.13,50.4,49.02,49.35,
AXON,2019-01-16,49.36,50.005,48.68,49.63,
AXON,2019-01-17,49.41,50.61,49.3917,50.22,
AXON,2019-01-18,50.42,50.87,50.02,50.19,
AXON,2019-01-22,49.86,49.895,48.05,48.7,
AXON,2019-01-23,49.08,50.05,47.46,48.06,
AXON,2019-01-24,48.11,48.49,47.13,48.43,
AXON,2019-01-25,48.83,49.58,48.31,49.1,
AXON,2019-01-28,48.79,49.39,48.345,49.1,
AXON,2019-01-29,49.14,49.96,48.92,49.04,
AXON,2019-01-30,49.08,49.94,48.04,49.74,
AXON,2019-01-31,49.63,51.29,49.63,51.01,
AXON,2019-02-01,51.11,51.25,50.45,50.65,
AXON,2019-02-04,50.81,52.96,50.7101,52.91,
AXON,2019-02-05,53.0,53.82,52.2201,52.5,
AXON,2019-02-06,52.69,52.72,51.42,52.12,
AXON,2019-02-07,51.84,52.41,51.14,51.98,
AXON,2019-02-08,51.75,51.83,50.81,51.43,
AXON,2019-02-11,51.52,53.24,51.52,53.13,
AXON,2019-02-12,53.8,54.04,52.72,53.3,
AXON,2019-02-13,53.66,53.96,53.06,53.7,
AXON,2019-02-14,53.36,54.77,53.35,54.59,
AXON,2019-02-15,54.9,55.59,54.41,55.43,
AXON,2019-02-19,55.43,56.08,55.21,55.81,
AXON,2019-02-20,55.88,56.34,55.58,56.0,
AXON,2019-02-21,55.98,56.1799,55.25,55.49,
AXON,2019-02-22,55.62,55.95,55.01,55.74,
AXON,2019-02-25,56.44,58.495,56.28,58.05,
AXON,2019-02-26,58.62,60.3,58.52,60.22,
AXON,2019-02-27,55.46,55.65,51.6001,55.49,
AXON,2019-02-28,55.13,55.75,53.55,53.83,
AXON,2019-03-01,54.29,54.6,53.19,54.45,
AXON,2019-03-04,54.54,54.86,50.81,51.2,
AXON,2019-03-05,51.41,51.64,50.5,51.4,
AXON,2019-03-06,51.51,52.23,49.8102,49.98,
AXON,2019-03-07,49.82,50.075,48.2,48.47,
AXON,2019-03-08,47.75,47.75,46.28,46.86,
AXON,2019-03-11,46.86,48.15,46.5,47.97,
AXON,2019-03-12,47.96,48.52,47.12,48.33,
AXON,2019-03-13,48.5,48.9,47.5393,47.63,
AXON,2019-03-14,47.69,48.0307,47.01,47.05,
AXON,2019-03-15,47.05,47.99,46.85,47.96,
AXON,2019-03-18,48.12,50.06,48.09,50.02,
AXON,2019-03-19,51.3,53.24,51.0766,52.04,
AXON,2019-03-20,52.26,53.06,50.86,52.65,
AXON,2019-03-21,52.28,54.55,52.28,54.54,
AXON,2019-03-22,54.11,55.08,52.0,52.05,
AXON,2019-03-25,52.0,53.35,51.4388,52.89,
AXON,2019-03-26,53.47,53.61,52.51,53.36,
AXON,2019-03-27,53.34,54.21,51.75,52.52,
AXON,2019-03-28,52.7,53.98,52.6018,53.85,
AXON,2019-03-29,54.37,55.07,53.93,54.41,
AXON,2019-04-01,54.99,55.75,54.35,55.26,
AXON,2019-04-02,55.44,55.59,54.32,54.38,
AXON,2019-04-03,54.68,55.72,54.44,55.38,
AXON,2019-04-04,55.42,56.27,54.75,55.12,
AXON,2019-04-05,56.61,57.85,55.8652,57.73,
AXON,2019-04-08,59.56,60.66,58.32,60.32,
AXON,2019-04-09,59.83,60.3578,58.45,58.66,
AXON,2019-04-10,58.75,60.37,58.2663,60.12,
AXON,2019-04-11,60.09,61.04,60.0498,60.92,
AXON,2019-04-12,61.74,62.0,61.05,61.87,
AXON,2019-04-15,61.84,62.17,60.5,60.75,
AXON,2019-04-16,61.21,61.61,60.9228,61.55,
AXON,2019-04-17,61.86,62.24,60.26,61.5,
AXON,2019-04-18,61.46,61.46,59.17,59.82,
AXON,2019-04-22,59.82,61.02,59.59,60.74,
AXON,2019-04-23,61.07,63.18,60.99,62.87,
AXON,2019-04-24,62.9,64.0,62.34,62.58,
AXON,2019-04-25,62.58,63.16,61.8,62.86,
AXON,2019-04-26,62.68,63.21,62.205,62.86,
AXON,2019-04-29,63.02,64.0,62.28,63.37,
AXON,2019-04-30,63.25,64.015,62.93,63.5,
AXON,2019-05-01,63.83,64.27,63.23,63.79,
AXON,2019-05-02,63.8,64.45,63.56,64.26,
AXON,2019-05-03,64.7,66.11,64.42,65.3,
AXON,2019-05-06,63.79,66.0998,63.3765,65.84,
AXON,2019-05-07,64.81,65.83,63.8671,64.64,
AXON,2019-05-08,64.96,67.87,64.75,67.0,
AXON,2019-05-09,66.49,67.2967,65.02,66.73,
AXON,2019-05-10,67.0,68.8,61.71,63.73,
AXON,2019-05-13,62.22,65.04,62.0,64.76,
AXON,2019-05-14,64.82,66.73,64.8,66.33,
AXON,2019-05-15,65.38,65.94,64.5,65.41,
AXON,2019-05-16,65.51,68.49,65.46,68.18,
AXON,2019-05-17,67.71,68.79,67.35,68.0,
AXON,2019-05-20,67.21,67.8185,65.07,65.43,
AXON,2019-05-21,66.01,67.93,65.24,67.84,
AXON,2019-05-22,67.43,68.32,67.0,68.3,
AXON,2019-05-23,67.18,67.81,66.2701,67.03,
AXON,2019-05-24,67.09,67.48,66.29,67.14,
AXON,2019-05-28,67.46,69.4,67.45,68.51,
AXON,2019-05-29,67.7,68.86,67.55,68.02,
AXON,2019-05-30,68.33,68.57,67.855,68.05,
AXON,2019-05-31,66.93,69.03,66.46,66.78,
AXON,2019-06-03,66.65,67.54,64.7,67.46,
AXON,2019-06-04,67.99,68.39,67.06,67.63,
AXON,2019-06-05,67.98,68.97,67.44,68.0,
AXON,2019-06-06,67.91,68.3663,67.16,67.97,
AXON,2019-06-07,68.45,69.55,68.0,69.18,
AXON,2019-06-10,69.76,72.29,69.5001,71.91,
AXON,2019-06-11,72.0,72.35,69.14,70.43,
AXON,2019-06-12,70.24,70.485,69.24,70.35,
AXON,2019-06-13,70.64,71.13,70.36,71.11,
AXON,2019-06-14,70.66,71.48,70.605,70.67,
AXON,2019-06-17,70.83,71.0276,66.61,68.17,
AXON,2019-06-18,69.58,71.22,65.51,66.04,
AXON,2019-06-19,64.5,69.92,64.1503,69.9,
AXON,2019-06-20,70.21,73.26,70.15,73.21,
AXON,2019-06-21,72.48,73.48,70.35,73.3,
AXON,2019-06-24,73.35,74.93,72.8019,73.21,
AXON,2019-06-25,71.0,71.5,68.14,68.83,
AXON,2019-06-26,69.2,69.8483,66.65,66.87,
AXON,2019-06-27,67.0,67.42,66.22,66.89,
AXON,2019-06-28,66.7,66.79,64.08,64.21,
AXON,2019-07-01,65.22,65.9,63.4,64.55,
AXON,2019-07-02,64.75,64.75,63.02,63.8,
AXON,2019-07-03,64.05,64.475,63.92,64.32,
AXON,2019-07-05,63.9,64.48,63.18,64.06,
AXON,2019-07-08,63.81,63.935,62.05,62.31,
AXON,2019-07-09,62.1,63.11,61.7,62.96,
AXON,2019-07-10,63.32,64.16,63.22,63.3,
AXON,2019-07-11,63.46,64.1,62.73,62.92,
AXON,2019-07-12,62.9,64.73,61.88,64.5,
AXON,2019-07-15,64.65,65.37,63.67,63.78,
AXON,2019-07-16,63.79,64.0769,62.83,63.9,
AXON,2019-07-17,64.22,65.44,63.81,64.82,
AXON,2019-07-18,64.71,65.83,64.515,65.76,
AXON,2019-07-19,65.83,66.77,65.69,65.92,
AXON,2019-07-22,65.8,66.44,65.1,65.41,
AXON,2019-07-23,66.18,66.52,65.2,66.18,
AXON,2019-07-24,66.0,69.42,65.9,68.75,
AXON,2019-07-25,69.04,69.46,68.05,68.3,
AXON,2019-07-26,68.48,70.55,68.48,69.5,
AXON,2019-07-29,69.68,70.0809,68.09,68.48,
AXON,2019-07-30,68.0,69.66,67.51,69.64,
AXON,2019-07-31,69.76,71.69,69.52,70.22,
AXON,2019-08-01,70.12,70.96,68.38,68.44,
AXON,2019-08-02,68.09,69.24,67.5,69.08,
AXON,2019-08-05,67.58,67.58,64.26,65.91,
AXON,2019-08-06,65.36,67.49,65.23,65.36,
AXON,2019-08-07,64.52,65.94,64.1,65.54,
AXON,2019-08-08,68.41,69.14,66.25,68.41,
AXON,2019-08-09,60.0,61.98,56.11,58.09,
AXON,2019-08-12,58.51,60.27,56.88,57.5,
AXON,2019-08-13,57.57,60.62,57.21,58.78,
AXON,2019-08-14,58.68,58.86,57.05,57.86,
AXON,2019-08-15,57.85,58.76,56.95,57.36,
AXON,2019-08-16,57.79,59.39,56.92,59.22,
AXON,2019-08-19,60.4,60.91,59.59,60.11,
AXON,2019-08-20,60.27,60.97,59.35,60.75,
AXON,2019-08-21,61.35,61.35,60.23,60.34,
AXON,2019-08-22,60.53,62.625,60.35,62.37,
AXON,2019-08-23,62.15,62.69,59.14,59.37,
AXON,2019-08-26,60.09,61.02,59.05,60.96,
AXON,2019-08-27,61.45,62.35,60.4,60.98,
AXON,2019-08-28,60.71,61.91,59.21,59.94,
AXON,2019-08-29,61.15,62.06,60.935,61.33,
AXON,2019-08-30,61.56,61.745,59.72,59.97,
AXON,2019-09-03,59.53,59.53,57.9,58.99,
AXON,2019-09-04,59.71,60.24,59.13,59.97,
AXON,2019-09-05,60.87,61.93,60.13,61.19,
AXON,2019-09-06,61.16,62.49,60.64,61.99,
AXON,2019-09-09,62.44,62.44,59.2348,59.55,
AXON,2019-09-10,59.29,60.6,58.11,60.57,
AXON,2019-09-11,60.78,62.99,60.32,62.94,
AXON,2019-09-12,63.0,64.72,62.01,64.37,
AXON,2019-09-13,64.5,65.66,63.96,65.11,
AXON,2019-09-16,64.84,66.8,64.3956,66.19,
AXON,2019-09-17,66.42,66.48,65.18,66.15,
AXON,2019-09-18,66.15,66.48,64.93,65.44,
AXON,2019-09-19,65.0,65.41,62.25,63.14,
AXON,2019-09-20,63.09,64.14,62.1645,63.54,
AXON,2019-09-23,63.21,64.375,62.34,62.5,
AXON,2019-09-24,62.61,63.565,59.8,60.95,
AXON,2019-09-25,60.84,61.25,59.11,60.43,
AXON,2019-09-26,60.44,60.555,58.2401,59.01,
AXON,2019-09-27,59.32,59.32,57.61,58.31,
AXON,2019-09-30,58.28,58.55,56.7,56.78,
AXON,2019-10-01,56.85,57.33,53.95,54.22,
AXON,2019-10-02,53.68,53.68,51.28,53.26,
AXON,2019-10-03,53.09,54.35,52.16,54.3,
AXON,2019-10-04,54.47,55.09,53.57,54.86,
AXON,2019-10-07,54.65,55.16,53.75,54.62,
AXON,2019-10-08,54.01,54.63,52.59,52.76,
AXON,2019-10-09,53.13,53.33,52.12,52.34,
AXON,2019-10-10,52.215,52.76,51.8848,52.54,
AXON,2019-10-11,53.24,54.89,53.01,53.16,
AXON,2019-10-14,52.98,53.43,51.88,52.83,
AXON,2019-10-15,52.84,53.64,52.44,53.32,
AXON,2019-10-16,52.94,53.14,51.51,51.89,
AXON,2019-10-17,52.0,52.59,51.66,51.75,
AXON,2019-10-18,51.42,51.48,49.8,50.55,
AXON,2019-10-21,51.19,52.47,50.57,52.315,
AXON,2019-10-22,52.3,53.42,51.7786,53.2,
AXON,2019-10-23,53.4,54.21,53.2,53.705,
AXON,2019-10-24,53.82,55.06,53.56,54.92,
AXON,2019-10-25,54.69,55.17,54.2,54.26,
AXON,2019-10-28,54.73,55.25,54.19,54.75,
AXON,2019-10-29,54.56,55.21,52.81,52.98,
AXON,2019-10-30,52.84,53.46,51.8,52.53,
AXON,2019-10-31,52.47,52.67,50.78,51.13,
AXON,2019-11-01,51.49,53.33,51.0,52.52,
AXON,2019-11-04,53.15,53.3485,51.48,51.87,
AXON,2019-11-05,51.87,54.13,51.72,53.085,
AXON,2019-11-06,53.14,53.69,51.94,52.24,
AXON,2019-11-07,53.23,55.73,52.2,52.41,
AXON,2019-11-08,61.94,71.0,61.0,65.285,
AXON,2019-11-11,64.76,65.54,62.61,64.45,
AXON,2019-11-12,64.48,64.75,63.34,64.01,
AXON,2019-11-13,63.53,64.98,63.2572,64.65,
AXON,2019-11-14,64.65,67.05,64.44,66.69,
AXON,2019-11-15,67.35,68.35,66.37,67.37,
AXON,2019-11-18,67.24,67.83,66.35,67.72,
AXON,2019-11-19,67.87,69.11,67.64,68.48,
AXON,2019-11-20,67.94,72.0,67.45,71.98,
AXON,2019-11-21,72.0,73.07,71.225,71.9,
AXON,2019-11-22,72.15,72.44,71.1707,72.09,
AXON,2019-11-25,72.74,74.85,72.4055,74.33,
AXON,2019-11-26,74.8,77.66,74.5,76.93,
AXON,2019-11-27,74.81,76.07,72.02,75.57,
AXON,2019-11-29,75.07,75.85,73.64,73.8,
AXON,2019-12-02,74.14,75.27,73.43,73.72,
AXON,2019-12-03,72.31,74.125,71.31,73.83,
AXON,2019-12-04,74.22,75.65,72.57,72.76,
AXON,2019-12-05,72.36,73.874,72.02,72.82,
AXON,2019-12-06,73.58,74.255,71.68,71.87,
AXON,2019-12-09,71.89,73.7,71.52,72.27,
AXON,2019-12-10,72.93,72.93,72.16,72.64,
AXON,2019-12-11,72.68,73.42,71.93,72.49,
AXON,2019-12-12,72.37,73.07,70.61,71.81,
AXON,2019-12-13,71.71,72.8187,71.46,72.47,
AXON,2019-12-16,72.7,74.66,72.68,73.19,
AXON,2019-12-17,72.63,72.87,71.13,71.35,
AXON,2019-12-18,71.38,71.72,69.52,69.83,
AXON,2019-12-19,69.84,70.35,69.1,70.32,
AXON,2019-12-20,70.54,71.43,70.2,71.24,
AXON,2019-12-23,71.74,72.2512,71.1,72.24,
AXON,2019-12-24,72.44,73.335,72.3,73.09,
AXON,2019-12-26,73.16,73.72,72.39,72.9,
AXON,2019-12-27,73.04,73.265,72.41,72.9,
AXON,2019-12-30,72.9,74.64,72.59,73.51,
AXON,2019-12-31,73.19,74.08,72.72,73.28,
AXON,2020-01-02,74.02,76.62,73.34,76.56,
AXON,2020-01-03,72.3,75.5699,68.68,73.925,
AXON,2020-01-06,74.12,74.49,68.09,68.75,
AXON,2020-01-07,68.82,70.73,68.315,69.77,
AXON,2020-01-08,69.95,71.625,69.51,69.61,
AXON,2020-01-09,70.09,71.0,69.935,70.19,
AXON,2020-01-10,70.22,70.85,69.21,69.51,
AXON,2020-01-13,69.83,70.9,69.5,70.77,
AXON,2020-01-14,70.67,71.85,69.47,71.365,
AXON,2020-01-15,71.54,72.965,71.54,72.7,
AXON,2020-01-16,73.12,75.31,73.12,75.22,
AXON,2020-01-17,75.53,75.85,73.55,73.6,
AXON,2020-01-21,73.25,75.4399,73.25,75.26,
AXON,2020-01-22,75.6,79.45,75.6,79.08,
AXON,2020-01-23,79.07,80.6581,78.58,78.64,
AXON,2020-01-24,79.19,80.84,77.285,80.55,
AXON,2020-01-27,78.59,79.455,77.82,77.91,
AXON,2020-01-28,78.31,80.14,77.79,78.97,
AXON,2020-01-29,79.77,80.79,78.75,79.91,
AXON,2020-01-30,79.2,80.04,77.14,78.34,
AXON,2020-01-31,78.16,78.61,76.375,76.81,
AXON,2020-02-03,77.37,78.29,76.5,77.59,
AXON,2020-02-04,78.99,82.49,78.6949,81.79,
AXON,2020-02-05,83.23,83.6277,79.77,81.81,
AXON,2020-02-06,82.22,83.9,81.25,83.53,
AXON,2020-02-07,83.36,83.85,81.67,82.85,
AXON,2020-02-10,82.88,85.73,82.78,85.44,
AXON,2020-02-11,86.04,87.51,84.89,87.14,
AXON,2020-02-12,87.77,88.23,86.435,87.98,
AXON,2020-02-13,87.53,89.16,87.23,87.74,
AXON,2020-02-14,87.86,88.44,86.7,87.11,
AXON,2020-02-18,87.22,87.73,86.12,87.31,
AXON,2020-02-19,87.88,90.1,87.46,88.9,
AXON,2020-02-20,86.15,87.89,82.33,86.46,
AXON,2020-02-21,86.74,87.09,84.61,85.99,
AXON,2020-02-24,79.74,84.81,77.95,82.41,
AXON,2020-02-25,82.82,84.22,79.14,79.51,
AXON,2020-02-26,79.6,82.862,79.4907,80.4,
AXON,2020-02-27,77.9,80.82,74.21,77.12,
AXON,2020-02-28,73.03,78.11,71.0,77.37,
AXON,2020-03-02,77.93,82.68,75.75,82.34,
AXON,2020-03-03,82.7,83.48,77.27,78.1,
AXON,2020-03-04,79.8,81.27,78.28,80.66,
AXON,2020-03-05,78.24,79.64,73.85,75.17,
AXON,2020-03-06,72.46,75.64,71.55,74.44,
AXON,2020-03-09,69.17,70.52,62.66,66.11,
AXON,2020-03-10,69.02,69.02,63.6,67.11,
AXON,2020-03-11,64.88,66.36,59.6,60.47,
AXON,2020-03-12,54.19,59.98,51.86,56.72,
AXON,2020-03-13,60.33,62.79,54.696,62.43,
AXON,2020-03-16,54.32,58.65,52.7575,53.92,
AXON,2020-03-17,54.42,57.3754,51.3,57.15,
AXON,2020-03-18,53.2,55.87,50.051,52.61,
AXON,2020-03-19,52.89,64.2514,52.2397,62.01,
AXON,2020-03-20,62.15,65.22,59.8,60.78,
AXON,2020-03-23,60.53,65.01,58.06,63.41,
AXON,2020-03-24,66.66,70.96,66.5,69.83,
AXON,2020-03-25,69.84,74.09,66.59,71.15,
AXON,2020-03-26,72.64,77.86,72.305,76.52,
AXON,2020-03-27,73.08,77.23,71.87,74.41,
AXON,2020-03-30,74.3,76.36,69.1,69.46,
AXON,2020-03-31,69.03,72.72,67.96,70.77,
AXON,2020-04-01,67.58,69.67,63.7,64.72,
AXON,2020-04-02,64.99,67.29,61.23,62.64,
AXON,2020-04-03,61.99,62.415,60.55,61.51,
AXON,2020-04-06,64.56,68.65,63.76,68.0,
AXON,2020-04-07,70.67,71.99,68.1,68.96,
AXON,2020-04-08,70.27,73.4,69.3973,72.48,
AXON,2020-04-09,73.74,76.25,72.6,74.7,
AXON,2020-04-13,73.76,74.38,71.67,73.49,
AXON,2020-04-14,75.1,77.54,74.9,76.62,
AXON,2020-04-15,73.89,75.49,72.34,74.13,
AXON,2020-04-16,74.52,75.0,70.65,72.77,
AXON,2020-04-17,75.85,77.23,75.1,76.72,
AXON,2020-04-20,74.48,80.16,74.38,76.78,
AXON,2020-04-21,74.75,76.41,69.65,70.6,
AXON,2020-04-22,73.05,74.02,71.238,73.33,
AXON,2020-04-23,74.05,75.2499,70.6,70.75,
AXON,2020-04-24,71.09,72.2,69.35,71.84,
AXON,2020-04-27,72.5,73.91,71.67,72.15,
AXON,2020-04-28,73.63,76.0,71.12,75.34,
AXON,2020-04-29,77.47,77.47,73.9075,75.24,
AXON,2020-04-30,75.0,75.23,71.9039,72.71,
AXON,2020-05-01,71.4,72.93,69.05,69.52,
AXON,2020-05-04,68.14,69.0,65.5,67.0,
AXON,2020-05-05,68.09,68.81,65.77,65.85,
AXON,2020-05-06,66.901,68.23,65.64,66.13,
AXON,2020-05-07,67.54,71.57,67.0,70.28,
AXON,2020-05-08,77.29,86.48,76.5314,86.13,
AXON,2020-05-11,85.901,89.43,84.07,84.92,
AXON,2020-05-12,84.01,85.99,83.41,83.48,
AXON,2020-05-13,84.0,84.91,79.095,80.17,
AXON,2020-05-14,78.8,79.08,74.74,75.6,
AXON,2020-05-15,75.4,77.75,73.62,73.91,
AXON,2020-05-18,76.0343,79.0,73.62,74.86,
AXON,2020-05-19,74.39,76.2197,73.695,74.73,
AXON,2020-05-20,76.86,77.3738,75.66,76.21,
AXON,2020-05-21,76.22,77.535,72.88,76.56,
AXON,2020-05-22,77.11,77.19,73.6,74.11,
AXON,2020-05-26,75.75,76.79,74.79,75.8,
AXON,2020-05-27,76.79,76.79,71.21,75.7,
AXON,2020-05-28,77.08,78.68,73.04,73.2,
AXON,2020-05-29,72.78,76.14,72.14,75.96,
AXON,2020-06-01,84.185,92.0,82.8006,89.75,
AXON,2020-06-02,91.8,99.615,91.0,97.85,
AXON,2020-06-03,97.48,97.96,90.32,91.18,
AXON,2020-06-04,91.0,93.5889,90.4,93.34,
AXON,2020-06-05,96.18,97.219,92.03,92.79,
AXON,2020-06-08,96.57,98.58,94.2,97.27,
AXON,2020-06-09,96.75,104.76,96.1,100.27,
AXON,2020-06-10,101.54,104.9,100.28,103.25,
AXON,2020-06-11,98.51,98.58,90.0,90.01,
AXON,2020-06-12,97.6,97.6,91.63,94.09,
AXON,2020-06-15,91.8,100.41,91.55,100.35,
AXON,2020-06-16,100.485,100.52,91.8,93.66,
AXON,2020-06-17,93.12,96.925,93.0,94.85,
AXON,2020-06-18,94.36,96.3499,91.8,91.81,
AXON,2020-06-19,92.78,93.49,88.6901,90.12,
AXON,2020-06-22,90.5,93.7,88.53,92.5,
AXON,2020-06-23,93.41,97.7422,92.0785,95.54,
AXON,2020-06-24,94.4,97.1599,91.86,93.43,
AXON,2020-06-25,92.71,95.95,91.53,95.95,
AXON,2020-06-26,95.88,97.72,94.17,96.06,
AXON,2020-06-29,97.19,97.25,92.41,95.8,
AXON,2020-06-30,95.2,100.65,95.2,98.13,
AXON,2020-07-01,98.64,100.14,97.54,99.37,
AXON,2020-07-02,100.23,101.838,99.4,100.34,
AXON,2020-07-06,102.0,102.4,98.85,99.64,
AXON,2020-07-07,99.04,101.05,95.61,96.06,
AXON,2020-07-08,96.83,99.0,96.06,96.93,
AXON,2020-07-09,97.17,98.04,95.18,96.42,
AXON,2020-07-10,96.14,97.85,95.34,95.91,
AXON,2020-07-13,97.17,97.17,90.28,90.77,
AXON,2020-07-14,90.75,92.86,87.75,92.83,
AXON,2020-07-15,94.0,94.7,91.56,92.64,
AXON,2020-07-16,92.35,92.35,90.275,91.08,
AXON,2020-07-17,91.55,91.6188,90.26,90.72,
AXON,2020-07-20,91.0,93.4,90.7601,92.24,
AXON,2020-07-21,94.14,95.0,91.76,92.11,
AXON,2020-07-22,91.63,93.06,88.23,89.12,
AXON,2020-07-23,88.92,89.8887,86.56,87.53,
AXON,2020-07-24,86.57,87.47,83.66,85.62,
AXON,2020-07-27,86.14,87.4,84.97,86.44,
AXON,2020-07-28,86.04,86.81,84.96,85.85,
AXON,2020-07-29,86.07,86.79,84.73,84.89,
AXON,2020-07-30,84.06,85.71,83.48,84.88,
AXON,2020-07-31,85.66,86.05,82.45,83.13,
AXON,2020-08-03,83.79,88.9,83.5,88.5,
AXON,2020-08-04,88.02,89.57,87.5,89.51,
AXON,2020-08-05,90.0,93.12,89.41,92.64,
AXON,2020-08-06,92.55,93.71,91.06,91.67,
AXON,2020-08-07,85.5,88.0,82.5,83.88,
AXON,2020-08-10,84.24,85.15,82.95,83.14,
AXON,2020-08-11,83.5,83.5,79.12,79.23,
AXON,2020-08-12,79.6,80.1406,78.28,79.76,
AXON,2020-08-13,80.15,82.315,79.88,80.41,
AXON,2020-08-14,80.87,81.83,79.13,79.58,
AXON,2020-08-17,80.07,80.65,79.35,79.62,
AXON,2020-08-18,79.89,80.0,78.3601,79.35,
AXON,2020-08-19,79.73,82.08,79.17,80.96,
AXON,2020-08-20,80.36,82.08,80.29,81.75,
AXON,2020-08-21,81.54,82.68,80.65,82.61,
AXON,2020-08-24,83.66,84.14,81.68,83.25,
AXON,2020-08-25,83.26,87.51,82.8637,85.23,
AXON,2020-08-26,85.01,86.42,84.28,85.19,
AXON,2020-08-27,86.19,86.73,85.265,85.39,
AXON,2020-08-28,85.39,85.9686,83.29,83.84,
AXON,2020-08-31,83.74,85.95,83.5,85.68,
AXON,2020-09-01,85.2,88.65,84.78,87.43,
AXON,2020-09-02,88.14,88.74,86.145,88.13,
AXON,2020-09-03,87.52,87.5995,83.395,84.54,
AXON,2020-09-04,84.98,85.52,81.15,82.67,
AXON,2020-09-08,80.5,83.135,79.72,81.35,
AXON,2020-09-09,82.25,85.58,82.195,85.24,
AXON,2020-09-10,85.47,87.285,83.9102,84.29,
AXON,2020-09-11,84.95,85.26,83.12,83.91,
AXON,2020-09-14,84.26,85.44,82.82,83.84,
AXON,2020-09-15,84.58,84.58,83.05,84.4,
AXON,2020-09-16,85.0,85.04,83.4,83.73,
AXON,2020-09-17,83.0,83.239,81.65,82.83,
AXON,2020-09-18,83.15,83.35,80.75,82.55,
AXON,2020-09-21,81.33,83.7606,80.54,83.18,
AXON,2020-09-22,84.01,87.12,83.07,86.88,
AXON,2020-09-23,87.0,88.69,86.0,86.71,
AXON,2020-09-24,85.1101,86.73,84.1,85.39,
AXON,2020-09-25,85.25,87.38,84.58,87.2,
AXON,2020-09-28,88.09,89.52,87.55,87.91,
AXON,2020-09-29,87.92,89.15,87.1,88.62,
AXON,2020-09-30,89.36,91.8325,89.17,90.7,
AXON,2020-10-01,91.84,96.09,91.305,95.61,
AXON,2020-10-02,93.5,94.49,90.87,91.55,
AXON,2020-10-05,92.22,93.45,90.1706,91.84,
AXON,2020-10-06,92.2,94.47,91.46,93.22,
AXON,2020-10-07,94.54,96.355,93.91,96.07,
AXON,2020-10-08,96.85,97.38,95.54,97.07,
AXON,2020-10-09,97.57,99.67,97.56,98.99,
AXON,2020-10-12,99.72,100.12,98.13,99.18,
AXON,2020-10-13,99.0,101.87,98.595,101.75,
AXON,2020-10-14,102.0,103.71,100.17,101.42,
AXON,2020-10-15,100.05,106.55,99.0001,105.86,
AXON,2020-10-16,107.51,109.735,105.77,109.16,
AXON,2020-10-19,109.78,113.0,107.43,107.62,
AXON,2020-10-20,108.41,109.34,105.27,106.07,
AXON,2020-10-21,106.69,107.62,103.06,103.26,
AXON,2020-10-22,104.17,105.49,102.67,103.64,
AXON,2020-10-23,104.2,104.72,102.16,102.91,
AXON,2020-10-26,102.0,103.32,100.51,101.93,
AXON,2020-10-27,102.21,102.556,100.595,101.05,
AXON,2020-10-28,100.0,102.8,99.09,102.0,
AXON,2020-10-29,102.85,104.12,101.75,103.4,
AXON,2020-10-30,103.01,103.43,98.01,98.9,
AXON,2020-11-02,99.67,101.32,96.6607,97.95,
AXON,2020-11-03,97.92,101.98,97.72,101.68,
AXON,2020-11-04,103.01,107.41,103.0,105.05,
AXON,2020-11-05,106.07,110.4,105.71,108.5,
AXON,2020-11-06,116.01,127.49,116.0,122.59,
AXON,2020-11-09,126.51,128.385,121.27,124.26,
AXON,2020-11-10,123.01,125.175,116.795,119.0,
AXON,2020-11-11,119.42,121.77,117.58,118.3,
AXON,2020-11-12,118.01,119.59,117.0,118.15,
AXON,2020-11-13,119.05,121.2,117.36,120.98,
AXON,2020-11-16,122.1,122.1,117.695,119.33,
AXON,2020-11-17,118.44,119.545,116.62,119.05,
AXON,2020-11-18,119.64,121.85,118.98,119.83,
AXON,2020-11-19,119.66,124.463,119.405,123.1,
AXON,2020-11-20,124.19,125.45,121.81,124.81,
AXON,2020-11-23,126.29,127.22,123.137,126.5,
AXON,2020-11-24,127.54,130.41,126.01,127.49,
AXON,2020-11-25,127.68,128.23,125.29,127.74,
AXON,2020-11-27,128.7,128.7,124.2,125.55,
AXON,2020-11-30,126.89,127.385,123.361,125.69,
AXON,2020-12-01,127.03,127.4,124.29,125.26,
AXON,2020-12-02,124.29,124.499,122.59,123.92,
AXON,2020-12-03,123.92,126.62,123.42,123.85,
AXON,2020-12-04,123.85,124.93,123.15,124.18,
AXON,2020-12-07,124.99,126.0,122.45,122.79,
AXON,2020-12-08,122.37,125.74,122.36,125.56,
AXON,2020-12-09,125.22,128.88,121.68,123.19,
AXON,2020-12-10,122.02,126.25,121.1,125.48,
AXON,2020-12-11,126.06,127.58,122.55,123.12,
AXON,2020-12-14,124.5,129.8,124.5,127.24,
AXON,2020-12-15,129.13,129.36,126.71,128.81,
AXON,2020-12-16,127.13,127.9,119.05,119.94,
AXON,2020-12-17,119.81,122.81,118.53,120.75,
AXON,2020-12-18,121.7,125.8,121.55,125.34,
AXON,2020-12-21,126.12,128.23,124.51,127.87,
AXON,2020-12-22,127.58,131.63,126.38,128.5,
AXON,2020-12-23,129.04,134.73,129.04,131.83,
AXON,2020-12-24,132.0,132.455,129.31,130.75,
AXON,2020-12-28,132.5,133.49,125.15,125.16,
AXON,2020-12-29,126.0,126.609,120.85,123.33,
AXON,2020-12-30,123.95,126.46,123.57,123.88,
AXON,2020-12-31,123.88,123.88,121.3,122.53,
AXON,2021-01-04,123.01,123.39,115.57,116.85,
AXON,2021-01-05,116.41,122.54,116.01,122.3,
AXON,2021-01-06,122.22,123.07,118.44,121.69,
AXON,2021-01-07,121.82,125.05,121.04,124.57,
AXON,2021-01-08,124.89,128.28,123.6,125.36,
AXON,2021-01-11,125.18,127.87,123.6,124.84,
AXON,2021-01-12,126.36,135.05,126.36,135.0,
AXON,2021-01-13,136.67,146.055,135.245,145.26,
AXON,2021-01-14,146.09,152.0,145.41,149.64,
AXON,2021-01-15,161.9,166.49,150.0,150.77,
AXON,2021-01-19,154.83,159.85,154.0,159.36,
AXON,2021-01-20,162.74,168.48,162.41,164.56,
AXON,2021-01-21,168.03,168.4,161.71,162.54,
AXON,2021-01-22,161.08,171.73,160.85,170.26,
AXON,2021-01-25,173.46,177.705,168.03,174.54,
AXON,2021-01-26,176.52,180.69,175.25,176.65,
AXON,2021-01-27,171.32,176.65,168.41,170.04,
AXON,2021-01-28,166.37,176.6,162.57,163.97,
AXON,2021-01-29,161.6,168.97,160.296,164.16,
AXON,2021-02-01,167.13,168.0,163.37,166.15,
AXON,2021-02-02,171.62,171.95,165.01,166.53,
AXON,2021-02-03,167.85,169.06,163.86,167.55,
AXON,2021-02-04,169.8,175.57,166.025,175.34,
AXON,2021-02-05,178.223,178.52,172.97,177.18,
AXON,2021-02-08,180.0,182.48,176.52,182.39,
AXON,2021-02-09,180.24,184.89,180.24,183.16,
AXON,2021-02-10,185.0,190.04,182.155,187.98,
AXON,2021-02-11,190.0,212.37,189.64,203.51,
AXON,2021-02-12,202.0,202.46,194.808,195.54,
AXON,2021-02-16,198.23,198.88,175.92,175.93,
AXON,2021-02-17,177.17,180.891,175.0,178.38,
AXON,2021-02-18,176.21,178.38,171.13,173.75,
AXON,2021-02-19,176.38,180.99,175.99,177.0,
AXON,2021-02-22,177.15,180.0,168.95,170.0,
AXON,2021-02-23,163.01,170.68,156.89,169.14,
AXON,2021-02-24,170.96,171.82,160.03,161.45,
AXON,2021-02-25,161.9,168.74,158.5,159.9,
AXON,2021-02-26,160.9,169.0,160.0,165.49,
AXON,2021-03-01,170.74,174.83,167.22,169.65,
AXON,2021-03-02,169.99,172.71,163.486,166.15,
AXON,2021-03-03,164.65,167.79,153.94,155.01,
AXON,2021-03-04,151.83,155.36,138.26,144.9,
AXON,2021-03-05,144.54,145.0,128.01,143.04,
AXON,2021-03-08,143.08,147.0,137.5,138.59,
AXON,2021-03-09,143.48,147.89,143.07,144.4,
AXON,2021-03-10,147.49,150.79,140.43,141.1,
AXON,2021-03-11,146.506,153.76,146.12,152.76,
AXON,2021-03-12,150.92,154.83,147.36,152.26,
AXON,2021-03-15,153.26,155.286,150.63,153.71,
AXON,2021-03-16,156.64,159.021,144.71,147.03,
AXON,2021-03-17,145.2,149.266,142.5,148.43,
AXON,2021-03-18,148.17,148.17,138.89,139.96,
AXON,2021-03-19,139.11,146.075,137.865,144.75,
AXON,2021-03-22,146.78,148.99,144.33,144.77,
AXON,2021-03-23,144.01,146.0,138.8,139.62,
AXON,2021-03-24,140.389,140.5,133.05,133.45,
AXON,2021-03-25,130.0,137.09,127.25,136.77,
AXON,2021-03-26,137.51,139.061,131.69,137.82,
AXON,2021-03-29,137.49,138.47,131.82,134.32,
AXON,2021-03-30,134.17,140.18,133.0,139.28,
AXON,2021-03-31,140.36,143.96,140.36,142.42,
AXON,2021-04-01,144.42,147.515,142.55,143.06,
AXON,2021-04-05,146.2,147.25,144.0,146.33,
AXON,2021-04-06,147.06,148.28,145.06,145.6,
AXON,2021-04-07,147.03,147.76,144.46,147.27,
AXON,2021-04-08,148.07,152.0,147.51,150.57,
AXON,2021-04-09,149.6,150.53,145.35,149.42,
AXON,2021-04-12,149.16,149.812,145.5,149.17,
AXON,2021-04-13,150.0,152.62,148.765,152.55,
AXON,2021-04-14,153.48,156.37,152.09,152.44,
AXON,2021-04-15,155.0,156.06,152.0,153.25,
AXON,2021-04-16,153.233,154.84,151.06,152.74,
AXON,2021-04-19,150.5,151.11,145.2,150.55,
AXON,2021-04-20,150.5,154.343,147.255,150.79,
AXON,2021-04-21,149.9,152.96,147.66,149.89,
AXON,2021-04-22,150.1,156.0,150.1,153.65,
AXON,2021-04-23,154.92,156.11,153.78,153.94,
AXON,2021-04-26,154.65,159.64,150.44,159.285,
AXON,2021-04-27,159.96,161.51,156.61,156.61,
AXON,2021-04-28,156.61,159.105,154.7,155.55,
AXON,2021-04-29,156.26,157.02,152.0,154.05,
AXON,2021-04-30,152.17,154.82,151.0,151.61,
AXON,2021-05-03,152.26,152.53,148.65,148.98,
AXON,2021-05-04,148.01,148.33,141.724,142.46,
AXON,2021-05-05,142.47,144.87,140.16,141.24,
AXON,2021-05-06,140.69,141.39,128.34,130.86,
AXON,2021-05-07,138.08,141.11,132.07,134.74,
AXON,2021-05-10,132.84,133.99,127.5,129.0,
AXON,2021-05-11,125.0,134.65,123.16,131.96,
AXON,2021-05-12,129.13,130.12,123.27,124.09,
AXON,2021-05-13,124.56,127.76,123.02,126.25,
AXON,2021-05-14,128.09,133.09,128.09,132.76,
AXON,2021-05-17,130.75,134.13,130.43,133.59,
AXON,2021-05-18,134.31,134.46,121.09,123.43,
AXON,2021-05-19,123.81,128.3,123.53,126.8,
AXON,2021-05-20,127.81,131.5,127.09,130.31,
AXON,2021-05-21,131.5,131.99,126.48,127.07,
AXON,2021-05-24,128.81,131.61,127.86,129.99,
AXON,2021-05-25,130.65,134.2,130.62,130.73,
AXON,2021-05-26,131.89,137.28,131.38,136.06,
AXON,2021-05-27,136.12,139.78,135.07,139.48,
AXON,2021-05-28,140.09,143.38,139.48,140.59,
AXON,2021-06-01,142.42,142.95,136.53,139.15,
AXON,2021-06-02,139.53,141.86,137.32,141.59,
AXON,2021-06-03,139.0,140.415,137.45,138.19,
AXON,2021-06-04,138.34,141.344,138.34,141.16,
AXON,2021-06-07,141.13,146.94,139.55,146.61,
AXON,2021-06-08,148.09,151.99,145.94,151.06,
AXON,2021-06-09,152.85,153.0,147.82,148.05,
AXON,2021-06-10,148.55,151.4,147.12,150.72,
AXON,2021-06-11,151.71,157.79,151.51,157.44,
AXON,2021-06-14,158.49,160.07,156.36,156.99,
AXON,2021-06-15,157.0,158.6,153.99,154.49,
AXON,2021-06-16,155.29,156.84,151.11,152.0,
AXON,2021-06-17,151.12,154.07,151.1,153.6,
AXON,2021-06-18,152.08,163.16,152.08,156.85,
AXON,2021-06-21,157.44,159.97,154.56,158.76,
AXON,2021-06-22,158.27,161.1,157.295,160.62,
AXON,2021-06-23,160.65,167.61,160.65,165.98,
AXON,2021-06-24,166.92,168.12,164.446,167.87,
AXON,2021-06-25,169.0,173.0,167.361,172.18,
AXON,2021-06-28,174.14,176.0,170.66,172.06,
AXON,2021-06-29,172.17,176.0,171.59,174.14,
AXON,2021-06-30,176.1,179.3,175.7,176.8,
AXON,2021-07-01,176.8,176.8,172.38,173.26,
AXON,2021-07-02,174.79,178.17,173.66,177.79,
AXON,2021-07-06,177.88,177.88,174.59,176.7,
AXON,2021-07-07,177.21,177.574,172.92,175.81,
AXON,2021-07-08,170.5,177.94,168.41,177.68,
AXON,2021-07-09,178.74,178.74,175.22,178.29,
AXON,2021-07-12,178.95,180.595,174.59,179.92,
AXON,2021-07-13,178.93,185.287,178.22,182.3,
AXON,2021-07-14,182.39,183.63,176.355,177.31,
AXON,2021-07-15,177.73,178.6,169.26,173.61,
AXON,2021-07-16,174.3,177.06,173.21,173.76,
AXON,2021-07-19,170.77,176.39,169.48,175.7,
AXON,2021-07-20,175.97,182.66,172.75,180.56,
AXON,2021-07-21,180.06,182.685,177.27,181.45,
AXON,2021-07-22,181.76,182.13,178.14,180.55,
AXON,2021-07-23,180.72,184.0,179.28,183.03,
AXON,2021-07-26,183.3,184.78,180.73,182.04,
AXON,2021-07-27,181.11,181.99,176.55,180.54,
AXON,2021-07-28,180.54,186.86,179.27,186.09,
AXON,2021-07-29,186.34,188.2,184.78,186.42,
AXON,2021-07-30,185.28,188.37,184.41,186.02,
AXON,2021-08-02,186.8,191.83,186.4,189.64,
AXON,2021-08-03,189.4,191.0,184.622,187.32,
AXON,2021-08-04,187.05,193.28,186.55,191.12,
AXON,2021-08-05,190.42,195.29,188.29,193.49,
AXON,2021-08-06,196.39,198.0,189.96,192.59,
AXON,2021-08-09,191.83,194.14,189.33,192.37,
AXON,2021-08-10,191.79,191.79,183.35,183.79,
AXON,2021-08-11,183.28,185.49,180.5,184.65,
AXON,2021-08-12,183.53,187.39,181.7,186.45,
AXON,2021-08-13,186.61,188.35,184.67,185.14,
AXON,2021-08-16,183.4,187.37,182.15,186.24,
AXON,2021-08-17,183.81,184.63,180.89,183.45,
AXON,2021-08-18,183.52,185.0,180.7,182.71,
AXON,2021-08-19,182.03,184.32,180.29,181.52,
AXON,2021-08-20,181.54,186.92,181.23,186.83,
AXON,2021-08-23,187.26,189.595,186.33,186.73,
AXON,2021-08-24,187.3,187.995,184.82,185.8,
AXON,2021-08-25,186.3,187.875,184.28,186.4,
AXON,2021-08-26,187.23,188.67,183.69,185.15,
AXON,2021-08-27,186.02,189.5,185.95,187.01,
AXON,2021-08-30,187.86,193.22,185.86,192.84,
AXON,2021-08-31,193.41,194.0,181.61,181.87,
AXON,2021-09-01,181.78,184.67,181.22,181.65,
AXON,2021-09-02,181.62,184.91,181.06,182.87,
AXON,2021-09-03,182.0,185.515,180.65,184.89,
AXON,2021-09-07,184.27,185.99,181.585,182.67,
AXON,2021-09-08,181.85,183.74,180.16,182.56,
AXON,2021-09-09,182.99,187.085,180.95,181.15,
AXON,2021-09-10,183.282,183.282,178.801,179.81,
AXON,2021-09-13,180.0,180.505,175.13,176.25,
AXON,2021-09-14,175.64,179.39,175.64,177.26,
AXON,2021-09-15,176.01,178.71,172.67,177.83,
AXON,2021-09-16,177.83,180.39,177.83,179.54,
AXON,2021-09-17,176.74,178.3,170.29,172.38,
AXON,2021-09-20,169.91,173.82,168.76,172.94,
AXON,2021-09-21,173.87,176.74,173.87,174.65,
AXON,2021-09-22,175.4,176.08,173.53,175.0,
AXON,2021-09-23,175.83,177.58,174.16,176.73,
AXON,2021-09-24,175.61,180.53,175.61,179.75,
AXON,2021-09-27,178.9,179.73,177.675,179.02,
AXON,2021-09-28,177.88,178.38,172.85,177.59,
AXON,2021-09-29,178.73,180.2,174.67,175.14,
AXON,2021-09-30,176.28,179.1,174.75,175.02,
AXON,2021-10-01,176.44,179.32,173.54,178.77,
AXON,2021-10-04,177.56,177.56,164.62,166.09,
AXON,2021-10-05,166.95,170.0,164.65,165.28,
AXON,2021-10-06,164.06,166.99,161.855,166.02,
AXON,2021-10-07,166.79,170.26,166.55,168.94,
AXON,2021-10-08,169.35,169.85,164.32,164.55,
AXON,2021-10-11,164.28,171.3,162.76,167.5,
AXON,2021-10-12,168.23,173.02,168.0,171.43,
AXON,2021-10-13,173.12,177.37,172.62,176.62,
AXON,2021-10-14,178.52,180.61,177.7,179.03,
AXON,2021-10-15,179.77,180.51,177.73,177.94,
AXON,2021-10-18,177.27,182.81,176.31,181.7,
AXON,2021-10-19,183.03,185.86,181.08,185.27,
AXON,2021-10-20,186.39,187.41,178.88,179.05,
AXON,2021-10-21,179.33,185.428,179.3,184.6,
AXON,2021-10-22,185.35,186.0,179.7,182.65,
AXON,2021-10-25,184.86,184.86,179.62,179.8,
AXON,2021-10-26,182.18,183.55,179.46,180.2,
AXON,2021-10-27,180.61,182.04,176.09,176.3,
AXON,2021-10-28,175.98,177.95,173.16,174.64,
AXON,2021-10-29,174.21,180.5,173.77,179.96,
AXON,2021-11-01,180.99,182.69,178.96,180.67,
AXON,2021-11-02,181.72,182.25,179.36,181.6,
AXON,2021-11-03,182.2,185.41,181.502,184.91,
AXON,2021-11-04,186.1,187.83,182.953,184.54,
AXON,2021-11-05,186.1,188.8,181.68,182.64,
AXON,2021-11-08,182.5,182.605,176.05,176.65,
AXON,2021-11-09,176.78,180.06,175.35,176.4,
AXON,2021-11-10,175.01,177.27,169.36,170.25,
AXON,2021-11-11,171.11,171.495,168.29,168.95,
AXON,2021-11-12,169.52,170.81,168.23,170.41,
AXON,2021-11-15,172.23,173.575,167.25,167.41,
AXON,2021-11-16,208.84,209.0,174.78,177.79,
AXON,2021-11-17,180.4,180.44,172.4,172.89,
AXON,2021-11-18,172.66,180.87,172.0,174.43,
AXON,2021-11-19,174.84,183.43,174.84,181.94,
AXON,2021-11-22,182.12,186.84,179.26,180.98,
AXON,2021-11-23,180.29,182.32,170.54,174.35,
AXON,2021-11-24,174.46,180.265,173.32,179.86,
AXON,2021-11-26,176.72,181.11,174.46,177.2,
AXON,2021-11-29,178.59,180.67,176.61,179.75,
AXON,2021-11-30,177.73,181.08,168.75,168.79,
AXON,2021-12-01,162.81,172.63,162.1,164.77,
AXON,2021-12-02,164.53,164.9,158.35,159.36,
AXON,2021-12-03,160.03,160.08,149.38,151.41,
AXON,2021-12-06,150.25,150.96,145.94,148.22,
AXON,2021-12-07,150.52,155.785,148.804,153.79,
AXON,2021-12-08,153.79,153.79,149.57,151.47,
AXON,2021-12-09,152.9,153.49,146.32,146.47,
AXON,2021-12-10,147.84,148.32,139.41,141.45,
AXON,2021-12-13,141.67,144.49,138.68,138.89,
AXON,2021-12-14,143.05,148.81,141.26,145.73,
AXON,2021-12-15,144.93,147.77,142.15,147.54,
AXON,2021-12-16,148.14,148.55,141.26,142.11,
AXON,2021-12-17,141.54,146.21,139.6,144.93,
AXON,2021-12-20,146.0,152.14,144.93,150.86,
AXON,2021-12-21,150.61,157.46,149.0,156.7,
AXON,2021-12-22,156.27,159.54,153.578,159.01,
AXON,2021-12-23,160.0,162.25,158.71,160.54,
AXON,2021-12-27,160.6,162.571,159.395,161.12,
AXON,2021-12-28,160.95,160.999,153.625,153.81,
AXON,2021-12-29,153.25,155.55,151.8,154.7,
AXON,2021-12-30,153.96,157.68,153.96,156.07,
AXON,2021-12-31,155.17,157.25,154.58,157.0,
AXON,2022-01-03,156.6,157.5,150.85,152.87,
AXON,2022-01-04,151.96,152.4,149.125,151.51,
AXON,2022-01-05,150.63,150.81,146.91,147.99,
AXON,2022-01-06,148.23,151.59,146.0,150.14,
AXON,2022-01-07,150.01,151.89,144.81,145.19,
AXON,2022-01-10,143.62,147.74,140.615,147.51,
AXON,2022-01-11,147.34,150.23,145.91,149.76,
AXON,2022-01-12,150.68,151.82,146.42,151.03,
AXON,2022-01-13,151.9,152.48,143.44,143.65,
AXON,2022-01-14,140.63,143.126,135.15,137.17,
AXON,2022-01-18,137.14,137.53,132.0,132.2,
AXON,2022-01-19,132.42,135.366,130.8,132.55,
AXON,2022-01-20,133.71,137.581,133.6,133.82,
AXON,2022-01-21,132.97,136.494,131.36,132.96,
AXON,2022-01-24,130.07,135.88,124.66,135.59,
AXON,2022-01-25,133.0,135.59,128.01,128.07,
AXON,2022-01-26,129.72,135.0,127.37,128.19,
AXON,2022-01-27,129.18,130.84,127.28,129.4,
AXON,2022-01-28,129.72,136.11,128.31,136.07,
AXON,2022-01-31,136.74,141.0,136.0,139.93,
AXON,2022-02-01,142.05,144.04,139.035,144.0,
AXON,2022-02-02,144.3,144.3,141.26,142.15,
AXON,2022-02-03,139.16,140.675,137.42,139.99,
AXON,2022-02-04,140.41,144.585,137.57,142.99,
AXON,2022-02-07,142.99,145.92,142.27,144.46,
AXON,2022-02-08,143.12,148.11,142.39,145.33,
AXON,2022-02-09,147.18,148.87,145.76,148.75,
AXON,2022-02-10,144.72,148.29,143.22,144.18,
AXON,2022-02-11,145.24,145.5,138.36,139.59,
AXON,2022-02-14,139.2,143.52,137.51,140.51,
AXON,2022-02-15,142.14,144.094,140.6,143.25,
AXON,2022-02-16,142.28,143.29,139.34,141.41,
AXON,2022-02-17,139.54,139.54,132.46,132.58,
AXON,2022-02-18,132.79,133.98,128.34,128.47,
AXON,2022-02-22,127.68,130.63,125.81,126.76,
AXON,2022-02-23,128.14,129.37,121.91,122.44,
AXON,2022-02-24,118.38,130.45,117.05,130.15,
AXON,2022-02-25,135.49,135.84,125.06,134.14,
AXON,2022-02-28,134.25,142.14,133.6,140.25,
AXON,2022-03-01,138.73,144.43,138.08,142.12,
AXON,2022-03-02,142.17,145.47,138.61,144.61,
AXON,2022-03-03,146.06,146.505,138.85,140.15,
AXON,2022-03-04,140.52,143.17,136.17,138.13,
AXON,2022-03-07,137.94,139.14,125.83,126.13,
AXON,2022-03-08,125.16,127.97,122.63,125.03,
AXON,2022-03-09,127.32,132.48,126.93,131.63,
AXON,2022-03-10,128.96,131.13,126.9,130.33,
AXON,2022-03-11,132.87,132.87,124.58,124.66,
AXON,2022-03-14,124.06,126.0,117.78,120.3,
AXON,2022-03-15,121.215,121.64,118.585,121.18,
AXON,2022-03-16,123.72,127.39,122.86,127.3,
AXON,2022-03-17,126.45,131.66,124.875,131.34,
AXON,2022-03-18,131.83,136.86,131.83,134.89,
AXON,2022-03-21,133.65,135.37,131.12,134.37,
AXON,2022-03-22,134.32,138.37,133.515,137.67,
AXON,2022-03-23,136.91,137.35,133.86,134.82,
AXON,2022-03-24,135.95,138.84,134.05,138.15,
AXON,2022-03-25,139.26,139.26,132.17,132.69,
AXON,2022-03-28,132.32,135.67,131.36,135.11,
AXON,2022-03-29,136.21,140.33,136.21,138.99,
AXON,2022-03-30,138.81,139.3,135.26,139.0,
AXON,2022-03-31,139.0,139.96,137.25,137.73,
AXON,2022-04-01,137.69,140.0,137.37,139.31,
AXON,2022-04-04,140.21,142.5,139.14,140.0,
AXON,2022-04-05,141.17,141.84,137.86,138.93,
AXON,2022-04-06,136.76,136.76,130.12,131.17,
AXON,2022-04-07,130.13,133.57,130.13,132.79,
AXON,2022-04-08,132.64,133.01,127.805,127.82,
AXON,2022-04-11,126.4,128.01,124.32,124.4,
AXON,2022-04-12,126.0,128.09,124.39,125.63,
AXON,2022-04-13,125.63,127.47,124.01,125.27,
AXON,2022-04-14,125.4,125.44,122.03,123.22,
AXON,2022-04-18,122.14,122.52,118.01,122.33,
AXON,2022-04-19,122.05,130.47,121.92,130.0,
AXON,2022-04-20,129.36,129.415,124.43,124.64,
AXON,2022-04-21,126.76,128.049,120.14,120.65,
AXON,2022-04-22,121.35,123.51,118.01,118.02,
AXON,2022-04-25,117.13,121.18,115.64,120.79,
AXON,2022-04-26,119.61,119.92,113.34,113.34,
AXON,2022-04-27,113.82,115.86,112.33,113.64,
AXON,2022-04-28,114.98,116.28,111.38,116.06,
AXON,2022-04-29,115.33,118.65,111.78,112.2,
AXON,2022-05-02,112.35,116.67,110.74,116.26,
AXON,2022-05-03,116.03,118.17,114.03,114.85,
AXON,2022-05-04,116.17,116.76,108.465,115.54,
AXON,2022-05-05,116.76,116.81,96.32,99.51,
AXON,2022-05-06,97.5,99.0,94.8,95.99,
AXON,2022-05-09,93.91,93.91,87.35,87.89,
AXON,2022-05-10,92.68,93.9999,85.88,89.46,
AXON,2022-05-11,87.16,93.415,83.575,84.37,
AXON,2022-05-12,83.6,89.36,82.4944,87.04,
AXON,2022-05-13,90.37,100.16,90.37,98.22,
AXON,2022-05-16,95.84,97.87,93.0,95.44,
AXON,2022-05-17,98.01,99.98,93.905,96.8,
AXON,2022-05-18,95.37,97.8368,94.78,96.25,
AXON,2022-05-19,96.06,99.97,96.06,98.58,
AXON,2022-05-20,100.99,101.31,96.82,99.4,
AXON,2022-05-23,95.77,97.08,90.81,94.74,
AXON,2022-05-24,93.34,93.47,89.9012,92.56,
AXON,2022-05-25,91.45,95.81,91.45,95.54,
AXON,2022-05-26,96.01,99.4138,96.01,98.52,
AXON,2022-05-27,99.91,102.86,98.5,102.52,
AXON,2022-05-31,102.14,102.65,99.06,101.36,
AXON,2022-06-01,101.8,104.205,97.91,99.35,
AXON,2022-06-02,99.25,105.29,99.25,105.11,
AXON,2022-06-03,102.94,104.76,101.64,103.09,
AXON,2022-06-06,104.0,105.87,100.98,102.68,
AXON,2022-06-07,101.32,104.98,100.86,104.07,
AXON,2022-06-08,103.99,105.86,102.704,102.88,
AXON,2022-06-09,102.65,103.33,100.01,101.04,
AXON,2022-06-10,98.2,99.48,95.2244,96.51,
AXON,2022-06-13,92.38,93.49,88.9,89.81,
AXON,2022-06-14,90.09,90.45,86.21,87.51,
AXON,2022-06-15,89.17,92.095,88.29,90.88,
AXON,2022-06-16,88.07,89.26,83.79,85.12,
AXON,2022-06-17,86.16,89.17,86.04,87.61,
AXON,2022-06-21,88.38,90.145,84.08,84.44,
AXON,2022-06-22,83.77,87.89,83.01,86.36,
AXON,2022-06-23,86.97,91.39,86.325,91.03,
AXON,2022-06-24,92.14,96.59,92.0,96.16,
AXON,2022-06-27,96.65,97.13,93.69,96.79,
AXON,2022-06-28,97.41,98.98,94.58,95.0,
AXON,2022-06-29,95.44,96.22,92.25,95.64,
AXON,2022-06-30,94.17,95.36,90.67,93.17,
AXON,2022-07-01,93.72,94.5425,91.37,93.23,
AXON,2022-07-05,92.63,95.73,89.76,95.65,
AXON,2022-07-06,96.25,96.79,92.0,94.03,
AXON,2022-07-07,93.99,98.69,93.99,97.9,
AXON,2022-07-08,95.98,97.92,94.44,96.85,
AXON,2022-07-11,96.45,96.45,92.66,93.62,
AXON,2022-07-12,94.52,95.7065,91.48,92.49,
AXON,2022-07-13,91.61,94.17,90.3,92.57,
AXON,2022-07-14,91.15,91.9899,88.6115,91.26,
AXON,2022-07-15,92.54,94.99,91.85,94.65,
AXON,2022-07-18,95.57,97.71,94.855,95.05,
AXON,2022-07-19,96.63,98.445,95.93,97.63,
AXON,2022-07-20,98.62,103.975,97.84,103.48,
AXON,2022-07-21,103.54,105.63,103.3,104.47,
AXON,2022-07-22,105.14,105.21,101.22,102.12,
AXON,2022-07-25,102.12,102.395,99.7505,101.4,
AXON,2022-07-26,100.89,100.89,97.86,98.84,
AXON,2022-07-27,100.43,104.72,99.5166,104.41,
AXON,2022-07-28,104.54,108.41,104.54,107.92,
AXON,2022-07-29,107.33,111.13,106.11,110.19,
AXON,2022-08-01,109.38,112.27,107.5,111.0,
AXON,2022-08-02,109.63,113.93,109.63,113.01,
AXON,2022-08-03,114.34,116.95,113.58,116.67,
AXON,2022-08-04,117.06,117.99,114.32,116.6,
AXON,2022-08-05,114.98,117.47,114.1,116.29,
AXON,2022-08-08,117.89,120.61,115.78,116.23,
AXON,2022-08-09,114.22,114.96,111.02,111.62,
AXON,2022-08-10,119.43,129.48,119.35,126.07,
AXON,2022-08-11,126.49,127.4,123.31,124.1,
AXON,2022-08-12,124.0,129.56,123.15,129.49,
AXON,2022-08-15,127.48,132.71,127.48,131.92,
AXON,2022-08-16,130.65,133.26,129.04,133.23,
AXON,2022-08-17,131.04,132.41,129.02,130.57,
AXON,2022-08-18,131.61,132.18,130.26,132.14,
AXON,2022-08-19,130.79,131.36,129.49,130.7,
AXON,2022-08-22,127.59,129.72,126.2,128.14,
AXON,2022-08-23,128.12,129.16,121.81,121.86,
AXON,2022-08-24,121.81,125.25,121.76,123.38,
AXON,2022-08-25,124.18,127.76,123.856,127.66,
AXON,2022-08-26,127.7,127.7,122.02,122.24,
AXON,2022-08-29,120.38,122.02,118.55,120.62,
AXON,2022-08-30,121.33,124.211,117.01,117.71,
AXON,2022-08-31,118.44,120.14,115.63,116.68,
AXON,2022-09-01,115.13,115.83,111.93,115.0,
AXON,2022-09-02,116.75,116.97,113.42,115.78,
AXON,2022-09-06,115.44,117.875,114.582,117.71,
AXON,2022-09-07,117.8,124.17,117.28,123.73,
AXON,2022-09-08,122.15,124.5,121.605,122.73,
AXON,2022-09-09,123.06,125.12,123.06,124.19,
AXON,2022-09-12,124.99,125.4,122.62,124.8,
AXON,2022-09-13,119.8,120.415,117.9,118.72,
AXON,2022-09-14,118.98,120.21,116.01,120.01,
AXON,2022-09-15,120.25,122.59,118.5,120.17,
AXON,2022-09-16,118.1,119.43,115.585,118.34,
AXON,2022-09-19,118.04,119.89,115.685,117.96,
AXON,2022-09-20,116.7,117.92,114.195,117.09,
AXON,2022-09-21,118.2,120.53,116.13,116.19,
AXON,2022-09-22,115.2,115.2,110.89,111.95,
AXON,2022-09-23,110.0,113.755,109.31,113.46,
AXON,2022-09-26,112.42,114.88,110.01,110.65,
AXON,2022-09-27,111.89,113.915,109.469,113.24,
AXON,2022-09-28,113.94,116.06,113.32,115.69,
AXON,2022-09-29,113.75,114.7,111.33,114.16,
AXON,2022-09-30,113.92,118.69,113.92,115.75,
AXON,2022-10-03,116.09,116.985,112.535,115.97,
AXON,2022-10-04,119.45,121.7,119.26,120.95,
AXON,2022-10-05,119.17,124.23,118.56,123.29,
AXON,2022-10-06,123.57,128.79,123.57,126.44,
AXON,2022-10-07,123.94,124.548,121.63,123.75,
AXON,2022-10-10,124.13,128.09,121.53,126.16,
AXON,2022-10-11,125.79,127.83,120.18,121.35,
AXON,2022-10-12,121.35,122.45,119.67,120.58,
AXON,2022-10-13,118.01,122.035,115.03,120.92,
AXON,2022-10-14,122.41,122.98,117.355,119.45,
AXON,2022-10-17,121.89,125.77,121.89,124.73,
AXON,2022-10-18,128.29,129.92,126.22,128.16,
AXON,2022-10-19,127.96,128.29,121.78,124.35,
AXON,2022-10-20,123.19,128.37,123.17,126.61,
AXON,2022-10-21,126.6,130.78,124.11,130.6,
AXON,2022-10-24,130.96,139.19,129.5,137.87,
AXON,2022-10-25,138.06,139.822,134.48,137.12,
AXON,2022-10-26,135.91,141.135,135.02,137.03,
AXON,2022-10-27,137.94,140.62,136.525,139.99,
AXON,2022-10-28,140.27,142.18,138.61,142.07,
AXON,2022-10-31,142.17,145.5,140.64,145.44,
AXON,2022-11-01,147.17,148.675,145.43,147.59,
AXON,2022-11-02,146.61,149.65,144.82,145.22,
AXON,2022-11-03,142.68,148.56,142.46,147.4,
AXON,2022-11-04,149.71,149.82,143.68,148.66,
AXON,2022-11-07,149.29,149.29,145.5,148.44,
AXON,2022-11-08,149.0,150.01,144.82,150.0,
AXON,2022-11-09,162.0,177.88,161.7,171.84,
AXON,2022-11-10,177.0,184.75,175.0,182.75,
AXON,2022-11-11,178.17,188.74,178.002,182.94,
AXON,2022-11-14,180.53,185.245,177.614,180.89,
AXON,2022-11-15,180.72,188.185,180.612,187.96,
AXON,2022-11-16,187.11,191.39,180.725,191.04,
AXON,2022-11-17,189.1,192.24,186.15,192.14,
AXON,2022-11-18,193.85,193.85,183.94,185.22,
AXON,2022-11-21,184.71,188.98,182.11,186.95,
AXON,2022-11-22,187.06,188.0,184.034,187.31,
AXON,2022-11-23,188.66,189.85,186.8,187.75,
AXON,2022-11-25,187.37,188.28,185.86,187.92,
AXON,2022-11-28,187.0,188.67,183.645,183.94,
AXON,2022-11-29,184.22,185.211,181.08,181.26,
AXON,2022-11-30,181.28,185.15,180.59,184.03,
AXON,2022-12-01,177.95,186.94,176.38,185.55,
AXON,2022-12-02,183.24,190.475,181.57,188.83,
AXON,2022-12-05,186.39,188.305,183.19,184.01,
AXON,2022-12-06,176.9,176.9,168.69,169.43,
AXON,2022-12-07,170.41,171.835,168.3,170.16,
AXON,2022-12-08,171.78,175.0,169.83,171.71,
AXON,2022-12-09,171.62,172.725,168.38,168.61,
AXON,2022-12-12,170.26,171.22,168.44,168.59,
AXON,2022-12-13,175.29,175.49,169.25,170.81,
AXON,2022-12-14,171.45,175.735,170.07,173.52,
AXON,2022-12-15,172.2,172.825,169.79,171.06,
AXON,2022-12-16,169.73,171.96,168.29,169.34,
AXON,2022-12-19,168.96,171.42,166.65,167.57,
AXON,2022-12-20,167.2,171.87,166.61,171.37,
AXON,2022-12-21,172.63,175.65,171.86,174.72,
AXON,2022-12-22,172.64,173.11,165.63,167.82,
AXON,2022-12-23,168.2,171.24,165.5,168.98,
AXON,2022-12-27,168.73,172.475,166.23,166.25,
AXON,2022-12-28,165.87,167.81,164.25,165.1,
AXON,2022-12-29,166.49,168.2,165.16,165.58,
AXON,2022-12-30,163.87,166.71,162.39,165.93,
AXON,2023-01-03,167.88,168.92,164.665,168.24,
AXON,2023-01-04,168.24,171.13,166.65,168.76,
AXON,2023-01-05,166.97,170.66,165.72,165.74,
AXON,2023-01-06,166.47,171.52,166.14,170.9,
AXON,2023-01-09,171.96,178.87,171.96,177.45,
AXON,2023-01-10,177.77,181.19,176.99,179.33,
AXON,2023-01-11,180.87,183.25,178.02,181.43,
AXON,2023-01-12,181.44,184.65,179.01,184.08,
AXON,2023-01-13,182.69,189.62,182.125,188.13,
AXON,2023-01-17,188.31,189.14,184.27,184.47,
AXON,2023-01-18,186.33,188.76,181.66,182.27,
AXON,2023-01-19,181.52,185.5,181.52,184.06,
AXON,2023-01-20,186.08,186.5,182.72,185.02,
AXON,2023-01-23,187.22,194.8,185.92,188.95,
AXON,2023-01-24,188.13,189.84,184.5,188.96,
AXON,2023-01-25,188.34,193.18,184.04,192.18,
AXON,2023-01-26,193.91,194.73,186.72,192.33,
AXON,2023-01-27,192.29,193.69,188.715,191.61,
AXON,2023-01-30,191.27,198.4,189.75,191.46,
AXON,2023-01-31,191.8,195.64,191.8,195.44,
AXON,2023-02-01,197.16,199.435,192.714,198.39,
AXON,2023-02-02,200.0,204.99,196.41,198.54,
AXON,2023-02-03,196.2,202.44,195.7,198.19,
AXON,2023-02-06,197.36,200.69,194.58,195.95,
AXON,2023-02-07,194.76,194.76,168.295,188.58,
AXON,2023-02-08,186.79,189.57,184.74,185.0,
AXON,2023-02-09,187.0,191.22,183.45,183.81,
AXON,2023-02-10,181.03,187.83,180.97,184.55,
AXON,2023-02-13,186.88,190.45,183.655,190.32,
AXON,2023-02-14,189.6,194.31,188.43,193.9,
AXON,2023-02-15,194.79,199.3,192.91,198.99,
AXON,2023-02-16,197.35,200.97,195.91,196.05,
AXON,2023-02-17,192.86,193.56,186.51,189.26,
AXON,2023-02-21,188.87,191.78,187.639,189.77,
AXON,2023-02-22,191.14,194.87,190.41,193.59,
AXON,2023-02-23,195.53,196.55,192.52,195.04,
AXON,2023-02-24,192.26,196.744,191.51,193.55,
AXON,2023-02-27,194.44,199.53,194.13,194.97,
AXON,2023-02-28,194.52,201.67,194.37,200.31,
AXON,2023-03-01,208.74,221.31,202.85,221.06,
AXON,2023-03-02,215.0,219.69,212.2,218.31,
AXON,2023-03-03,212.52,224.0,212.52,220.95,
AXON,2023-03-06,217.59,223.81,216.12,221.38,
AXON,2023-03-07,222.12,224.485,219.735,222.24,
AXON,2023-03-08,226.0,226.0,220.57,221.8,
AXON,2023-03-09,221.34,222.0,217.88,217.89,
AXON,2023-03-10,218.47,218.47,212.74,213.0,
AXON,2023-03-13,209.56,214.783,207.0,211.0,
AXON,2023-03-14,214.77,216.175,212.14,215.0,
AXON,2023-03-15,212.54,213.4,207.3,211.21,
AXON,2023-03-16,210.3,217.12,208.97,216.98,
AXON,2023-03-17,215.36,216.58,210.955,213.12,
AXON,2023-03-20,214.15,215.445,212.02,213.72,
AXON,2023-03-21,218.6,221.69,217.5,219.68,
AXON,2023-03-22,218.75,218.935,213.22,213.51,
AXON,2023-03-23,215.3,217.66,211.285,215.72,
AXON,2023-03-24,213.56,216.99,212.38,216.58,
AXON,2023-03-27,218.75,220.8,215.72,218.59,
AXON,2023-03-28,217.62,218.99,214.78,215.6,
AXON,2023-03-29,217.86,219.07,215.82,216.83,
AXON,2023-03-30,219.3,219.386,216.249,217.7,
AXON,2023-03-31,219.64,227.555,218.41,224.85,
AXON,2023-04-03,223.98,227.49,221.99,227.39,
AXON,2023-04-04,227.9,229.0,221.2,223.0,
AXON,2023-04-05,221.2,223.0,213.73,217.29,
AXON,2023-04-06,217.0,219.77,215.7,219.71,
AXON,2023-04-10,218.67,222.78,217.55,222.63,
AXON,2023-04-11,224.66,226.377,222.135,224.01,
AXON,2023-04-12,225.0,226.505,221.505,222.22,
AXON,2023-04-13,224.46,225.08,220.8,223.31,
AXON,2023-04-14,222.35,224.72,221.41,223.91,
AXON,2023-04-17,225.0,228.79,224.525,225.57,
AXON,2023-04-18,225.96,228.6,225.25,227.53,
AXON,2023-04-19,225.85,227.5,224.0,226.34,
AXON,2023-04-20,224.36,228.01,223.31,224.47,
AXON,2023-04-21,224.61,227.268,223.31,225.02,
AXON,2023-04-24,224.66,226.814,222.38,224.5,
AXON,2023-04-25,223.89,224.5,220.35,220.85,
AXON,2023-04-26,220.0,221.02,216.09,216.13,
AXON,2023-04-27,216.76,217.48,212.56,215.55,
AXON,2023-04-28,213.82,214.34,207.72,210.71,
AXON,2023-05-01,211.33,216.345,210.3,216.0,
AXON,2023-05-02,216.58,220.58,214.01,220.22,
AXON,2023-05-03,220.83,229.95,220.16,220.88,
AXON,2023-05-04,219.5,222.32,216.0,219.1,
AXON,2023-05-05,218.46,220.572,214.0,219.91,
AXON,2023-05-08,219.91,222.66,219.73,221.86,
AXON,2023-05-09,222.08,228.405,221.5,226.88,
AXON,2023-05-10,222.73,224.11,186.321,192.73,
AXON,2023-05-11,197.84,204.902,197.0,204.595,
AXON,2023-05-12,205.12,207.15,200.18,201.5,
AXON,2023-05-15,200.2,205.3,198.5,203.47,
AXON,2023-05-16,203.25,204.99,201.131,201.21,
AXON,2023-05-17,201.93,202.93,196.75,197.68,
AXON,2023-05-18,201.49,202.0,199.49,201.7,
AXON,2023-05-19,201.89,203.15,196.21,196.86,
AXON,2023-05-22,197.58,203.2,196.26,201.75,
AXON,2023-05-23,200.01,204.23,193.91,195.8,
AXON,2023-05-24,194.42,195.99,191.795,192.81,
AXON,2023-05-25,193.49,194.52,189.63,193.96,
AXON,2023-05-26,195.0,197.65,194.13,194.95,
AXON,2023-05-30,196.0,197.49,191.9,193.16,
AXON,2023-05-31,192.47,193.395,189.9,192.91,
AXON,2023-06-01,191.59,195.376,190.51,192.14,
AXON,2023-06-02,193.34,194.79,190.81,193.25,
AXON,2023-06-05,192.86,193.53,190.21,191.86,
AXON,2023-06-06,191.88,195.96,191.18,194.88,
AXON,2023-06-07,194.88,199.84,193.4,197.88,
AXON,2023-06-08,196.52,199.0,194.51,194.74,
AXON,2023-06-09,195.54,197.0,194.09,194.82,
AXON,2023-06-12,195.9,198.045,194.49,196.85,
AXON,2023-06-13,196.85,198.38,195.195,196.66,
AXON,2023-06-14,195.83,198.712,195.0,197.81,
AXON,2023-06-15,196.88,203.38,196.88,202.09,
AXON,2023-06-16,203.63,206.33,199.96,202.36,
AXON,2023-06-20,201.5,205.4,199.29,204.77,
AXON,2023-06-21,205.65,205.65,197.25,197.54,
AXON,2023-06-22,197.0,198.59,194.34,196.92,
AXON,2023-06-23,194.67,194.7,188.65,188.71,
AXON,2023-06-26,189.365,190.15,186.88,189.63,
AXON,2023-06-27,191.13,195.735,191.13,195.38,
AXON,2023-06-28,195.76,196.405,193.67,194.59,
AXON,2023-06-29,194.85,197.35,193.228,195.83,
AXON,2023-06-30,196.58,196.885,194.615,195.12,
AXON,2023-07-03,194.31,194.93,189.882,194.58,
AXON,2023-07-05,193.31,195.787,192.445,193.61,
AXON,2023-07-06,192.41,193.005,188.1,188.82,
AXON,2023-07-07,189.59,190.86,186.69,188.1,
AXON,2023-07-10,189.03,195.42,188.86,195.36,
AXON,2023-07-11,195.35,196.89,193.87,195.58,
AXON,2023-07-12,197.37,197.37,192.47,195.88,
AXON,2023-07-13,196.51,197.42,193.53,194.03,
AXON,2023-07-14,192.76,193.965,190.92,192.24,
AXON,2023-07-17,192.23,196.92,191.8,196.16,
AXON,2023-07-18,195.78,196.66,191.95,192.25,
AXON,2023-07-19,192.27,193.91,187.71,189.53,
AXON,2023-07-20,189.54,190.07,183.155,184.03,
AXON,2023-07-21,184.95,185.299,179.61,179.96,
AXON,2023-07-24,179.54,181.34,177.14,178.3,
AXON,2023-07-25,176.84,180.41,176.08,180.03,
AXON,2023-07-26,179.36,180.765,176.31,180.04,
AXON,2023-07-27,181.24,185.545,180.47,182.09,
AXON,2023-07-28,184.12,186.36,182.47,182.64,
AXON,2023-07-31,183.15,186.15,182.905,185.93,
AXON,2023-08-01,184.45,186.05,183.26,183.33,
AXON,2023-08-02,181.94,182.31,177.905,178.02,
AXON,2023-08-03,177.01,178.818,175.365,177.1,
AXON,2023-08-04,178.49,182.92,178.375,180.86,
AXON,2023-08-07,181.9,182.58,178.89,179.67,
AXON,2023-08-08,179.22,180.08,175.59,175.73,
AXON,2023-08-09,198.12,207.86,196.49,200.44,
AXON,2023-08-10,203.81,208.92,202.35,204.12,
AXON,2023-08-11,203.18,211.89,202.32,211.23,
AXON,2023-08-14,209.59,211.65,206.06,206.62,
AXON,2023-08-15,206.62,207.36,202.59,203.05,
AXON,2023-08-16,201.87,202.155,198.2,200.78,
AXON,2023-08-17,200.42,200.42,195.0,195.39,
AXON,2023-08-18,193.11,200.72,192.87,200.1,
AXON,2023-08-21,199.56,201.07,195.67,196.94,
AXON,2023-08-22,196.86,199.54,196.0,198.96,
AXON,2023-08-23,199.45,200.59,197.64,200.3,
AXON,2023-08-24,200.44,204.18,195.86,196.01,
AXON,2023-08-25,195.73,198.62,193.31,198.43,
AXON,2023-08-28,199.73,203.36,199.73,200.71,
AXON,2023-08-29,200.11,206.29,199.265,205.14,
AXON,2023-08-30,204.8,211.59,204.8,211.1,
AXON,2023-08-31,212.0,215.28,211.845,212.91,
AXON,2023-09-01,213.61,215.475,212.38,215.39,
AXON,2023-09-05,214.5,214.9,208.15,212.25,
AXON,2023-09-06,212.61,215.44,211.71,213.5,
AXON,2023-09-07,213.41,216.805,210.428,216.06,
AXON,2023-09-08,215.34,217.61,214.105,214.71,
AXON,2023-09-11,214.47,215.0,210.81,213.19,
AXON,2023-09-12,210.83,213.13,210.26,211.93,
AXON,2023-09-13,211.0,211.885,208.05,209.86,
AXON,2023-09-14,209.95,213.51,209.315,212.51,
AXON,2023-09-15,211.38,211.68,204.95,206.21,
AXON,2023-09-18,204.6,211.19,203.01,208.18,
AXON,2023-09-19,207.23,207.23,201.24,203.8,
AXON,2023-09-20,205.34,206.32,203.19,203.35,
AXON,2023-09-21,201.03,201.71,196.01,196.13,
AXON,2023-09-22,196.88,197.565,194.5,195.42,
AXON,2023-09-25,193.95,195.35,192.5,193.24,
AXON,2023-09-26,190.64,192.2,189.12,189.61,
AXON,2023-09-27,190.85,195.71,190.69,194.65,
AXON,2023-09-28,193.41,196.545,191.603,196.08,
AXON,2023-09-29,197.86,201.54,197.58,198.99,
AXON,2023-10-02,197.29,199.1,195.05,196.15,
AXON,2023-10-03,195.39,196.06,190.82,192.06,
AXON,2023-10-04,192.03,194.9,190.01,194.61,
AXON,2023-10-05,194.81,196.545,192.785,196.11,
AXON,2023-10-06,193.12,201.45,192.63,199.7,
AXON,2023-10-09,202.2,209.94,200.99,208.81,
AXON,2023-10-10,210.0,216.31,209.61,215.29,
AXON,2023-10-11,216.64,220.71,216.0,220.0,
AXON,2023-10-12,220.68,220.68,214.19,215.41,
AXON,2023-10-13,216.63,217.88,214.277,215.43,
AXON,2023-10-16,217.2,220.46,216.68,220.05,
AXON,2023-10-17,218.53,223.3,218.045,222.54,
AXON,2023-10-18,222.0,223.12,219.41,219.53,
AXON,2023-10-19,218.88,218.88,210.66,212.31,
AXON,2023-10-20,212.93,212.93,207.2,210.86,
AXON,2023-10-23,209.98,212.675,208.05,210.08,
AXON,2023-10-24,212.8,215.17,212.21,213.33,
AXON,2023-10-25,212.58,212.58,206.63,207.87,
AXON,2023-10-26,207.87,210.015,204.32,204.57,
AXON,2023-10-27,204.68,205.89,199.29,200.755,
AXON,2023-10-30,203.59,203.92,200.546,201.73,
AXON,2023-10-31,202.32,205.615,199.5,204.49,
AXON,2023-11-01,204.95,208.19,203.16,207.15,
AXON,2023-11-02,209.77,212.58,209.025,210.27,
AXON,2023-11-03,211.97,219.36,211.97,217.25,
AXON,2023-11-06,219.39,220.22,214.83,216.86,
AXON,2023-11-07,216.92,219.02,214.7,216.37,
AXON,2023-11-08,224.5,231.71,219.072,229.58,
AXON,2023-11-09,230.23,230.655,212.885,215.7,
AXON,2023-11-10,216.16,220.0,215.435,217.94,
AXON,2023-11-13,218.27,219.747,216.725,218.66,
AXON,2023-11-14,221.36,223.57,220.51,221.58,
AXON,2023-11-15,222.0,225.38,220.77,221.08,
AXON,2023-11-16,222.05,223.81,220.78,222.76,
AXON,2023-11-17,224.95,224.95,222.28,223.48,
AXON,2023-11-20,224.37,227.35,224.16,226.22,
AXON,2023-11-21,226.0,230.4,226.0,228.42,
AXON,2023-11-22,228.43,230.815,226.79,226.87,
AXON,2023-11-24,227.14,228.72,227.14,228.42,
AXON,2023-11-27,227.36,230.06,227.0,228.16,
AXON,2023-11-28,228.4,230.38,226.49,227.07,
AXON,2023-11-29,228.83,230.021,225.115,225.86,
AXON,2023-11-30,226.41,230.33,224.28,229.87,
AXON,2023-12-01,229.87,233.8,226.553,231.51,
AXON,2023-12-04,229.6,236.38,229.32,236.28,
AXON,2023-12-05,234.02,234.99,229.021,231.72,
AXON,2023-12-06,232.64,235.65,231.83,232.34,
AXON,2023-12-07,233.33,235.98,232.78,235.33,
AXON,2023-12-08,235.41,238.04,234.83,236.38,
AXON,2023-12-11,236.99,238.96,235.33,238.78,
AXON,2023-12-12,239.74,243.61,238.07,241.97,
AXON,2023-12-13,242.12,248.1,240.49,248.06,
AXON,2023-12-14,250.0,253.725,248.3,253.12,
AXON,2023-12-15,252.91,256.82,250.17,255.98,
AXON,2023-12-18,253.46,256.01,251.464,255.69,
AXON,2023-12-19,257.69,260.35,254.61,255.92,
AXON,2023-12-20,255.92,257.65,252.11,252.77,
AXON,2023-12-21,256.94,257.675,253.5,256.84,
AXON,2023-12-22,258.3,260.69,257.12,259.03,
AXON,2023-12-26,257.94,259.23,256.86,258.11,
AXON,2023-12-27,257.81,259.95,257.17,259.08,
AXON,2023-12-28,259.65,259.88,257.915,258.59,
AXON,2023-12-29,258.0,259.45,256.38,258.33,
AXON,2024-01-02,254.47,256.01,249.53,251.63,
AXON,2024-01-03,250.62,252.24,247.27,247.43,
AXON,2024-01-04,247.43,249.556,244.345,244.93,
AXON,2024-01-05,244.5,246.1,241.72,244.21,
AXON,2024-01-08,244.45,251.75,244.01,251.61,
AXON,2024-01-09,248.48,250.54,247.81,249.1,
AXON,2024-01-10,249.98,250.965,248.0,249.02,
AXON,2024-01-11,249.81,251.72,247.12,249.54,
AXON,2024-01-12,250.81,253.896,248.44,250.69,
AXON,2024-01-16,250.28,251.61,246.985,249.47,
AXON,2024-01-17,247.12,250.68,247.12,250.51,
AXON,2024-01-18,251.06,254.19,250.65,254.1,
AXON,2024-01-19,254.98,256.86,251.865,256.79,
AXON,2024-01-22,258.12,262.95,257.17,259.66,
AXON,2024-01-23,261.28,261.28,254.925,255.01,
AXON,2024-01-24,257.34,257.34,250.43,251.24,
AXON,2024-01-25,252.78,253.927,250.63,252.7,
AXON,2024-01-26,252.58,254.06,249.01,251.36,
AXON,2024-01-29,251.99,254.77,251.75,254.73,
AXON,2024-01-30,254.24,255.735,253.4,254.25,
AXON,2024-01-31,254.94,255.018,248.378,249.06,
AXON,2024-02-01,250.65,254.135,247.04,252.7,
AXON,2024-02-02,252.7,258.62,251.126,256.99,
AXON,2024-02-05,255.97,257.755,252.2,257.47,
AXON,2024-02-06,258.64,259.69,255.581,259.46,
AXON,2024-02-07,260.34,270.95,259.12,265.47,
AXON,2024-02-08,265.0,269.5,264.53,269.0,
AXON,2024-02-09,270.82,271.389,268.44,270.98,
AXON,2024-02-12,270.53,273.535,265.05,266.71,
AXON,2024-02-13,261.28,269.28,255.68,264.45,
AXON,2024-02-14,268.02,271.42,264.87,270.84,
AXON,2024-02-15,272.1,274.78,268.0,272.79,
AXON,2024-02-16,272.02,273.91,269.71,269.8,
AXON,2024-02-20,267.38,269.16,265.23,267.7,
AXON,2024-02-21,267.03,268.19,260.265,263.73,
AXON,2024-02-22,267.58,272.305,267.38,271.54,
AXON,2024-02-23,272.87,273.72,268.99,270.63,
AXON,2024-02-26,272.15,274.27,270.82,271.59,
AXON,2024-02-27,273.51,273.62,265.32,271.82,
AXON,2024-02-28,280.7,318.9,275.0,309.22,
AXON,2024-02-29,309.22,311.04,299.07,307.37,
AXON,2024-03-01,303.0,314.49,302.24,314.25,
AXON,2024-03-04,316.0,325.63,314.95,319.88,
AXON,2024-03-05,319.48,319.81,311.94,315.1,
AXON,2024-03-06,315.01,318.0,310.25,314.97,
AXON,2024-03-07,315.1,317.99,313.96,315.13,
AXON,2024-03-08,315.13,320.755,308.83,312.79,
AXON,2024-03-11,310.94,313.5,308.834,310.93,
AXON,2024-03-12,309.85,312.07,305.92,311.37,
AXON,2024-03-13,311.56,312.55,304.52,306.78,
AXON,2024-03-14,307.43,310.852,304.75,306.43,
AXON,2024-03-15,304.18,309.695,304.18,307.65,
AXON,2024-03-18,310.7,311.995,307.1,308.45,
AXON,2024-03-19,308.45,312.91,306.32,312.13,
AXON,2024-03-20,312.45,314.507,308.62,314.28,
AXON,2024-03-21,316.56,319.12,314.63,316.09,
AXON,2024-03-22,318.18,318.18,312.34,316.32,
AXON,2024-03-25,316.5,317.53,313.84,315.47,
AXON,2024-03-26,315.47,320.555,314.745,319.14,
AXON,2024-03-27,321.04,321.77,314.17,315.64,
AXON,2024-03-28,316.97,316.97,311.85,312.88,
AXON,2024-04-01,314.34,314.77,309.955,311.37,
AXON,2024-04-02,309.35,310.12,304.8,309.36,
AXON,2024-04-03,308.19,311.675,308.19,309.1,
AXON,2024-04-04,312.12,315.61,306.61,306.83,
AXON,2024-04-05,306.82,312.25,306.563,309.9,
AXON,2024-04-08,311.19,314.2,309.15,311.21,
AXON,2024-04-09,310.59,311.44,306.27,311.27,
AXON,2024-04-10,308.81,320.343,307.86,318.26,
AXON,2024-04-11,319.39,329.87,315.4,324.09,
AXON,2024-04-12,322.23,323.5,310.25,310.81,
AXON,2024-04-15,317.17,317.17,301.55,303.31,
AXON,2024-04-16,302.0,303.435,295.095,300.31,
AXON,2024-04-17,301.37,302.55,296.725,299.82,
AXON,2024-04-18,300.0,303.513,297.3,297.59,
AXON,2024-04-19,299.18,299.45,291.35,293.565,
AXON,2024-04-22,294.86,296.88,291.395,293.8,
AXON,2024-04-23,296.71,302.57,295.35,301.56,
AXON,2024-04-24,304.07,308.115,302.29,302.41,
AXON,2024-04-25,300.99,308.83,297.93,306.24,
AXON,2024-04-26,306.57,311.865,306.57,308.23,
AXON,2024-04-29,308.24,313.59,307.25,313.3,
AXON,2024-04-30,311.31,314.78,309.204,313.66,
AXON,2024-05-01,312.18,316.0,309.11,311.57,
AXON,2024-05-02,313.22,318.19,310.93,316.75,
AXON,2024-05-03,319.24,321.0,316.64,318.55,
AXON,2024-05-06,322.0,329.175,321.463,327.64,
AXON,2024-05-07,312.82,317.5,304.86,312.73,
AXON,2024-05-08,312.55,316.32,309.53,311.86,
AXON,2024-05-09,310.64,313.63,307.8,309.09,
AXON,2024-05-10,309.38,309.705,303.32,303.43,
AXON,2024-05-13,303.88,305.105,300.03,300.23,
AXON,2024-05-14,299.01,299.01,290.66,296.46,
AXON,2024-05-15,299.24,300.0,292.785,293.95,
AXON,2024-05-16,293.6,294.16,288.38,290.44,
AXON,2024-05-17,292.45,292.6,286.68,288.79,
AXON,2024-05-20,289.92,292.885,288.19,292.03,
AXON,2024-05-21,291.87,291.985,285.06,287.95,
AXON,2024-05-22,288.48,289.68,282.1,284.87,
AXON,2024-05-23,285.0,286.27,279.187,279.99,
AXON,2024-05-24,280.48,285.78,279.0,285.63,
AXON,2024-05-28,286.04,288.2,284.23,288.2,
AXON,2024-05-29,285.2,288.4,283.5,284.19,
AXON,2024-05-30,284.46,286.16,280.26,281.73,
AXON,2024-05-31,281.72,283.0,275.192,281.67,
AXON,2024-06-03,281.35,283.0,275.79,278.53,
AXON,2024-06-04,277.73,278.55,273.52,276.22,
AXON,2024-06-05,278.56,282.28,276.23,282.13,
AXON,2024-06-06,282.13,283.48,276.92,279.15,
AXON,2024-06-07,279.57,282.6,278.243,280.5,
AXON,2024-06-10,280.08,286.81,280.08,285.35,
AXON,2024-06-11,285.33,287.06,283.33,287.01,
AXON,2024-06-12,290.01,297.24,288.9,295.65,
AXON,2024-06-13,295.62,297.78,292.29,293.48,
AXON,2024-06-14,292.0,294.362,287.23,292.33,
AXON,2024-06-17,292.85,297.38,290.19,297.17,
AXON,2024-06-18,297.48,300.85,292.04,293.52,
AXON,2024-06-20,295.465,296.8,290.38,293.41,
AXON,2024-06-21,293.22,293.22,282.89,291.15,
AXON,2024-06-24,291.93,296.62,290.38,292.65,
AXON,2024-06-25,293.19,294.49,290.63,292.57,
AXON,2024-06-26,292.04,293.32,288.685,292.89,
AXON,2024-06-27,292.67,298.4,290.8,298.35,
AXON,2024-06-28,300.0,304.56,293.58,294.24,
AXON,2024-07-01,296.56,296.56,287.19,289.21,
AXON,2024-07-02,288.25,293.595,286.92,293.18,
AXON,2024-07-03,294.05,297.32,292.8,296.56,
AXON,2024-07-05,296.91,298.69,294.144,298.55,
AXON,2024-07-08,299.77,303.53,299.19,302.48,
AXON,2024-07-09,304.37,306.35,298.4,298.51,
AXON,2024-07-10,299.0,299.0,292.99,293.29,
AXON,2024-07-11,293.73,295.0,290.02,291.16,
AXON,2024-07-12,292.24,296.98,290.08,292.66,
AXON,2024-07-15,294.77,308.9,293.02,308.87,
AXON,2024-07-16,311.02,319.8,311.02,319.43,
AXON,2024-07-17,321.2,326.25,315.35,317.78,
AXON,2024-07-18,318.0,319.502,303.7,305.67,
AXON,2024-07-19,307.93,310.49,303.62,308.45,
AXON,2024-07-22,310.5,317.0,306.81,316.76,
AXON,2024-07-23,318.0,324.86,317.51,319.55,
AXON,2024-07-24,318.02,318.88,310.01,313.11,
AXON,2024-07-25,312.45,316.84,307.99,310.81,
AXON,2024-07-26,314.07,314.07,308.01,310.46,
AXON,2024-07-29,312.4,312.4,307.65,309.0,
AXON,2024-07-30,309.96,314.365,304.48,304.72,
AXON,2024-07-31,307.49,308.56,298.999,299.93,
AXON,2024-08-01,300.0,302.717,296.089,299.62,
AXON,2024-08-02,294.1,295.36,287.47,292.25,
AXON,2024-08-05,279.64,291.75,279.64,286.07,
AXON,2024-08-06,289.4,298.7,286.26,295.02,
AXON,2024-08-07,330.0,367.95,323.885,348.99,
AXON,2024-08-08,350.9,371.99,344.0,368.46,
AXON,2024-08-09,367.27,370.23,359.31,365.0,
AXON,2024-08-12,368.1,375.95,366.14,368.03,
AXON,2024-08-13,368.03,370.823,364.78,368.97,
AXON,2024-08-14,368.8,371.93,365.99,370.57,
AXON,2024-08-15,366.15,378.247,366.15,373.69,
AXON,2024-08-16,374.99,377.19,372.0,373.69,
AXON,2024-08-19,373.75,376.422,370.96,373.07,
AXON,2024-08-20,374.45,375.73,370.04,373.05,
AXON,2024-08-21,373.06,378.89,371.45,375.1,
AXON,2024-08-22,375.94,377.25,372.44,372.6,
AXON,2024-08-23,375.69,376.048,369.434,370.7,
AXON,2024-08-26,369.11,370.64,358.1,360.19,
AXON,2024-08-27,360.49,364.455,357.85,363.43,
AXON,2024-08-28,364.6,368.052,361.59,362.45,
AXON,2024-08-29,364.01,368.86,361.97,362.0,
AXON,2024-08-30,363.99,366.275,361.44,364.97,
AXON,2024-09-03,361.35,363.22,354.52,355.19,
AXON,2024-09-04,351.72,356.73,349.02,355.35,
AXON,2024-09-05,353.53,356.34,352.11,354.86,
AXON,2024-09-06,356.73,357.5,346.71,354.92,
AXON,2024-09-09,358.61,369.44,358.61,364.39,
AXON,2024-09-10,364.89,364.89,357.105,359.35,
AXON,2024-09-11,357.82,364.485,355.04,361.94,
AXON,2024-09-12,364.88,384.73,364.6,384.51,
AXON,2024-09-13,382.98,385.0,375.71,379.61,
AXON,2024-09-16,380.99,386.54,379.98,385.77,
AXON,2024-09-17,384.03,386.14,376.53,382.57,
AXON,2024-09-18,383.598,387.31,380.505,383.16,
AXON,2024-09-19,390.0,391.55,383.03,389.74,
AXON,2024-09-20,387.07,393.58,387.06,393.48,
AXON,2024-09-23,394.29,397.32,392.0,393.94,
AXON,2024-09-24,395.59,395.69,388.39,393.66,
AXON,2024-09-25,394.39,395.8,392.02,395.26,
AXON,2024-09-26,396.23,398.74,391.97,393.63,
AXON,2024-09-27,394.12,395.59,388.37,395.34,
AXON,2024-09-30,395.5,400.33,394.24,399.49,
AXON,2024-10-01,399.48,400.78,395.37,399.31,
AXON,2024-10-02,400.0,405.995,397.53,404.53,
AXON,2024-10-03,404.17,415.11,403.16,415.0,
AXON,2024-10-04,418.0,422.33,413.68,421.8,
AXON,2024-10-07,421.0,425.225,416.88,420.77,
AXON,2024-10-08,424.06,433.48,420.49,426.88,
AXON,2024-10-09,424.4,432.86,422.21,432.28,
AXON,2024-10-10,430.78,431.925,424.34,428.64,
AXON,2024-10-11,430.19,436.55,428.77,434.98,
AXON,2024-10-14,437.14,440.89,435.44,437.98,
AXON,2024-10-15,437.98,438.044,425.273,434.07,
AXON,2024-10-16,433.36,435.4,428.5,433.83,
AXON,2024-10-17,436.0,437.9,432.734,434.48,
AXON,2024-10-18,438.78,438.78,434.0,438.05,
AXON,2024-10-21,439.0,444.16,435.29,443.98,
AXON,2024-10-22,446.44,455.17,443.44,449.61,
AXON,2024-10-23,447.52,449.203,440.67,442.69,
AXON,2024-10-24,442.58,446.747,438.17,443.12,
AXON,2024-10-25,446.4,449.83,442.71,444.52,
AXON,2024-10-28,444.77,444.77,443.25,444.77,
AXON,2024-10-29,444.96,447.625,443.7,444.0,
AXON,2024-10-30,443.33,445.48,438.78,438.78,
AXON,2024-10-31,434.07,436.24,422.38,423.5,
AXON,2024-11-01,426.82,430.155,424.57,425.84,
AXON,2024-11-04,425.84,435.504,424.99,431.57,
AXON,2024-11-05,433.97,442.77,433.97,441.09,
AXON,2024-11-06,459.03,462.64,450.72,459.535,
AXON,2024-11-07,465.5,471.0,462.811,468.75,
AXON,2024-11-08,540.0,611.88,515.01,604.18,
AXON,2024-11-11,612.0,624.84,588.02,616.14,
AXON,2024-11-12,595.32,595.32,591.74,595.32,
AXON,2024-11-13,600.0,617.15,599.72,601.43,
AXON,2024-11-14,603.03,609.37,592.21,604.56,
AXON,2024-11-15,599.53,601.77,594.423,599.35,
AXON,2024-11-18,601.07,610.33,592.0,600.0,
AXON,2024-11-19,598.3,618.07,598.01,610.2,
AXON,2024-11-20,609.18,612.77,598.95,609.82,
AXON,2024-11-21,621.99,640.51,611.0,631.27,
AXON,2024-11-22,637.94,641.2,623.505,636.95,
AXON,2024-11-25,619.0,619.0,607.2,619.0,
AXON,2024-11-26,622.6,633.0,621.215,632.16,
AXON,2024-11-27,629.768,636.365,625.81,634.96,
AXON,2024-11-29,639.0,652.225,639.0,646.96,
AXON,2024-12-02,649.2,649.394,634.95,636.39,
AXON,2024-12-03,652.38,675.475,638.0,669.87,
AXON,2024-12-04,667.09,689.39,667.09,687.39,
AXON,2024-12-05,688.01,695.94,677.4,689.78,
AXON,2024-12-06,692.425,698.67,680.242,687.69,
AXON,2024-12-09,687.69,687.97,631.032,642.59,
AXON,2025-01-27,597.79,608.01,587.14,604.68,
AXON,2025-01-28,606.58,639.34,604.37,637.53,
AXON,2025-01-29,640.0,644.86,632.14,639.97,
AXON,2025-01-30,646.5,657.0,643.55,653.43,
AXON,2025-01-31,655.44,671.06,649.76,652.18,
AXON,2025-02-03,641.965,671.215,635.55,658.11,
AXON,2025-02-04,657.14,674.0,652.58,662.91,
AXON,2025-02-05,662.91,680.972,662.91,680.52,
AXON,2025-02-06,680.99,684.36,661.0,677.4,
AXON,2025-02-07,680.0,689.54,677.93,679.24,
AXON,2025-02-10,684.32,686.08,672.0,677.85,
AXON,2025-02-11,678.475,678.475,656.715,669.26,
AXON,2025-02-12,656.49,668.567,652.26,665.08,
AXON,2025-02-13,667.75,671.44,655.069,664.7,
AXON,2025-02-14,662.57,686.17,648.85,683.41,
AXON,2025-02-18,694.02,715.99,691.86,710.01,
AXON,2025-02-19,700.0,705.1,592.76,593.42,
AXON,2025-02-20,581.0,584.0,521.655,541.81,
AXON,2025-02-21,551.655,551.655,510.534,513.22,
AXON,2025-02-24,516.51,524.35,496.19,499.73,
AXON,2025-02-25,498.0,502.243,480.87,497.01,
AXON,2025-02-26,584.95,600.99,558.21,572.4,
AXON,2025-02-27,578.874,578.874,521.7,525.51,
AXON,2025-02-28,526.97,531.36,514.04,529.04,
AXON,2025-03-03,532.84,541.75,520.67,526.13,
AXON,2025-03-04,513.87,543.41,504.01,528.28,
AXON,2025-03-05,529.75,538.98,526.15,534.96,
AXON,2025-03-06,522.585,526.19,495.0,499.31,
AXON,2025-03-07,500.0,527.94,500.0,526.4,
AXON,2025-03-10,508.005,521.12,501.85,515.59,
AXON,2025-03-11,518.26,539.175,509.0,526.64,
AXON,2025-03-12,539.13,560.725,539.13,557.89,
AXON,2025-03-13,558.81,569.358,530.22,534.56,
AXON,2025-03-14,544.55,557.41,544.55,556.26,
AXON,2025-03-17,552.72,563.7,549.83,554.82,
AXON,2025-03-18,548.7,550.34,532.52,539.99,
AXON,2025-03-19,544.51,571.4,542.65,568.11,
AXON,2025-03-20,560.16,572.82,556.495,558.41,
AXON,2025-03-21,550.63,562.28,544.34,560.0,
AXON,2025-03-24,571.99,574.155,561.0,572.52,
AXON,2025-03-25,569.21,579.675,567.625,577.18,
AXON,2025-03-26,575.57,578.2,553.56,559.06,
AXON,2025-03-27,554.78,557.0,540.27,550.65,
AXON,2025-03-28,550.4,550.4,529.0,534.95,
AXON,2025-03-31,522.67,528.83,507.38,525.91,
AXON,2025-04-01,521.59,542.985,520.93,541.2,
AXON,2025-04-02,530.69,560.3,530.69,558.42,
AXON,2025-04-03,532.67,553.6,528.76,539.69,
AXON,2025-04-04,511.26,520.0,486.1,497.68,
AXON,2025-04-07,469.8,524.82,469.8,502.94,
AXON,2025-04-08,522.71,536.525,497.99,504.68,
AXON,2025-04-09,503.15,567.036,497.99,559.35,
AXON,2025-04-10,543.85,564.36,534.22,551.09,
AXON,2025-04-11,546.89,569.0,541.519,567.98,
AXON,2025-04-14,578.0,590.0,571.715,574.83,
AXON,2025-04-15,580.37,582.99,578.42,578.42,
AXON,2025-04-16,572.01,581.105,564.68,571.85,
AXON,2025-04-17,578.2,578.2,556.39,559.53,
AXON,2025-04-21,550.0,556.63,531.22,541.93,
AXON,2025-04-22,551.32,561.811,546.0,555.52,
AXON,2025-04-23,576.4,594.462,576.4,576.76,
AXON,2025-04-24,576.15,593.836,571.0,590.67,
AXON,2025-04-25,590.72,603.98,590.72,603.78,
AXON,2025-04-28,605.66,614.0,594.54,602.46,
AXON,2025-04-29,602.5,612.03,598.81,611.13,
AXON,2025-04-30,591.01,614.76,585.49,613.12,
AXON,2025-05-01,617.96,627.73,613.02,621.1,
AXON,2025-05-02,636.0,637.514,626.46,628.16,
AXON,2025-05-05,624.99,631.158,620.99,621.4,
AXON,2025-05-06,608.97,611.835,597.561,601.67,
AXON,2025-05-07,602.01,607.599,594.52,601.82,
AXON,2025-05-08,647.87,698.265,647.87,686.83,
AXON,2025-05-09,684.01,697.39,677.61,684.59,"Dow Jones Futures Rise As Trump Says 80% China Tariff 'Seems Right'; Robinhood Leads 6 New Buys Stocks jumped Thursday on a Trump trade deal with the U.K., but pared gains on a report that Trump wants to hike taxes on the wealthy. Robinhood led new buys."
AXON,2025-05-12,693.06,693.06,667.0,693.06,"Axon president talks tariff impacts & full-year outlook Axon (AXON) beat expectations on both revenue and earnings in the first quarter, and also raised its full-year outlook. Axon president Josh Isner joins Market Domination to explain what drove the beat and why the company felt confident raising its full-year forecast. To watch more expert insights and analysis on the latest market action, check out more Market Domination here."
AXON,2025-05-13,695.0,732.166,694.71,724.77,
AXON,2025-05-14,725.0,729.205,715.589,728.53,"[""Axon Enterprise (NASDAQ:AXON) Shareholders Should Be Cautious Despite Solid Earnings Axon Enterprise, Inc.'s (NASDAQ:AXON) stock performed strongly after the recent earnings report. However, we think that investors should be cautious when interpreting the profit numbers. We've discovered 1 warning sign about Axon Enterprise. View them for free. To properly understand Axon Enterprise's profit results, we need to consider the US$268m gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And that's as you'd expect, given these boosts are described as 'unusual'. Axon Enterprise had a rather significant contribution from unusual items relative to its profit to March 2025. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Just as we noted the unusual items, we must inform you that Axon Enterprise received a tax benefit which contributed US$7.7m to the bottom line. This is meaningful because companies usually pay tax rather than receive tax benefits. We're sure the company was pleased with its tax benefit. However, the devil in the detail is that these kind of benefits only impact in the year they are booked, and are often one-off in nature. Assuming the tax benefit is not repeated every year, we could see its profitability drop noticeably, all else being equal. So while we think it's great to receive a tax benefit, it does tend to imply an increased risk that the statutory profit overstates the sustainable earnings power of the business. In its last report Axon Enterprise received a tax benefit which might make its profit look better than it really is on a underlying level. And on top of that, it also saw an unusual item boost its profit, suggesting that next year might see a lower profit number, if these events are not repeated. Considering all this we'd argue Axon Enterprise's profits probably give an overly generous impression of its sustainable level of profitability. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Every company has risks, and we've spotted 1 warning sign for Axon Enterprise you should know about. In this article we've looked at a number of factors that can impair the utility of profit numbers, and we've come away cautious. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""Goldman Sachs Adjusts Price Target on Axon Enterprise Inc to $830 From $730, Maintains Buy Rating Axon Enterprise Inc (AXON) has an average rating of overweight and mean price target of $713.46, acc""]"
AXON,2025-05-15,725.495,732.222,722.0,728.39,"[""Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It Axon Enterprise (AXON) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this maker of stun guns and body cameras have returned +27.4% over the past month versus the Zacks S&P 500 composite's +9% change. The Zacks Aerospace - Defense Equipment industry, to which Axon belongs, has gained 4.6% over this period. Now the key question is: Where could the stock be headed in the near term? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Axon is expected to post earnings of $1.47 per share for the current quarter, representing a year-over-year change of +22.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +81.8%. The consensus earnings estimate of $6.15 for the current fiscal year indicates a year-over-year change of +3.5%. This estimate has changed -30.8% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $7.55 indicates a change of +22.8% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +0.7%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Axon. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. For Axon, the consensus sales estimate for the current quarter of $641.21 million indicates a year-over-year change of +27.2%. For the current and next fiscal years, $2.65 billion and $3.23 billion estimates indicate +27.2% and +22% changes, respectively. Axon reported revenues of $603.63 million in the last reported quarter, representing a year-over-year change of +31%. EPS of $1.41 for the same period compares with $1.15 a year ago. Compared to the Zacks Consensus Estimate of $589.09 million, the reported revenues represent a surprise of +2.47%. The EPS surprise was +11.02%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon Stock Is In A Buy Zone After Reaching A New High Axon Enterprise stock broke out of a cup base and is in a buy zone. The company recently reported record quarterly revenue.""]"
AXON,2025-05-16,732.0,735.68,724.741,733.18,
AXON,2025-05-19,721.99,742.34,721.049,742.32,
AXON,2025-05-20,741.41,744.51,734.89,742.75,"Here’s Why Baron Discovery Fund Sold Axon Enterprise (AXON) Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the fund was down 6.17% (Institutional Shares), outperforming the -11.12% return for the Russell 2000 Growth Index. The market began strong in February but faded due to Trump's serious tariff enactment, which the market perceives as inflationary and slowing economic growth. The decline accelerated after April 2nd, causing fears of a trade war and global recession. In addition, please check the fund’s top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Axon Enterprise, Inc. (NASDAQ:AXON). Axon Enterprise, Inc. (NASDAQ:AXON) manufactures conducted energy devices (CEDs) under the TASER brand. The one-month return of Axon Enterprise, Inc. (NASDAQ:AXON) was 33.63%, and its shares gained 157.79% of their value over the last 52 weeks. On May 19, 2025, Axon Enterprise, Inc. (NASDAQ:AXON) stock closed at $742.32 per share with a market capitalization of $57.788 billion. Baron Discovery Fund stated the following regarding Axon Enterprise, Inc. (NASDAQ:AXON) in its Q1 2025 investor letter: A technician in a white coat testing an in-car system on a modern military vehicle. Axon Enterprise, Inc. (NASDAQ:AXON) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 64 hedge fund portfolios held Axon Enterprise, Inc. (NASDAQ:AXON) at the end of the fourth quarter compared to 46 in the third quarter. In the first quarter, Axon Enterprise, Inc.’s (NASDAQ:AXON) revenue grew 31% year-over-year to $604 million. While we acknowledge the potential of Axon Enterprise, Inc. (NASDAQ:AXON) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Axon Enterprise, Inc. (NASDAQ:AXON) and shared the list of stocks with consistent growth you want to buy. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey."
AXON,2025-05-21,738.0,748.8,730.01,735.38,
AXON,2025-05-22,734.07,735.0,722.03,723.75,"With 79% institutional ownership, Axon Enterprise, Inc. (NASDAQ:AXON) is a favorite amongst the big guns Institutions' substantial holdings in Axon Enterprise implies that they have significant influence over the company's share price The top 17 shareholders own 50% of the company Insiders have sold recently This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A look at the shareholders of Axon Enterprise, Inc. (NASDAQ:AXON) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 79% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. Let's delve deeper into each type of owner of Axon Enterprise, beginning with the chart below. View our latest analysis for Axon Enterprise Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Axon Enterprise does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Axon Enterprise's earnings history below. Of course, the future is what really matters. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Hedge funds don't have many shares in Axon Enterprise. The Vanguard Group, Inc. is currently the company's largest shareholder with 11% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 9.3% of common stock, and State Street Global Advisors, Inc. holds about 4.0% of the company stock. Additionally, the company's CEO Patrick Smith directly holds 3.9% of the total shares outstanding. A closer look at our ownership figures suggests that the top 17 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Axon Enterprise, Inc.. It is a very large company, and board members collectively own US$2.7b worth of shares (at current prices). It is good to see this level of investment. You can check here to see if those insiders have been buying recently. The general public-- including retail investors -- own 16% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Axon Enterprise is showing 2 warning signs in our investment analysis , you should know about... If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
AXON,2025-05-23,717.98,735.426,714.0,731.37,
AXON,2025-05-27,740.58,748.14,736.63,746.08,
AXON,2025-05-28,748.81,755.05,743.628,751.0,
AXON,2025-05-29,753.19,754.808,729.16,730.29,"Axon Enterprise, Inc (AXON) is Attracting Investor Attention: Here is What You Should Know Axon Enterprise (AXON) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this maker of stun guns and body cameras have returned +22.5%, compared to the Zacks S&P 500 composite's +6.7% change. During this period, the Zacks Aerospace - Defense Equipment industry, which Axon falls in, has gained 12.5%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Axon is expected to post earnings of $1.47 per share, indicating a change of +22.5% from the year-ago quarter. The Zacks Consensus Estimate has changed +66.7% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $6.15 points to a change of +3.5% from the prior year. Over the last 30 days, this estimate has changed -33.8%. For the next fiscal year, the consensus earnings estimate of $7.55 indicates a change of +22.8% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +0.3%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Axon is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of Axon, the consensus sales estimate of $641.21 million for the current quarter points to a year-over-year change of +27.2%. The $2.65 billion and $3.23 billion estimates for the current and next fiscal years indicate changes of +27.2% and +22%, respectively. Axon reported revenues of $603.63 million in the last reported quarter, representing a year-over-year change of +31%. EPS of $1.41 for the same period compares with $1.15 a year ago. Compared to the Zacks Consensus Estimate of $589.09 million, the reported revenues represent a surprise of +2.47%. The EPS surprise was +11.02%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-05-30,731.01,751.99,729.14,749.84,"Axon Enterprise (NASDAQ:AXON) Is Experiencing Growth In Returns On Capital Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. With that in mind, we've noticed some promising trends at Axon Enterprise (NASDAQ:AXON) so let's look a bit deeper. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Axon Enterprise, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.011 = US$53m ÷ (US$6.1b - US$1.3b) (Based on the trailing twelve months to March 2025). Thus, Axon Enterprise has an ROCE of 1.1%. Ultimately, that's a low return and it under-performs the Aerospace & Defense industry average of 11%. View our latest analysis for Axon Enterprise In the above chart we have measured Axon Enterprise's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Axon Enterprise . We're delighted to see that Axon Enterprise is reaping rewards from its investments and is now generating some pre-tax profits. About five years ago the company was generating losses but things have turned around because it's now earning 1.1% on its capital. In addition to that, Axon Enterprise is employing 596% more capital than previously which is expected of a company that's trying to break into profitability. We like this trend, because it tells us the company has profitable reinvestment opportunities available to it, and if it continues going forward that can lead to a multi-bagger performance. In summary, it's great to see that Axon Enterprise has managed to break into profitability and is continuing to reinvest in its business. And a remarkable 682% total return over the last five years tells us that investors are expecting more good things to come in the future. So given the stock has proven it has promising trends, it's worth researching the company further to see if these trends are likely to persist. One more thing to note, we've identified 2 warning signs with Axon Enterprise and understanding them should be part of your investment process. While Axon Enterprise isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
AXON,2025-06-02,755.0,765.0,742.8,758.57,
AXON,2025-06-03,761.0,766.26,750.0,759.07,"Axon Enterprise Trades Near 52-Week High: Should You Buy Now or Wait? Shares of Axon Enterprise, Inc. AXON have been showing impressive gains of late, trading close to its 52-week high of $765.00. The stock closed at $758.57 on Monday, 0.8% below the highest point. Shares of the conducted energy devices (CEDs) manufacturer have surged 27.7% year to date, outpacing the Zacks sub-industry’s and the S&P 500’s growth of 14.4% and 0.1%, respectively.The company’s peers, including Kratos Defense & Security Solutions, Inc. KTOS and Teledyne Technologies Incorporated TDY, have gained 44.2% and 6.5%, respectively, over the same time frame. Image Source: Zacks Investment Research The stock is also trading above both its 50-day and 200-day moving averages, indicating solid upward momentum and price stability. This reflects a positive market sentiment and confidence in the company's financial health and long-term prospects. Image Source: Zacks Investment Research The strongest driver of Axon Enterprise’s business at the moment is solid momentum in its Connected Devices segment. The segment’s revenues increased 26.1% year over year in the first quarter of 2025. The company continues to witness growing popularity for its next-generation TASER 10 products, whose shipment began in 2023. Growth in cartridge revenues, driven by the higher adoption of the TASER products, has been driving the segment’s performance.Axon Enterprise introduced its next-generation body-worn camera, Axon Body 4, in April 2023. With upgraded features such as a bi-directional communications facility and a point-of-view camera module option, this body camera is generating significant demand, thus bolstering the segment’s growth. Shipment of this body camera began in June 2023 and the customer response has been impressive so far.An increase in the aggregate number of users to the Axon Enterprise network is aiding the Software & Services segment. After witnessing a year-over-year 33.4% jump in 2024, revenues from the segment also increased 39% in the first quarter. Continued momentum in digital evidence management and increased demand for premium add-on features are driving the segment’s growth.Adoption of premium subscription plans also continues to rise as more customers recognize the value of enhanced capabilities. This ongoing expansion supports a growing base of annual recurring revenues (ARR). Strong customer alignment, broader adoption across sectors and continuous product innovation led Axon Enterprise to raise its guidance for 2025.AXON now expects revenues to be in the band of $2.60-$2.70 billion compared with $2.55-$2.65 billion expected earlier, indicating growth of approximately 27% year over year at the midpoint.The company’s strategic partnership with other companies enables it to expand its product offerings and customer base. In June 2024, Axon Enterprise entered into a partnership with Skydio (a leading U.S. drone manufacturer) to introduce a comprehensive line of drones in public safety that includes a scalable Drone as First Responder (DFR) solution. The combined offering will support the company’s DFR programs across its customer base and strengthen its market position in this category. Axon Enterprise’s trailing 12-month return on equity (ROE) is indicative of its growth potential. ROE for the trailing 12 months is 21.98%, higher than the industry’s 11.08%. This reflects the company’s efficient usage of shareholder funds. In comparison, ROE for its peers, Kratos Defense & Security Solutions and Teledyne Technologies, is pegged at 5.68% and 9.95%, respectively. Image Source: Zacks Investment Research Earnings estimates for AXON have moved north over the past 30 days, reflecting analysts’ optimism. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The Zacks Consensus Estimate for 2025 earnings is pegged at $6.15 per share, reflecting an increase of 0.7% in the past 30 days. The figure indicates year-over-year growth of 3.5%. The consensus mark for 2026 earnings is pinned at $7.55 per share, increasing 0.3% in the past 30 days. The figure also indicates year-over-year growth of 22.8%. Image Source: Zacks Investment Research Despite the positives, the escalating costs and expenses are a concern for Axon Enterprise’s bottom line. In 2024, its cost of sales soared 39% year over year on higher wages and stock-based compensation expenses. The metric, as a percentage of sales, was 40.4% in the year, up 160 basis points. The trend followed in first-quarter 2025, with the cost of sales increasing 18.2% year over year. Also, the company’s quarterly selling, general and administrative expenses increased 48% year over year. AXON’s lofty valuation remains another concern. The stock is trading at a forward 12-month price-to-earnings (P/E) ratio of 112.59X, significantly higher than the industry average of 42.04X. This elevated valuation could make the stock vulnerable to further pullbacks if market sentiment sours. In comparison with AXON’s valuation, Kratos Defense & Security and Teledyne Technologies are trading at 67.16X and 22.07X. Strong momentum across the Connected Devices and Software & Services segments, along with its investments in the AI space, drones and robotics, positions AXON favorably for impressive growth in the long run. Also, its collaboration with other companies to enhance public safety offerings and positive earnings estimates instill investor confidence. However, a few challenges, such as escalating operating expenses and premium valuation, are limiting this Zacks Rank #3 (Hold) company’s near-term prospects.While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains and provide a better entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-06-04,760.0,780.61,757.45,780.0,"The maker of Taser is the highest paid CEO, taking home $165 million—his new pay package and soaring stock made him a billionaire last year Axon CEO Rick Smith topped the highest-paid CEOs list, reportedly raking in $165 million through stock incentives at his company, selling Tasers, security cameras, drones, and VR training. Smith became a billionaire last year due to his compensation package, boasting a net worth of $2.5 billion. But the tragic backstory behind his $17 billion company, which has driven its business ethos, may be partly false. When imagining the highest paid CEOs, one might guess Jensen Huang leading Nvidia’s breakout success, or Elon Musk helming his multiple tech successes. But the top executive taking home the bacon is the boss of Tasers. Rick Smith, the co-founder and chief executive of Axon Enterprise, was the highest-paid CEO in 2024, a new report has revealed. According to the WSJ, the Axon CEO got a $165 million pay package last year—topping that of Larry Culp’s $89 million, Stephen Schwartzman’s $84 million, and Tim Cook’s $75 million. Smith’s total pay is a 999% increase from his compensation in 2023, which has shot up dramatically since Axon’s compensation revamp last year. The Axon leader has run the company since 1993, and became a billionaire last year after the company changed its CEO wage strategy. Smith said he was inspired to launch the company—which manufactures Tasers, and has expanded to security cameras, drones, and VR training largely for government agencies—after two of his high school friends were gunned down. He saw Taser devices as a less lethal way to help end gun violence. But family members of the victims have rejected his claims. While Smith tops this year’s list of highest-paid CEOs, he made headlines last year for rising to billionaire status with a highly lucrative pay strategy. Last year, Axon modeled its chief executive’s total compensation after Musk’s package at Tesla. Nearly all of his money lies in stock awards—which have been soaring over the past few years. Axon’s revenue had grown more than 30% for three years straight by 2024, reeling in a record-breaking annual net income of $377 million. The business’s shares also more than doubled in 2023, skyrocketing by over 50%. Combined with the rest of his pay package, he finally made the Bloomberg Billionaires index in 2024, boasting a net worth of $2.5 billion. This type of compensation is high-risk, but also high-reward—if Axon doesn’t meet its stock price, operations targets, and minimum service requirements for the years from 2024 to 2030, Smith doesn’t receive his full pay package. An Axon spokesperson told Fortune that the $165 million pay package “does not represent realized pay, but rather the potential value of the award if all performance milestones are fully achieved over the life of the program.” The WSJ reported that two of Axon’s seven performance targets had been met by March, according to the company’s filings. The Journal’s analysis used data from MyLogIQ, a provider of public-company data, and included CEOs on the job for at least a year at more than 400 S&P 500 companies reporting pay through mid-May for fiscal years ending after June 30, 2024 However, one thing is clear: Smith’s net worth has been ballooning as the company has grown. In 2019, he had a reported pay of $246 million catapulted by growing stocks. And over the past year, Axon’s stock price rose 160%, pushing its market cap to $50 billion, and making the shares underlying Smith’s rewards worth around $500 million. The main ethos of the $17 billion company is to save lives—Smith espouses Taser devices as a less lethal alternative to guns. He has repeatedly said he got the inspiration to found the company after two of his high school friends on his football team were shot and killed. But the validity of his tragic backstory has been called into question. Smith has long pushed this narrative, telling the story to crowds of law-enforcement officers; citing it in a filing with the U.S. Securities and Exchange Commission in 2020; and running it in company campaigns—including one celebrating Axon’s 30th anniversary. But an investigation from Reuters has found many of Smith’s claims appear to be false. It reported that Smith was not close friends with the deceased, and cited incorrect details about the incident. Axon spokesperson Alex Engel told Reuters that Smith got to know the slain young men through “team-related social events.” One of the victim’s fathers has accused Axon of running “a whole advertising campaign based on the murder of [his] son.” The victim’s sister also said Smith was “making money off of being a great liar.” Whether or not the CEO was close friends with the shooting victims, a spokesperson from the company told Fortune it stands by his account that the tragic event inspired “him to dedicate his life to reducing violence through technology.” “We’re proud of the mission-driven culture at Axon and remain focused on the work ahead,” a spokesperson said while taking aim at Reuters’ reporting, which they described as a”five-year crusade to falsely defame our company.” This story was originally featured on Fortune.com"
AXON,2025-06-05,780.53,793.24,773.99,788.46,"[""These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Broadcom Results Ahead As the stock market extends its rebound, it's important to watch the stocks most loved among equity analysts. Netflix and GE Aerospace are two of the seven best stocks where investors can find magnificent profit growth prospects. Of 54 analysts covering Netflix, 38 have buy or overweight ratings on the video streaming service."", ""10 stocks in this year\u2019s strongest sector expected to grow fastest through 2027 Let\u2019s begin with a table that might surprise you \u2014 here is how the 11 sectors of the S&P 500 have been performing, with dividends reinvested: You might need to scroll the table to see all of the data. I bought my mother-in-law a condo \u2014 and she took out a $30,000 car loan. Now she refuses to get a roommate. \u2018He failed in his fiduciary duty\u2019: My brother liquidated our mother\u2019s 401(k) for her nursing home. He claimed the rest. S&P 500 changes are imminent. Robinhood and these other stocks could join the index. I help my elderly mother every day and drive her to appointments. Can I recoup my costs from her estate? \u2018The situation is extreme\u2019: I\u2019m 65 and leaving my estate to only one grandchild. Can the others contest my will? The sectors are sorted by this year\u2019s performance. The full S&P 500 SPX is included at the bottom of the table. We have gone further back with the performance data to show how the sectors and the full index have performed through the pattern that included a broad decline in 2022, strong rallies in 2023 and 2024, and this year\u2019s volatility brought about in part by President Donald Trump\u2019s fluctuating trade and tariff policies. The industrial sector has been the best performer in the S&P 500 this year. It has also outperformed the index for the full period since the end of 2021, for the third-best performance behind the energy and information technology sectors. The industrial sector underperformed the full index during 2023 and 2024, but it held up much better than the index did during the down year of 2022. Now let\u2019s look at the sectors again, this time sorting by projected compound annual growth rates for revenue. The projections are based on consensus estimates among analysts polled by FactSet, weighted by companies\u2019 market capitalization: The industrial sector is at the top again, with the highest projected revenue CAGR from 2025 through 2025. The table also includes projected CAGR for earnings per share and weighted forward price-to-earnings ratios for the sectors and the full S&P 500. The industrial sector has the second highest expected EPS CAGR, after the energy sector. The industrial sector\u2019s forward P/E ratio is higher than that of the full index, but the premium may be warranted by the higher expected growth rates. There are easy ways to invest in all 78 companies in the S&P 500 industrial sector as a group using exchange-traded funds. The Industrial Select Sector SPDR ETF XLI holds all 78 stocks in the sector weighted by market cap, which means its largest holding, GE Aerospace GE, makes up 6.1% of the portfolio. Rounding out the top five holdings of the fund are RTX Corp. RTX, Uber Technologies Inc. UBER, Caterpillar Inc. CAT and Boeing Co. BA. The five together make up 21.7% of the portfolio. For a less concentrated sector approach, you can consider the Invesco S&P 500 Equal Weight Industrials ETF RSPN, which is rebalanced quarterly. Among the 78 companies in the S&P 500 industrial sector, consensus revenue estimates are available through 2027 for 74 of them. These are calendar-year estimates as adjusted by FactSet for companies whose fiscal reporting periods don\u2019t match the calendar. Here are the 10 companies in the S&P 500 industrial sector expected to increase revenue most rapidly from 2025 through 2027: The table also includes projected EPS CAGR for all of the companies except for Boeing, which is expected to post a net loss of $1.32 a share this year, with consensus estimates for positive EPS of $3.95 in 2026 and $6.50 in 2027. Leaving the 10 stocks in the same order, here is a summary of analysts\u2019 opinions: All but Deere DE are rated a buy or the equivalent by a majority of analysts polled by FactSet. Among the 26 analysts polled by FactSet who cover the company, 10 rate Deere a buy or the equivalent, while 15 have neutral ratings and one analyst rates the shares \u201cunderweight.\u201d You can see that for many of these stocks, the consensus price targets are below or close to the current share prices. Then again, these are 12-month price targets, and that might be a relatively short period for a committed long-term investor. Click the tickers for more about each company, index or ETF. Read: Tomi Kilgore\u2019s detailed guide to the information available on the MarketWatch quote page Don\u2019t miss: 10 nuclear stocks expected to rise as much as 94% after Meta-Constellation deal Never mind the tariffs and tantrums. The \u2018dual equity pain trade\u2019 means new highs for stocks. What\u2019s at stake if world\u2019s most powerful market finally buckles after decades-long U.S. debt splurge Circle\u2019s stock is having another big day. What the blockbuster IPO has meant for other cryptocurrency plays. \u2018I\u2019m not wildly wealthy, but I\u2019ve done well\u2019: I\u2019m 79 and have $3 million in assets. Should I set up 529 plans for my grandkids? \u2018I was pushed out of her life when she was 18\u2019: My estranged daughter, 29, misuses drugs. Should I leave her my Roth IRA?""]"
AXON,2025-06-06,794.92,798.16,784.636,791.85,"[""Why Is Axon (AXON) Up 14.8% Since Last Earnings Report? A month has gone by since the last earnings report for Axon Enterprise (AXON). Shares have added about 14.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Axon due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted 66.67% due to these changes. Currently, Axon has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Axon has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Axon belongs to the Zacks Aerospace - Defense Equipment industry. Another stock from the same industry, Mercury Systems (MRCY), has gained 13% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. Mercury Systems reported revenues of $211.36 million in the last reported quarter, representing a year-over-year change of +1.5%. EPS of $0.06 for the same period compares with -$0.26 a year ago. For the current quarter, Mercury Systems is expected to post earnings of $0.22 per share, indicating a change of -4.4% from the year-ago quarter. The Zacks Consensus Estimate has changed +6.1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Mercury Systems. Also, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report Mercury Systems Inc (MRCY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon Enterprise's Expenses are on the Rise: Will It Affect Margins? Axon Enterprise, Inc. AXON has been grappling with rising costs and expenses over time. AXON reported an uptick in costs and expenses during the first quarter of 2025. The company\u2019s cost of sales rose 18.2% year over year in the first quarter. The metric surged 39% year over year in 2024. AXON\u2019s selling, general and administrative (SG&A) expenses also increased 48% year over year in the first quarter. The same rose 49.8% year over year in 2024. Key factors behind the company\u2019s high costs and SG&A expenses included business integration activities, increased headcount, higher wages and stock-based compensation expense.Despite the rising costs, in the first quarter, AXON\u2019s adjusted gross margin increased 40 basis points to 63.6%. Also, its adjusted EBITDA margin increased to 25.7% from 23.7% in the year-ago period. The improvement in margins was driven by higher revenues generated from robust sales for TASER 10, Axon Body 4 and platform sensor products. The company reported revenues of $603.6 million in the quarter, which increased 31.3% year over year. Axon Enterprise\u2019s focus on effective cost management and revenue improvement is likely to expand its margin performance. For 2025, AXON expects adjusted EBITDA in the range of $650-$675 million, implying an adjusted EBITDA margin of approximately 25%.It's worth noting that, effective first-quarter 2025, Axon Enterprise realigned its business segments. This realignment is expected to enhance the company\u2019s visibility into segment-specific performance and enable it to effectively manage its costs. This strategic move will likely support Axon Enterprise\u2019s ongoing margin improvement and operational efficiency. Among its major peers, Kratos Defense & Security Solutions, Inc. KTOS is facing cost pressure. Its cost of sales increased 11.1% in the first quarter of 2025. Kratos\u2019 SG&A expenses rose 4.8%, year over year in the same period. Kratos\u2019 gross margin declined 30 basis points to 24.3% in the first quarter.The escalating costs and expenses are also a concern for Teledyne Technologies Incorporated TDY. Teledyne\u2019s cost of sales rose 7.8% year over year in the first quarter of 2025. The company\u2019s SG&A expenses also increased 6.5% year over year. Teledyne\u2019s gross margin declined 320 basis points to 42.7% in the same period. Shares of Axon Enterprise have surged 181.1% in the past year compared with the industry\u2019s growth of 20.8%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 1,195.30X above the industry\u2019s average of 45.34X. Axon carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s 2025 earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-06-09,795.83,806.64,775.855,783.8,
AXON,2025-06-10,778.54,787.61,751.25,762.66,"[""Daily Spotlight: Bond Spreads Tick Wider Treasury bond yields have been rising in recent weeks as concerns have mounted over the White House's fiscal policies and the high level of federal debt. Corporate bond yields have headed higher as well, and at a faster rate than Treasury yields. As a consequence, spreads between corporate and Treasury bond yields have widened, though they remain tighter than historical averages. For example, the spread between AAA-rated corporate bonds and 10-year government bonds in May was 114 basis points (bps), up from 52 bps in December but still lower than the historical average of 122 bps. The gap between the government 10-year bond yield and a BAA-rated bond (still investment grade) in May was 189 basis points, below the historical average spread of 228 bps but wider by about 50 bps since the presidential election. We watch these spreads closely for several reasons. From an asset-allocation standpoint, tight corporate bond spreads signal that corporate bond prices are above historical fair value, and we may look to under-weight the segment in our model portfolios. From a broad market standpoint, the changes in the spreads offer clues to the bond market's view of corporate financial strength, which appears to be turning somewhat cautious given the widening spreads. Lately, bond investors are demanding higher interest payments to account for potential default risk. Indeed, bond rating company Moody's recently concluded that the average risk of default for U.S. public companies reached a post-global financial crisis high of 9.2% at the end of 2024 and is predicted to remain elevated throughout 2025."", ""Wall Street Analysts Look Bullish on Axon (AXON): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Axon Enterprise (AXON). Axon currently has an average brokerage recommendation (ABR) of 1.43, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 15 brokerage firms. An ABR of 1.43 approximates between Strong Buy and Buy. Of the 15 recommendations that derive the current ABR, 10 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 66.7% and 20% of all recommendations. Check price target & stock forecast for Axon here>>> While the ABR calls for buying Axon, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every \""Strong Sell\"" recommendation, brokerage firms assign five \""Strong Buy\"" recommendations. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. In terms of earnings estimate revisions for Axon, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $6.34. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Axon. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Axon. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Jim Cramer Notes Axon (AXON) is a \u201cNew High Natural\u201d We recently published a list of Jim Cramer Recently Looked at These 18 Stocks. In this article, we are going to take a look at where Axon Enterprise, Inc. (NASDAQ:AXON) stands against other stocks that Jim Cramer discusses. While discussing Axon Enterprise, Inc. (NASDAQ:AXON), Cramer said that it has a \u201cgreat software business.\u201d Axon (NASDAQ:AXON) produces TASER-branded conducted energy devices and provides a range of hardware, cloud software, and mobile tools that support public safety operations, evidence management, and real-time data integration across various industries. In a February episode of Mad Money, Cramer remarked: A technician in a white coat testing an in-car system on a modern military vehicle. Overall, AXON ranks 15th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of AXON as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.""]"
AXON,2025-06-11,764.67,782.785,746.9,778.36,
AXON,2025-06-12,773.16,781.12,772.605,775.2,"[""Stock Market Adjusts to Tariff Turmoil The Portfolio Selector features the Argus Focus List, a group of 30 \""best idea\"" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research\u2019s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Texas Instruments Inc. (TXN); Western Digital Corp. (WDC); DoorDash Inc (DASH); Axon Enterprise Inc (AXON) and the Focus List deletions are Applied Materials Inc. (AMAT); L3Harris Technologies Inc (LHX); Toll Brothers Inc. (TOL); United Therapeutics Corp (UTHR)."", ""Will Strong TASER Demand Continue to Guide Axon's Connected Devices Unit? Axon Enterprise, Inc. AXON is expanding its footprint in the public safety technology space, with the Connected Devices segment playing an important role in overall growth. In the first quarter of 2025, the segment\u2019s revenues surged 26.1% year over year, reflecting strong momentum across its product lines. The ongoing demand for TASER devices is the core component of the segment\u2019s success. AXON continues to benefit from the rising popularity of its next-generation TASER 10 products, which began shipping in 2023. Revenues from TASER devices increased $30.9 million year over year in the first quarter, driven by the higher volume of TASER 10 handles and cartridges. Solid demand for virtual reality training services and counter drone equipment continues to support the segment\u2019s growth. Axon launched the next-generation body-worn camera, Axon Body 4, in April 2023, which has added momentum as well. Equipped with enhanced features such as a bi-directional communication facility and a point-of-view camera module option, the product is generating strong customer demand, thus bolstering the segment\u2019s growth. The Connected Devices unit is also benefiting from increased warranty revenues from a higher volume of deployed devices in the field. With rising global security concerns, including increasing instances of terrorism and criminal activities, demand for advanced public safety technologies is expected to remain strong. These trends are likely to support the ongoing demand for Axon\u2019s Connected Devices portfolio, positioning the segment well for sustained momentum in the quarters ahead. Among its major peers, Kratos Defense & Security Solutions, Inc.\u2019s KTOS Kratos Government Solutions segment reported net revenues of $239.5 million in the first quarter of 2025, increasing 10% on a year-over-year basis. Kratos generated 79.1% of its total revenues from this segment in the quarter. The revenue improvement for Kratos\u2019 segment can be attributed to notable growth in its C5ISR, Defense Rocket Support and Microwave Products businesses. Teledyne Technologies Incorporated\u2019s TDY Digital Imaging segment\u2019s first-quarter 2025 revenues increased 2.2% year over year to $757 million. This was driven by higher sales of Teledyne\u2019s commercial infrared imaging components and surveillance systems. Teledyne derived 52.2% of its total revenues from this segment during the quarter. Shares of Axon have surged 165.2% in the past year compared with the industry\u2019s growth of 42.1%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 1,156.40X above the industry\u2019s average of 46.32X. Axon carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s second-quarter 2025 earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Allegion Stock Earns Relative Strength Rating Upgrade Allegion stock had its Relative Strength (RS) Rating upgraded from 65 to 72 Wednesday \u2014 a welcome improvement, but still short of the 80 or better score you look for. See if Allegion stock can continue to show renewed price strength and hit that benchmark. Is Allegion Stock A Buy?"", ""Axon Enterprise Insiders Sell US$78m Of Stock, Possibly Signalling Caution In the last year, many Axon Enterprise, Inc. (NASDAQ:AXON) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, if numerous insiders are selling, shareholders should investigate more. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The Chief Product Officer & CTO, Jeffrey Kunins, made the biggest insider sale in the last 12 months. That single transaction was for US$26m worth of shares at a price of US$613 each. That means that even when the share price was below the current price of US$778, an insider wanted to cash in some shares. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 32% of Jeffrey Kunins's stake. Insiders in Axon Enterprise didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction! See our latest analysis for Axon Enterprise I will like Axon Enterprise better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying. The last quarter saw substantial insider selling of Axon Enterprise shares. In total, insiders sold US$24m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap. I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that Axon Enterprise insiders own 4.7% of the company, worth about US$2.8b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. Insiders sold Axon Enterprise shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. But since Axon Enterprise is profitable and growing, we're not too worried by this. It is good to see high insider ownership, but the insider selling leaves us cautious. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To assist with this, we've discovered 2 warning signs that you should run your eye over to get a better picture of Axon Enterprise. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""Axon Enterprise (AXON) Increases Despite Market Slip: Here's What You Need to Know Axon Enterprise (AXON) closed the latest trading day at $778.36, indicating a +2.06% change from the previous session's end. The stock outpaced the S&P 500's daily loss of 0.27%. Shares of the maker of stun guns and body cameras witnessed a gain of 5.23% over the previous month, trailing the performance of the Aerospace sector with its gain of 8.18%, and the S&P 500's gain of 6.9%. The upcoming earnings release of Axon Enterprise will be of great interest to investors. The company's earnings per share (EPS) are projected to be $1.54, reflecting a 28.33% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $641.21 million, indicating a 27.2% upward movement from the same quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $6.34 per share and a revenue of $2.65 billion, representing changes of +6.73% and +27.17%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Axon Enterprise. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Axon Enterprise currently has a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Axon Enterprise has a Forward P/E ratio of 120.32 right now. This valuation marks a premium compared to its industry average Forward P/E of 36.19. We can also see that AXON currently has a PEG ratio of 4.24. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Aerospace - Defense Equipment industry stood at 2.75 at the close of the market yesterday. The Aerospace - Defense Equipment industry is part of the Aerospace sector. This industry currently has a Zacks Industry Rank of 30, which puts it in the top 13% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-06-13,771.81,786.775,767.6,780.63,
AXON,2025-06-16,786.37,797.5,779.28,780.61,
AXON,2025-06-17,776.39,782.751,770.201,777.54,"Here's Why We Think Axon Enterprise (NASDAQ:AXON) Might Deserve Your Attention Today Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Axon Enterprise (NASDAQ:AXON). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. In the last three years Axon Enterprise's earnings per share took off; so much so that it's a bit disingenuous to use these figures to try and deduce long term estimates. Thus, it makes sense to focus on more recent growth rates, instead. Axon Enterprise boosted its trailing twelve month EPS from US$3.53 to US$4.26, in the last year. This amounts to a 21% gain; a figure that shareholders will be pleased to see. Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. On the revenue front, Axon Enterprise has done well over the past year, growing revenue by 33% to US$2.2b but EBIT margin figures were less stellar, seeing a decline over the last 12 months. So if EBIT margins can stabilize, this top-line growth should pay off for shareholders. The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image. View our latest analysis for Axon Enterprise Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for Axon Enterprise. We would not expect to see insiders owning a large percentage of a US$61b company like Axon Enterprise. But we are reassured by the fact they have invested in the company. Notably, they have an enviable stake in the company, worth US$2.8b. This suggests that leadership will be very mindful of shareholders' interests when making decisions! One positive for Axon Enterprise is that it is growing EPS. That's nice to see. If that's not enough on its own, there is also the rather notable levels of insider ownership. These two factors are a huge highlight for the company which should be a strong contender your watchlists. You should always think about risks though. Case in point, we've spotted 2 warning signs for Axon Enterprise you should be aware of. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of companies which have demonstrated growth backed by significant insider holdings. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
AXON,2025-06-18,775.85,779.89,761.9,770.79,"Is Axon Enterprise Stock Outperforming the Nasdaq? Scottsdale, Arizona-based Axon Enterprise, Inc. (AXON) is a technology provider in global public safety for law enforcement, military, and civilians. Valued at a market cap of $60.5 billion, the company operates through two segments, Software and Sensors, and TASER. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Axon Enterprise fits this description perfectly. The company is known for its TASER energy weapons. It also provides body-worn cameras, digital evidence management systems, and AI-powered software through its cloud-based Axon Cloud platform. Trump Is Giving Tesla’s Robotaxis a Leg Up Ahead of June 22. Should You Buy TSLA Stock Now? Dear Nvidia Stock Fans, Mark Your Calendars for July 16 The Trump Family Is Betting Big on Mobile Phones. Should Apple Stock Investors Be Worried? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. AXON stock has declined 3.6% from its 52-week high of $806.64 recorded on June 9. AXON Enterprise stock has surged 40.1% over the past three months, notably surpassing the broader Nasdaq Composite ($NASX), which increased 9.6% during the same period. In the longer term, AXON stock is up 30.8% on a YTD basis, significantly outperforming NASX's 1.1% return. Additionally, shares of AXON have soared 161.7% over the past 52 weeks, compared to NASX’s 9.3% gain over the same period. Despite a few fluctuations, the stock has been trading above its 50-day and 200-day moving averages since last year. Shares of AXON climbed 14.1% following its better-than-expected Q1 2025 results on May 7. It posted record quarterly revenue of $603.6 million, up 31.3% year-over-year, significantly beating Wall Street expectations. The strong performance was driven by growth in Software & Services, robust adoption of TASER 10 and Axon Body 4, and rising demand for its platform sensors. Adjusted EPS came in at $1.41, marking a 22.6% increase from the year-ago quarter and surpassing consensus estimates. Encouraged by the momentum, AXON also raised its full-year 2025 revenue guidance to a range of $2.6 billion to $2.7 billion, up from its previous projection of $2.55 billion to $2.65 billion. Compared to its rival, L3Harris Technologies, Inc. (LHX) has lagged behind AXON stock. LHX stock has increased 13.7% over the past 52 weeks and 19.3% on a YTD basis. Due to AXON’s strong performance, analysts are strongly optimistic about its prospects. Among the 15 analysts covering the stock, there is a consensus rating of “Strong Buy,” and it is currently trading above the mean price target of $735. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com"
AXON,2025-06-20,780.28,781.0,767.08,777.32,
AXON,2025-06-23,773.48,791.38,767.318,783.24,"[""Axon Enterprise vs. Kratos: Which Defense & Security Stock has Greater Upside? Axon Enterprise, Inc. AXON and Kratos Defense & Security Solutions, Inc. KTOS are two prominent names operating in the aerospace and defense equipment industry. As rivals, both companies are engaged in producing highly engineered public security and defense solutions in the United States and internationally. Both companies have been enjoying significant growth opportunities in the public safety and defense industries on account of growing instances of terrorism and criminal activities and the expansionary U.S. budgetary policy. Let\u2019s take a closer look at their fundamentals, growth prospects and challenges. Axon Enterprise has been witnessing persistent strength in its Connected Devices segment. The company continues to witness growing popularity for its next-generation TASER 10 products, whose shipment began a couple of years back. Growth in cartridge revenues, supported by the higher adoption of the TASER products, has also been driving the segment\u2019s performance. The segment\u2019s revenues increased 26.1% year over year in the first quarter of 2025. Axon Enterprise introduced its next-generation body-worn camera, Axon Body 4, in 2023. With upgraded features such as a bi-directional communications facility and a point-of-view camera module option, this body camera is generating significant demand, thus bolstering the segment\u2019s growth. The Software & Services segment has been benefiting from solid growth in the aggregate number of users to the Axon Enterprise network. After witnessing a year-over-year 33.4% jump in 2024, revenues from the segment also increased 39% in the first quarter. The segment\u2019s growth has been bolstered by continued momentum in digital evidence management and increased demand for premium add-on features. The company remains focused on strategic partnerships to expand its product offerings and customer base. In June 2024, Axon Enterprise entered into a partnership with Skydio (a leading U.S. drone manufacturer) to introduce a comprehensive line of drones in public safety that includes a scalable Drone as First Responder (DFR) solution. The combined offering supports AXON\u2019s DFR programs and strengthens its market position in this category. On the flip side, escalating costs and expenses are a concern for Axon Enterprise\u2019s bottom line. In the first quarter, its cost of sales and SG&A expenses increased 18.2% and 48%, respectively, year over year. The company incurred high costs and expenses related to business integration activities, an increase in headcount and higher wages and stock-based compensation expenses. Kratos is the primary unmanned aerial target drone system provider for the U.S. Air Force, Navy, Army and numerous allied foreign defense agencies. To enhance its footprint in this space, the company has been making significant efforts. It is currently under contract with a U.S. Government Agency for a Next Generation Target Drone (5GAT). In January 2025, Kratos obtained a $34.8 million contract for Valkyrie Mission System Integration from the U.S. Marine Corps to support the XQ-58A UAS mission systems and subsystems. In March 2025, the company won a $59.3 million contract for additional 70 BQM-177A Surface Launched Aerial Targets (SSAT). The U.S. Navy also awarded KTOS a contract worth nearly $19.1 million for contractor logistical support and engineering services for the BQM-177A Subsonic Aerial Target System. With it being the sole source provider of the BQM-177A to the U.S. Navy, such contract wins reflect the solid demand that Kratos enjoys in the unmanned aerial market. Apart from manufacturing unmanned aerial drone systems, Kratos also focuses on expanding its product portfolio with other products, especially in hypersonics. In January 2025, the company won a five-year contract worth $1.45 billion for the Multi-Service Advanced Capability Hypersonic Test Bed (MACH-TB) 2.0. This constituted the largest single award in its history. Such a diverse product portfolio ushers in solid order flows for the company, which, in turn, resulted in a robust backlog worth $1.51 billion at the end of the first-quarter 2025. This implies solid revenue generation prospects for the company. KTOS expects to recognize nearly 48% of the total backlog as revenues in 2025, an additional 25% in 2026 and the balance thereafter. However, Kratos continues to be affected by supply-chain disruptions that have been plaguing industries across the globe. This might impact the company\u2019s production and top line in the quarters ahead. In the past six months, Axon Enterprise shares have risen 23.2%, while Kratos stock has gained 61.7%. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s 2025 sales and earnings per share (EPS) implies year-over-year growth of 27.2% and 6.6%, respectively. Although the EPS estimates for 2025 have decreased over the past 30 days, the estimate for 2026 has increased. Image Source: Zacks Investment Research The Zacks Consensus Estimate for KTOS\u2019 2025 sales implies growth of 12.8% year over year, while the EPS estimate implies breakeven level. KTOS\u2019 EPS estimates have been stable for 2025, while the same is trending northward for 2026 over the past 30 days. Image Source: Zacks Investment Research Kratos is trading at a forward 12-month price-to-earnings ratio of 74.74X, while Axon Enterprise\u2019s forward earnings multiple sits much higher at 109.34X. Image Source: Zacks Investment Research Axon Enterprise and Kratos have a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Axon Enterprise\u2019s strength in both the segments has been dented by rising costs and expenses, which might affect its margins and profitability. Also, AXON\u2019s expensive valuation warrants a cautious approach for existing investors. In Contrast, Kratos\u2019 growth prospects remain solid, backed by the U.S. administration\u2019s stable funding provisions. Additionally, KTOS\u2019 attractive valuation is more appealing and its upwardly revised earnings estimates instill confidence. Given these factors, KTOS seems a better pick for investors than AXON currently. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""The Best Stocks to Invest $50,000 in Right Now Meta has a wide moat in social media and digital advertising and a track record of steady growth. Axon has built a unique business in law enforcement technology. 10 stocks we like better than Axon Enterprise \u203a If you have $50,000 to invest, you're in a good position. That's enough to make a significant difference for your retirement or whatever else you're investing for. With $50,000 to invest, you'll likely want to find stocks that can deliver growth, but with relatively low risk. Luckily, there are a number of stocks available on the market that embody those characteristics. Keep reading to see two of them. Meta Platforms (NASDAQ: META) may be the best example of a business that can burn through billions in cash on a side project, but is still overwhelmingly successful. Meta has lost more than $60 billion on its metaverse and artificial intelligence (AI)-focused division, Reality Labs. But the success of its advertising business and the growth of its family of apps division has more than made up for it. Over the last three years, the stock is up more than 300%. It's fended off a threat from TikTok with its Reels. Meta's AI tools are also helping the company better monetize its ad inventory and help its advertisers use AI for images and ad copy. Meta effectively has a duopoly in digital advertising with Alphabet, but it's outgrowing its large rival. In the first quarter, revenue jumped 16% to $42.3 billion, and Meta reported an operating profit of $17.5 billion, or an operating margin of 41%. The company benefits from a dream business model where it sells ads on user-generated content, and has more than 3 billion daily active users across its apps, primarily including Facebook and Instagram. Meta's wide-moat advantage in digital advertising and social media isn't likely to go anywhere, and the business should continue to experience solid growth as long as the economy is healthy. Meta is also a top AI competitor. Meta AI's chatbot now has nearly 1 billion users, giving it the biggest user base of any AI platform. The company's deal with Scale AI should also accelerate its AI ambitions. Finally, the stock trades at a price-to-earnings ratio of 27, which looks like a great valuation for a company growing at its pace. Overall, Meta combines solid growth, wide profit margins, a strong competitive advantage, and a good valuation, making it a great stock for a large investment. The company looks like a good bet to continue outperforming the market at relatively low risk. Axon Enterprise (NASDAQ: AXON) may not be a household name the way Meta is, but it similarly dominates its niche of law enforcement technology. Axon makes Taser electrical weapons, body and dashboard cameras, and software systems that help law enforcement agencies make use of the data the cameras generate. The complementary hardware and software products have created a strong moat for Axon, and its stock has gained more than 2,000% over the last decade. These days, Axon is expanding beyond its traditional core in law enforcement into private sector businesses like packaged delivery companies. In fact, its biggest contract in 2024 was with a large logistics company, which demonstrates that there are applications for its camera systems beyond law enforcement. The company also released a generative-AI product called Draft One, which writes first drafts of police reports based on camera footage. The product has been well-received by law enforcement as it's saving valuable time, allowing officers to focus on more pressing matters. Axon continues to deliver strong growth, with revenue up 31% to $604 million in the first quarter. It reported adjusted net income of $115 million, showing that it's growing fast and has wide profit margins. The company also raised its full-year revenue guidance from $2.55 billion to $2.65 billion to $2.6 billion to $2.7 billion, showing confidence in its growth the rest of the year. With little direct competition across its product portfolio, Axon looks poised for more long-term tailwinds due to its innovation and growth in new markets like logistics. Before you buy stock in Axon Enterprise, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now\u2026 and Axon Enterprise wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you\u2019d have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you\u2019d have $881,731!* Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 994% \u2014 a market-crushing outperformance compared to 172% for the S&P 500. Don\u2019t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks \u00bb *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jeremy Bowman has positions in Axon Enterprise and Meta Platforms. The Motley Fool has positions in and recommends Alphabet, Axon Enterprise, and Meta Platforms. The Motley Fool has a disclosure policy. The Best Stocks to Invest $50,000 in Right Now was originally published by The Motley Fool""]"
AXON,2025-06-24,785.0,799.66,758.24,794.25,
AXON,2025-06-25,800.0,801.0,780.66,785.07,"[""Robert W. Baird Maintains a Buy Rating on Axon Enterprise (AXON), Keeps the PT Axon Enterprise, Inc. (NASDAQ:AXON) is one of the 12 Best Stocks to Buy and Hold for the Long Term. On June 8, analyst William Power of Robert W. Baird maintained a Buy rating on Axon Enterprise, Inc. (NASDAQ:AXON) with a price target of $800. The maintained bullish sentiment comes after President Donald Trump signed two major executive orders on June 6, aimed at significantly enhancing the commercial use of drones in the United States. William Power noted, that the executive orders to enhance the commercial use of drones significantly improve the strategic position of Axon Enterprise, Inc. (NASDAQ:AXON). This becomes more relevant considering the company\u2019s strategic partnership with Skydio to deliver scalable drones as first responders for public safety. Power believes the drone market is expected to grow significantly as regulations will allow more drone operations. A technician in a white coat testing an in-car system on a modern military vehicle. Additionally, Axon Enterprise, Inc. (NASDAQ:AXON) acquired Dedrone last year which also strengthens its capabilities in drone technology and provides its field importance. According to analyst Power, the drone and robotics industries are valued to be worth more than $20 billion, thereby presenting an opportunity for the company to deploy more DFR programs. Axon Enterprise, Inc. (NASDAQ:AXON) is a global technology company focused on public safety. It manufactures and provides various products including TASER energy devices, body and in-car cameras, and cloud-based software for managing digital evidence. While we acknowledge the potential of AXON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None."", ""Why Axon Enterprise (AXON) Outpaced the Stock Market Today In the latest close session, Axon Enterprise (AXON) was up +1.41% at $794.25. This change outpaced the S&P 500's 1.11% gain on the day. On the other hand, the Dow registered a gain of 1.19%, and the technology-centric Nasdaq increased by 1.43%. The stock of maker of stun guns and body cameras has risen by 7.09% in the past month, leading the Aerospace sector's gain of 6.17% and the S&P 500's gain of 3.92%. The investment community will be closely monitoring the performance of Axon Enterprise in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $1.54, reflecting a 28.33% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $641.21 million, reflecting a 27.2% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $6.34 per share and revenue of $2.65 billion, indicating changes of +6.73% and +27.17%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for Axon Enterprise. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Axon Enterprise is carrying a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Axon Enterprise has a Forward P/E ratio of 123.57 right now. For comparison, its industry has an average Forward P/E of 37.74, which means Axon Enterprise is trading at a premium to the group. We can also see that AXON currently has a PEG ratio of 4.35. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. AXON's industry had an average PEG ratio of 2.84 as of yesterday's close. The Aerospace - Defense Equipment industry is part of the Aerospace sector. This industry, currently bearing a Zacks Industry Rank of 53, finds itself in the top 22% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-06-26,791.81,805.48,791.81,804.4,"[""Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It Axon Enterprise (AXON) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this maker of stun guns and body cameras have returned +4.5% over the past month versus the Zacks S&P 500 composite's +5.1% change. The Zacks Aerospace - Defense Equipment industry, to which Axon belongs, has gained 9.5% over this period. Now the key question is: Where could the stock be headed in the near term? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Axon is expected to post earnings of $1.54 per share for the current quarter, representing a year-over-year change of +28.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged. For the current fiscal year, the consensus earnings estimate of $6.34 points to a change of +6.7% from the prior year. Over the last 30 days, this estimate has remained unchanged. For the next fiscal year, the consensus earnings estimate of $7.97 indicates a change of +25.7% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +0.1%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Axon. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of Axon, the consensus sales estimate of $641.21 million for the current quarter points to a year-over-year change of +27.2%. The $2.65 billion and $3.23 billion estimates for the current and next fiscal years indicate changes of +27.2% and +22%, respectively. Axon reported revenues of $603.63 million in the last reported quarter, representing a year-over-year change of +31%. EPS of $1.41 for the same period compares with $1.15 a year ago. Compared to the Zacks Consensus Estimate of $589.09 million, the reported revenues represent a surprise of +2.47%. The EPS surprise was +11.02%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon's $1.75B Senior Notes Raise: Can Growth Plans Deliver Returns? Axon Enterprise, Inc. AXON is leveraging the debt markets to support its next phase of growth. In the first quarter of 2025, the company issued $1.75 billion in senior notes to bolster its long-term growth. The debt raise, split between $1.0 billion of 6.125% notes due in 2030 and $750 million of 6.250% notes due in 2033, significantly boosted its liquidity. In the first quarter, AXON reported cash and cash equivalents of $1.09 billion and short-term investments of $1.1 billion. A portion of the proceeds was used to retire approximately $403 million of Axon\u2019s 0.50% convertible notes due in 2027. This reduced the future dilution risk and simplified the company\u2019s capital structure. However, AXON reported a $28.7 million debt inducement expense in the first quarter. Axon\u2019s interest expense also rose to $7.8 million in the quarter, up approximately 329% on a year-over-year basis. Axon plans to use the capital to develop AI-powered products, bolster its global reach and expand infrastructure projects. These initiatives are intended to drive recurring revenues and deepen customer relationships across law enforcement, corrections and enterprise sectors. The shift in AXON\u2019s capital structure shows its confidence in a multi-year growth strategy and offers flexibility in a volatile macro and regulatory environment. How the company manages these initiatives will shape the next stage of its growth story. Among its major peers, Kratos Defense & Security Solutions, Inc.\u2019s KTOS long-term debt at the end of the first quarter amounted to $236 million. Kratos\u2019 current debt was nil. Hence, Kratos\u2019 cash reserve was higher than the long-term debt as well as the current debt levels. Teledyne Technologies Incorporated\u2019s TDY cash and cash equivalents as of March 30, 2025, amounted to $0.46 billion. Teledyne\u2019s long-term debt, as of the same date, was $2.97 billion, which came in much higher than its cash reserve. However, Teledyne\u2019s current debt of $0.2 million as of March 30, 2025, was almost insignificant when compared with its cash balance. Shares of Axon have surged 163.1% in the past year compared with the industry\u2019s growth of 46.4%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 1,114.20X, above the industry\u2019s average of 47.19X. Axon carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s second-quarter 2025 earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Should You Invest in Axon (AXON) Based on Bullish Wall Street Views? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's take a look at what these Wall Street heavyweights have to say about Axon Enterprise (AXON) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Axon currently has an average brokerage recommendation (ABR) of 1.43, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 15 brokerage firms. An ABR of 1.43 approximates between Strong Buy and Buy. Of the 15 recommendations that derive the current ABR, 10 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 66.7% and 20% of all recommendations. Check price target & stock forecast for Axon here>>> The ABR suggests buying Axon, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every \""Strong Sell\"" recommendation, brokerage firms assign five \""Strong Buy\"" recommendations. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. In terms of earnings estimate revisions for Axon, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $6.34. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Axon. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Axon. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-06-27,804.85,820.83,802.284,818.92,"Are Strong Financial Prospects The Force That Is Driving The Momentum In Axon Enterprise, Inc.'s NASDAQ:AXON) Stock? Axon Enterprise's (NASDAQ:AXON) stock is up by a considerable 50% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Particularly, we will be paying attention to Axon Enterprise's ROE today. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits. Trump has pledged to ""unleash"" American oil and gas and these 15 US stocks have developments that are poised to benefit. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Axon Enterprise is: 13% = US$332m ÷ US$2.6b (Based on the trailing twelve months to March 2025). The 'return' is the yearly profit. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.13 in profit. Check out our latest analysis for Axon Enterprise We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or ""retain"", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. At first glance, Axon Enterprise seems to have a decent ROE. Even when compared to the industry average of 12% the company's ROE looks quite decent. Consequently, this likely laid the ground for the impressive net income growth of 63% seen over the past five years by Axon Enterprise. We reckon that there could also be other factors at play here. Such as - high earnings retention or an efficient management in place. Next, on comparing with the industry net income growth, we found that Axon Enterprise's growth is quite high when compared to the industry average growth of 14% in the same period, which is great to see. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about Axon Enterprise's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. Axon Enterprise doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above. On the whole, we feel that Axon Enterprise's performance has been quite good. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
AXON,2025-06-30,818.75,830.21,816.855,827.4,
AXON,2025-07-01,825.89,829.5,765.5,775.55,"[""Returns On Capital Are Showing Encouraging Signs At Axon Enterprise (NASDAQ:AXON) There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. So on that note, Axon Enterprise (NASDAQ:AXON) looks quite promising in regards to its trends of return on capital. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. To calculate this metric for Axon Enterprise, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) \u00f7 (Total Assets - Current Liabilities) 0.011 = US$53m \u00f7 (US$6.1b - US$1.3b) (Based on the trailing twelve months to March 2025). So, Axon Enterprise has an ROCE of 1.1%. Ultimately, that's a low return and it under-performs the Aerospace & Defense industry average of 11%. View our latest analysis for Axon Enterprise Above you can see how the current ROCE for Axon Enterprise compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Axon Enterprise . The fact that Axon Enterprise is now generating some pre-tax profits from its prior investments is very encouraging. The company was generating losses five years ago, but now it's earning 1.1% which is a sight for sore eyes. Not only that, but the company is utilizing 596% more capital than before, but that's to be expected from a company trying to break into profitability. This can indicate that there's plenty of opportunities to invest capital internally and at ever higher rates, both common traits of a multi-bagger. In summary, it's great to see that Axon Enterprise has managed to break into profitability and is continuing to reinvest in its business. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. In light of that, we think it's worth looking further into this stock because if Axon Enterprise can keep these trends up, it could have a bright future ahead. On a final note, we've found 2 warning signs for Axon Enterprise that we think you should be aware of. If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""Can Axon Enterprise Sustain EBITDA Margin Momentum Amid Cost Pressures? Axon Enterprise, Inc. AXON achieved a solid adjusted EBITDA of $155.2 million in the first quarter of 2025, which increased 9.6% year over year. The company's adjusted EBITDA margin reached 25.7%, reflecting an increase of 200 basis points (bps). This improved margin not only reflects its strong operational efficiency but also benefits from the continued adoption of its premier products and solutions. Despite rising operating expenses, AXON\u2019s adjusted gross margin grew 40 basis points to 63.6%. The improvement in margins was driven by higher revenues generated from robust sales of TASER 10, Axon Body 4, personal sensors and platform sensor products. It\u2019s worth noting that the company reported revenues of $603.6 million in the first quarter, which increased 31.3% year over year. Axon Enterprise\u2019s focus on effective cost management and revenue improvement is likely to expand its margin performance. For 2025, AXON currently expects adjusted EBITDA in the range of $650-$675 million, higher than its previous outlook of $640-$670 million. The updated guided range implies an adjusted EBITDA margin of approximately 25%. It's worth noting that, effective first-quarter 2025, Axon Enterprise realigned its business segments. This realignment is expected to enhance the company\u2019s visibility into segment-specific performance and enable it to effectively manage its costs. This strategic move will likely support Axon Enterprise\u2019s ongoing margin improvement and operational efficiency. While AXON is putting its best foot forward to improve margins, the road ahead for its peers like Kratos Defense & Security Solutions, Inc. KTOS and Teledyne Technologies Incorporated TDY looks bumpy as they struggle to maintain healthy margins. Among its major peers, Kratos Defense is facing cost pressure. In the first quarter of 2025, its cost of sales increased 11.1% year over year, while its SG&A expenses rose 4.8%. Kratos Defense\u2019s gross margin declined 30 bps to 24.3% in the quarter. Teledyne Technologies\u2019 cost of sales rose 7.8% year over year in first-quarter 2025. The company\u2019s SG&A expenses also increased 6.5% year over year. Teledyne Technologies\u2019 gross margin declined 320 basis points to 42.7% in the same period. Shares of Axon Enterprise have surged 48.3% in the past three months compared with the industry\u2019s growth of 22.5%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 115.81X above the industry\u2019s average of 48.85X. Axon Enterprise carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s 2025 earnings has declined 0.8% over the past 60 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-07-02,774.68,782.981,756.73,774.67,"Jim Cramer on Axon: “You Can’t Just Buy it All Right Here” Axon Enterprise, Inc. (NASDAQ:AXON) is one of the 21 stocks on Jim Cramer’s radar. When a caller asked about the stock during the episode, Cramer commented: A technician in a white coat testing an in-car system on a modern military vehicle. Axon Enterprise, Inc. (NASDAQ:AXON) makes TASER devices and provides tools like body cameras, software, and apps to help public safety workers record, manage, and share digital evidence. The company supports police, security, and other safety services. In the first week of June, Cramer mentioned the stock and said: While we acknowledge the potential of AXON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None."
AXON,2025-07-03,781.77,797.89,780.0,795.48,
AXON,2025-07-07,796.02,804.438,790.0,802.16,
AXON,2025-07-08,802.72,815.0,774.096,790.22,"[""Strength in Connected Devices Unit Drives Axon: Can the Momentum Sustain? Axon Enterprise, Inc. AXON is thriving on the back of persistent strength in its Connected Devices segment. The company continues to witness growing popularity for its next-generation TASER 10 products, whose shipment began in 2023. Growth in cartridge revenues, driven by the higher adoption of TASER 10 handles, has been driving the segment\u2019s performance. Revenues from TASER devices increased 19% year over year in the first quarter of 2025. Axon introduced its next-generation body-worn camera, Axon Body 4, in April 2023. With upgraded features such as a bi-directional communications facility and a point-of-view camera module option, this body camera is witnessing strong demand, thus bolstering the segment\u2019s growth. Shipment of this body camera began in June 2023 and the customer response has been impressive so far. AXON\u2019s Connected Devices segment is also benefiting from increased warranty revenues from a higher volume of deployed devices in the field. Driven by solid demand for its products, the segment\u2019s revenues increased 26.1% year over year in first-quarter 2025. With growing instances of terrorism and criminal activities globally, the demand for advanced public safety technologies is expected to remain strong going forward. This is likely to support the ongoing demand for AXON\u2019s Connected Devices portfolio, positioning the segment well for sustained momentum in the quarters ahead. Among its major peers, Woodward, Inc.\u2019s WWD Industrial business segment reported net sales of $321.9 million in the second quarter of fiscal 2025, down 4.7% year over year. Woodward generated 36.4% of its total sales from this segment in the quarter. The decline in revenues for Woodward\u2019s segment is primarily due to lower on-highway volume in China. Its another peer, Teledyne Technologies Incorporated\u2019s TDY Digital Imaging segment\u2019s first-quarter 2025 revenues increased 2.2% year over year to $757 million. Higher revenues were augmented by increased demand for Teledyne\u2019s commercial infrared imaging components and surveillance systems. Teledyne generated 52.2% of its total revenues from this segment in the quarter. Shares of Axon have gained 38.9% in the past six months compared with the industry\u2019s growth of 22.6%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 111.71X above the industry\u2019s average of 47.16X. Axon carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s second-quarter 2025 earnings has increased 4.8% over the past 60 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Woodward, Inc. (WWD) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Wolfe Research Initiates Axon Enterprise at Outperform With $875 Price Target Axon Enterprise (AXON) has an average rating of overweight and mean price target of $751.43, accordi"", ""AppLovin's Strategic Shift Fuels Omnichannel Advertising Growth AppLovin Corporation APP is accelerating its transformation from a mobile-first advertising platform into a diversified digital advertising powerhouse. At the heart of this evolution is a strategic expansion into high-growth areas, including web advertising, e-commerce and connected TV (CTV). A key driver of this shift is AppLovin\u2019s acquisition of Wurl, a streaming-focused content distribution and advertising platform. This move extends the reach of APP\u2019s AI-driven AXON monetization engine beyond mobile apps into the lucrative CTV and digital commerce spaces. The CTV advertising market is booming, driven by a significant shift in consumer viewing habits from traditional linear TV to streaming platforms. Wurl\u2019s infrastructure strengthens AppLovin\u2019s ability to deliver targeted, measurable campaigns across CTV devices, enhancing both reach and performance. Additionally, by integrating e-commerce capabilities, the company creates a feedback loop where ad performance is measured not just in impressions but in actual conversions, boosting its appeal to performance-focused advertisers. As user attention fragments across screens \u2014 mobile, web, and TV \u2014 AppLovin is uniquely positioned to offer a unified advertising platform that addresses the entire consumer journey. This omnichannel approach not only opens up new revenue streams but also reduces reliance on any single platform, insulating the company from ecosystem-specific risks. If APP can execute this strategy effectively, it stands to emerge as a dominant player in the next generation of digital advertising. AppLovin faces competition in this evolving landscape. The Trade Desk TTD, a leader in the Demand-Side Platform space, continues to bolster its CTV capabilities through strong partnerships with content providers and ongoing investments in its Unified ID solution. These enhancements support precise, data-driven ad targeting, keeping Trade Desk well-positioned as advertisers seek scalable reach and transparency. Roku ROKU is also a formidable rival, leveraging its proprietary operating system and vast streaming ecosystem to power a robust advertising business. Its platform-first approach allows for deep targeting accuracy and direct control over ad inventory. Roku has steadily expanded its ad tech stack to attract performance marketers and remain competitive in the increasingly crowded CTV arena. As the digital ad space becomes more fragmented and performance-driven, AppLovin\u2019s bold pivot into CTV and commerce offers both opportunity and challenge. Success will depend on its ability to integrate Wurl\u2019s infrastructure seamlessly, drive measurable outcomes across channels, and differentiate itself from established players like Trade Desk and Roku. With the right execution, AppLovin could reshape its narrative from a mobile ad company into a major contender in the future of omnichannel advertising. The stock has gained 46.5% in the past three months compared with the industry\u2019s 42.7% growth. Image Source: Zacks Investment Research From a valuation standpoint, APP trades at a forward price-to-earnings ratio of 33.48, well above the industry\u2019s 23.29. It carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for APP\u2019s earnings has been on the rise over the past 30 days. Image Source: Zacks Investment Research APP currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AppLovin Corporation (APP) : Free Stock Analysis Report The Trade Desk (TTD) : Free Stock Analysis Report Roku, Inc. (ROKU) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-07-09,794.3,809.99,785.0,805.86,
AXON,2025-07-10,802.11,803.0,728.43,732.99,"[""Axon Enterprise (AXON) Beats Stock Market Upswing: What Investors Need to Know In the latest close session, Axon Enterprise (AXON) was up +1.98% at $805.86. The stock exceeded the S&P 500, which registered a gain of 0.61% for the day. Elsewhere, the Dow gained 0.49%, while the tech-heavy Nasdaq added 0.95%. The stock of maker of stun guns and body cameras has risen by 3.61% in the past month, leading the Aerospace sector's gain of 1.1% and undershooting the S&P 500's gain of 3.85%. Market participants will be closely following the financial results of Axon Enterprise in its upcoming release. The company is forecasted to report an EPS of $1.54, showcasing a 28.33% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $641.21 million, indicating a 27.2% upward movement from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.34 per share and revenue of $2.65 billion. These totals would mark changes of +6.73% and +27.17%, respectively, from last year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Axon Enterprise. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Currently, Axon Enterprise is carrying a Zacks Rank of #3 (Hold). Digging into valuation, Axon Enterprise currently has a Forward P/E ratio of 124.67. This expresses a premium compared to the average Forward P/E of 38.37 of its industry. It is also worth noting that AXON currently has a PEG ratio of 4.39. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Aerospace - Defense Equipment industry held an average PEG ratio of 3. The Aerospace - Defense Equipment industry is part of the Aerospace sector. This group has a Zacks Industry Rank of 90, putting it in the top 37% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon Enterprise, Inc (AXON) is Attracting Investor Attention: Here is What You Should Know Axon Enterprise (AXON) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this maker of stun guns and body cameras have returned +3.5%, compared to the Zacks S&P 500 composite's +4.4% change. During this period, the Zacks Aerospace - Defense Equipment industry, which Axon falls in, has gained 3.3%. The key question now is: What could be the stock's future direction? While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Axon is expected to post earnings of $1.54 per share, indicating a change of +28.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. For the current fiscal year, the consensus earnings estimate of $6.34 points to a change of +6.7% from the prior year. Over the last 30 days, this estimate has remained unchanged. For the next fiscal year, the consensus earnings estimate of $7.97 indicates a change of +25.7% from what Axon is expected to report a year ago. Over the past month, the estimate has remained unchanged. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Axon is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. For Axon, the consensus sales estimate for the current quarter of $641.21 million indicates a year-over-year change of +27.2%. For the current and next fiscal years, $2.65 billion and $3.23 billion estimates indicate +27.2% and +22% changes, respectively. Axon reported revenues of $603.63 million in the last reported quarter, representing a year-over-year change of +31%. EPS of $1.41 for the same period compares with $1.15 a year ago. Compared to the Zacks Consensus Estimate of $589.09 million, the reported revenues represent a surprise of +2.47%. The EPS surprise was +11.02%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-07-11,729.62,729.62,723.001,729.62,"[""AppLovin (APP) Just Got a $430 Price Target\u2014Here\u2019s Why Wall Street Is Buzzing AppLovin Corporation (NASDAQ:APP) is one of the AI Stocks Making Waves on Wall Street. On July 8, Scotiabank analyst Nathaniel Schindler initiated coverage on the stock with a \u201cSector Outperform\u201d rating and a $430 price target. With AppLovin\u2019s artificial intelligence tools expanding beyond gaming, the firm believes the mobile marketing specialist is pulling ahead in performance advertising. It said that its proprietary AXON engine, which has been trained on more than $10 billion of historical ad spend, augments campaigns in real time and formulates a \u201cvast moat to cross for new entrants.\u201d AppLovin has been allowing smaller brands into its network, potentially tapping a \u201csecond core revenue vertical\u201d worth more than $1 billion. The bank\u2019s positive assessment reflects renewed confidence in terms of growth prospects for the company. According to them, AppLovin has \u201cblown through the Rule of 40,\u201d which is a key metric for software investors balancing revenue growth with profit margins. A company\u2019s combined growth rate and profit margin should exceed 40% to pass the Rule of 40. Even though shares look expensive when compared to sales, the firm said they are trading at an attractive multiple of future earnings. Three catalysts are also working in favor of AppLovin; namely, broader adoption of AXON across advertisers seeking conversion\u2011based campaigns, booming budget shifts from social\u2011media platforms toward AppLovin\u2019s network, and sustained insulation from data\u2011privacy changes due to the company\u2019s on\u2011device footprint. Needless to say, there are also some risks. These include rising competition in demand\u2011side platforms as well as potential regulatory shifts. AppLovin Corporation (NASDAQ:APP) provides a leading marketing platform powered by AI technology. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Trending AI Stocks on News and Ratings and 10 AI Stocks Investors Are Watching This Week. Disclosure: None."", ""Morgan Stanley Adjusts Price Target on Axon Enterprise to $885 From $695, Maintains Overweight Rating Axon Enterprise (AXON) has an average rating of overweight and mean price target of $765, according""]"
AXON,2025-07-14,727.1,752.97,723.99,750.26,"AXON's Software & Services Growth Picks Up: More Upside to Come? Axon Enterprise, Inc. AXON is witnessing strong momentum in its Software & Services segment. Solid growth in the aggregate number of users to the Axon network is driving the Software & Services segment’s performance. After witnessing a year-over-year increase of 33.4% in 2024, revenues from the segment also increased 39% in the first quarter of 2025. Increased demand for digital evidence management and premium add-on features has been supporting the segment’s growth. Adoption of premium subscription plans also continues to rise as more customers recognize the value of enhanced capabilities. Strong customer satisfaction and engagement have led to a growing base of annual recurring revenues (ARR), which increased 34% year over year to $1.1 billion in the first quarter. With almost 70% of AXON’s domestic user base still on basic plans, the Software & Services segment holds significant growth potential. New product introductions and add-on features are likely to continue playing an important role in its overall growth as customers are increasingly adopting products like Draft One and the OSP 10 premium bundle. With growing instances of terrorism and criminal activities globally, the demand for advanced public safety technologies is expected to remain strong. This is likely to support the ongoing demand for Axon Enterprise’s Software & Services portfolio, positioning the segment well for sustained momentum in the quarters ahead. Among its major peers, Woodward, Inc.’s WWD Industrial business segment reported net sales of $321.9 million in the second quarter of fiscal 2025, down 4.7% year over year. Woodward generated 36.4% of its total sales from this segment in the quarter. The decline in revenues for Woodward’s segment is primarily due to lower on-highway volume in China. Kratos Defense & Security Solutions, Inc.’s KTOS Government Solutions segment’s first-quarter 2025 revenues increased 10% year over year to $239.5 million. This was driven by higher sales of Kratos Defense’s businesses, with the most notable growth in its C5ISR, Defense Rocket Support and Microwave Products units. Kratos Defense derived 79.1% of its total revenues from this segment during the quarter. Shares of Axon Enterprise have surged 25.8% in the past six months compared with the industry’s growth of 21.8%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 101.23X, above the industry’s average of 47.88X. Axon Enterprise carries a Value Score of F. Image Source: Zacks Investment Research While the Zacks Consensus Estimate for AXON’s second-quarter 2025 earnings increased over the past 60 days, the same for 2025 declined. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Woodward, Inc. (WWD) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-07-15,752.74,753.57,740.16,745.87,"Axon Enterprise (AXON): A Bull Case Theory We came across a bullish thesis on Axon Enterprise on Compounding Your Wealth's Substack by Sergey. As of 9ᵗʰ July, Axon Enterprise's share was trading at $805.86. AXON's trailing and forward P/E were 196.07 and 129.98 respectively according to Yahoo Finance. A technician in a white coat testing an in-car system on a modern military vehicle. Axon Enterprise, a public safety technology company, has evolved from a conducted energy weapons manufacturer into a comprehensive public safety ecosystem provider. The company operates through two primary segments: Software and Sensors, and TASER devices. Axon's mission is to 'Protect Life' and aims to create a world where bullets are obsolete. With a strong brand recognition and a wide economic moat, Axon maintains a significant competitive advantage in the public safety technology market. The company's total addressable market has expanded to $129 billion in 2025, driven by AI integration, product innovation, and growth into new verticals. Axon's recent performance shows strong revenue growth, with a 31% YoY increase in Q1 2025. The company's Software & Services segment grew 39% YoY, driven by the adoption of AI-powered solutions and digital evidence management. Axon's connected devices revenue reached $341 million, up 26% YoY, driven by strong performance across TASER10, Axon Body4, and other products. The company's ARR (Annual Recurring Revenue) reached $1.104 billion, growing 34% YoY, and the retention rate remains high at 123%. Despite the strong growth, Axon's valuation appears high, with a Forward EV/Sales multiple of 21.81 and a Forward P/E of 125.0. However, the company's growth prospects, expanding total addressable market, and strong competitive advantages justify its premium valuation. Axon's innovative products, strategic acquisitions, and partnerships are expected to drive future growth. The company's commitment to innovation and its mission-driven approach are expected to sustain its long-term growth and create a significant impact in the public safety technology sector. Previously, we covered a bullish thesis on Axon Enterprise by Hidden Market Gems in June 2025, which highlighted strategically broadening its market presence by deeply integrating artificial intelligence (AI) across its suite of products. The company's stock price has appreciated by 7.5% roughly. Sergey's view shares a similar bullish stance but emphasizes different aspects of the company's growth potential. Axon Enterprise is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge fund portfolios held AXON at the end of first quarter which was 64 in the previous quarter. While we acknowledge the risk and potential of AXON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to Blackrock. Disclosure: None."
AXON,2025-07-16,743.56,748.27,725.05,742.77,"[""UBS Initiates Axon Enterprise at Neutral With $820 Price Target Axon Enterprise (AXON) has an average rating of overweight and mean price target of $768.67, accordi"", ""Axon vs. Teledyne: Which Defense & Security Stock has Better Prospects? Axon Enterprise, Inc. AXON and Teledyne Technologies Incorporated TDY are two prominent names operating in the aerospace and defense equipment industry. As rivals, both companies are engaged in manufacturing highly engineered public security and digital imaging solutions in the United States and internationally. Both companies have been enjoying significant growth opportunities in the public safety and surveillance industries on account of growing instances of terrorism and criminal activities across the world. Let\u2019s take a closer look at their fundamentals, growth prospects and challenges. The strongest driver of Axon\u2019s business at the moment is the persistent strength in its Connected Devices segment. Growing popularity for its next-generation TASER 10 products and growth in cartridge revenues, supported by the higher adoption of the TASER products, have been driving the segment\u2019s performance, of late. The segment\u2019s revenues increased 26.1% year over year in the first quarter of 2025. Axon introduced its next-generation body-worn camera, Axon Body 4, in 2023. Featuring upgraded features like a bi-directional communications facility and point-of-view camera module option, this body camera is generating significant demand, thus boosting the segment\u2019s growth. The company is also witnessing strong momentum in its Software & Services segment. Solid growth in the aggregate number of users of the Axon network is driving the Software & Services segment\u2019s results. After witnessing a year-over-year increase of 33.4% in 2024, revenues from the segment also increased 39% in the first quarter. Higher demand for digital evidence management and premium add-on features has also been supporting the segment\u2019s growth. Strong customer satisfaction and engagement have led to a growing base of annual recurring revenues (ARR), which increased 34% year over year to $1.1 billion in the first quarter. With almost 70% of AXON\u2019s domestic user base still on basic plans, the Software & Services segment holds significant growth potential. New product introductions and add-on features are likely to continue playing an important role in its overall growth as customers are increasingly adopting products like Draft One and the OSP 10 premium bundle. On the flip side, escalating costs and expenses are a concern for Axon\u2019s margins and profitability. In first-quarter 2025, its cost of sales and SG&A expenses increased 18.2% and 48%, respectively, year over year. Total operating expenses climbed 54.7% year over year to $374.5 million. AXON incurred high costs and expenses related to business integration activities, an increase in headcount, and higher wages and stock-based compensation expenses. Steady improvement in commercial air travel remains a major growth catalyst for Teledyne, with it being a notable provider of onboard avionics systems and ground-based applications for commercial aircraft. Notably, its first-quarter sales from the Aerospace and Defense Electronics segment improved 30.6% year over year, with commercial sales constituting 20% growth. Teledyne\u2019s Digital Imaging segment has been witnessing strength driven by higher sales of commercial infrared imaging components and surveillance systems. Increased demand for the company\u2019s high-performance image sensors and digital cameras has been augmenting the segment\u2019s performance. The Digital Imaging segment\u2019s first-quarter sales were $757 million, reflecting an increase of 2.2%. However, TDY experienced supply-chain challenges, including increased lead times, as well as cost inflation for parts and components, logistics and labor due to availability constraints and high demand in the recent past. This has also delayed the company\u2019s ability to convert backlog to revenues and negatively impacted its profit margin in the past few quarters. To this end, the International Air Transport Association (IATA) announced in its December 2024 report that it expects severe supply-chain issues to continue to impact the aviation industry into 2025. The escalating costs and operating expenses have also been major headwinds for the company. For instance, its cost of sales in the first quarter totaled $830 million, representing an increase of 7.8% year over year. Its SG&A expenses increased 6.5% in the same period. High costs and expenses, if not controlled, might adversely impact its margins and profitability. High debt levels have also been a major concern for TDY as they raise financial obligations and might drain its profitability. Teledyne exited first-quarter 2025 with a long-term debt (net of current portion) of $2.96 billion, reflecting an increase of 12% sequentially. Its current liabilities were $1.36 billion, much higher than the cash equivalents of $461.5 million. In the past six months, Axon shares have risen 25.6%, while Teledyne stock has gained 12.9%. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON\u2019s 2025 sales and earnings per share (EPS) implies year-over-year growth of 27.2% and 6.7%, respectively. Although the EPS estimates for 2025 have decreased over the past 60 days, the estimate for 2026 has increased. Image Source: Zacks Investment Research The Zacks Consensus Estimate for TDY\u2019s 2025 sales implies growth of 6.8% year over year, while the EPS estimate indicates an increase of 8.8%. TDY\u2019s EPS estimates have been trending northward for both 2025 and 2026 over the past 60 days. Image Source: Zacks Investment Research Teledyne is trading at a forward 12-month price-to-earnings ratio of 23.54X, while Axon\u2019s forward earnings multiple sits much higher at 103.36X. Image Source: Zacks Investment Research Axon\u2019s diversified product portfolio, growth investments and persistent strength in the Connected Devices and Software & Services segments provide it with a competitive advantage to leverage the long-term demand prospects in the public safety markets. Despite its steeper valuation, AXON holds robust prospects due to strong estimates, stock price appreciation and better forecasts for sales and profit growth. In contrast, Teledyne\u2019s strength in the Aerospace & Defense as well as Digital Imaging segments has been dented by the supply-chain challenges and rising operating costs and expenses. Also, TDY\u2019s highly leveraged balance sheet warrants a cautious approach for existing investors. Given these factors, AXON seems a better choice for investors than TDY currently. While AXON carries a Zacks Rank #3 (Hold), TDY currently carries a Zacks Rank #4 (Sell). You can see the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon Enterprise's Strong Growth Already Reflected in Valuation, UBS Says Axon Enterprise (AXON) offers strong long-term growth prospects driven by demand for its law enforce""]"
AXON,2025-07-17,744.8,753.25,739.79,745.86,"[""JPMorgan Adjusts Price Target on Axon Enterprise Inc to $850 From $730, Maintains Overweight Rating Axon Enterprise Inc (AXON) has an average rating of overweight and mean price target of $768.67, acc"", ""Insiders At Axon Enterprise Sold US$78m In Stock, Alluding To Potential Weakness Many Axon Enterprise, Inc. (NASDAQ:AXON) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag. While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In the last twelve months, the biggest single sale by an insider was when the Chief Product Officer & CTO, Jeffrey Kunins, sold US$26m worth of shares at a price of US$613 per share. That means that even when the share price was below the current price of US$743, an insider wanted to cash in some shares. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. We note that the biggest single sale was only 32% of Jeffrey Kunins's holding. Insiders in Axon Enterprise didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! See our latest analysis for Axon Enterprise If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar). Over the last three months, we've seen significant insider selling at Axon Enterprise. In total, insiders sold US$24m worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all. Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Axon Enterprise insiders own about US$2.7b worth of shares (which is 4.6% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. Insiders sold Axon Enterprise shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. On the plus side, Axon Enterprise makes money, and is growing profits. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Axon Enterprise has 2 warning signs we think you should be aware of. Of course Axon Enterprise may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."", ""What to Expect From Axon Enterprise's Next Quarterly Earnings Report With a market cap of $57.8 billion, Axon Enterprise, Inc. (AXON) develops and sells conducted energy devices under the TASER brand, along with a suite of software and sensor technologies for public safety. Operating through its TASER and Software & Sensors segments, it provides hardware, cloud-based solutions, and services to law enforcement and a range of security-related industries worldwide. The Scottsdale, Arizona-based company is expected to release its fiscal Q2 2025 earnings results on Tuesday, Aug. 5. Ahead of this event, analysts project AXON to report an EPS of $0.08, an 81.8% drop from $0.44 in the year-ago quarter. The company has exceeded Wall Street's bottom-line estimates in one of the last four quarters while missing on three other occasions. Dear Google Stock Fans, Mark Your Calendars for July 23 Retirement Ready: 3 Dividend Stocks to Set and Forget Dear UnitedHealth Stock Fans, Mark Your Calendars for July 29 Stop Missing Market Moves: Get the FREE Barchart Brief \u2013 your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For fiscal 2025, analysts forecast the law enforcement vendor to report EPS of $0.31, down 85.2% from $2.09 in fiscal 2024. However, EPS is expected to rebound and grow significantly, 262.5% year-over-year to $1.13 in fiscal 2026. Shares of Axon Enterprise have surged 132.5% over the past 52 weeks, significantly outperforming the broader S&P 500 Index's ($SPX) 10.5% return and the Industrial Select Sector SPDR Fund's (XLI) 17.3% gain over the same period. Shares of Axon Enterprise surged 14.1% after the company reported strong Q1 2025 results on May 7. The company delivered record revenue of $603.6 million, marking a 31% increase year-over-year, while adjusted EPS reached $1.41, both exceeding analyst expectations. Annual recurring revenue climbed 34% to $1.1 billion, with software revenue leading the way with 39% growth, highlighting the strength of Axon\u2019s high-margin business model. Moreover, Axon raised its full-year revenue guidance to a range of $2.6 billion to $2.7 billion and adjusted EBITDA to between $650 million and $675 million, further fueling investor optimism. Analysts' consensus view on AXON stock is bullish, with an overall \""Strong Buy\"" rating. Among 17 analysts covering the stock, 11 suggest a \""Strong Buy,\"" three give a \""Moderate Buy,\"" and three provide a \""Hold\"" rating. As of writing, the stock is trading below the average analyst price target of $745. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com""]"
AXON,2025-07-18,747.83,757.98,741.07,756.09,"Axon (AXON): 3 Reasons We Love This Stock Axon currently trades at $746.40 and has been a dream stock for shareholders. It’s returned 709% since July 2020, blowing past the S&P 500’s 93.6% gain. The company has also beaten the index over the past six months as its stock price is up 23.3% thanks to its solid quarterly results. Is now still a good time to buy AXON? Or are investors being too optimistic? Find out in our full research report, it’s free. Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Law Enforcement Suppliers company because there’s a ceiling to what customers will pay. Axon’s units sold punched in at 138,018 in the latest quarter, and over the last two years, averaged 32% year-on-year growth. This performance was fantastic and shows its offerings have a unique value proposition (and perhaps some degree of customer loyalty). Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. As you can see below, Axon’s margin expanded by 20.3 percentage points over the last five years. This is encouraging, and we can see it became a less capital-intensive business because its free cash flow profitability rose more than its operating profitability. Axon’s free cash flow margin for the trailing 12 months was 16.8%. ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Over the last few years, Axon’s ROIC has increased. This is a good sign, but we recognize its lack of profitable growth during the COVID era was the primary reason for the change. These are just a few reasons why we think Axon is one of the best industrials companies out there, and with its shares topping the market in recent months, the stock trades at 125.3× forward P/E (or $746.40 per share). Is now a good time to initiate a position? See for yourself in our comprehensive research report, it’s free. Trump’s April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines. Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."
AXON,2025-07-21,755.92,758.25,741.91,751.55,"2 Industrials Stocks with Competitive Advantages and 1 We Find Risky Whether you see them or not, industrials businesses play a crucial part in our daily activities. Still, their generally high capital requirements expose them to the ups and downs of economic cycles, and the market seems confused about where we could go next. This uncertainty has led to a flat return for the industry over the past six months while the S&P 500 was up 4.1%. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. With that said, here are two industrials stocks boasting durable advantages and one we’re steering clear of. Market Cap: $44.9 million Founded in 1968, TPI Composites (NASDAQ:TPIC) manufactures composite wind turbine blades and provides related precision molding and assembly systems. Why Should You Dump TPIC? TPI Composites’s stock price of $0.94 implies a valuation ratio of 0.8x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including TPIC in your portfolio, it’s free. Market Cap: $58.86 billion Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Why Is AXON a Good Business? At $755 per share, Axon trades at 127x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free. Market Cap: $34.52 billion Started with the invention of the steam drill, Ingersoll Rand (NYSE:IR) provides mission-critical air, gas, liquid, and solid flow creation solutions. Why Could IR Be a Winner? Ingersoll Rand is trading at $85.53 per share, or 24.8x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free. When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses. Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."
AXON,2025-07-22,749.01,749.01,720.18,720.74,"[""Axon to Release Second Quarter 2025 Earnings on August 4, 2025 SCOTTSDALE, Ariz., July 21, 2025 /PRNewswire/ -- Axon (Nasdaq: AXON), the global public safety technology leader, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. Axon will host a live Zoom video webinar to discuss the company's financial results at 5 p.m. ET that same day. The live webinar to discuss financial results, followed by Q&A, will be linked from Axon's investor relations website at https://investor.axon.com. An archived replay will be available after the call ends. Upcoming Conference Participation The Company also announced that Axon will participate in the Goldman Sachs Communacopia + Technology Conference on Tuesday, September 9, 2025. If applicable, events will be webcast live and archived on Axon's investor relations website at https://investor.axon.com. About Axon Axon is a technology leader in global public safety. Our moonshot goal is to cut gun-related deaths between police and the public by 50% before 2033. Axon is building the public safety operating system of the future by integrating a suite of hardware devices and cloud software solutions that lead modern policing. Axon's suite includes TASER energy devices, body cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. Axon's growing global customer base includes first responders across international, federal, state and local law enforcement, fire, corrections and emergency medical services, as well as the justice sector, enterprises and consumers. Non-Axon trademarks are property of their respective owners. Axon, the Delta Logo, Protect Life and TASER are trademarks of Axon Enterprise, Inc., some of which are registered in the United States and other countries. For more information, visit www.axon.com/legal. All rights reserved. Follow Axon here: Axon on X: https://x.com/axon_us Axon on Facebook: https://www.facebook.com/Axon.ProtectLife/ Axon on LinkedIn: https://www.linkedin.com/company/axon-protect-life/ Note to Investors Please visit http://investor.axon.com, https://www.axon.com/press, https://x.com/axon_us and https://www.facebook.com/Axon.ProtectLife/ where Axon discloses information about the company, its financial information and its business. CONTACT: Investor Relations Axon Enterprise, Inc. IR@axon.com View original content to download multimedia:https://www.prnewswire.com/news-releases/axon-to-release-second-quarter-2025-earnings-on-august-4-2025-302509835.html SOURCE Axon"", ""Here's Why We Think Axon Enterprise (NASDAQ:AXON) Is Well Worth Watching It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. In contrast to all that, many investors prefer to focus on companies like Axon Enterprise (NASDAQ:AXON), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Over the last three years, Axon Enterprise has grown earnings per share (EPS) at as impressive rate from a relatively low point, resulting in a three year percentage growth rate that isn't particularly indicative of expected future performance. So it would be better to isolate the growth rate over the last year for our analysis. Axon Enterprise boosted its trailing twelve month EPS from US$3.53 to US$4.26, in the last year. There's little doubt shareholders would be happy with that 21% gain. It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. On the revenue front, Axon Enterprise has done well over the past year, growing revenue by 33% to US$2.2b but EBIT margin figures were less stellar, seeing a decline over the last 12 months. So it seems the future may hold further growth, especially if EBIT margins can remain steady. In the chart below, you can see how the company has grown earnings and revenue, over time. Click on the chart to see the exact numbers. See our latest analysis for Axon Enterprise You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Axon Enterprise's future profits. Owing to the size of Axon Enterprise, we wouldn't expect insiders to hold a significant proportion of the company. But we are reassured by the fact they have invested in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at US$2.7b. This suggests that leadership will be very mindful of shareholders' interests when making decisions! One important encouraging feature of Axon Enterprise is that it is growing profits. To add an extra spark to the fire, significant insider ownership in the company is another highlight. These two factors are a huge highlight for the company which should be a strong contender your watchlists. Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Axon Enterprise that you should be aware of. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of companies which have demonstrated growth backed by significant insider holdings. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.""]"
AXON,2025-07-23,725.8,728.95,694.72,705.22,"Axon Eyes Expansion in Drone Equipment Space: Can It Deliver Growth? Axon Enterprise, Inc. AXON has been focusing on strategic collaborations with other companies to expand its drone offerings and customer base. For instance, in June 2024, Axon entered into a partnership with Skydio (a leading U.S. drone manufacturer) to introduce a comprehensive line of drones in public safety that includes a scalable Drone as First Responder (DFR) solution. The offering incorporates autonomous drones, onsite docking stations and integrated flight control solutions from Skydio and real-time operations, real-time crime center capabilities and evidence management solutions from Axon. The combined offering supports Axon’s DFR programs across its customer base and strengthens its market position in this category. Also, in October 2024, the company acquired Dedrone, a global leader in airspace security. The inclusion of Dedrone’s advanced airspace technology boosted AXON's capability to enable customers to protect their communities against drone threats and improve response to critical incidents. In addition, Axon continues to invest in and support DroneSense, an Axon ecosystem partner and leading provider of Drone software. With growing instances of terrorism and criminal activities globally, the demand for advanced public safety technologies is expected to remain strong going forward. This is likely to support the ongoing demand for AXON’s drone equipment, positioning it well for sustained momentum in the quarters ahead. Among its major peers, Woodward, Inc.’s WWD Industrial business segment reported net sales of $321.9 million in the second quarter of fiscal 2025, down 4.7% year over year. Woodward generated 36.4% of its total sales from this segment in the quarter. The decline in revenues for Woodward’s segment is primarily due to lower on-highway volume in China. Its another peer, Teledyne Technologies Incorporated’s TDY Digital Imaging segment’s first-quarter 2025 revenues increased 2.2% year over year to $757 million. Higher revenues were augmented by increased demand for Teledyne’s commercial infrared imaging components and surveillance systems. Teledyne generated 52.2% of its total revenues from this segment in the quarter. Shares of Axon have gained 130.2% in the past year compared with the industry’s growth of 47.5%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 99.45X, above the industry’s average of 51.68X. Axon carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON’s 2025 earnings has increased a penny over the past 30 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Woodward, Inc. (WWD) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-07-24,705.22,715.745,695.0,709.26,"Here is What to Know Beyond Why Axon Enterprise, Inc (AXON) is a Trending Stock Axon Enterprise (AXON) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this maker of stun guns and body cameras have returned -10.2%, compared to the Zacks S&P 500 composite's +5.7% change. During this period, the Zacks Aerospace - Defense Equipment industry, which Axon falls in, has gained 3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Axon is expected to post earnings of $1.54 per share, indicating a change of +28.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +12% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $6.35 points to a change of +6.9% from the prior year. Over the last 30 days, this estimate has changed +3.3%. For the next fiscal year, the consensus earnings estimate of $7.98 indicates a change of +25.8% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +0.1%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Axon. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. For Axon, the consensus sales estimate for the current quarter of $642.19 million indicates a year-over-year change of +27.4%. For the current and next fiscal years, $2.66 billion and $3.24 billion estimates indicate +27.4% and +22% changes, respectively. Axon reported revenues of $603.63 million in the last reported quarter, representing a year-over-year change of +31%. EPS of $1.41 for the same period compares with $1.15 a year ago. Compared to the Zacks Consensus Estimate of $589.09 million, the reported revenues represent a surprise of +2.47%. The EPS surprise was +11.02%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-07-25,711.39,742.23,709.82,735.01,"[""Wall Street Analysts See Axon (AXON) as a Buy: Should You Invest? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Axon Enterprise (AXON). Axon currently has an average brokerage recommendation (ABR) of 1.50, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.50 approximates between Strong Buy and Buy. Of the 17 recommendations that derive the current ABR, 11 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 64.7% and 17.7% of all recommendations. Check price target & stock forecast for Axon here>>> The ABR suggests buying Axon, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every \""Strong Sell\"" recommendation, brokerage firms assign five \""Strong Buy\"" recommendations. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Looking at the earnings estimate revisions for Axon, the Zacks Consensus Estimate for the current year has increased 3.3% over the past month to $6.35. Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Axon. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for Axon may serve as a useful guide for investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""TD Cowen Adjusts Price Target on Axon Enterprise to $825 From $800, Maintains Buy Rating Axon Enterprise (AXON) has an average rating of overweight and mean price target of $789.67, accordi""]"
AXON,2025-07-28,740.36,747.3,722.07,736.29,"Will Axon's AI-Driven Platform Continue to Enhance Community Safety? Axon Enterprise, Inc. AXON is strengthening its position in the public safety technology space with its Artificial Intelligence (AI) powered software platform. The company’s AI tools are developed and delivered through the Software & Services segment, which plays a key role in equipping public safety professionals with technology that enhances response times and reduces risks. This segment has been a major growth driver for AXON, with revenues rising 39% year over year in the first quarter of 2025, following a 33.4% year-over-year increase in 2024. A growing number of agencies are adopting Axon’s AI-powered tools that simplify workflows and improve decision-making in the field. Among these innovations is Draft One, an AI-powered report-writing assistant that helps officers write reports faster and more accurately, freeing up time for community engagement. With nearly 30,000 active users, it’s one of Axon’s fastest-growing software products. Another key tool is Redaction Assistant, which uses AI to automatically blur sensitive information in video evidence and cuts redaction time by up to 75%. These tools are part of premium subscription bundles like Officer Safety Plan 10 (OSP 10), which continue to gain traction. With nearly 70% of Axon’s U.S. user base still on basic plans, there is strong potential for future upgrades. As AXON continues to expand its AI capabilities and drive adoption through its Software & Services segment, it is well-positioned to play a leading role in building safer, more efficient and better-connected communities in the near term. Among its major peers, Kratos Defense & Security Solutions, Inc.’s KTOS Government Solutions segment’s first-quarter 2025 revenues increased 10% year over year to $239.5 million. Higher sales of Kratos Defense’s businesses, with the most notable growth in its C5ISR, Defense Rocket Support and Microwave Products units, aided the results. Kratos Defense derived 79.1% of its total revenues from this segment during the quarter. Teledyne Technologies Incorporated’s TDY Digital Imaging segment’s first-quarter 2025 revenues increased 2.2% year over year to $757 million. This was driven by higher sales of Teledyne’s commercial infrared imaging components and surveillance systems. Teledyne derived 52.2% of its total revenues from this segment during the quarter. Shares of Axon have surged 137.9% in the past year compared with the industry’s growth of 48.3%. Image Source: Zacks Investment Research From a valuation standpoint, AXON is trading at a forward price-to-earnings ratio of 925.57X, above the industry’s average of 51.21X. Axon carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for AXON’s second-quarter 2025 earnings has been on the rise over the past 60 days. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-07-29,742.19,742.19,725.79,728.74,
AXON,2025-07-30,728.74,749.8,725.0,748.6,
AXON,2025-07-31,752.62,762.05,747.24,755.86,"Carbyne Raises $100 Million in Funding to Accelerate AI-Powered Emergency Response and Intelligence Emergency communications leader posts 477% YoY growth of APEX ARR; new funding to fuel cloud-native AI innovation, global expansion. NEW YORK, July 31, 2025 /PRNewswire/ -- Carbyne, the leading provider of cloud-native emergency communications and response solutions, today announced it has raised $100 million in new financing. This funding round underscores Carbyne's rapid growth and will enable the company to accelerate development of its AI-driven 911 emergency response platform, expand into new mission critical industries, and continue its international growth while upholding the highest standards of cybersecurity and compliance. Participants in the financing included AT&T Ventures, Axon Enterprise, Cox Enterprises, Global Medical Response, Hanaco Growth, Hercules Capital, RCM Private Markets Fund managed by Rokos Capital Management (US) LP, and Silicon Valley Bank (SVB), a division of First Citizens Bank. Carbyne consulted with Goldman Sachs throughout the process. ""This significant investment is a strong vote of confidence in Carbyne's vision and execution,"" said Amir Elichai, CEO and Founder of Carbyne. ""Over the past year, we've demonstrated that our cloud-native approach and AI innovations can truly transform emergency communications – not only for 911 centers but also for broader markets in need of modern incident response solutions."" Carbyne's momentum over the past year has been exceptional, highlighted by triple-digit growth across its core platform. Key performance milestones from the last 12 months include: +477% year-over-year growth in APEX annual recurring revenue (ARR): Carbyne's flagship APEX cloud platform – a next-generation 911 call-handling solution – reflecting surging demand from emergency call centers. +105% increase in APEX platform customers: The number of public safety agencies utilizing Carbyne's APEX platform has more than doubled, as 911 centers adopt cloud-native systems to replace aging legacy infrastructure. Continued growth will be supported by Carbyne bringing its technology to new, non-Public Safety Answering Point (PSAP) environments with critical incident response needs. Nearly 300 sites worldwide, across 23 U.S. states and six countries with 7,000+ calltakers using Carbyne globally: Carbyne has experienced exponential growth that's rooted in a commitment to a sustained investment in assistive AI built for mission-critical environments. Unlike bolt-on solutions, Carbyne's AI is integrated into its all-in-one platform, delivering intelligent, real-time support across call handling, dispatch, resource coordination, and emergency decision-making. Today, hundreds of public safety agencies are already leveraging Carbyne's AI Suite, and the feedback has been nothing short of phenomenal. Carbyne's proprietary, high-quality data sets — generated from millions of emergency interactions — give us a unique edge in training highly accurate virtual agents that truly understand the urgency and nuance of mission-critical scenarios. From dramatically reducing response times to alleviating frontline staffing pressures, Carbyne's AI is not a vision — it's already delivering tangible outcomes in the field. ""As AI adoption accelerates in public safety, Carbyne is uniquely positioned to lead,"" said Alex Dizengof, Co-Founder and CTO of Carbyne. ""By building AI into the core of our platform, we're not just enhancing emergency response — we're setting the standard for faster, smarter, and more reliable outcomes when every second counts."" Carbyne is a leader in delivering a cloud-native, mission-critical communications platform for emergency communication centers at scale. While others are still trying to figure out how to migrate off legacy infrastructure, Carbyne is accelerating into the intelligence era — deploying AI-driven solutions that are designed to save lives today. With this funding, Carbyne will expand its innovation pipeline, scale operations globally, and continue to provide security, privacy, and reliability as a core to its platform. The company's mission remains clear — to build a safer, smarter world by transforming how public safety agencies and critical infrastructure providers leverage technology. ""Every day, first responders and 911 operators face critical, split-second decisions,"" said Axon Senior Vice President of Strategy and Corporate Development Henrik Kuhl. ""Carbyne is transforming how emergency calls are managed — delivering real-time, AI-powered intelligence to those on the front lines of public safety. We're proud to work with Carbyne to help accelerate the global deployment of these life-saving technologies and unlock new opportunities to integrate Axon's connected devices and real-time operational tools with Carbyne's emergency data platform — enabling faster, more informed decisions when every moment counts."" ""Across the country when seconds count, Global Medical Response (GMR) is there to deliver the highest quality emergency care,"" said Edward ""Ted"" Van Horne, Chief Operating Officer, GMR. ""Investing in Carbyne and furthering our partnership supports GMR in continuing to improve that care — bringing cloud-native, data-rich technology to the front lines of emergency response for increased safety in the communities we serve."" Carbyne will use the new capital to grow its R&D and engineering teams, deepen its AI capabilities, and bolster its go-to-market efforts in North America, Latin America, and EMEA. Carbyne also plans to invest in strategic partnerships and integrations to further enrich the ecosystem of tools available to emergency responders. About Carbyne Carbyne is setting a new standard for how the world responds to emergencies. Our cloud-native platform — built for speed, clarity, and action — uses AI to help emergency responders move faster, see more, and make confident decisions when lives are on the line. Carbyne connects responders with real-time data, live video, multilingual transcription and translation, and intelligent tools that streamline complex workflows and enhance coordination. Deployed across dozens of jurisdictions, integrated with leading public safety systems, and trusted to process over 250 million data points annually with 99.999% call handling uptime, Carbyne delivers resilience at scale. With global reach and an unrelenting focus on impact, we help communities stay safer, better prepared, and more connected — because every second matters, and every person counts. Learn more at Carbyne.com. Contact: Kara Erwin 398948@email4pr.com (512) 771-6911 View original content to download multimedia:https://www.prnewswire.com/news-releases/carbyne-raises-100-million-in-funding-to-accelerate-ai-powered-emergency-response-and-intelligence-302518401.html SOURCE Carbyne"
AXON,2025-08-01,739.46,747.408,728.0,742.7,"[""Palantir, AMD, Shopify Headline Another Busy Week of Tech Earnings Expectations are high for Palantir stock, which continues to hold near all-time highs ahead of its Q2 earnings report."", ""Should Axon Enterprise Stock be in Your Portfolio Pre-Q2 Earnings? Axon Enterprise, Inc. AXON is scheduled to release second-quarter 2025 results on Aug. 4, after market close. The Zacks Consensus Estimate for earnings is currently pegged at $1.54 per share on revenues of $643 million. The company\u2019s second-quarter earnings estimates have increased 4.8% over the past 60 days. The bottom-line projection indicates an increase of 28.3% from the year-ago number. The Zacks Consensus Estimate for quarterly revenues indicates year-over-year growth of 27.6%. Image Source: Zacks Investment Research Axon Enterprise has an impressive earnings surprise history. The company\u2019s earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.8%. In the last reported quarter, it delivered an earnings surprise of 11%. Our proven model predicts an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks before they are reported with our Earnings ESP Filter. AXON has an Earnings ESP of +0.54% as the Most Accurate Estimate is pegged at $1.55 per share, higher than the Zacks Consensus Estimate of $1.54. It carries a Zacks Rank of 2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Axon Enterprise, Inc price-eps-surprise | Axon Enterprise, Inc Quote Strong demand for TASER devices and higher cartridge revenues is expected to have boosted the performance of Axon Enterprise\u2019s Connected Devices segment in the second quarter. Also, strong customer response for its next-generation body-worn camera, Axon Body 4, and solid demand for virtual reality training services are expected to have driven the segment\u2019s performance. The Zacks Consensus Estimate for the Connected Devices segment\u2019s revenues is pegged at $364 million, which indicates an increase of 23.4% from the year-ago number. The Software & Services segment is expected to have put up an impressive show in the upcoming earnings, supported by the addition of new users and associated devices to the AXON network. Strong momentum in Axon Evidence and cloud services, driven by an increase in the aggregate number of users, average revenue per user and software add-ons, is also likely to have augmented the segmental top line. Rise in adoption of software applications, driven by increased demand for cloud-connected TASER devices, has been driving Axon Evidence and cloud services\u2019 growth within the segment. The Zacks Consensus Estimate for the Software & Services segment\u2019s net sales is pegged at $283 million, indicating a 35.4% jump from the year-ago number. The company remains focused on buyouts and strategic collaborations to expand its product offerings and customer base. This is likely to reflect in its second-quarter results. For instance, in October 2024, the company acquired Dedrone, a global leader in airspace security. The inclusion of Dedrone\u2019s advanced airspace technology boosted AXON's capability to enable customers to protect their communities against drone threats and improve response to critical incidents. Also, in June 2024, Axon Enterprise entered into a partnership with Skydio (a leading U.S. drone manufacturer) to introduce a comprehensive line of drones in public safety that includes a scalable Drone as a First Responder solution. However, rising costs and operating expenses, due to business integration activities, higher wages and stock-based compensation expenses, are likely to have weighed on AXON\u2019s bottom line. AXON shares have gained 20.3% in the past three months compared with the Zacks Aerospace - Defense Equipment industry\u2019s 20.8% growth. The company\u2019s shares have also fared comparatively better than the S&P 500\u2019s increase of 12.2%. With respect to its major peers, Kratos Defense & Security Solutions, Inc. KTOS and Teledyne Technologies Incorporated TDY have surged 61.8% and 15.1%, respectively, in the same period. Image Source: Zacks Investment Research AXON\u2019s lofty valuation remains a concern. The stock is trading at a forward 12-month price-to-earnings (P/E) ratio of 103.48X, much higher than the industry average of 52.76X. This elevated valuation could make the stock vulnerable to further pullbacks if market sentiment sours. In comparison with AXON\u2019s valuation, its peers, Kratos Defense & Security and Teledyne Technologies, are trading cheaper. Notably, Kratos Defense & Security and Teledyne Technologies are trading at 99.12X and 24.15X, respectively. Image Source: Zacks Investment Research With a comprehensive and diversified product portfolio, Axon Enterprise has been capitalizing on the growing opportunities in the safety, drones and robotics end markets. The company\u2019s strategic collaborations, investments in AI products and strength in the TASER 10 device market bode well ahead of its second-quarter earnings. An increase in the aggregate number of users to the Axon network, along with benefits from acquired assets, is likely to drive the company\u2019s performance in the quarters ahead. Solid momentum across end markets, innovative product offerings, accretive acquisitions and strategic market expansions position Axon Enterprise favorably for strong second-quarter results. With a positive analyst sentiment, strong earnings projections and robust growth prospects, AXON is well-positioned to deliver sustained growth and shareholder\u2019 value. We believe that the AXON stock is an ideal candidate for investor's portfolio addition. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teledyne Technologies Incorporated (TDY) : Free Stock Analysis Report Kratos Defense & Security Solutions, Inc. (KTOS) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-08-04,751.04,755.0,736.95,744.88,
AXON,2025-08-05,818.0,885.915,802.96,867.12,"[""Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More U.S. equities declined at midday following a soft services industry report and President Donald Trump's comments on new tariffs. Nvidia and other semiconductor makers saw their shares fall when Trump said tariffs on the chip industry were coming soon. Axon Enterprise, DuPont, and Palantir Technologies all beat profit and sales forecasts and raised their guidance. U.S. equities fell at midday following a weak report on the services industry and concerns about new tariffs. The S&P 500, and Nasdaq dropped about 0.5% and the Dow Jones Industrial Average slipped 0.3%. Gartner (IT) was the worst-performing stock in the S&P 500 when the research and advisory firm slashed its guidance on declining revenue at its largest research unit. Shares of Vertex Pharmaceuticals (VRTX) slumped after the drugmaker announced a Phase 2 trial of its experimental pain medicine missed a key goal, and that it would no longer continue its development. Shares of Nvidia (NVDA) and other chipmakers slid when President Donald Trump said in an interview he would be announcing new semiconductor tariffs soon. Axon Enterprise (AXON) shares took off when the Taser maker exceeded earnings and revenue estimates and boosted its outlook on strong demand for its security products. DuPont (DD) also raised its guidance as it lowered its estimate for how much tariffs would impact full-year earnings. In addition, the chemical and materials maker reported better-than-expected results, and shares gained. Software analytics firm Palantir Technologies (PLTR) beat profit and sales estimates and lifted its outlook as it benefited from artificial intelligence product demand and more government contracts. Oil futures slid. Gold prices rose. The yield on the 10-year Treasury note was little changed. The U.S. dollar was up on the yen, but lost ground to the euro and pound. Major cryptocurrencies traded down. Read the original article on Investopedia"", ""Axon, D-Wave, Fox: Trending Tickers Axon (AXON) hit a record high after topping second quarter expectations. D-Wave (QBTS) was initiated by Stifel with a Buy rating. Fox (FOX) plans to launch a new streaming service \""Fox One\"" this August. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts."", ""Axon Tops Q2 Earnings & Revenue Estimates, Raises 2025 Guidance Axon Enterprise, Inc. AXON reported second-quarter 2025 adjusted earnings of $2.12 per share, which surpassed the Zacks Consensus Estimate of $1.54. The bottom line surged 73.8% year over year despite a rise in the cost of sales. Total revenues of $668.5 million surpassed the consensus estimate of $643 million and increased 33% year over year. The top line benefited from strong demand for TASER 10, Axon Body 4 and counter-drone equipment. Growing adoption of premium software solutions also augmented the top-line results. Effective first-quarter 2025, AXON realigned its business segments. The company now reports results under two business segments, namely Connected Devices and Software & Services. Connected Devices: The segment\u2019s revenues jumped 28.6% year over year to $376.4 million, driven by increase in demand for TASER 10 devices and associated cartridges, and Axon Body 4 as well as growth in platform solutions. The adjusted gross margin decreased year over year to 51.1% from 53.4%. The Zacks Consensus Estimate for Connected Devices\u2019 revenues was pegged at $366 million. Software & Services: The segment\u2019s revenues rose 38.8% year over year to $292.2 million. The uptick was driven by an increase in the aggregate number of users and growing adoption of premium software offerings. The adjusted gross margin increased to 78.9% from 76. 6% in the year-ago period due to a higher software mix. The Zacks Consensus Estimate for Software & Services\u2019 revenues was pegged at $284 million. Axon Enterprise, Inc price-consensus-eps-surprise-chart | Axon Enterprise, Inc Quote Axon\u2019s cost of sales increased 11.3% year over year to $264.8 million. Selling, general and administrative expenses increased 8.4% year over year to $242.2 million. Total operating expenses climbed 8.1% year over year to $404.8 million. The adjusted gross margin increased to 63.3% from 63.1% in the year-ago period. At the end of second-quarter 2025, Axon had cash and cash equivalents of $615.5 million compared with $454.8 million at December 2024-end. Long-term lease liabilities totaled $43.6 million compared with $41.4 million at 2024-end. In the first six months of 2025, the company used net cash of $65.9 million from operating activities against $66.8 million in cash generated in the previous year period. Adjusted free cash flow was a negative $113.7 million in the first six months of 2025 compared with $39.3 million in the prior-year period. For 2025, Axon expects revenues to be in the band of $2.65-$2.73 billion compared with $2.60-$2.70 billion anticipated earlier. The metric indicates approximately 29% year-over-year growth at the midpoint. Adjusted EBITDA is expected to be in the range of $665-$685 million, implying an adjusted EBITDA margin of about 25%. The company expects capital expenditures to be between $170 million and $185 million. This includes investments in long-term research & development projects, continued capacity expansion, global facility build-outs and new product development. It anticipates stock-based compensation expenses to be in the range of $580-$630 million. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here. Some other top-ranked companies are discussed below: TransDigm Group Incorporated TDG presently carries a Zacks Rank #2 (Buy). TDG\u2019s earnings surpassed the consensus estimate in each of the trailing four quarters. The average earnings surprise was 5.1%. In the past 60 days, the Zacks Consensus Estimate for Transdigm\u2019s 2025 earnings has inched up 0.2%. Woodward, Inc. WWD currently carries a Zacks Rank of 2. WWD has an impressive earnings surprise history, having outperformed the consensus estimate in each of the preceding four quarters, the average surprise being 15%. In the past 60 days, the Zacks Consensus Estimate for Woodward\u2019s fiscal 2025 (ending September 2025) earnings has increased 3.4%. HEICO Corporation HEI currently carries a Zacks Rank of 2. HEI outperformed the consensus estimate in each of the preceding four quarters, with an average surprise of 11.9%. In the past 60 days, the Zacks Consensus Estimate for HEICO\u2019s 2025 earnings has increased 2%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Transdigm Group Incorporated (TDG) : Free Stock Analysis Report Woodward, Inc. (WWD) : Free Stock Analysis Report Heico Corporation (HEI) : Free Stock Analysis Report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-08-06,859.76,879.22,843.023,863.65,"[""Argus Adjusts Price Target on Axon Enterprise to $900 From $780, Maintains Buy Rating Axon Enterprise (AXON) has an average rating of overweight and mean price target of $882.07, accordi"", ""S&P 500 Gains and Losses Today: Gartner Stock Plunges; Palantir, Axon Surge After Earnings The S&P 500 declined 0.5% on Tuesday, Aug. 5, 2025, as a key gauge of the services sector showed a slump in July and trade talks remained in focus. Gartner shares tumbled after the IT research firm missed quarterly estimates and cut its outlook, citing soft demand as businesses rein in spending. Shares of Taser maker Axon Enterprise and analytics software provider Palantir Technologies surged after both companies delivered strong quarterly results driven by demand for AI tools. Major U.S. equities indexes slipped on Tuesday after data revealed an unexpected downtick in the country's services sector in July, while traders monitored the latest developments on tariffs. The S&P 500 fell 0.5% on Tuesday, failing to extend its positive momentum from the trading week's opening session. The Dow slid 0.1%, while the Nasdaq Composite was down 0.7%. Shares of the technology-focused research and advisory firm Gartner (IT) logged the S&P 500's weakest performance on Tuesday, plummeting nearly 28%. Although second-quarter revenue and adjusted earnings per share topped estimates, Gartner reduced its full-year sales guidance, and its updated revenue outlook fell short of consensus expectations. The company cited soft demand within its insights segment\u2014Gartner's largest research unit accounting for more than half of sales\u2014as businesses moderate spending in response to the uncertain economic environment. Vertex Pharmaceuticals (VRTX) shares dropped 21%. Despite beating top- and bottom-line estimates with its second-quarter results, boosted by sales growth from its treatment for cystic fibrosis, the biopharmaceutical company announced it would halt development on an experimental next-generation pain treatment that failed to reach its primary endpoint in a recent Phase 2 trial. TransDigm Group (TDG), a supplier of engineered aircraft components, missed sales and profit estimates for its fiscal third quarter. A disappointing performance from TransDigm's commercial original equipment manufacturing segment, which the company attributed to inventory destocking and sluggish build rates, weighed on the results. TransDigm shares tumbled 12%. Axon Enterprise (AXON) shares jumped more than 16%, rising the most of any S&P 500 stock, after the maker of the Taser and other law enforcement gear surpassed sales and profit estimates for the second quarter and lifted its full-year outlook. Strong growth in annual recurring revenue suggested that Axon is gaining momentum in its software business, and the firm has seen strong demand for its generative artificial intelligence products, including a tool that drafts an initial police report based on camera footage. AI software giant Palantir Technologies (PLTR) also increased its 2025 outlook after topping second-quarter sales and profit estimates, highlighting strong demand for its Artificial Intelligence Platform as a key contributor to a record $1 billion in quarterly revenue. Following the strong results, analysts at Bank of America, Morgan Stanley, and Deutsche Bank raised their price targets on Palantir stock. Shares of the data analytics company surged 7.8%. Shares Leidos Holdings (LDOS) jumped 7.5% in the wake of the aerospace and defense contractor's quarterly earnings release. Adjusted EPS came in well ahead of expectations, while revenue edged out forecasts. Leidos noted an uptick in demand across its customer segments, with particular strength in its defense systems unit as geopolitical tensions remain elevated. Advances in the areas of AI and maritime autonomy also helped underpin the strong performance. Read the original article on Investopedia"", ""Stocks to Watch Recap: Palantir, Coinbase, Gartner, Pfizer \u2197\ufe0f Palantir (PLTR): Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and boosted its annual outlook. \u2198\ufe0fCoinbase Global (COIN): Shares in the cryptocurrency exchange dropped 6."", ""Buy Axon, avoid Byrna: Good Buy or Goodbye Tematica Research chief investment officer Chris Versace joins Market Domination with Josh Lipton to explain why he suggests buying Axon (AXON) and avoiding Byrna (BYRN). To watch more expert insights and analysis on the latest market action, check out more Market Domination."", ""BofA Adjusts Price Target on Axon Enterprise to $1,000 From $895, Maintains Buy Rating Axon Enterprise Inc (AXON) has an average rating of overweight and mean price target of $882.07, acc"", ""Axon Rallies On Earnings, After Joby, Defense Stocks Rise Joby stock gains on deal for Blade's passenger air taxi business. Boeing faces new strike. Axon clears earnings views.""]"
AXON,2025-08-07,867.23,885.0,860.98,870.97,"[""Here's A Conservative Way To Take Advantage Of Bullish Axon Stock Traders looking for a more conservative way to play a prospering Axon stock through options could use a bull put spread."", ""Axon Enterprise (AXON) Vs Palantir Technologies (PLTR): Which is the Better Investment? Strong Q2 results have led to a further uproar in Axon Enterprise AXON and Palantir Technologies PLTR shares this week, remaining two of the hottest momentum stocks. Axon\u2019s stock has now spiked over +40% year to date, with Palantir shares surging more than +130%. More astonishing, AXON is up over +640% in the last three years with PLTR skyrocketing more than 1,700%. Considering their millionaire-maker-like gains, investors are surely wondering which of these hot stocks is the better investment at the moment. Image Source: Zacks Investment Research Thanks to increased global defense and public safety spending, Axon easily surpassed its Q2 expectations while posting stellar top and bottom line growth. The innovative manufacturer of weapons for the U.S. and international governments posted Q2 sales of $668.54 million, which soared nearly 33% year over year and comfortably topped estimates of $642.98 billion by 4%. Furthermore, this marked the 14th consecutive quarter of revenue growth above 25%, with CEO Rick Smith stating Axon is seeing broad demand across the company\u2019s portfolio, including for its AI services, drones, cameras, and virtual reality solutions. More impressive, Axon\u2019s Q2 earnings came in at $2.12 per share, crushing expectations of $1.54 by 37% and soaring 76% from $1.20 in the prior period. Axon has now exceeded the Zacks EPS Consensus for a remarkable 33 consecutive quarters, with a very impressive average earnings surprise of 25.87% in its last four quarterly reports. Image Source: Zacks Investment Research Also thriving from increased defense spending, including the securement of a $10 billion contract with the U.S. Army, Palantir achieved its first-ever billion-dollar quarter, topping estimates of $938.33 million. This was a 48% spike from Q2 sales of $678.13 million a year ago, as the software provider saw strong demand for its artificial intelligence platform (AIP) outside of the intelligence communities. Pinpointing increased commercial demand for AIP, Palantir CEO Alex Karp stated that companies are using Palantir\u2019s tools not just to optimize operations, but to reshape entire business models. Palantir is also taking advantage of its expansive sales growth, with Q2 EPS of $0.16 rising from $0.09 a share in the comparative quarter and edging expectations of $0.14. Notably, Palantir has now reached of exceeded the Zacks EPS Consensus for 11 consecutive quarters with an average earnings surprise of 13.17% over the last four quarters. Image Source: Zacks Investment Research Adding fuel to investor sentiment is that Axon and Palantir have raised their full-year revenue guidance. Optimistically, Axon now forecasts fiscal 2025 revenue at $2.65-$2.73 billion, up from $2.6-$2.7 billion. It\u2019s also noteworthy that Axon expects full-year adjusted EBITDA of $665-$685 million, raised from $650-$675 million. Pivoting to Palantir, the company raised its FY25 revenue forecast to $4.142 billion-$4.15 billion, up from previous guidance of $3.89 billion-$3.9 billion. The bump is specifically attributed to full-year commercial revenue guidance increasing to over $1 billion, reflecting at least 85% growth. Additionally, Palantir raised its adjusted income from operations guidance to between $1.912 billion-1.92 billion and increased its adjusted free cash flow guidance to $1.8 billion-$2 billion. While Axon is well ahead in terms of moving further past the probability line than Palantir, the price-to-sales ratio may still be a better indicator of judging the value these hot stocks offer to investors at their current levels, rather than price-to-earnings. That said, Axon is also growing into its lofty valuation more swiftly regarding the P/S ratio after a rebranding to reflect its broader mission in public safety technology. To that point, Axon trades at 25X forward sales, which is far more reasonable than Palantir\u2019s 104X. Image Source: Zacks Investment Research Conclusion & Final Thoughts Although Palantir\u2019s ability to benefit from the AI boom makes it the better momentum stock at the moment, Axon appears to be the overall better investment when considering its more justifiable valuation. Axon\u2019s profitability also makes it a more sound investment, and earnings estimate revisions (EPS) have remained higher, correlating with AXON sporting a Zacks Rank #1 (Strong Buy). On the other hand, Palantir stock lands a Zacks Rank #3 (Hold), and investors may certainly be looking for better entry points given PLTR doesn\u2019t offer much fundamental value after such a monstrous year-to-date rally. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report Palantir Technologies Inc. (PLTR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Looking for Aerospace Stocks? The Zacks Rank Can Help You Find Winners It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck. Axon Enterprise was upgraded to the Zacks Rank #1 list on August 5, 2025. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors. Headquartered in Scottsdale, AZ, Axon. develops and manufactures weapons for selling to U.S. state and local governments, the U.S. federal government, international government customers and commercial enterprises. Focused on global public safety, Axon\u2019s suite of products includes conducted energy devices, body-worn cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. The company generates the majority of its revenues through direct sales, including its online store. Axon faces strong competition in both its hardware and software markets from companies like Motorola Solutions, Panasonic, IBM and others. On a geographical basis, the company has operations in the United States (85% of 2024 net sales) and other international markets (15%). For fiscal 2025, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.1 to $6.44 per share. AXON boasts an average earnings surprise of 25.9%. Earnings are expected to grow 8.4% for the current fiscal year, while revenue is projected to increase 30.2%. AXON has been moving higher over the past four weeks as well, up 7.2% compared to the S&P 500's gain of 1.2% . With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Axon Enterprise could be just the stock to help your portfolio generate returns that could fund your retirement, your kids' college tuition, or your short- and long-term savings goals. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report Zacks Investment Research"", ""Earnings Growth & Price Strength Make Axon Enterprise (AXON) a Stock to Watch If you're a beginner investor, the idea of creating a portfolio from the ground up can feel like an impossible goal to achieve. That's why you should start by looking at stocks that are set to beat the market over the next 12 months, a strategy that's been proven to generate strong returns. Let's now take a look at one standout stock that could be a perfect fit for your portfolio. Headquartered in Scottsdale, AZ, Axon. develops and manufactures weapons for selling to U.S. state and local governments, the U.S. federal government, international government customers and commercial enterprises. Focused on global public safety, Axon\u2019s suite of products includes conducted energy devices, body-worn cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. The company generates the majority of its revenues through direct sales, including its online store. Axon faces strong competition in both its hardware and software markets from companies like Motorola Solutions, Panasonic, IBM and others. On a geographical basis, the company has operations in the United States (85% of 2024 net sales) and other international markets (15%). AXON was added to the Zacks Focus List on June 3, 2020 at $97.85 per share. Since then, shares have increased 782.63% to $863.65. For fiscal 2025, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.1 to $6.44. AXON boasts an average earnings surprise of 25.9%. Earnings for Axon Enterprise's are forecasted to see growth of 8.4% for the current fiscal year as well. It can be very profitable to buy stocks with rising earnings estimates, as stock prices respond to revisions. By adding a Focus List stock like AXON, there's a great chance you'll be getting into a company whose future earnings estimates will be raised, which can lead to price momentum. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Here's How Much a $1000 Investment in Axon Enterprise Made 10 Years Ago Would Be Worth Today For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks. What if you'd invested in Axon Enterprise (AXON) ten years ago? It may not have been easy to hold on to AXON for all that time, but if you did, how much would your investment be worth today? With that in mind, let's take a look at Axon Enterprise's main business drivers. Headquartered in Scottsdale, AZ, Axon. develops and manufactures weapons for selling to U.S. state and local governments, the U.S. federal government, international government customers and commercial enterprises. Focused on global public safety, Axon\u2019s suite of products includes conducted energy devices, body-worn cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. The company generates the majority of its revenues through direct sales, including its online store. Axon faces strong competition in both its hardware and software markets from companies like Motorola Solutions, Panasonic, IBM and others. On a geographical basis, the company has operations in the United States (85% of 2024 net sales) and other international markets (15%). Effective first-quarter 2025, AXON realigned its business segments. The company now reports results under the following two segments: Connected Devices (56.3% of total revenues in the second quarter of 2025): This segment focuses on the design, production and sale of fully integrated hardware solutions including conducted energy devices (CEDs), body cameras, drones, various accessories and other related hardware products. The CEDs is a weapon system designed to temporarily incapacitate a subject with the help of an electrical current. Devices like the Axon Body 4 are equipped with built-in AI features, including real-time translation and voice-enabled support. The segment also includes Axon Vehicle Intelligence, which uses fixed and mobile video solutions, like Axon Outpost and Lightpost, to deliver license plate recognition and detailed vehicle information. It develops tools, such as TASER devices (energy weapon systems), virtual reality training services and consumer devices, to support public safety officers in de-escalating situations, avoiding or minimizing the use of force and aiding consumer personal protection. These are sold to law enforcement agencies, attorneys, emergency services personnel and the U.S. military. Software and Services (43.7%): This segment focuses on the development and sale of fully integrated cloud-based software platforms. Key offerings under this segment include Axon Evidence, Records Management System, Draft One and other AI-powered tools. These solutions enable law enforcement to securely store, manage, share and analyze video. Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Axon Enterprise a decade ago, you're probably feeling pretty good about your investment today. A $1000 investment made in August 2015 would be worth $35,323.11, or a gain of 3,432.31%, as of August 7, 2025, according to our calculations. This return excludes dividends but includes price appreciation. In comparison, the S&P 500's gained 204.53% and the price of gold went up 196.70% over the same time frame. Analysts are forecasting more upside for AXON too. Axon is witnessing strength across its businesses. Its Connected Devices segment is driven by solid demand for TASER 10 devices, virtual reality training services and counter drone equipment. Higher adoption of the TASER products has been driving the segment's performance. An increase in the aggregate number of users to the Axon network is aiding the Software & Services segment's growth. The company is actively pursuing strategic partnerships to enhance its product offerings and expand its customer reach. Benefits from acquired assets are likely to drive Axon's performance in the quarters ahead. However, escalating operating expenses, due to higher compensation expenses and business integration activities, have been weighing on Axon's performance. Given its international presence, foreign exchange headwinds may be worrying. The stock is up 7.17% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 2 higher, for fiscal 2025. The consensus estimate has moved up as well. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Is Axon Enterprise (AXON) Outperforming Other Aerospace Stocks This Year? For those looking to find strong Aerospace stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Axon Enterprise (AXON) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Aerospace sector should help us answer this question. Axon Enterprise is one of 58 individual stocks in the Aerospace sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Axon Enterprise is currently sporting a Zacks Rank of #1 (Strong Buy). Over the past 90 days, the Zacks Consensus Estimate for AXON's full-year earnings has moved 413.6% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that AXON has returned about 45.3% since the start of the calendar year. In comparison, Aerospace companies have returned an average of 27.8%. This means that Axon Enterprise is outperforming the sector as a whole this year. Rolls-Royce Holdings PLC (RYCEY) is another Aerospace stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 106.6%. The consensus estimate for Rolls-Royce Holdings PLC's current year EPS has increased 4.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Axon Enterprise belongs to the Aerospace - Defense Equipment industry, which includes 33 individual stocks and currently sits at #100 in the Zacks Industry Rank. On average, stocks in this group have gained 27.5% this year, meaning that AXON is performing better in terms of year-to-date returns. Rolls-Royce Holdings PLC is also part of the same industry. Axon Enterprise and Rolls-Royce Holdings PLC could continue their solid performance, so investors interested in Aerospace stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report Rolls-Royce Holdings PLC (RYCEY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon Enterprise (AXON) Sees Q2 Revenue Rise To US$669 Million Axon Enterprise recently reported its second-quarter 2025 earnings, showcasing a revenue growth to $669 million, up from $503 million a year ago, while net income experienced a decline to $36 million from $41 million. Concurrently, the company upgraded its full-year revenue guidance, suggesting optimistic future sales expectations. These events, coupled with a generally positive market environment, where the S&P 500 and Nasdaq Composite posted solid gains while digesting various earnings and global trade developments, likely provided a backdrop that supported the company\u2019s 26% share price surge over the past quarter. The market\u2019s robust performance perhaps added momentum to Axon\u2019s share price movements, complementing the company\u2019s adjusted forward guidance. Every company has risks, and we've spotted 2 possible red flags for Axon Enterprise you should know about. Find companies with promising cash flow potential yet trading below their fair value. The recent earnings announcement and revenue guidance upgrade could enhance Axon's narrative by underscoring its potential for continued growth, particularly through international expansion and AI-driven products. Despite the quarterly net income decline, the revenue jump to US$669 million points to successful product rollouts and market demand, which may positively influence future revenue and earnings forecasts. However, political and competitive risks could still introduce volatility in their earnings potential. Over the long term, Axon's shares have delivered a very large total return exceeding 982% over five years, suggesting significant value creation and growth beyond short-term fluctuations. This impressive performance contrasts with its one-year return, which exceeded the broader US market's 22.4% and the Aerospace & Defense industry's 40% return, highlighting Axon's robust market position. With the stock currently priced at US$863.65, its alignment with the analyst price target of US$873.67 suggests limited immediate upside, reflecting a modest 1.16% discount to the price target. This relatively small difference indicates analysts believe Axon's shares are fairly priced, and future price movements may depend on the company meeting or exceeding revenue and earnings expectations spurred by current positive developments and strategic initiatives. Assess Axon Enterprise's future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AXON. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"", ""Law Enforcement Software Market worth $32.96 billion by 2030 | MarketsandMarkets\u2122 DELRAY BEACH, Fla., Aug 7, 2025 /PRNewswire/ -- According to MarketsandMarkets\u2122, the Law Enforcement Software Market is expected to reach USD 32.96 billion by 2030 from USD 20.25 billion in 2025 at a compounded annual growth rate (CAGR) of 10.2% during the forecast period. Browse in-depth TOC on \""Law Enforcement Software Market\"" 221 \u2013 Tables 52 \u2013 Figures 279 \u2013 Pages Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=8292078 Scope of Report The increasing rates of crime, terrorism, and civil unrest worldwide are driving the demand for advanced law enforcement software solutions that enhance public safety and situational awareness. Law enforcement agencies face increasing pressure to respond quickly and effectively to diverse security challenges, requiring tools that support real-time data analysis, incident tracking, and coordinated response efforts. Modern software platforms offer features such as predictive analytics, digital evidence management, and integrated communication systems that help agencies monitor and manage incidents more efficiently. Additionally, the complexity and scale of threats necessitate technologies that enable proactive crime prevention and enhanced decision-making. This growing need for timely, data-driven policing strategies significantly contributes to law enforcement software adoption across various regions and jurisdictions. Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=8292078 Solutions offering segment is expected to hold the largest market share during the forecast period The solutions segment is anticipated to witness significant adoption in the Law Enforcement Software Market, driven by an increasing demand for advanced tools that support key police operations such as records management, computer-aided dispatch, case management, digital evidence handling, and crime analytics. These software solutions enable law enforcement agencies to streamline processes, enhance situational awareness, and improve decision-making through real-time data access and predictive insights. Agencies focus on integrated platforms that offer scalability, flexibility, and customization to meet diverse operational requirements. Additionally, the rising need for automation, digital transformation, and efficient resource utilization encourages agencies to invest in comprehensive software solutions. The growing crime rates, public safety concerns, and government initiatives to modernize policing infrastructure further contribute to the segment's strong market position. The solutions segment continues to be essential for law enforcement agencies aiming to optimize operations and enhance public security outcomes. Cloud deployment segment is expected to record the highest CAGR during the forecast period Law enforcement agencies are increasingly adopting cloud deployment models due to their scalability, flexibility, and cost-efficiency. Cloud-based law enforcement software enables centralized data management, real-time analytics, and streamlined information sharing across departments and jurisdictions, improving decision-making and operational efficiency. It supports remote access to systems, allowing officers and staff to access critical data securely from various locations. Integrating advanced technologies such as artificial intelligence, big data analytics, and IoT within cloud platforms enhances investigative capabilities, incident response, and crime prevention measures. Cloud deployment also minimizes the need for substantial upfront investments in hardware and IT infrastructure, making it a preferred choice for agencies with limited resources. Regular software updates and security enhancements that cloud services provide ensure system reliability and data protection. These benefits encourage law enforcement bodies worldwide to transition from traditional on-premises systems to cloud-based solutions, driving significant growth in this segment. Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=8292078 Asia Pacific region is expected to grow at the highest CAGR during the forecast period Asia Pacific is anticipated to experience the fastest Law Enforcement Software Market growth, supported by rising investments in public safety technologies across China, India, Japan, and Australia. Regional law enforcement agencies are increasingly adopting advanced software solutions such as crime analytics, incident management, surveillance systems, and real-time data sharing platforms to improve operational efficiency and public safety outcomes. Growing urbanization, increasing crime rates, and expanding innovative city initiatives further drive the regional demand for integrated law enforcement software. Additionally, a growing focus is on cloud-based and AI-powered law enforcement software due to its scalability, flexibility, and cost-effectiveness. India and China are enhancing their IT infrastructure to support modern policing requirements. These combined factors contribute to Asia Pacific emerging as the fastest-growing regional market for law enforcement software, as agencies prioritize digital transformation to manage evolving security challenges. Top Key Companies in Law Enforcement Software Market: Some of the law enforcement software vendors are Motorola Solutions (US), Axon Enterprise (US), NICE (Israel), NEC Corporation (Japan), Hexagon (Sweden), Palantir Technologies (US), IBM (US), Nuance Communications (US), Esri (US), and Gentec (Canada). Browse Adjacent Markets: Software and Services Market Research Reports & Consulting Related Reports: Tax Management Market - Global Forecast to 2030 Computer Aided Engineering Market - Global Forecast to 2030 Facility Management Market - Global Forecast to 2030 Knowledge Graph Market - Global Forecast to 2030 API Management Market - Global Forecast to 2029 Get access to the latest updates on Law Enforcement Software Companies and Law Enforcement Software Industry About MarketsandMarkets\u2122 MarketsandMarkets\u2122 has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets\u2122 is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines \u2013 TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore\u2122, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets\u2122.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets\u2122 INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg View original content:https://www.prnewswire.com/news-releases/law-enforcement-software-market-worth-32-96-billion-by-2030--marketsandmarkets-302524135.html SOURCE MarketsandMarkets""]"
AXON,2025-08-08,872.47,878.617,835.7,842.5,"[""Why Axon (AXON) Might be Well Poised for a Surge Investors might want to bet on Axon Enterprise (AXON), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of stun guns and body cameras, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008. For Axon Enterprise, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year. The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate: The company is expected to earn $1.54 per share for the current quarter, which represents a year-over-year change of +6.2%. The Zacks Consensus Estimate for Axon has increased 12% over the last 30 days, as one estimate has gone higher compared to no negative revisions. For the full year, the company is expected to earn $6.44 per share, representing a year-over-year change of +8.4%. In terms of estimate revisions, the trend for the current year also appears quite encouraging for Axon. Over the past month, two estimates have moved higher compared to no negative revisions, helping the consensus estimate increase 413.62%. The promising estimate revisions have helped Axon earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500. Axon shares have added 7.2% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Investors Heavily Search Axon Enterprise, Inc (AXON): Here is What You Need to Know Axon Enterprise (AXON) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this maker of stun guns and body cameras have returned +18.8% over the past month versus the Zacks S&P 500 composite's +1.9% change. The Zacks Aerospace - Defense Equipment industry, to which Axon belongs, has gained 2.3% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Axon is expected to post earnings of $1.63 per share, indicating a change of +12.4% from the year-ago quarter. The Zacks Consensus Estimate has changed +12% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $6.44 points to a change of +8.4% from the prior year. Over the last 30 days, this estimate has changed +3.3%. For the next fiscal year, the consensus earnings estimate of $7.99 indicates a change of +24.1% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +0.3%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Axon is rated Zacks Rank #1 (Strong Buy). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of Axon, the consensus sales estimate of $698.22 million for the current quarter points to a year-over-year change of +28.3%. The $2.71 billion and $3.34 billion estimates for the current and next fiscal years indicate changes of +30.3% and +23.1%, respectively. Axon reported revenues of $668.54 million in the last reported quarter, representing a year-over-year change of +32.6%. EPS of $2.12 for the same period compares with $1.2 a year ago. Compared to the Zacks Consensus Estimate of $642.98 million, the reported revenues represent a surprise of +3.97%. The EPS surprise was +37.66%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #1 does suggest that it may outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-08-11,842.89,844.15,817.36,818.69,"Axon Enterprise (NASDAQ:AXON) delivers shareholders enviable 60% CAGR over 5 years, surging 13% in the last week alone For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality companies can see their share prices grow by huge amounts. To wit, the Axon Enterprise, Inc. (NASDAQ:AXON) share price has soared 958% over five years. If that doesn't get you thinking about long term investing, we don't know what will. It's also good to see the share price up 16% over the last quarter. But this move may well have been assisted by the reasonably buoyant market (up 9.2% in 90 days). We love happy stories like this one. The company should be really proud of that performance! On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years of share price growth, Axon Enterprise moved from a loss to profitability. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains. Since the company was unprofitable five years ago, but not three years ago, it's worth taking a look at the returns in the last three years, too. We can see that the Axon Enterprise share price is up 539% in the last three years. During the same period, EPS grew by 27% each year. This EPS growth is lower than the 86% average annual increase in the share price over three years. So one can reasonably conclude the market is more enthusiastic about the stock than it was three years ago. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. It's nice to see that Axon Enterprise shareholders have received a total shareholder return of 129% over the last year. That gain is better than the annual TSR over five years, which is 60%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 2 warning signs for Axon Enterprise that you should be aware of. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned."
AXON,2025-08-12,819.64,824.66,767.51,768.57,
AXON,2025-08-13,776.98,779.0,731.742,765.52,"[""Axon\u2019s Q2 Earnings Call: Our Top 5 Analyst Questions Axon's second quarter drew strong positive market reaction, reflecting the company\u2019s ongoing ability to exceed Wall Street\u2019s expectations. Management credited the company\u2019s robust performance to accelerating adoption of new software solutions, as well as deeper customer relationships across state, local, and international markets. CEO Patrick Smith highlighted rapid uptake of products like Draft One and TASER 10, noting that \u201cdemand for new technology from our customers is accelerating, and it\u2019s outpacing even my most optimistic expectations.\u201d The quarter was also characterized by a record-breaking contract in the state and local segment and notable contributions from the corrections and enterprise verticals. Is now the time to buy AXON? Find out in our full research report (it\u2019s free). Revenue: $668.5 million vs analyst estimates of $641 million (32.8% year-on-year growth, 4.3% beat) Adjusted EPS: $2.12 vs analyst estimates of $1.46 (45% beat) Adjusted EBITDA: $171.6 million vs analyst estimates of $161.3 million (25.7% margin, 6.4% beat) The company lifted its revenue guidance for the full year to $2.69 billion at the midpoint from $2.65 billion, a 1.5% increase EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations Operating Margin: -0.2%, down from 6.7% in the same quarter last year Annual Recurring Revenue: $1.18 billion vs analyst estimates of $1.14 billion (39.2% year-on-year growth, 3.7% beat) Market Capitalization: $60.34 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Keith Housum (Northcoast Research) asked about which products are driving enterprise market traction. Chief Operating Officer Joshua Isner highlighted broad product suite adoption, noting both body cameras and AI solutions are seeing strong interest. Andrew Sherman (TD Cowen) inquired about accelerating demand for AI Era Plan products. Isner confirmed demand is \u201cabsolutely accelerating,\u201d crediting customer feedback and visible time savings as key adoption drivers. William Power (Baird) sought more detail on counter-drone growth and its law enforcement versus enterprise mix. CEO Patrick Smith described Dedrone as a \u201cmarket leader,\u201d with broadening demand across both sectors and rapid iteration to address evolving threats. Meta Marshall (Morgan Stanley) questioned how Axon overcomes adoption hurdles for new AI products. Isner explained that hands-on user feedback and pilot programs are most effective, with customers quickly seeing practical value. Alyssa Shreves (Barclays) asked if international outperformance will shift segment mix. Isner replied that while international will grow, the U.S. remains strong, so mix changes may be gradual rather than rapid. Looking ahead, our analysts will focus on (1) the pace of customer upgrades from basic to premium and AI-enabled product bundles, (2) Axon\u2019s ability to manage tariff-driven cost pressures while protecting margins, and (3) execution on large international and enterprise contracts. Progress in R&D hiring and new product launches will also be essential indicators of Axon\u2019s long-term trajectory. Axon currently trades at $772, up from $742.75 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it\u2019s free). When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that\u2019s already erased most losses. Don\u2019t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""Axon Enterprise Insider Sold Shares Worth $8,312,886, According to a Recent SEC Filing Patrick W Smith, Director, CEO, on August 11, 2025, sold 10,000 shares in Axon Enterprise (AXON) for"", ""AXON Q2 Deep Dive: Software, AI, and International Expansion Drive Outperformance Self defense company AXON (NASDAQ:AXON) reported Q2 CY2025 results exceeding the market\u2019s revenue expectations , with sales up 32.8% year on year to $668.5 million. The company\u2019s full-year revenue guidance of $2.69 billion at the midpoint came in 1.1% above analysts\u2019 estimates. Its non-GAAP profit of $2.12 per share was 45% above analysts\u2019 consensus estimates. Is now the time to buy AXON? Find out in our full research report (it\u2019s free). Revenue: $668.5 million vs analyst estimates of $641 million (32.8% year-on-year growth, 4.3% beat) Adjusted EPS: $2.12 vs analyst estimates of $1.46 (45% beat) Adjusted EBITDA: $171.6 million vs analyst estimates of $161.3 million (25.7% margin, 6.4% beat) The company lifted its revenue guidance for the full year to $2.69 billion at the midpoint from $2.65 billion, a 1.5% increase EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations Operating Margin: -0.2%, down from 6.7% in the same quarter last year Annual Recurring Revenue: $1.18 billion vs analyst estimates of $1.14 billion (39.2% year-on-year growth, 3.7% beat) Market Capitalization: $60.34 billion Axon's second quarter drew strong positive market reaction, reflecting the company\u2019s ongoing ability to exceed Wall Street\u2019s expectations. Management credited the company\u2019s robust performance to accelerating adoption of new software solutions, as well as deeper customer relationships across state, local, and international markets. CEO Patrick Smith highlighted rapid uptake of products like Draft One and TASER 10, noting that \u201cdemand for new technology from our customers is accelerating, and it\u2019s outpacing even my most optimistic expectations.\u201d The quarter was also characterized by a record-breaking contract in the state and local segment and notable contributions from the corrections and enterprise verticals. Looking forward, Axon's updated guidance is anchored by continued momentum in its software and AI product portfolio, as well as investments in research and development and new international opportunities. CFO Brittany Bagley emphasized that upcoming tariff-related expenses and increased hiring, especially in R&D, are factored into the company\u2019s outlook. Management believes that sustained growth in annual recurring revenue and ongoing expansion into emerging markets will be key, with Bagley stating, \u201cWe continue to expect to increase hiring over the remainder of the year, particularly in R&D, as we prioritize investing behind the incredible product road map.\u201d Management attributed the quarter\u2019s results to rapid adoption of new software, significant contract wins, and broader product usage across markets. Accelerated AI product adoption: Customer uptake of Axon's AI Era Plan, including Draft One and new AI assistant features, was a major driver. Over $150 million in bookings for AI Era Plan were recorded in Q2, with management noting that these solutions deliver tangible time savings for public safety workers. Largest contract in company history: The state and local sales team closed Axon's biggest deal to date, including a full suite of products from drones to AI. Corrections and enterprise verticals also saw record contracts, reflecting broader adoption across customer types. International and enterprise momentum: Axon expanded further in Africa by securing its largest TASER customer in the region, and signed a gaming industry contract that introduced AI products into a new vertical. Management noted that international deals are becoming larger, contributing to revenue diversity. Platform Solutions and counter-drone growth: The Platform Solutions segment saw strong growth, particularly in counter-drone technology, driven by heightened awareness of drone threats in global security contexts. The Dedrone acquisition positions Axon as a market leader in this space. Product bundling increases customer value: The per-officer value of contracts has risen above $600 thanks to new products layered onto base offerings, such as TASERs, body cameras, and AI solutions. Management stressed that only about 30% of customers are currently on premium plans, leaving significant room for future upsell. Axon\u2019s guidance reflects confidence in sustained growth from software and AI adoption, international expansion, and continued product innovation. Heavy investment in R&D: Management plans to expand hiring, particularly in research and development, to fuel ongoing product innovation and support new market entries. These investments are expected to set the foundation for long-term growth beyond this year. Tariff-related margin headwinds: The company is anticipating higher tariff expenses in the second half, which are already incorporated into margin guidance. Management is working to mitigate these pressures through operational efficiency and product mix adjustments. International and enterprise focus: Axon highlighted a robust pipeline in international and enterprise markets, particularly in Europe and Latin America. Management expects large deals in these regions to contribute meaningfully to growth, although they cautioned that such deals can be lumpy by nature due to their size and complexity. Looking ahead, our analysts will focus on (1) the pace of customer upgrades from basic to premium and AI-enabled product bundles, (2) Axon\u2019s ability to manage tariff-driven cost pressures while protecting margins, and (3) execution on large international and enterprise contracts. Progress in R&D hiring and new product launches will also be essential indicators of Axon\u2019s long-term trajectory. Axon currently trades at $772, up from $742.75 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it\u2019s free). Donald Trump\u2019s April 2025 \""Liberation Day\"" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don\u2019t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.""]"
AXON,2025-08-14,764.26,764.26,745.0,749.83,"Axon Uses AI to Enhance Public Safety Axon President Josh Isner joins Open Interest to discuss AI innovation in public safety, aiding the government with new technologies, and expansion plans to international and enterprise sales."
AXON,2025-08-15,750.21,762.0,739.01,754.24,"[""Axon Enterprise (AXON) Reports Q2 Revenue Climb To US$669 Million Axon Enterprise recently showcased its Q2 results with revenue climbing to $669 million, though net income and earnings per share experienced declines. The company also raised its full-year 2025 revenue guidance, reflecting confidence in future growth prospects. Despite completing part of their share buyback plan, no shares were repurchased in the latest quarter. Over the past quarter, Axon Enterprise's stock rose by 5.1%. This movement aligns with broader market trends where indices reached record highs, and the company's positive guidance would have added weight to these gains, complementing the overall upward market trajectory. We've spotted 2 risks for Axon Enterprise you should be aware of. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent Q2 performance of Axon Enterprise, alongside its raised full-year 2025 revenue guidance, supports the narrative of technology adoption driving customer value and growth. The company's commitment to innovation with advanced tech and SaaS offerings is evident through its efforts in modernizing public safety solutions. However, the lack of share buybacks in the latest quarter might signal a cautious approach towards capital allocation, which could impact future earnings and revenue forecasts, aligning with analyst expectations of moderate profit margin shrinkage. Over the past five years, Axon's shares delivered a very large total return of 845.55%, reflecting strong long-term investor confidence. In the past year, Axon's share price performance exceeded the US market, which saw a return of 19.4%, highlighting its solid one-year growth compared to broader market trends. However, it underperformed the US Aerospace & Defense industry, which had a higher return of 34.2%. The current share price of US$765.52 sits below the analysts' consensus price target of US$873.67, indicating a potential upside but also portraying varying analyst expectations about future performance. The company's focus on global expansion and addressing public safety challenges continues to underpin its growth trajectory. The positive reception of their latest products suggests potential for sustained revenue and earnings growth, reinforcing analyst projections. The raised revenue guidance by the company could provide additional momentum, though the competitive landscape and reliance on government funding still pose risks. Despite these factors, the marginal difference between current share pricing and projected targets underscores a consensus on its fair valuation as analysts strive for balanced future outlooks. Explore Axon Enterprise's analyst forecasts in our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AXON. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com"", ""BTIG Raises Price Target for AppLovin (APP), Keeps Buy Rating AppLovin Corporation (NASDAQ:APP) is one of the 11 Best Revenue Growth Stocks to Buy Now. On August 7, BTIG increased its price target for AppLovin Corporation (NASDAQ:APP) from $483 to $547 while keeping a Buy rating. This decision came after AppLovin Corporation (NASDAQ:APP) reported Q2 2025 results, which were slightly better than BTIG\u2019s expectations and in line with market consensus. Small business owners with their laptops sitting at a coffee shop, discussing their digital advertising strategy. However, the firm noted that the more important news was the confirmation of the launch and expansion date for AppLovin Corporation\u2019s (NASDAQ:APP) self-serve advertising tool, called AXON Ads Manager. BTIG noted that the company is launching AXON Ads Manager during the seasonally strongest quarter, when about 45% of annual advertising budgets are deployed. Additionally, AppLovin Corporation (NASDAQ:APP) is growing its marketing customers through a referral program and expanding into new international markets. The firm also pointed out that AppLovin Corporation (NASDAQ:APP) has started to explore non-gaming supply partnerships, which could increase supply starting in the first half of 2026. AppLovin Corporation (NASDAQ:APP) is an American technology company that provides end-to-end software and AI solutions for businesses of all sizes to reach, monetize, and grow their global audiences. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you\u2019re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 14 Best Aggressive Growth Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey.""]"
AXON,2025-08-18,755.18,792.64,753.77,791.62,
AXON,2025-08-19,779.83,783.995,755.0,758.29,"[""CEO pay at top US companies accelerates at fastest pace in four years Pay for S&P 500 chief executives rose by 7.7 per cent last year as packages at the US\u2019s biggest companies keep increasing. Median total pay"", ""Axon (AXON): Buy, Sell, or Hold Post Q2 Earnings? Axon currently trades at $792 and has been a dream stock for shareholders. It\u2019s returned 878% since August 2020, blowing past the S&P 500\u2019s 90.8% gain. The company has also beaten the index over the past six months as its stock price is up 33.5% thanks to its solid quarterly results. Following the strength, is AXON a buy right now? Or is the market overestimating its value? Find out in our full research report, it\u2019s free. Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful Law Enforcement Suppliers company because there\u2019s a ceiling to what customers will pay. Over the last two years, Axon\u2019s units sold averaged 28.8% year-on-year growth. This performance was fantastic and shows its offerings have a unique value proposition (and perhaps some degree of customer loyalty). We track the long-term change in earnings per share (EPS) because it highlights whether a company\u2019s growth is profitable. Axon\u2019s EPS grew at an astounding 45.6% compounded annual growth rate over the last five years, higher than its 32.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). We like to invest in businesses with high returns, but the trend in a company\u2019s ROIC is what often surprises the market and moves the stock price. Over the last few years, Axon\u2019s ROIC has increased. This is a good sign, but we recognize its lack of profitable growth during the COVID era was the primary reason for the change. These are just a few reasons why we think Axon is a high-quality business, and with its shares topping the market in recent months, the stock trades at 119.5\u00d7 forward P/E (or $792 per share). Is now a good time to buy? See for yourself in our full research report, it\u2019s free. Donald Trump\u2019s April 2025 \""Liberation Day\"" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. The smart money is already positioning for the next leg up. Don\u2019t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""Why Axon Enterprise (AXON) is a Top Stock for the Long-Term Building an investment portfolio from scratch can be difficult, especially if you're new to investing. It's easy to feel overwhelmed with so many different investment options out there, but focusing on stocks that are set to outperform the market over the next 12 months is an excellent place to start. Now, let's break down why adding this one exceptional stock, highlighted below, to your portfolio could be a recipe for success. Headquartered in Scottsdale, AZ, Axon. develops and manufactures weapons for selling to U.S. state and local governments, the U.S. federal government, international government customers and commercial enterprises. Focused on global public safety, Axon\u2019s suite of products includes conducted energy devices, body-worn cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. The company generates the majority of its revenues through direct sales, including its online store. Axon faces strong competition in both its hardware and software markets from companies like Motorola Solutions, Panasonic, IBM and others. On a geographical basis, the company has operations in the United States (85% of 2024 net sales) and other international markets (15%). AXON was added to the Zacks Focus List on June 3, 2020 at $97.85 per share. Since then, shares have increased 709.01% to $791.62. Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.59 to $6.93. AXON also boasts an average earnings surprise of 25.9%. Additionally, Axon Enterprise's earnings are expected to grow 16.7% for the current fiscal year. Since stock prices respond to earnings estimate revisions, it can be very profitable to buy stocks with an increased earnings outlook. By buying a Focus List stock like AXON, then, you're likely getting into a company whose future earnings estimates will be raised, potentially leading to price momentum. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Axon (AXON) Stock Trades Up, Here Is Why Shares of self defense company AXON (NASDAQ:AXON) jumped 4% in the afternoon session after investment firm TD Cowen reiterated its 'Buy' rating and $925 price target on the stock, citing confidence in the company's growth prospects. The investment firm highlighted its confidence in the public safety technology company's growth prospects following a recent investor meeting. TD Cowen pointed to several expansion drivers, including AI initiatives, drones, and international growth. The firm's positive outlook is supported by Axon's strong fundamentals, such as its recent 32.41% revenue growth. The analyst note also mentioned that despite delivering strong second-quarter results with raised guidance in early August, the stock had recently pulled back approximately 13%, suggesting the current price could be a favorable entry point for investors. After the initial pop the shares cooled down to $788.81, up 4.6% from previous close. Is now the time to buy Axon? Access our full analysis report here, it\u2019s free. Axon\u2019s shares are very volatile and have had 22 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 13 days ago when the stock gained 15.4% on the news that the company reported stellar second-quarter financial results and raised its full-year forecast. The public safety technology company announced its quarterly revenue climbed 33% year-over-year to $669 million, which surpassed analyst expectations. Earnings per share came in at $2.12, a significant jump from the prior year and a positive surprise of over 37% compared to estimates. This strong performance stemmed from a 39% increase in the company's high-margin Software & Services revenue. Axon's Annual Recurring Revenue (ARR), a key metric that showed sustained demand, also leaped 39% to $1.2 billion. Following the impressive quarter, Axon boosted its revenue and adjusted earnings guidance for the full year. Axon is up 32.2% since the beginning of the year, but at $788.81 per share, it is still trading 9.4% below its 52-week high of $870.97 from August 2025. Investors who bought $1,000 worth of Axon\u2019s shares 5 years ago would now be looking at an investment worth $9,941. Unless you\u2019ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.""]"
AXON,2025-08-20,754.17,763.71,740.5,760.89,"[""Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It Axon Enterprise (AXON) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this maker of stun guns and body cameras have returned +5.2%, compared to the Zacks S&P 500 composite's +2% change. During this period, the Zacks Aerospace - Defense Equipment industry, which Axon falls in, has lost 5%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Axon is expected to post earnings of $1.65 per share for the current quarter, representing a year-over-year change of +13.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +25%. For the current fiscal year, the consensus earnings estimate of $6.93 points to a change of +16.7% from the prior year. Over the last 30 days, this estimate has changed +201.9%. For the next fiscal year, the consensus earnings estimate of $8.18 indicates a change of +18.1% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +2.5%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Axon is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. For Axon, the consensus sales estimate for the current quarter of $698.22 million indicates a year-over-year change of +28.3%. For the current and next fiscal years, $2.71 billion and $3.34 billion estimates indicate +30.3% and +23.1% changes, respectively. Axon reported revenues of $668.54 million in the last reported quarter, representing a year-over-year change of +32.6%. EPS of $2.12 for the same period compares with $1.2 a year ago. Compared to the Zacks Consensus Estimate of $642.98 million, the reported revenues represent a surprise of +3.97%. The EPS surprise was +37.66%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance. Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""REV Group, TPI Composites, AeroVironment, nLIGHT, and Axon Shares Plummet, What You Need To Know A number of stocks fell in the after-market session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week. The downturn in the market was largely attributed to a significant sell-off in megacap tech and chipmaker shares. Nvidia, Advanced Micro Devices (AMD), and Broadcom all saw notable drops, dragging down the VanEck Semiconductor ETF. Other major tech-related companies like Tesla, Meta Platforms, and Netflix were also under pressure. A key reason for this trend is that much of the recent market gains have been concentrated in the \""AI trade,\"" which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Heavy Transportation Equipment company REV Group (NYSE:REVG) fell 4.5%. Is now the time to buy REV Group? Access our full analysis report here, it\u2019s free. Renewable Energy company TPI Composites (NASDAQ:TPIC) fell 8.7%. Is now the time to buy TPI Composites? Access our full analysis report here, it\u2019s free. Defense Contractors company AeroVironment (NASDAQ:AVAV) fell 5.5%. Is now the time to buy AeroVironment? Access our full analysis report here, it\u2019s free. Electronic Components company nLIGHT (NASDAQ:LASR) fell 4.2%. Is now the time to buy nLIGHT? Access our full analysis report here, it\u2019s free. Law Enforcement Suppliers company Axon (NASDAQ:AXON) fell 4.3%. Is now the time to buy Axon? Access our full analysis report here, it\u2019s free. TPI Composites\u2019s shares are extremely volatile and have had 112 moves greater than 5% over the last year. In that context, today\u2019s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 1 day ago when the stock dropped 46.2% on the news that the stock extended its negative momentum as the company filed for Chapter 11 bankruptcy. The wind blade manufacturer announced it has voluntarily filed for Chapter 11 bankruptcy to pursue a financial restructuring. This move follows a period of financial difficulty, highlighted by a recent second-quarter earnings report where both revenue and earnings per share missed analyst estimates significantly. TPI Composites is down 93.2% since the beginning of the year, and at $0.12 per share, it is trading 97.5% below its 52-week high of $4.92 from October 2024. Investors who bought $1,000 worth of TPI Composites\u2019s shares 5 years ago would now be looking at an investment worth $3.81. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we\u2019ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.""]"
AXON,2025-08-21,763.0,768.0,752.5,763.51,
AXON,2025-08-22,764.37,784.14,757.5,766.24,
AXON,2025-08-25,766.22,777.54,762.27,763.52,"My 3 Favorite Stocks to Buy Right Now Tariff-worried investors sent Walmart shares lower following its Q2 earnings report, ignoring how well the company's actually doing. It's not difficult to see what Warren Buffett likes about Domino's Pizza, even if it hasn't helped the stock much of late. Axon Enterprise isn't a household name, but the company's still entering an era of unprecedented opportunity. 10 stocks we like better than Axon Enterprise › There's no denying that a whole bunch of stocks are very richly valued right now, making it difficult to feel good about buying much of anything. Not every stock, though. A handful of high-quality names have lagged of late and, as such, may still be worth stepping into. Here's a closer look at three of my favorites among this small bunch. Yes, Walmart (NYSE: WMT) shares tumbled following the release of last quarter's numbers. Although revenue of $177.4 billion topped estimates of $175.9 billion, for the first time in a long time, earnings of $0.66 per share missed analysts' consensus estimate of $0.73. Profit guidance for the quarter now underway was also a bit disappointing, with the company conceding that newly imposed tariffs were taking a toll on its business. Indeed, after several months of lethargy, thanks to the post-earnings pullback, Walmart's stock is back to where it was at the beginning of this year. Investors as a whole, however, seem to have lost perspective on Walmart's continued resilience. Yes, earnings fell short. Consider the circumstances, though. Given the impact that tariffs could be making (and seem to be making on other retailers), the improvement from the year-ago per-share profit of $0.67 is acceptable...particularly in light of companywide year-over-year revenue growth of 4.8% and U.S. same-store sales growth of 4.6%. It's also worth noting that Walmart's total cost of sales for the quarter in question was up only 4.7%, in step with sales growth rather than exceeding it. Most of the new pressure on the bottom line actually came from higher interest payment costs that are largely beyond the company's control. Let's also not forget that while its second-quarter earnings and Q3 earnings guidance fell short of investors' expectations, the company still upped its sales and profit guidance for the full fiscal year. It was looking for a top-line improvement of between 3% and 4%. Now it's calling for an increase of between 3.75% and 4.75%. Its previous profit guidance of between $2.50 and $2.60 per share was raised to a range of $2.52 to $2.62 as well, likely fueled by still-strong growth of its e-commerce and U.S. advertising ventures, which improved 25% and 36% (respectively) in the recently ended second quarter. The point is, so fixated on the potential impact of tariffs, most investors seem to be missing the fact that the world's biggest brick-and-mortar retailer is actually doing quite well. The stock will eventually reflect this continued strength, though. When Warren Buffett's Berkshire Hathaway first established a stake in pizza chain Domino's Pizza (NASDAQ: DPZ) late last year, plenty of people followed that lead. They've not been particularly well rewarded, however. The stock's back to where it was then. If you're going to buy a Buffett stock, though, you need to have Buffett-like patience. That means a willingness to hold it for years on end and not worry about any volatility it experiences in the meantime. The thing is, this is the right kind of stock to be patient with. It's not an industry-specific detail most people give much thought to. But pizza may be the perfect fast-food business to be in. Its raw ingredients are relatively cheap, and the process of making a pizza (in assembly line fashion) is fairly simple and can be done within a relatively small footprint that doesn't require customer seating. Each market can somewhat customize its menu and pricing, too. And perhaps most important, pizza is always marketable because it's always a relatively cost-effective meal or snack. These are nuances that just don't broadly apply to most -- and ubiquitous -- hamburger restaurant chains. And Domino's Pizza's long-term results say as much. Removing pandemic-skewed comparisons from the mix, this company hasn't failed to grow its top line in any quarter since late 2012, growing its annualized sales from less than $1.7 billion then to nearly $4.8 billion now. Profit growth hasn't been quite as consistent but certainly as impressive. The company's 2012 net income of $113 million has since grown to nearly $600 million. Look for more of the same going forward, too. Last quarter's total revenue growth of 5.6% and same-store sales growth of 3.4% within the all-important U.S. market bodes well for the 178 stores it opened during that three-month stretch, with the same pace of store openings anticipated for the second half of the year. It's just a well-run company with lots of opportunity ahead of it. It's not difficult to see why Buffett and his lieutenants like it despite the stock's recent volatility and net weakness. Finally, I'm adding Axon Enterprise (NASDAQ: AXON) to my list of favorite stocks to buy now. Unlike Walmart and Domino's, Axon shares have actually been performing very well of late, reaching a record high earlier this month thanks to a more than 100% run-up since August of last year and its nearly 800% rally from its 2022 low. I believe there's still more upside left to tap, however, and so do analysts. Their consensus price target of $888.64 is about 14% above the stock's current price. But this may be one of those cases where the analyst community could be willing to continue raising their targets as shares continue to make forward progress. But what is it? You may be more familiar with Axon than you realize. Ever heard of a TASER gun (which is a brand name rather than a type, by the way)? They're made by Axon. The company may be better known, however, for its body cams now commonly worn by law enforcement professionals. Axon Enterprise also offers all the training and evidentiary software that this equipment requires if and when their usage needs to be examined during a court trial. The company even makes aerial surveillance drones when sending a person to a particular place could prove too dangerous or impractical. Say what you want about the sociocultural reasons that the need for such tools exists in the first place. Just don't deny that the need translates into opportunity. Industry research outfit Technavio says the worldwide body-worn camera market is set to grow at an average annual pace of 19% through 2029, while Mordor Intelligence believes the directed energy weapon (stun guns, or TASER guns) business is likely to expand at an average yearly pace of more than 16% through 2030. For Axon's part, following last quarter's top-line year-over-year growth of 33%, analysts expect full-year sales growth of 31% to $2.7 billion en route to $4.10 billion by 2027. You'd be hard-pressed to find a more promising growth prospect right now despite this stock's fairly steep valuation. Before you buy stock in Axon Enterprise, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Axon Enterprise wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $649,657!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,090,993!* Now, it’s worth noting Stock Advisor’s total average return is 1,057% — a market-crushing outperformance compared to 185% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axon Enterprise, Berkshire Hathaway, Domino's Pizza, and Walmart. The Motley Fool has a disclosure policy. My 3 Favorite Stocks to Buy Right Now was originally published by The Motley Fool"
AXON,2025-08-26,764.2,775.0,761.12,769.02,"[""Axon Enterprise, Inc. (AXON): A Bull Case Theory We came across a bullish thesis on Axon Enterprise, Inc. on Arya\u2019s Substack by Arya. In this article, we will summarize the bulls\u2019 thesis on AXON. Axon Enterprise, Inc.'s share was trading at $758.29 as of August 19th. AXON\u2019s trailing and forward P/E were 186.77 and 107.53 respectively according to Yahoo Finance. Kbiros/Shutterstock.com Axon Enterprise delivered another standout quarter in Q2 2025, underscoring its transition from a hardware-driven business into a vertically integrated SaaS platform embedded in public safety. Revenue rose 33% to $669 million, marking the sixth consecutive quarter above 30% growth, with Annual Recurring Revenue climbing 39% to $1.2 billion. Software & Services grew 39% to $292 million, now comprising ~44% of total revenue, while Connected Devices rose 29% to $376 million, driven by demand for TASER 10, Axon Body 4, and new \u201cplatform\u201d products such as drones and VR training kits. Profitability also improved, with adjusted EBITDA up 37% to $172 million, reflecting strong operating leverage, while net revenue retention remained robust at 124%, highlighting Axon\u2019s ability to expand within its customer base through premium bundle adoption and AI-powered modules. The backlog surged 43% to a record $10.7 billion, providing multi-year revenue visibility and prompting management to raise full-year revenue guidance to $2.65\u20132.73 billion. Strategically, Axon\u2019s Officer Safety Plan bundles continue to move upmarket, with agencies increasingly adopting premium and AI-enhanced packages that lift monetization per officer fivefold compared to earlier offerings. This hardware-enabled SaaS model, where every device sold seeds recurring software revenue, has created Apple-like ecosystem dynamics, deepening customer lock-in. With a $129 billion addressable market spanning global public safety, federal agencies, corrections, and enterprise security, Axon is still underpenetrated, particularly internationally. Looking ahead, sustained 25\u201330% growth could drive revenues to $5\u20136 billion by 2028 with expanding margins as software becomes the majority of sales, positioning Axon as the dominant global platform for public safety technology. Previously we covered a bullish thesis on Axon Enterprise, Inc. (AXON) by RadnorCapital in March 2025, which highlighted sustained 30%+ growth, expanding international demand, and a record bookings pipeline. The stock has appreciated ~52% since then as execution delivered. The thesis still stands with strong contracted revenue visibility. Arya shares a similar view but emphasizes Axon\u2019s SaaS shift, ARR strength, and ecosystem lock-in. Axon Enterprise, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge fund portfolios held AXON at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the potential of AXON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None."", ""Is Now The Time To Put Axon Enterprise (NASDAQ:AXON) On Your Watchlist? The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Axon Enterprise (NASDAQ:AXON). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. Trump has pledged to \""unleash\"" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. It certainly is nice to see that Axon Enterprise has managed to grow EPS by 27% per year over three years. As a result, we can understand why the stock trades on a high multiple of trailing twelve month earnings. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. On the one hand, Axon Enterprise's EBIT margins fell over the last year, but on the other hand, revenue grew. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead. In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart. View our latest analysis for Axon Enterprise The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Axon Enterprise's future EPS 100% free. Owing to the size of Axon Enterprise, we wouldn't expect insiders to hold a significant proportion of the company. But we are reassured by the fact they have invested in the company. We note that their impressive stake in the company is worth US$2.8b. Holders should find this level of insider commitment quite encouraging, since it would ensure that the leaders of the company would also experience their success, or failure, with the stock. For growth investors, Axon Enterprise's raw rate of earnings growth is a beacon in the night. Further, the high level of insider ownership is impressive and suggests that the management appreciates the EPS growth and has faith in Axon Enterprise's continuing strength. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. It is worth noting though that we have found 2 warning signs for Axon Enterprise that you need to take into consideration. Although Axon Enterprise certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.""]"
AXON,2025-08-27,774.76,779.79,767.0,769.68,"If You Invested $1000 in Axon Enterprise a Decade Ago, This is How Much It'd Be Worth Now How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and industries. Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks. What if you'd invested in Axon Enterprise (AXON) ten years ago? It may not have been easy to hold on to AXON for all that time, but if you did, how much would your investment be worth today? With that in mind, let's take a look at Axon Enterprise's main business drivers. Headquartered in Scottsdale, AZ, Axon. develops and manufactures weapons for selling to U.S. state and local governments, the U.S. federal government, international government customers and commercial enterprises. Focused on global public safety, Axon’s suite of products includes conducted energy devices, body-worn cameras, in-car cameras, cloud-hosted digital evidence management solutions, productivity software and real-time operations capabilities. The company generates the majority of its revenues through direct sales, including its online store. Axon faces strong competition in both its hardware and software markets from companies like Motorola Solutions, Panasonic, IBM and others. On a geographical basis, the company has operations in the United States (85% of 2024 net sales) and other international markets (15%). Effective first-quarter 2025, AXON realigned its business segments. The company now reports results under the following two segments: Connected Devices (56.3% of total revenues in the second quarter of 2025): This segment focuses on the design, production and sale of fully integrated hardware solutions including conducted energy devices (CEDs), body cameras, drones, various accessories and other related hardware products. The CEDs is a weapon system designed to temporarily incapacitate a subject with the help of an electrical current. Devices like the Axon Body 4 are equipped with built-in AI features, including real-time translation and voice-enabled support. The segment also includes Axon Vehicle Intelligence, which uses fixed and mobile video solutions, like Axon Outpost and Lightpost, to deliver license plate recognition and detailed vehicle information. It develops tools, such as TASER devices (energy weapon systems), virtual reality training services and consumer devices, to support public safety officers in de-escalating situations, avoiding or minimizing the use of force and aiding consumer personal protection. These are sold to law enforcement agencies, attorneys, emergency services personnel and the U.S. military. Software and Services (43.7%): This segment focuses on the development and sale of fully integrated cloud-based software platforms. Key offerings under this segment include Axon Evidence, Records Management System, Draft One and other AI-powered tools. These solutions enable law enforcement to securely store, manage, share and analyze video. Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Axon Enterprise, if you bought shares a decade ago, you're likely feeling really good about your investment today. A $1000 investment made in August 2015 would be worth $34,384.98, or a gain of 3,338.50%, as of August 27, 2025, according to our calculations. This return excludes dividends but includes price appreciation. Compare this to the S&P 500's rally of 233.21% and gold's return of 189.69% over the same time frame. Analysts are forecasting more upside for AXON too. Axon is witnessing strength across its businesses. Its Connected Devices segment is driven by solid demand for TASER 10 devices, virtual reality training services and counter drone equipment. Higher adoption of the TASER products has been driving the segment's performance. An increase in the aggregate number of users to the Axon network is aiding the Software & Services segment's growth. The company is actively pursuing strategic partnerships to enhance its product offerings and expand its customer reach. Benefits from acquired assets are likely to drive Axon's performance in the quarters ahead. However, escalating operating expenses, due to higher compensation expenses and business integration activities, have been weighing on Axon's performance. Given its international presence, foreign exchange headwinds may be worrying. The stock is up 5.53% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 6 higher, for fiscal 2025. The consensus estimate has moved up as well. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"
AXON,2025-08-28,772.83,794.29,771.5,781.9,"[""Q2 Earnings Outperformers: Axon (NASDAQ:AXON) And The Rest Of The Aerospace and Defense Stocks As the Q2 earnings season wraps, let\u2019s dig into this quarter\u2019s best and worst performers in the aerospace and defense industry, including Axon (NASDAQ:AXON) and its peers. Emissions and automation are important in aerospace, so companies that boast advances in these areas can take market share. On the defense side, geopolitical tensions\u2013whether it be Russia\u2019s invasion of Ukraine or China\u2019s aggression toward Taiwan\u2013have highlighted the need for consistent or even elevated defense spending. As for challenges, demand for aerospace and defense products can ebb and flow with economic cycles and national defense budgets, which are unpredictable and particularly painful for companies with high fixed costs. The 30 aerospace and defense stocks we track reported a strong Q2. As a group, revenues beat analysts\u2019 consensus estimates by 2.9% while next quarter\u2019s revenue guidance was 0.7% below. In light of this news, share prices of the companies have held steady as they are up 1.7% on average since the latest earnings results. Providing body cameras and tasers for first responders, AXON (NASDAQ:AXON) develops technology solutions and weapons products for military, law enforcement, and civilians. Axon reported revenues of $668.5 million, up 32.8% year on year. This print exceeded analysts\u2019 expectations by 4.3%. Overall, it was an exceptional quarter for the company with a solid beat of analysts\u2019 ARR estimates and a beat of analysts\u2019 EPS estimates. Interestingly, the stock is up 3.4% since reporting and currently trades at $768. Read why we think that Axon is one of the best aerospace and defense stocks, our full report is free. Founded in 1981, Mercury Systems (NASDAQ:MRCY) specializes in providing processing subsystems and components for primarily defense applications. Mercury Systems reported revenues of $273.1 million, up 9.9% year on year, outperforming analysts\u2019 expectations by 11.9%. The business had an incredible quarter with an impressive beat of analysts\u2019 organic revenue estimates and a beat of analysts\u2019 EPS estimates. The market seems happy with the results as the stock is up 28.4% since reporting. It currently trades at $68.98. Is now the time to buy Mercury Systems? Access our full analysis of the earnings results here, it\u2019s free. Headquartered in Maryland, Famous for the F-35 aircraft, Lockheed Martin (NYSE:LMT) specializes in defense, space, homeland security, and information technology products. Lockheed Martin reported revenues of $18.16 billion, flat year on year, falling short of analysts\u2019 expectations by 2.3%. It was a softer quarter as it posted full-year EPS guidance missing analysts\u2019 expectations significantly and a significant miss of analysts\u2019 adjusted operating income estimates. As expected, the stock is down 1.3% since the results and currently trades at $455.25. Read our full analysis of Lockheed Martin\u2019s results here. Providing a one-stop shop that integrates multiple services and product offerings, AerSale (NASDAQ:ASLE) delivers full-service support to mid-life commercial aircraft. AerSale reported revenues of $107.4 million, up 39.3% year on year. This result beat analysts\u2019 expectations by 24.4%. It was an incredible quarter as it also recorded a beat of analysts\u2019 EPS estimates and an impressive beat of analysts\u2019 EBITDA estimates. AerSale delivered the biggest analyst estimates beat among its peers. The stock is up 42.1% since reporting and currently trades at $8.77. Read our full, actionable report on AerSale here, it\u2019s free. Originally known as Safariland, Cadre (NYSE:CDRE) specializes in manufacturing and distributing safety and survivability equipment for first responders. Cadre reported revenues of $157.1 million, up 8.9% year on year. This number surpassed analysts\u2019 expectations by 3.3%. Aside from that, it was a slower quarter as it recorded a significant miss of analysts\u2019 adjusted operating income estimates and full-year EBITDA guidance missing analysts\u2019 expectations. The stock is down 11.6% since reporting and currently trades at $30.59. Read our full, actionable report on Cadre here, it\u2019s free. As a result of the Fed\u2019s rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed\u2019s 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump\u2019s victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here."", ""What Makes Axon Enterprise (AXON) the Premier Operating System For Public Safety? ClearBridge Investments, an investment management company, released its \u201cClearBridge Mid Cap Growth Strategy\u201d second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Following the soft start to the year, the midcap fund rebounded in the second quarter, driven by demand for AI and a low-quality rally, which enabled the growth stocks to overcome the tariff-led uncertainty. The strategy failed to outpace the benchmark, despite strong absolute returns, due to limited exposure to several of the rally\u2019s leading participants. However, the firm is optimistic about the ability of the mid-cap growth universe to offer attractive long-term compounders. In addition, please check the fund\u2019s top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, ClearBridge Mid Cap Growth Strategy highlighted stocks such as Axon Enterprise, Inc. (NASDAQ:AXON). Axon Enterprise, Inc. (NASDAQ:AXON) manufactures conducted energy devices (CEDs) under the TASER brand. The one-month return of Axon Enterprise, Inc. (NASDAQ:AXON) was 1.88%, and its shares gained 112.62% of their value over the last 52 weeks. On August 27, 2025, Axon Enterprise, Inc. (NASDAQ:AXON) stock closed at $769.68 per share, with a market capitalization of $60.423 billion. ClearBridge Mid Cap Growth Strategy stated the following regarding Axon Enterprise, Inc. (NASDAQ:AXON) in its second quarter 2025 investor letter: Axon Enterprise, Inc. (NASDAQ:AXON) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 62 hedge fund portfolios held Axon Enterprise, Inc. (NASDAQ:AXON) at the end of the second quarter, which was 61 in the previous quarter. In the second quarter of 2025, Axon Enterprise, Inc. (NASDAQ:AXON) generated $669 million in revenue, representing a 33% increase year-over-year and marking its 14th consecutive quarter of revenue growth exceeding 25%. While we acknowledge the potential of Axon Enterprise, Inc. (NASDAQ:AXON) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Axon Enterprise, Inc. (NASDAQ:AXON) and shared a bullish thesis on the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey."", ""Are Wall Street Analysts Predicting Axon Enterprise Stock Will Climb or Sink? With a market cap of $60.4 billion, Axon Enterprise, Inc. (AXON) develops and sells conducted energy devices under the TASER brand, along with body cameras, software, and digital evidence management solutions for public safety. The company serves law enforcement, federal, corrections, healthcare, retail, and personal safety markets worldwide. Shares of the Scottsdale, Arizona-based company have significantly outperformed the broader market over the past 52 weeks. AXON stock has jumped 112.7% over this time frame, while the broader S&P 500 Index ($SPX) has returned 15.2%. Moreover, shares of the company are up 29.7% on a YTD basis, compared to SPX\u2019s 10.2% rise. Dear Broadcom Stock Fans, Mark Your Calendars for September 4 CEO Alex Karp Just Sold $60 Million in Palantir Stock. Should You Ditch PLTR Here Too? After a 222% Surge, Is SoFi Stock Headed Even Higher? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Focusing more closely, the TASER maker stock has also outpaced the Industrial Select Sector SPDR Fund\u2019s (XLI) 19.1% increase over the past 52 weeks and a 16.8% YTD gain. Shares of Axon jumped 16.4% following its Q2 2025 results on Aug. 4 as adjusted EPS came in at $2.12, exceeding Wall Street estimates. Revenue rose to $668.5 million, beating expectations and reflecting strong demand for TASER devices, body cameras, and software solutions. The company also raised its full-year 2025 revenue forecast to $2.65 billion - $2.73 billion, signaling confidence in continued growth from federal spending and executive security demand. For the fiscal year ending in December 2025, analysts expect Axon Enterprise\u2019s EPS to decline 54.6% year-over-year to $0.95. The company's earnings surprise history is mixed. It topped the consensus estimates in two of the last four quarters while missing on two other occasions. Among the 18 analysts covering the stock, the consensus rating is a \u201cStrong Buy.\u201d That\u2019s based on 13 \u201cStrong Buy\u201d ratings, three \u201cModerate Buys,\u201d and two \u201cHolds.\u201d This configuration is more bullish than three months ago, with 10 \u201cStrong Buy\u201d ratings on the stock. On Aug. 5, Northland analyst Michael Latimore raised Axon\u2019s price target to $800 with an \u201cOutperform\u201d rating. The mean price target of $869.73 represents a nearly 13% premium to AXON\u2019s current price levels. The Street-high price target of $940 suggests a 22.1% potential upside. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com""]"
AXON,2025-08-29,784.32,785.84,745.46,747.29,
AXON,2025-09-02,733.81,748.83,726.0,743.59,"Axon Enterprise (AXON) Continued Its Robust Performance in Q2 Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Mid-cap stocks rebounded in the second quarter, delivering a strong recovery. The Russell Midcap Growth Index (up 18.20%) outperformed the Russell Midcap® Value Index (up 5.34%) in the quarter. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. In its second-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Axon Enterprise, Inc. (NASDAQ:AXON). Axon Enterprise, Inc. (NASDAQ:AXON) manufactures conducted energy devices (CEDs) under the TASER brand. The one-month return of Axon Enterprise, Inc. (NASDAQ:AXON) was 0.32%, and its shares gained 104.75% of their value over the last 52 weeks. On August 29, 2025, Axon Enterprise, Inc. (NASDAQ:AXON) stock closed at $747.29 per share, with a market capitalization of $58.666 billion. Carillon Eagle Mid Cap Growth Fund stated the following regarding Axon Enterprise, Inc. (NASDAQ:AXON) in its second quarter 2025 investor letter: Axon Enterprise, Inc. (NASDAQ:AXON) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 62 hedge fund portfolios held Axon Enterprise, Inc. (NASDAQ:AXON) at the end of the second quarter, which was 61 in the previous quarter. In the second quarter, Axon Enterprise, Inc. (NASDAQ:AXON) generated $669 million in revenue, representing a 33% increase year-over-year and marking its 14th consecutive quarter of revenue growth exceeding 25%. While we acknowledge the potential of Axon Enterprise, Inc. (NASDAQ:AXON) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Axon Enterprise, Inc. (NASDAQ:AXON) and shared the list of stocks that Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey."
AXON,2025-09-03,737.26,738.0,713.205,725.06,"[""Axon Enterprise, Inc (AXON) is Attracting Investor Attention: Here is What You Should Know Axon Enterprise (AXON) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this maker of stun guns and body cameras have returned -14.3% over the past month versus the Zacks S&P 500 composite's +3% change. The Zacks Aerospace - Defense Equipment industry, to which Axon belongs, has lost 2.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Axon is expected to post earnings of $1.65 per share for the current quarter, representing a year-over-year change of +13.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +25%. The consensus earnings estimate of $6.93 for the current fiscal year indicates a year-over-year change of +16.7%. This estimate has changed +201.9% over the last 30 days. For the next fiscal year, the consensus earnings estimate of $8.18 indicates a change of +18.1% from what Axon is expected to report a year ago. Over the past month, the estimate has changed +2.5%. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Axon. The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth. In the case of Axon, the consensus sales estimate of $698.22 million for the current quarter points to a year-over-year change of +28.3%. The $2.71 billion and $3.34 billion estimates for the current and next fiscal years indicate changes of +30.3% and +23.1%, respectively. Axon reported revenues of $668.54 million in the last reported quarter, representing a year-over-year change of +32.6%. EPS of $2.12 for the same period compares with $1.2 a year ago. Compared to the Zacks Consensus Estimate of $642.98 million, the reported revenues represent a surprise of +3.97%. The EPS surprise was +37.66%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Axon is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Axon. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research"", ""Why Is Axon (AXON) Down 14.3% Since Last Earnings Report? It has been about a month since the last earnings report for Axon Enterprise (AXON). Shares have lost about 14.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Axon due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Axon reported second-quarter 2025 adjusted earnings of $2.12 per share, which surpassed the Zacks Consensus Estimate of $1.54. The bottom line surged 73.8% year over year despite a rise in the cost of sales. Total revenues of $668.5 million surpassed the consensus estimate of $643 million and increased 33% year over year. The top line benefited from strong demand for TASER 10, Axon Body 4 and counter-drone equipment. Growing adoption of premium software solutions also augmented the top-line results. Effective first-quarter 2025, AXON realigned its business segments. The company now reports results under two business segments, namely Connected Devices and Software & Services. Connected Devices: The segment\u2019s revenues jumped 28.6% year over year to $376.4 million, driven by increase in demand for TASER 10 devices and associated cartridges, and Axon Body 4 as well as growth in platform solutions. The adjusted gross margin decreased year over year to 51.1% from 53.4%. Software & Services: The segment\u2019s revenues rose 38.8% year over year to $292.2 million. The uptick was driven by an increase in the aggregate number of users and growing adoption of premium software offerings. The adjusted gross margin increased to 78.9% from 76. 6% in the year-ago period due to a higher software mix. Axon\u2019s cost of sales increased 34.4% year over year to $264.8 million. Selling, general and administrative expenses increased 41.7% year over year to $242.2 million. Total operating expenses climbed 48.6% year over year to $404.8 million. The adjusted gross margin increased to 63.3% from 63.1% in the year-ago period. At the end of second-quarter 2025, Axon had cash and cash equivalents of $615.5 million compared with $454.8 million at December 2024-end. Long-term lease liabilities totaled $43.6 million compared with $41.4 million at 2024-end. In the first six months of 2025, the company used net cash of $65.9 million from operating activities against $66.8 million in cash generated in the previous year period. Adjusted free cash flow was a negative $113.7 million in the first six months of 2025 compared with $39.3 million in the prior-year period. For 2025, Axon expects revenues to be in the band of $2.65-$2.73 billion compared with $2.60-$2.70 billion anticipated earlier. The metric indicates approximately 29% year-over-year growth at the midpoint. Adjusted EBITDA is expected to be in the range of $665-$685 million, implying an adjusted EBITDA margin of about 25%. The company expects capital expenditures to be between $170 million and $185 million. This includes investments in long-term research & development projects, continued capacity expansion, global facility build-outs and new product development. It anticipates stock-based compensation expenses to be in the range of $580-$630 million. It turns out, estimates review have trended downward during the past month. The consensus estimate has shifted 25% due to these changes. At this time, Axon has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the lowest quintile for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Axon has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Axon is part of the Zacks Aerospace - Defense Equipment industry. Over the past month, Hexcel (HXL), a stock from the same industry, has gained 6.3%. The company reported its results for the quarter ended June 2025 more than a month ago. Hexcel reported revenues of $489.9 million in the last reported quarter, representing a year-over-year change of -2.1%. EPS of $0.50 for the same period compares with $0.60 a year ago. Hexcel is expected to post earnings of $0.41 per share for the current quarter, representing a year-over-year change of -12.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -5.7%. Hexcel has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axon Enterprise, Inc (AXON) : Free Stock Analysis Report Hexcel Corporation (HXL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research""]"
AXON,2025-09-04,725.78,731.19,719.0,729.985,"DEA Marijuana Decision Showtime: MMJ Issues Demand Letter on DEA Duane Boise stated ""In a September 3rd letter to DEA Terry Cole, that the Administrative Procedure Act requires agencies to act ""within a reasonable time."" If no decision is issued soon, MMJ will pursue all available remedies in federal appeals court to the supreme court if necessary"". WASHINGTON, DC / ACCESS Newswire / September 4, 2025 / Newly confirmed DEA Administrator Terrance ""Terry"" Cole faces a defining first decision: Will he break from the DEA's long history of obstructing medical cannabis research, or will he side with entrenched bureaucrats accused of stifling science and patient care? At the center of this test is MMJ BioPharma Cultivation, Inc., a company that has spent more than seven years seeking DEA approval to cultivate pharmaceutical grade cannabis for FDA authorized clinical trials in Huntington's disease and Multiple Sclerosis. Despite earning FDA Orphan Drug Designations and passing multiple DEA inspections, MMJ remains stuck in what company officials describe as a ""Kafkaesque regulatory trap."" The Stakes: Patients, Law, and Science MMJ's application has become a flashpoint for systemic failures inside the DEA: Unconstitutional Process: MMJ was subjected to an in-house tribunal system later ruled unconstitutional by the Supreme Court in Axon v. FTC and Jarkesy v. SEC. Retroactive Rulemaking: DEA imposed new ""bona fide supply agreement"" requirements years after MMJ first applied in 2018. Excessive Delays: More than 2,300 days have passed without resolution-far beyond the 60-day timeline mandated under the Medical Marijuana and Cannabidiol Research Expansion Act. While bureaucrats stall, patients with devastating neurological conditions remain without access to investigational therapies. ""Every day of delay is a day of suffering,"" said Duane Boise, CEO of MMJ International Holdings. ""This isn't just bad governance-it's a moral failure."" Cole's Decision: Reform or Regression Administrator Cole, sworn in this summer, has two options: In a September 3rd letter, MMJ's counsel reminded Administrator Cole that the Administrative Procedure Act requires federal agencies to act ""within a reasonable time."" The letter warned that if no decision is issued soon, MMJ will pursue all available legal remedies-up to and including appeals in the federal courts and, if necessary, the U.S. Supreme Court. Why This Matters Beyond MMJ Cole's ruling comes at a crossroads for federal marijuana policy: Rescheduling Momentum: President Trump has signaled openness to moving cannabis to Schedule III, which would expand research and ease restrictions. Public Pressure: Nearly 70% of Americans support legalization, and trust in DEA leadership is at historic lows. Congressional Oversight: Lawmakers are increasingly critical of DEA roadblocks to scientific research. ""Administrator Cole has a chance to end the DEA's failed marijuana program,"" said Boise. ""The question is whether he'll step up as a reformer-or just become another defender of the status quo."" About MMJ BioPharma Cultivation, Inc. MMJ BioPharma Cultivation, a subsidiary of MMJ International Holdings, is advancing FDA compliant, pharmaceutical grade cannabinoid medicines. The company holds FDA Orphan Drug Designations for Huntington's disease and Multiple Sclerosis and has developed soft gel capsule formulations of THC and CBD under GMP standards. MMJ is committed to science, patient care, and full federal compliance in pioneering cannabinoid based therapies. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey MHisey@mmjih.com 203-231-8583 SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire"
AXON,2025-09-05,731.0,738.77,708.759,728.41,"Jim Cramer on Axon: “They Just Keep Delivering Great Numbers” Axon Enterprise, Inc. (NASDAQ:AXON) is one of the stocks that Jim Cramer discussed. Cramer called the company “incredibly run,” as he remarked: Photo by Yiorgos Ntrahas on Unsplash Axon Enterprise, Inc. (NASDAQ:AXON) develops TASER devices and provides hardware, software, and cloud solutions for law enforcement and public safety. Its products include body cameras, digital evidence management platforms, and connected safety technologies. While we acknowledge the potential of AXON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey."
AXON,2025-09-08,739.08,750.0,733.875,740.61,
AXON,2025-09-09,734.09,740.0,718.0,731.98,
AXON,2025-09-10,736.66,750.955,734.26,747.555,
AXON,2025-09-11,751.61,765.005,745.428,751.11,
AXON,2025-09-12,756.66,765.44,754.46,756.13,
AXON,2025-09-15,760.0,774.32,756.2,760.79,
AXON,2025-09-16,760.79,766.63,750.65,750.67,
AXON,2025-09-17,750.67,762.175,748.3,751.81,
AXON,2025-09-18,756.35,772.0,754.0,766.47,
AXON,2025-09-19,771.77,779.09,761.0,774.63,
AXON,2025-09-22,766.33,778.942,761.55,775.92,
AXON,2025-09-23,769.16,792.155,768.224,777.58,
AXON,2025-09-24,789.29,789.29,697.8,698.02,
AXON,2025-09-25,696.97,723.152,694.54,712.15,
AXON,2025-09-26,718.0,722.0,697.455,708.42,
AXON,2025-09-29,716.335,722.84,703.0,716.02,
AXON,2025-09-30,716.04,724.88,700.245,717.64,
AXON,2025-10-01,708.64,720.075,697.0,711.34,
AXON,2025-10-02,719.91,725.16,703.24,720.53,
AXON,2025-10-03,721.51,726.76,712.76,715.51,
AXON,2025-10-06,719.2,724.27,705.0,721.59,
AXON,2025-10-07,720.88,728.34,706.61,714.6,
AXON,2025-10-08,715.64,732.86,708.04,727.41,
AXON,2025-10-09,726.02,753.16,722.51,734.04,
AXON,2025-10-10,733.18,739.9999,702.27,703.03,
AXON,2025-10-13,705.53,717.9999,699.13,710.0,
AXON,2025-10-14,698.68,717.5298,690.46,704.69,
AXON,2025-10-15,708.53,714.0499,638.5,645.239,
AXON,2025-10-16,648.5,663.25,642.3601,652.17,
AXON,2025-10-17,645.51,677.06,639.5,670.68,
AXON,2025-10-20,675.14,686.97,673.0,683.13,
AXON,2025-10-21,687.99,708.02,685.0,707.04,
AXON,2025-10-22,701.09,701.09,683.35,701.09,
AXON,2025-10-23,704.41,718.19,704.01,716.39,
AXON,2025-10-24,726.44,737.5325,724.21,735.95,
AXON,2025-10-27,746.59,756.04,741.57,749.0,
AXON,2025-10-28,746.12,764.02,745.0,755.0,
AXON,2025-10-29,750.48,762.075,742.0,759.66,
AXON,2025-10-30,760.85,760.85,737.63,738.96,
AXON,2025-10-31,745.0,749.955,731.0,732.25,
AXON,2025-11-03,737.06,738.23,720.7356,724.13,
AXON,2025-11-04,715.46,719.92,698.315,706.13,
AXON,2025-11-05,563.84,657.3564,560.0,639.53,
AXON,2025-11-06,628.6,631.9899,584.21,587.14,
AXON,2025-11-07,587.0,611.21,577.8,602.51,
AXON,2025-11-10,611.35,611.35,580.39,584.75,
AXON,2025-11-11,583.16,584.87,561.915,572.18,
AXON,2025-11-12,570.35,575.92,565.37,569.51,
AXON,2025-11-13,565.88,580.0,556.6,557.49,
AXON,2025-11-14,548.9,569.04,546.64,554.37,
AXON,2025-11-17,554.56,554.65,538.36,543.22,
AXON,2025-11-18,541.27,549.2229,528.95,533.77,
AXON,2025-11-19,533.0,533.0,521.19,531.06,
AXON,2025-11-20,541.85,553.19,519.19,519.62,
AXON,2025-11-21,519.61,527.9,508.72,521.99,
AXON,2025-11-24,521.46,525.3,515.83,524.59,
AXON,2025-11-25,523.5,539.8,514.25,528.89,
AXON,2025-11-26,533.59,537.665,527.2175,533.05,
AXON,2025-11-28,538.74,542.7,533.18,540.14,
AXON,2025-12-01,531.52,540.45,525.0,533.21,
AXON,2025-12-02,534.81,542.53,532.6201,537.75,
AXON,2025-12-03,536.75,544.53,531.0,543.55,
AXON,2025-12-04,547.49,553.46,540.65,550.61,
AXON,2025-12-05,551.02,555.9999,544.805,550.95,
AXON,2025-12-08,553.7,555.38,548.22,553.11,
AXON,2025-12-09,550.99,552.71,540.0267,546.65,
AXON,2025-12-10,552.3,579.6,552.07,568.39,
AXON,2025-12-11,563.99,586.37,553.28,581.03,
AXON,2025-12-12,584.13,584.13,561.63,564.28,
AXON,2025-12-15,568.18,576.7175,541.9401,551.48,
AXON,2025-12-16,548.315,559.52,540.93,554.93,
AXON,2025-12-17,546.335,563.465,544.5,550.0,
AXON,2025-12-18,555.84,568.61,555.15,563.28,
AXON,2025-12-19,566.295,603.12,561.9101,594.14,
AXON,2025-12-22,603.95,617.97,596.5,600.19,
AXON,2025-12-23,597.26,608.38,584.29,591.02,
AXON,2025-12-24,587.04,591.82,581.71,591.15,
AXON,2025-12-26,591.15,591.15,577.1254,583.84,
AXON,2025-12-29,580.0,586.99,577.22,580.55,
AXON,2025-12-30,579.0,580.8899,571.137,572.11,
AXON,2025-12-31,572.94,574.19,567.83,567.93,
AXON,2026-01-02,573.37,579.58,554.4001,563.45,
AXON,2026-01-05,569.65,601.69,568.3611,591.16,
AXON,2026-01-06,602.91,633.92,595.0001,626.65,
AXON,2026-01-07,619.79,626.34,608.1127,620.91,
AXON,2026-01-08,630.6,640.72,609.145,612.98,
AXON,2026-01-09,617.72,636.01,615.0,631.69,
AXON,2026-01-12,631.0,633.27,617.58,631.73,
AXON,2026-01-13,635.0,649.89,623.34,641.51,
AXON,2026-01-14,636.36,649.0,617.59,629.22,
AXON,2026-01-15,636.01,642.18,627.77,637.19,
AXON,2026-01-16,641.09,649.3,633.085,636.04,
AXON,2026-01-20,625.97,635.9999,617.88,620.52,
AXON,2026-01-21,619.25,624.69,595.54,610.25,
AXON,2026-01-22,613.01,617.99,598.28,607.09,
AXON,2026-01-23,608.8,622.3899,605.0,613.14,
AXON,2026-01-26,611.555,616.08,603.11,605.07,
AXON,2026-01-27,604.0,614.21,596.0,610.22,
AXON,2026-01-28,610.65,612.125,549.1,549.86,
AXON,2026-01-29,555.01,556.5,502.56,509.57,
AXON,2026-01-30,505.36,509.12,481.35,483.65,
AXON,2026-02-02,482.0,491.26,459.51,459.99,
AXON,2026-02-03,471.75,471.75,434.62,451.22,
AXON,2026-02-04,447.63,453.99,420.57,430.57,
AXON,2026-02-05,426.41,430.365,397.82,399.65,
AXON,2026-02-06,410.0,414.96,396.41,414.2,
AXON,2026-02-09,418.215,434.61,412.0001,433.97,
AXON,2026-02-10,438.57,458.14,436.0,447.11,
AXON,2026-02-11,453.39,455.8275,432.0,434.47,
AXON,2026-02-12,438.21,443.19,428.05,435.94,
AXON,2026-02-13,440.495,446.0,420.61,429.525,
AXON,2026-02-17,433.62,444.83,426.49,432.14,
AXON,2026-02-18,433.99,443.53,427.01,430.03,
AXON,2026-02-19,429.05,443.0,426.02,441.03,